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ABSTRACT 
 
Adverse drug reactions (ADRs) are responsible for an increasing number of 
hospitalised patients, with the large majority of these ADRs classed as either type A 
or type B.  Drug hypersensitivity reactions fall within the type B category and one 
such drug responsible for this form of ADR is abacavir (ABC).  ABC, a nucleoside 
reverse transcriptase inhibitor, is used to treat the HIV-1 virus.  It is responsible for a 
potentially life-threatening type IV hypersensitivity reaction which occurs in patients 
bearing the HLA-B*57:01 allele.  Although many mechanisms have been proposed, 
it was the objective of this research to examine all these previous proposals to further 
extend and develop the mechanism of ABC toxicity. 
 
In Chapter 2, deuterated-ABC (D2-ABC) was designed and synthesised where the 
two 5'-H atoms were replaced with two 5'-D atoms.  The design of this analogue was 
intended to retard the oxidative metabolism of ABC to its aldehyde and carboxylic 
acid metabolites.  The synthesis of this compound was paramount to investigating 
this metabolism and through a series of metabolic experiments, described in Chapter 
3, a kinetic isotope effect between ABC and D2-ABC was determined, ultimately 
showing an altered metabolism between the two compounds. 
 
To investigate binding of ABC within the HLA-B*57:01 protein, analogues of ABC, 
with alterations at varying positions within the molecule, were required.  Using a 
racemic method, ABC enantiomers were synthesised and ABC’s enantiomer failed to 
stimulate T-cells in vitro.  The creation of further analogues required the 
development of an asymmetric synthetic route.  A total synthetic method was desired 
to synthesise intermediates to be used in future analogue synthesis. 
 
Finally, as described in Chapter 5, a range of 6-position analogues were designed, 
using a structure-activity relationship method, and synthesised, to further investigate 
the altered repertoire mechanism.  These analogues, consisting of primary and 
secondary amine and oxy moieties, were subjected to in vitro immunological assays 
to determine their stimulation of T-cells.  Additionally, the synthesised analogues 
were modelled in silico using molecular docking within the HLA protein.  The in 
silico results assisted in explaining the basis of such T-cell activation/inactivation 
and will direct future analogue design.  IC50 and EC50 values were determined for 
analogues that presented a negative T-cell response and a compound showing 
positive values was subjected to further pharmacokinetic testing. 
 
The oxidative metabolism of ABC was affected by isotopic substitution, but initial 
results have shown no altered T-cell stimulation of D2-ABC compared to ABC.  This 
mechanism cannot be discarded, with further investigational work required.  
However, the synthesised 6-position analogues have assisted in further examining 
the altered repertoire mechanism and initial findings have enabled further 
understanding of the binding of ABC within HLA-B*57:01.  This mechanism of 
ABC toxicity appears paramount to others proposed and the results presented in this 
thesis support this.  Additional analogue synthesis and in vivo experiments will assist 
in confirming this further. 
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1.1 Introduction 
 
1.2 Adverse Drug Reactions 
Adverse drug reactions (ADRs) pose a major risk to patients and are a cause of 
increasing hospital admissions.1 These adverse reactions are not limited to a certain 
class of drugs, although analgesics and cardiovascular drugs often contribute to a 
higher percentage of hospitalised patients.2 Careful drug design and thorough 
explanations of mechanisms of current ADRs will help in the future design and 
release of drugs, thereby reducing the number of hospital admissions and lowering 
the mortality rate resulting from ADRs. 
 
The widely accepted definition of an ADR is as follows: 
 
“An appreciably harmful or unpleasant reaction, resulting from an intervention 
related to the use of a medicinal product, which predicts hazard from future 
administration and warrants prevention or specific treatment, or alteration of the 
dosage regimen, or withdrawal of the product.”3 
 
1.2.1 Classification of adverse drug reactions. 
There are 5 classes of ADRs (Table 1.1), with most of these categorised into either 
type A or type B.  Other less common ADRs fall into types C–E.  The current 
classification system of ADRs was established in 2000 and previously only type A 
and B categories existed. 
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Table 1.1:  Classification of ADRs, types A–E.  ADR, adverse drug reaction; HIV, human 
immunodeficiency virus.  Adapted from Edwards et al.3 and Park et al.4 
 
 
Type of 
Reaction 
 
 
Feature of ADR 
 
Example Effect – Drug 
(Use) 
 
A 
 
• Dose-related 
• Common 
• Predictable 
• Usually resulting from 
pharmacological action of 
drug 
 
 
Excess bleeding – Warfarin 
(anticoagulant) 
 
B 
 
• Non-dose related 
• Uncommon 
• Idiosyncratic 
• Not related to 
pharmacological action of 
drug 
 
 
Hypersensitivity – Abacavir 
(antiviral, HIV) 
 
C 
 
• Dose-related and time 
related (continuing) 
• Uncommon 
• Resulting from cumulative 
dose 
 
 
Hepatotoxicity – 
Acetaminophen (analgesic) 
 
D 
 
• Time-related (delayed) 
• Uncommon 
• Usually dose-related 
• Delayed onset time 
 
 
Fetal hydantoin syndrome – 
Phenytoin (epilepsy) 
 
E 
 
• Withdrawal (end-of-use) 
• Uncommon 
• Symptoms appear quickly 
after withdrawal of drug 
 
 
Benzodiazepine withdrawal 
syndrome – Diazepam 
(sedative benzodiazepines) 
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Type A ADRs are more common and are more likely to be dose-related than type B 
ADRs.  They account for over 80% of ADRs.5 Type A ADRs are predictable from 
the known pharmacology of the drug, whether these are primary or secondary 
pharmacological characteristics.  These ADRs are quite often mild in nature in 
comparison to type B reactions; they have low mortality rates and are usually first 
detected in phase I–III clinical trials.6 Factors that influence development of a type A 
ADR include genetic polymorphisms, pharmacokinetic (PK) and pharmacodynamic 
(PD) variations and drug–drug interactions (DDIs).5,6 Frequently, these ADRs are 
seen in elderly patients5 or those undertaking numerous drug therapies.7 An example 
of a type A ADR can be seen in Table 1.1 where warfarin can cause excess bleeding 
– a toxicity that arises through genetic factors and DDIs, but can be reduced through 
a strict dosing regimen. 
 
Type B ADRs are less common, liable to higher mortality rates and are idiosyncratic, 
leading to their highly unpredictable nature.  Type B reactions account for 
approximately 16% of ADRs.8 There is no dose-dependent relationship with this 
toxicity and they can often arise not only from the parent drug or metabolite, but 
from chemically reactive metabolites.5 Although these reactions are relatively rare, 
they are often more serious in nature, affect multiple organ systems and can have a 
significant clinical and drug discovery impact.  Understanding the mechanisms 
behind these type B adverse reactions is vital to drug discovery and development. 
 
1.3 Immune Reactions 
A common reaction seen within the type B ADR category is drug hypersensitivity 
syndrome (DHS).  It results from an undesired stimulation of the immune system, 
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presenting serious effects and can often result in fatal consequences.  DHS accounts 
for approximately 13% of ADRs.9 During the 1960s, Coombs and Gell10 divided 
hypersensitivity reactions into four classes:  I, II, III and IV, the latter with its own 
set of subclasses (Table 1.2). 
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Table 1.2:  Classification of type I–IVd hypersensitivity reactions. 
 
 
Hypersensitivity 
Class 
 
 
Reaction Type  
(Mediators) 
 
Mechanism 
 
I 
 
 
IgE-mediated reactions 
(IgE) 
 
 
• Binding of IgE to IgE-
specific Fc receptors 
• IgE antibodies trigger 
mast cells and basophils to 
release active agents 
stimulating a response 
• Reactions are quickly 
onset 
 
 
II 
 
 
Cytotoxic reactions 
(IgM or IgG) 
 
• IgM or IgG antibodies 
bind to cell membrane or 
tissue and activate 
complement cascade, 
resulting in destruction of 
cell 
 
 
III 
 
 
Immune complex reactions 
(IgM or IgG) 
 
 
• Complexes of antigen and 
IgM or IgG antibody 
accumulate in tissue and 
activate complement 
cascade 
 
 
IV 
 
• Antigen causes activation 
of T-cells which release 
cytokines, resulting in 
activation of 
macrophages.  The types 
of T-cells involved define 
the subclass: 
 
 
IVa 
 
 
 
• Type 1 T-helper cells (Th1 
cells) 
 
IVb 
 
 
• Type 2 T-helper cells (Th2 
cells) 
 
 
IVc 
 
 
• Cytotoxic T-cells 
 
IVd 
 
 
 
 
 
 
 
 
 
Delayed-type reactions 
(T-cells) 
 
 
• IL-8 secreting T-cells 
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1.3.1 Type IV hypersensitivity. 
Of the four discrete classes, it is delayed-type hypersensitivity (DTH) class IV that is 
of most interest to this research, due to its relation with T-cell lymphocytes rather 
than antibodies (as seen with type I–III hypersensitivity reactions).  The first 
encounter of the antigen with the patient will sensitise them, and upon re-exposure to 
the antigen, type 1 T-helper cells (Th1) cells are activated and a hypersensitivity 
reaction will occur.  It is known as DTH due to the time delay of onset of symptoms 
– usually 24–72 hours after exposure to the antigen.11 Such a delay arises due to the 
migration of macrophages and T-cells to the site of exposure.11 The appearance of 
skin rashes, raised thickening of skin and itching are all typical characteristics of this 
type of hypersensitivity reaction. 
 
1.3.2 Mechanism of T-cell activation. 
There are two forms of the major histocompatability complex (MHC), MHC class I 
and MHC class II, which facilitate the presentation of both endogenous and 
exogenous peptides to T-cells.  Several differences occur between the two classes:  
MHC I molecules are found expressed within most cells and MHC II only within 
antigen presenting cells (APCs); MHC I molecules interact with CD8+ T-cells, 
whereas MHC II molecules interact with CD4+ T-cells and MHC I molecules are 
responsible for the presentation of smaller peptides (typically 9–11 amino acids in 
length) whilst MHC II present larger peptide chains. 
 
Within this research, it has been vital to understand the mechanism of T-cell 
activation, facilitated by MHC class I molecules only.  The MHC I molecules are 
coded for in humans by three major human leukocyte alleles (HLA):  HLA-A, HLA-
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B and HLA-C genes.  Firstly, a peptide must be transported to the endoplasmic 
reticulum (ER) using the transporter associated with antigen processing (TAP) 
pathway and once in the ER, it is loaded onto the MHC molecule with the assistance 
of the chaperones, ERp57 and tapasin.  The MHC-peptide molecule is then 
transported to the cell surface and is available for presentation to T-cells.  MHC I 
self-peptide complexes will interact with CD8+ T-cells with insufficient strength to 
stimulate a T-cell response.  However, should an exogenous peptide be bound within 
the MHC molecule, complementary T-cell receptors (TCRs) on T-cells will be 
activated, resulting in a cascade of mechanisms occurring due to this immune 
response. 
 
1.4 Mechanisms of Drug Hypersensitivity Reactions 
Three major concepts are well known that present possible mechanisms of immune-
mediated drug-induced responses in an MHC class I manner:  The hapten hypothesis, 
the pharmacological interaction (p-i) concept and the danger hypothesis. 
 
1.4.1 Hapten hypothesis. 
The hapten hypothesis is the most widely applied mechanism to idiosyncratic drug 
reactions.12 A hapten is a small, chemically reactive compound that must bind 
covalently to self-proteins/peptides before antigen processing4,13-16 (Figure 1.1).  A 
hapten molecule cannot initiate an immune response itself, but only when chemically 
bonded to a (endogenous) protein, forming a novel complex which is immunogenic.4 
Penicillins are example drugs that act in this manner.17 Other further examples 
include halothane18,19 and clozapine.20 
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A prohapten is a seemingly inert molecule but once metabolised, it forms a highly 
reactive species that is capable of covalently binding to proteins and subsequently 
activating an antigen-mediated T-cell response.  The metabolism usually occurs with 
the aid of cytochrome (CYP) P450 enzymes during phase I metabolism.  Once 
metabolised, molecules that are susceptible to becoming immunogenic will form 
electrophilic functional groups, such as quinone imines21 and nitroso intermediates.22 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1:  Presentation and recognition of a peptide within the MHC to the TCR (A).  The hapten 
hypothesis:  A drug is processed either within the APC, or previously, to form a reactive metabolite, 
which covalently (solid line) binds with endogenous proteins/peptides.  This adduct is presented on 
the MHC to T-cell lymphocytes (via TCR) forming non-covalent bonds (dashed lines) and as it is 
immunogenic, stimulates an immune response (B).  MHC, major histocompatability complex; TCR, 
T-cell receptor; APC, antigen-presenting cell. 
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 1.4.2 Pharmacological interaction concept. 
The p-i concept explains the mechanism behind T-cell activation with small drug 
molecules that are chemically inert, before or after metabolism.16,23 There is an 
absence of covalent binding with the TCR or the MHC during antigen presentation 
and weaker, non-covalent binding occurs8 (e.g. hydrogen, van der Waals bonding) 
(Figure 1.2).  It is the direct interaction of the molecule between the TCR and MHC 
that stimulates a response, with no previous metabolism or intracellular processing of 
the drug24 or other chemical reactions with endogenous proteins.  This mechanism 
has been applied to drugs such as sulfamethoxazole (SMX)25 and lidocaine.26   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2:  The pharmacological (p-i) concept.  This concept explains the stimulation of an immune 
response directly from a chemically inert drug.  There are no covalent bonds, but non-covalent bonds 
(dashed lines) are present between both the MHC and the TCR, resulting in a positive T-cell response. 
 
  
 TCR 
T-cell lymphocyte 
 APC 
Parent drug 
 MHC 
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1.4.3 Danger hypothesis. 
The danger hypothesis, proposed by Matzinger,27 provides an alternative approach to 
induced DHS, the basis of which is developed from the difficulty for the immune 
system to differentiate between self and non-self molecules.12 The hypothesis states 
that three signals must be present in order to induce an immune response.28 Signal 1, 
antigen recognition by T-cells, is not sufficient to stimulate T-lymphocytes and 
without signal 2 (co-stimulatory signal), tolerance will occur.  However, should 
signal 2, interaction of co-stimulatory molecules between the APC and T-cell, and 
signal 3, the presence of cytokines that act on T-cells, occur, T-lymphocytes will be 
activated.14 
 
1.5 HLA Association with DHS 
Although many factors, both genotypic and phenotypic, can affect a patient’s 
likelihood of developing DHS, there is a strong connection of HLA association due 
to the nature of its function.  The HLA, in particular types A, B and C, genes are 
some of the most variable genes within the human genome and are widely researched 
with respect to their connection with DHS.29 Examples of drugs that cause ADRs 
within an HLA-restricted manner can be seen in Table 1.3.  Of these drug examples, 
abacavir (ABC) and carbamazepine (CBZ) are both immune-mediated (associated 
with a DHS or Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) 
respectively) and these toxicities have positive HLA association.30-32 Flucloxacillin is 
responsible for a drug-induced liver injury, and this too has an HLA association.33 
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Table 1.3:  Examples of drug treatments and their HLA (MHC class I) relations with their associated 
toxicity.  HLA, human leukocyte antigen; ABC-HSR, abacavir hypersensitivity reaction; SJS/TEN, 
Stevens–Johnson syndrome/toxic epidermal necrolysis.  Adapted from Bharadwaj et al.29 
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1.6 Drug Metabolism 
Once a non-polar drug enters the body, it is metabolised to more polar metabolites to 
increase water solubility for easier excretion.  The majority of metabolism reactions 
occur in the liver, but some may occur in blood plasma or other tissues and such 
reactions are split into two categories:  Phase I and phase II metabolism. 
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1.6.1 Phase I metabolism. 
CYP P450 enzymes most commonly prefer phase I metabolism.  These enzymes are 
haemoproteins and are divided into 4 classes:  CYP1–CYP4.  Most drugs are 
metabolised by a select number of these isozymes including CYP3A4, CYP3A5, 
CYP2D6 and CYP1A2.  During this metabolism, polar groups are either added to the 
drug molecule, or are unmasked.  Two or more metabolism reactions often occur per 
molecule or in some cases, no metabolism takes place.  Oxidation is the major phase 
I metabolism pathway, but reduction and hydrolysis reactions will also take place.  
Examples of these reactions can be found in Table 1.4. 
 
Oxidation will occur on alkyl groups, alkenes and aromatic rings as well as 
dealkylation of amines and ethers and dehalogenation of alkyl halides.  Heteroatoms 
(namely nitrogen, sulfur and phosphorus) will also undergo oxidation reactions.  
During these oxidation reactions, co-factor reduced nicotinamide adenine 
dinucleotide phosphate (NADPH) and molecular oxidation is required (Figure 1.3). 
 
 
 
Figure 1.3:  Oxidation of a drug by CYP P450 enzymes using molecular oxygen and reduced 
NADPH.  CYP, cytochrome; NADPH, nicotinamide adenine dinucleotide phosphate. 
 
Further to the CYP P450 enzymes, other enzymes such as monoamine oxidases 
(metabolism of primary amines to aldehydes), alcohol and aldehyde dehydrogenases 
(oxidation of primary alcohols to aldehydes and aldehydes to carboxylic acids 
Drug H O2 NADPH H Drug OH NADP H2O
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respectively) and reductases, esterases and peptidases also metabolise drugs during 
phase I metabolism. 
 
Table 1.4:  Oxidation, reduction and hydrolysis phase I metabolism reactions.  Adapted from 
Introduction to Medicinal Chemistry.34 
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 1.6.2 Phase II metabolism. 
Most conjugation reactions occur during phase II metabolism.  During this 
metabolism, a large polar group is reacted with phase I products to increase the 
molecular weight and polarity of the metabolite.  These changes are designed not 
only to increase the water-solubility of the metabolite to aid the rate of excretion, but 
also to detoxify these phase I metabolites which are quite often reactive species.  
Examples of these metabolic pathways can be seen in Table 1.5.  The enzymes often 
implicated in these metabolic pathways include glucuronyltransferases (UGT), 
sulfotransferases (ST), glutathione-S-transferases (GST) and N-acetyltransferases 
(NAT).  These enzymes metabolise a wide range of substrates. 
 
Glucuronic acid conjugation, catalysed by UGT enzymes, is the most common 
method of phase II metabolism.  The formation of O-, N-, S- and C-glucuronides are 
possible, with phenols, alcohols and carboxylic acids common substrates for this 
metabolism. 
 
Sulfoconjugation also occurs during this metabolism, through addition of a sulfate 
group onto a nucleophilic part of a drug.  This process is mainly limited to secondary 
alcohols, phenols and aryl amines.  These reactions are catalysed by ST enzymes 
requiring 3'-phosphoadenosine-5'-phosphosulfate as the co-factor.  Primary alcohols 
are unsuitable substrates for this metabolic pathway due to the formation of reactive 
sulfate conjugates. 
 
GST enzymes will catalyse the reactions of electrophilic moieties, such as epoxides, 
alkyl halides and free radicals to form glutathione conjugates, which will undergo 
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further metabolism to mercapturic acids.  The electrophilic metabolites will react 
with the thiol of the glutathione tripeptide.  This method of metabolism is 
particularly useful in the removal of toxins or highly reactive electrophilic species.  
Carboxylic acids are often conjugated to amino acids (often glycine) during phase II 
metabolism following activation to a co-enzyme A thioester. 
 
Table 1.5:  Glucuronidation, sulfoconjugation and glutathione conjugation phase II metabolism 
pathways.  UDP, uridine diphosphate; PAPS, 3'-phosphoadenosine-5'-phosphosulfate.  Adapted from 
Introduction to Medicinal Chemistry.34 
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Other less frequently used phase II reactions include amino acid conjugation and 
methylation conjugation.  Methylation and acetylation reactions form less polar 
metabolites.  Methylation occurs on substrates such as phenols, amines and thiols, 
and such reactions are catalysed by catechol O-methyltransferase and co-factor S-
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adenosyl methionine.  Acetylation of primary amines will also occur through use of 
the acetyl-coA co-factor. 
 
The phase II metabolites are actively transported across the cellular membrane for 
excretion during phase III metabolism.  This is often achieved using the adenosine 
triphosphate (ATP)-binding cassette family of transporters (primary active 
transporters) where ATP hydrolysis is required.35 These transporters are found in the 
liver, brain, intestine and kidney and will prevent accumulation of metabolised 
xenobiotics. 
 
Together, phase I and phase II metabolism affects the overall change of a drug and 
its chemical properties through functionalisation.  Phase I metabolism, through 
addition of polar groups, prepares the drug for phase II metabolism, where often the 
pharmacological activity is terminated through addition of a larger functional group 
e.g. sulfate group, and this enhances excretion of the drug.  These processes in effect, 
prevent accumulation of a potentially toxic therapeutic agent. 
 
 1.6.3 Adverse metabolic reactions. 
There is significant variability of metabolic reactions and metabolite formation from 
patient to patient.  This is not only due to the formation of toxic or reactive 
metabolite intermediates but also to many other contributing factors.  All drugs are 
metabolised:  Pro-drugs or active drugs are/can be metabolised to their active 
metabolites and/or toxic metabolites, as well as possible metabolism to an inactive 
compound, resulting in loss of activity.  The variability of CYP P450 enzymes is a 
key factor when analysing the metabolism of a drug.  There is a 10-fold variability of 
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CYP3A434 in humans and this can have a huge impact on the metabolism of a drug.  
Additionally, some patients will lack the correct isozymes, increasing any risk 
further.  Certain chemicals can affect CYP P450 enzyme activity such as grapefruit 
juice, which inhibits CYP3A4.36 DDIs can also have a significant effect on 
metabolism.  Warfarin and cimetidine cannot be taken simultaneously as the latter 
inhibits CYP P450 enzymes, slowing the metabolism of warfarin and significantly 
impacting on drug plasma concentration levels.37 
 
 1.6.4 Drug metabolite formation inducing drug toxicity. 
Further to enzymatic variability from patient to patient and DDIs, toxic metabolite 
formation is inevitable with select drug therapies and this is often found with type B 
ADRs.  The pro-drug or active drug is metabolised to a reactive metabolite through a 
process known as bioactivation.  This toxic metabolite, often possessing electrophilic 
properties, must have a long enough lifetime to accumulate within cells and undergo 
attack with cellular components or proteins.38 An example of this is terfenadine, 
which presents serious side effects, through enzyme inhibition, if ingested with 
grapefruit juice.  This enzyme inhibition prevents metabolism of the parent drug and 
accumulation of this drug leads to toxicity. 
 
The formation of reactive metabolites can be formed from a large proportion of 
enzymes involved in drug metabolism and unsurprisingly, this form of toxicity is 
species dependent; the inter species difference in PK and PD properties is usually 
responsible for this.39,40 Further to this, toxicity can be enantiomerically dependent 
e.g. thalidomide.  Such reactive metabolites can cause toxicity through two major 
mechanisms:  i.) Covalent binding to macromolecules or ii.) Non-covalent binding 
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e.g. induction of oxidative stress or lipid peroxidation.41,42 Rather than a certain class 
of drug therapeutics contributing to drug-induced toxicity, it is the chemical 
functional groups that lead to the formation of such toxic metabolites.  A small 
number of these include acetanilides e.g. acetaminophen; hydrazines e.g. isoniazid; 
amines e.g. procainamide and heteroatoms e.g. furosemide.  A number of drugs 
known to form toxic metabolites in vivo are discussed here within. 
 
   1.6.4.1 Acetaminophen. 
Acetaminophen is an analgesic drug that although is safe in therapeutic doses, a 
larger dose can cause serious hepatotoxicity, and possible kidney and ocular 
damage.43,44 It is a widely studied drug and a key example of the toxicity associated 
with drug metabolism.  Acetaminophen undergoes dehydrogenation through 
metabolism by CYP P450 enzymes to form N-acetyl-p-benzoquinoneimine (NAPQI) 
(Figure 1.4).21,45 NAPQI, a highly electrophilic species, is the metabolite responsible 
for acetaminophen toxicity.21,46 At lower levels of NAPQI, glutathione is able to 
detoxify this metabolite through glutathione conjugation.  However, at excess levels 
of NAPQI, glutathione levels are depleted resulting in liver protein thiol covalent 
binding (Figure 1.4).  Although, through oxidative stress, non-covalent binding has 
also been shown to occur along with the covalent pathway.47 
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Figure 1.4:  Metabolism of acetaminophen through a CYP P450-mediated dehydrogenation 
mechanism to the toxic metabolite, NAPQI, followed by detoxification through phase II glutathione 
metabolism (pathway a).  Administration of a high dose of acetaminophen will result in high levels of 
NAPQI, leading to glutathione depletion.  This depletion would result in NAPQI binding with liver 
proteins leading to hepatotoxicity (pathway b).  NAPQI, N-acetyl-p-benzoquinoneimine. 
 
   1.6.4.2 Procainamide. 
Procainamide (PA) is a class IA anti-arrythmic drug and through long-term use can 
cause hypersensitivity reactions, agranulocytosis and systemic lupus erythematosus 
syndrome (SIE).  PA is metabolised to its equally active metabolite, N-
acetylprocainamide.  Alternatively, it can undergo metabolism to form a 
hydroxylamine intermediate (PAHA), which is in equilibrium with a highly reactive 
nitroso intermediate (Figure 1.5).  This intermediate is able to undergo covalent 
protein binding with hepatic proteins48-50 and histone protein.49 This has also shown 
to be the case with SMX, where SMX is also metabolised to a toxic nitroso 
metabolite, which has been shown to form protein adducts.22 Outside of the liver, 
Uetrecht et al. had shown the binding of this reactive metabolite to activated 
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monocytes,51 leading to the stimulation of T-cells and antibody synthesis,52 resulting 
in immunological toxicity. 
 
 
 
Figure 1.5:  Metabolism of procainamide (PA) to its active metabolite N-acetyl PA.  Alternatively, 
PA can be metabolised to a hydroxylamine intermediate (PAHA), which is in equilibrium with 
nitroso-PA.  Nitroso-PA has been shown to undergo covalent protein binding with hepatic and histone 
proteins leading to its associated toxicity.  PMN, polymorphonuclear leukocytes; MNL, mononuclear 
leukocytes; PMA, phorbol myristate acetate; MPO, myeloperoxidase.  Adapted from Uetrecht et 
al.49,53 
 
   1.6.4.3 Cyclophosphamide. 
An additional example of the formation of toxic metabolites can be shown with 
cyclophosphamide (Figure 1.6), which is used as an alkylating or 
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4-hydroxycyclophosphamide to 4-ketocyclophosphamide or aldophosphamide to 
carboxyphosphamide can occur enzymatically.54 This metabolic pathway is in 
competition with a non-enzymatic pathway through a β-elimination mechanism to 
form phosphoramide mustard (PM), which is the actively cytotoxic compound.  
However, this metabolic pathway also yields acrolein.54 Acrolein is highly reactive 
and has shown to cause bladder toxicity.55 This toxicity can be alleviated by 
increasing fluid intake and through administration of sulfhydroxyl donor compounds 
e.g. sodium-2-mercaptoethane sulfonate (mesna).  Additionally, PM and acrolein are 
associated with teratogenicity56 and nornitrogen mustard (NM), a metabolite of PM, 
has shown to contribute to the mutagenicity and carcinogenicity associated with this 
drug.57 
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Figure 1.6:  Metabolism of cyclophosphamide to a variety of metabolites, of which PM is the active 
metabolite.  However, PM can contribute to its toxicity (teratogenicity), along with acrolein (bladder 
toxicity) – a highly reactive by-product of this metabolic pathway.  Further to this, NM has also 
shown to contribute to mutagenic and carcinogen toxicity associated with this drug.  PM, 
phosphoramide mustard; NM, nornitrogen mustard; ALDH, aldehyde dehydrogenase.  Adapted from 
Foster et al.54 
 
The examples in Figure 1.6 demonstrate key structural toxicophores present in three 
drugs that become evident post drug metabolism.  Structure–activity relationship 
(SAR) studies are often required to abolish these drug metabolism related toxicities. 
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1.7 Structure–Activity Relationship 
With a selection of marketed therapeutic reagents responsible for ADRs, there has 
been much research into the elimination of their associated toxicities and this is often 
achieved in a SAR fashion.  SAR relates a 3D chemical structure of a drug to its 
properties or biological activity.  It has often been utilised to improve a drugs 
therapeutic activity, reduce toxicological issues and to probe mechanisms of drug 
mechanisms; either to determine a drugs pharmacophore, binding interactions, drug 
optimisation or within a toxicological sense.  In improving a drugs therapeutic value, 
it is essential that the drugs pharmacophore is not lost and its associated toxicological 
issues are ideally eliminated.  SAR is employed not only as a useful tool for 
medicinal chemists, but also in a biological and toxicological sense. 
 
Whilst improving a drugs therapeutic value from a medicinal chemistry viewpoint, 
strong consideration must be taken into the metabolism of the drug.  Drugs that must 
undergo metabolism to produce their high toxic effects can be modified to prevent 
toxic metabolite formation, through the use of SAR and isosteres.  Known functional 
groups that are avoided in drug design to avoid such metabolic liabilities include 
aromatic nitro and amine compounds and hydrazines.34 
 
During SAR studies, it is standard practice to use (bio)isosteres for analogue 
synthesis.  Isosteres are atoms or groups of molecules that have similar chemical or 
physical properties whilst maintaining the same valency.  Bioisosteres are functional 
groups that are used to replace other groups of atoms whilst maintaining the drugs 
therapeutic value.  Bioisosteres are often used when a functional group that is key to 
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the drugs activity also contributes to its toxicity.  A selection of classical bioisosteres 
can be seen in Table 1.6. 
 
Table 1.6:  Example classical bioisosteres used within drug discovery and drug optimisation as well 
as for probing mechanistic pathways.  Adapted from Meanwell.58 
 
 
Valency 
 
 
Bioisosteres 
D or F and H 
NH and OH 
 
Monovalent 
F, OH, NH2 and CH3 
C=C, C=N, C=O 
–CH2–, –NH–, –O– 
 
Bivalent 
 RCOR1, RCONHR1, 
RCOOR1 
R3CH, R3N 
Alkene, Imine 
 
Trivalent 
 –CH=CH– and –S– 
 
 1.7.1 Case study:  Nimesulide. 
There are many examples where an SAR approach has been used to improve a drug, 
such as modifications to achieve increased potency, improve PK parameters, or to 
reduce toxicity.  An example of where an SAR approach has been key to identifying 
and eliminating reactive metabolites whilst improving potency is seen with 
nimesulide 1 (Figure 1.7).  Nimesulide is within the non-steroidal anti-inflammatory 
drug (NSAID) class of drug compounds and more specifically, it is a COX-2 
inhibitor.  This drug has a poor safety profile and as a consequence, it has either 
failed to reach the drug market in many countries, or where it has been marketed, it 
has subsequently been withdrawn.59 Compound 1 is responsible for an idiosyncratic 
but rare hepatotoxicity.59 Once the drug is metabolised by CYP P450 enzymes, an 
amino des-nitro compound 2 is formed and upon further oxidation by CYP2C19 and 
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CYP1A2, a diiminoquinone intermediate 3 is formed (Figure 1.7).  This is a highly 
reactive electrophilic species, which has shown to irreversibly alkylate human serum 
albumin (HSA) in vitro to form adducts 4.59 Such adducts can exhibit antigenic 
properties.4,60 Further to this, it was found that this reactive metabolite also 
irreversibly inhibited CYP2C19, postulated to result from covalent bonding of the 
drug to amino acids in the enzymes active site. 
 
 
 
Figure 1.7:  Reductive metabolism of nimesulide 1 to form an amino des-nitro intermediate 2.  Upon 
oxidation by CYP2C19 and CYP1A2, a diiminoquinone species 3 is formed.  This species can 
undergo electrophilic reactions with thiol proteins forming potential antigenic adducts 4. 
 
To improve, not only the safety profiles of this drug, but also the potency, several 
SAR studies were conducted.61,62 To overcome the formation of the diiminoquinone 
intermediate, the benzene ring was replaced with pyridine.61 Further to this, the alkyl 
sulfonamide was replaced with a trifluoromethane sulfonamide and the bridge 
between the two aromatic moieties was also probed; with a secondary amine linkage 
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showing the most promising results (Figure 1.8).62 Compound 5 was shown to have 
increased potency and reduced toxicity than the parent drug but was less selective for 
COX-2.62 
 
 
 
 
Figure 1.8:  To reduce toxic metabolite formation and improve potency, SAR studies for nimesulide 
1 were completed.  The most promising compounds 5 and 6 from the first and second studies 
respectively are shown.  Compound 5 shows replacement of the benzene ring with pyridine and the 
alkyl sulfonamide moiety was replaced with a trifluoromethane sulfonamide.  Compound 6 was 
developed from compound 5 through replacement of the oxygen linker with an amine linker and 
benzene substitution with bromine.  SAR, structure–activity relationship. 
 
To improve 5 further, the benzene ring was probed with a halogen, alkyl or alkoxy 
chain substitution and replacement with cycloalkyl rings (Figure 1.8).62 Thirty-six 
analogues were synthesised in this SAR study and 6 showed the most promising 
results, with the highest COX-1/COX-2 inhibitory properties and improved anti-
inflammatory activity and safety profile compared to 1. 
 
This example has shown that (bio)isosteric substitution of functional groups can not 
only reduce the formation of toxic reactive metabolites, but also improve the potency 
of a drug. 
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 1.7.2 2',3'-dideoxynucleoside compounds:  Use of isosteres to reduce 
compound toxicity. 
Deoxynucleosides have been shown to be extremely effective against viruses, in 
particular, human immunodeficiency virus (HIV) treatment.  However, this class of 
compounds can cause a delayed clinical toxicity through inhibition of mitochondrial 
DNA (mtDNA) synthesis.63 A range of 2'- and 5-fluorinated deoxynucleosides were 
synthesised (isosteric substitution of H with F) by Tsai and co-workers (Figure 
1.9),63 and the 2'-β-fluorinated analogues were much less potent for inhibiting 
mtDNA with only slightly decreased activity against the HIV virus, compared to 
their non-fluorinated compounds.  It was discovered that β-F-ddC was 5000 times 
less potent than its non-fluorinated equivalent, ddC (Figure 1.9).  The effect of 2'-β-
hydrogen substitution for fluorine decreases the likelihood of reducing mtDNA 
synthesis. 
 
 
 
 
 
 
 
 
Figure 1.9:  A selection of non-fluorinated and 2'- and 5-fluorinated deoxynucleosides synthesised by 
Tsai et al.63 to reduce deoxynucleoside toxicity:  Demonstrated through inhibition of mtDNA.  It was 
shown that the 2'-β-fluorinated analogues were much less potent for inhibiting mtDNA compared with 
their deoxynucleoside equivalents. 
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1.8 Abacavir 
A model compound that probes the HLA association with DTH is ABC.  ABC 7, 
Figure 1.10, is a drug used within highly active antiretroviral therapy (HAART) in 
the treatment of the HIV-1 virus.  It is less commonly used alone as Ziagen and 
more commonly in combination therapy with lamivudine (Kivexa) or lamivudine 
and zidovudine (Trizivir).  Patented in 1998 by GlaxoSmithKline (GSK), it has 
been a well-utilised drug in antiviral therapy.   
 
The structural foundations of ABC were developed from carbovir (CBV) 8 (Figure 
1.10), an anti-HIV drug that was designed in the late 1980s.  CBV showed high 
potency against the HIV-1 virus in vitro, however, it was also associated with 
toxicity resulting from its low aqueous solubility and this impacted on its oral 
absorption.64,65 Further to this, CBV was shown to have difficulties in crossing the 
central nervous system (CNS)64,66 and these problems led to CBV being ineffective 
as a marketable HIV drug.  In order to resolve these problems, a library of novel 
carbocyclic analogues, based upon the CBV structure, were designed and ABC 
showed the most promising results. 
 
ABC falls within the nucleoside reverse transcriptase inhibitor (NRTI) class of HIV 
therapy as it acts as a DNA chain terminator, due to the lack of a 3'-OH group 
(replaced with a 2',3'-unsaturated bond).  ABC is an analogue of guanosine 9 (Figure 
1.10) and aside from the removal of the 3'-hydroxyl group, a carbocyclic ring 
replaces the sugar moiety, and a cyclopropylamino group is present at the 6-position. 
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Figure 1.10:  Abacavir, 7 (ABC), carbovir (CBV) 8 and guanosine 9. 
 
ABC is responsible for a potentially life-threatening type IV hypersensitivity reaction 
(ABC-HSR) in patients whom possess the HLA-B*57:01 allele.30,67 Symptoms of 
ABC-HSR reaction include fever, nausea, headache, skin rash and respiratory and 
gastrointestinal problems.68 These symptoms usually appear within 6 weeks of 
commencing treatment and stops within 72 hours of discontinuing the drug.24 Any 
re-challenge with the drug can cause more serious and life-threatening conditions 
with quicker on-set of symptoms. 
 
 1.8.1 ABC-HSR and HLA association. 
There is a strong association of ABC-HSR with the HLA-B*57:01 allele.  Two 
independent studies conducted in 2001 connected the presence of the allele HLA-
B*57:01 in those patients who displayed symptoms of ABC-HSR.30,67 Both studies 
were performed on a cohort of 200 patients.  Hetherington et al. found the 
association of this allele to patients with suspected ABC-HSR to be 55%, compared 
to 1% control population.67 Mallal et al. reported this association in 78% of patients, 
compared to 2% in the control population, although this study was almost 
exclusively Caucasian origin.30 In a further study, toxicity was found to be race 
dependent, reflecting occurrence of the HLA-B*57:01 allele, with a higher incidence 
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rate seen in Caucasians and Hispanics in comparison with other ethnic groups.69,70 
As a result of these findings, patients who wish to commence ABC treatment must 
undertake a patch test to determine the presence of the HLA-B*57:01 allele.  This 
non-invasive procedure has a 99% success rate71,72 and any patients who present a 
positive result are denied ABC therapy.  This efficient test effectively eliminates 
toxicity from ABC in susceptible patients. 
 
1.8.2 Metabolism and pharmacology of ABC. 
The pharmacology of ABC has been extensively studied.73-75 ABC itself is a prodrug.  
Following the major anabolic pathway (Figure 1.11):  It initially undergoes 
phosphorylation to form abacavir monophosphate (ABC-MP) 12, and then undergoes 
a deamination reaction by a cytosolic deaminase76 to form carbovir monophosphate 
(CBV-MP) 13.  Finally, following further phosphorylation via carbovir diphosphate 
(CBV-DP) 14 to its triphosphate form (CBV-TP) 15, the active drug is produced.  
This pathway bypasses the direct formation of CBV and so the problems associated 
with CBV are eliminated. 
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Figure 1.11:  In vivo metabolism of ABC 7 to the active compound CBV-TP 15.  Following the major 
anabolic pathway:  ABC undergoes phosphorylation to form ABC-MP 12 and this metabolite is 
oxidised by a cytosolic deaminase to form CBV-MP 13.  Further phosphorylation yields CBV-TP 15 
as the active compound.  Alternatively, less than 2% of ABC undertakes the minor pathway to form 6-
amino CBV 10, which is phosphorylated to form 6-amino CBV-MP 11.  Alternatively, 10 is oxidised 
to CBV 8.  The major pathway from 13–15 is then followed.  ABC, abacavir; CBV, carbovir; CBV-
MP, carbovir monophosphate; DP, diphosphate; TP, triphosphate.  Adapted from Piliero et al.75 
 
Two alternative metabolic pathways are shown in Figure 1.11, but both ultimately 
form the active compound 15.  
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1.8.3 Oxidative metabolism of ABC. 
The final phase I and phase II metabolites of ABC, determined by MacDowell et 
al.77 are a carboxylic acid 17a and a glucuronide metabolite 18 (Figure 1.12).  Using 
14C-ABC to determine the presence of metabolites, in urine; 30% of the dose was 
17a; 36% as 18; 1% as ABC itself and the final 16% as other metabolites, which 
have not all been characterised.  For those that were determined, they were found to 
be isomers of the carboxylic acid metabolite.  In faecal matter, the metabolites were 
mainly unmetabolised ABC and 17a. 
 
  
 
Figure 1.12:  Basic phase I and phase II metabolic pathways of ABC 7.  ABC is metabolised during 
phase I metabolism to the carboxylic acid metabolite 17a via an aldehyde intermediate 16a or 
alternatively, it is metabolised during phase II metabolism to the glucuronide metabolite 18.  Adapted 
from Walsh et al.78 
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To probe this oxidation mechanism, it is important to understand the mechanisms of 
the enzymes involved in ABC metabolism:  Liver alcohol dehydrogenase (ADH) and 
liver aldehyde dehydrogenase (ALDH). 
 
1.8.3.1 Liver alcohol dehydrogenase. 
ADH belongs to a class of oxidoreductase enzymes.  There are 5 (I–V) classes of 
ADH and the genes that code for this class of enzymes are ADH1, ADH2 and 
ADH3.  ADH class I is of the most abundance in the liver (85–90%)79 and is most 
commonly associated with the oxidation of ethanol to acetaldehyde, although, the 
ADH enzymes are capable of oxidising a wide range of primary and secondary 
alcohols to their aldehydes and ketones80 respectively.  Three isoforms of ADH class 
I exist:  ADH1A (α), ADH1B (β) and ADH1C (γ).  In mammals, a molecule of 
nicotinamide adenine dinucleotide (NAD+) is required for the reversible oxidation 
process81-83 (Figure 1.13) and an overall redox reaction occurs. 
 
 
 
Figure 1.13:  Oxidation of a primary alcohol to its aldehyde by ADH, using one molecule of NAD+ as 
the co-factor.  ADH, alcohol dehydrogenase; NAD+, nicotinamide adenine dinucleotide. 
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 1.8.3.1.1 Mechanism of ADH. 
The mechanism of ADH is shown in Figure 1.14.  It is crucial for the oxidation that a 
zinc ion and an NAD+ molecule are present.84 Initially, Zn2+ co-ordinates with the 
primary alcohol and then hydride transfer occurs from His 51 through Ser 48, from 
the substrate alcohol onto the molecule of NAD+.85 
 
 
 
Figure 1.14:  Mechanism of ADH, where a primary alcohol to oxidised to its aldehyde using a Zn2+ to 
co-ordinate and an NAD+ molecule for hydride transfer.  This occurs as a one-step process in which H 
is transferred through His 51 and Ser 48 from the alcohol substrate into a molecule of NAD+.  
Adapted from Introduction to Enzyme and Co-Enzyme Chemistry.85 
 
1.8.3.1.2 ADH and ABC oxidation. 
As discussed in Section 1.8.3 and established by Walsh et al.,78 ABC is oxidised to 
17a via an aldehyde intermediate 16a.  ADH completes the initial oxidation step with 
the second oxidation step potentially completed by ALDH (Figure 1.15).  ADH has 
been shown to also participate in this final oxidation step.78 Two isoforms of ADH 
class I (ADH1A (αα) and ADH1C (γ2γ2)) have been found to oxidise ABC, as can 
be seen in Figure 1.15.78 Only the ADH1A isoform is involved in the oxidation to 
16a and formation of the different carboxylic acid isomers 17a, 17b and 17c.  
ADH1C is also involved in the formation of 16a but its products are isomers of ABC 
(7b, 7c). 
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Figure 1.15:  Oxidation of ABC 7 to the major carboxylic acid 17a via an aldehyde intermediate 16a 
through metabolism of ADH isozymes αα and γ2γ2.  These ADH isoforms are also responsible for the 
formation of two alternative carboxylic acid metabolites (17b and 17c) via their respective aldehyde 
intermediates 16b and 16c.  Adapted from Walsh et al.78 
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classes I and II being most abundant in the liver.86 ALDH enzymes are involved in 
the oxidation of aldehydes to their respective carboxylic acids.  Aldehydes are highly 
reactive species that are formed in many endogenous metabolic pathways.87 They 
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metabolism to their carboxylic acids is vital.87 The oxidation process is NAD(P)+ 
dependent and the enzymes act in an irreversible manner.88 As determined through 
kinetic experiments with ADH, there is also ordered binding of co-factor and 
substrate with ALDH.89,90 ALDH2 is the main contributing isozyme involved in 
acetaldehyde oxidation to ethanolic acid88 and other substrates of ALDH include 
retinal, to form retinoic acid91 and γ-aminobutyraldehyde, forming γ-aminobutyric 
acid (GABA).87 Unlike the ADH enzymes, which have been extensively studied, 
significantly less literature can be found for the ALDH isozymes, with a proposed 
mechanism only suggested in 1999.92 
 
1.8.3.2.1 Mechanism of ALDH. 
Hempel et al.92 determined the precise mechanism of ALDH (Figure 1.16).  The 
amino acids involved in hydride transfer are Cys 302, Glu 268 and Asn 169 with 
amino acids Glu 399 and Lys 192 used for NAD(P)+ stability, via hydrogen bonding.  
Initially, Glu 268 extracts a proton from a molecule of water, which in turn extracts a 
proton from Cys 302.  This activates the thiol group, which undergoes nucleophilic 
addition into the carbonyl group of the aldehyde.  Through electronic arrangement, a 
hydride is transferred onto a molecule of NAD(P)+, which is stabilised by Glu 300 
and Lys 192.  Another molecule of water undergoes nucleophilic addition into the 
thioester and the carboxylic acid product is released along with a molecule of 
NAD(P)H. 
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Figure 1.16:  Mechanism of human liver ALDH.  Amino acid residues Glu 399 and Lys 192 undergo 
hydrogen bonding with co-factor, NAD(P)+.  The thiol group of Cys 302 is activated and undergoes 
nucleophilic addition into the carbonyl group of the aldehyde substrate with hydride transfer onto 
NAD(P)+.  The thioester undergoes nucleophilic substitution with a molecule of water, through 
assistance with Glu 268, forming the carboxylic acid product.  NAD(P)+, nicotinamide adenine 
dinucleotide (phosphate). 
  
1.8.3.2.2 ALDH and ABC oxidation. 
To date, no research has been published which confirms that aldehyde 16a is 
oxidised to carboxylic acid 17a by ALDH, but as stated earlier, it is possible that this 
can occur by ADH1A.78 However, it cannot be ruled out that ALDH may contribute 
to the ABC oxidation process. 
 
1.8.4 ABC metabolism applied to ABC-HSR:  Hapten hypothesis. 
With the developing knowledge of drug metabolites associated with ADRs and in 
particular hypersensitivity reactions, it is formally recognised that aldehyde 
metabolites could act as haptens and have been connected with (idiosyncratic) 
adverse reactions.93,94 With this knowledge, it was suggested that ABC toxicity arose 
from the formation of a reactive aldehyde metabolite.78 
 
Within this research, Walsh et al. showed with pure isoforms of ADH (αα and γ2γ2), 
that ABC was metabolised to 17a via 16a.  This aldehyde was trapped with 
methoxylamine forming compound 19 (Figure 1.17), and this was the only method of 
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detection due to the short half-life of this intermediate.  Metabolism was blocked 
using 4-methylpyrazole (4-MP), a known inhibitor of ADH, and furthermore, ABC-
protein adducts were detected:  The structures of these were unknown.  Incubations 
with dihydro-abacavir (DH-ABC) 20 (Figure 1.17) showed less ABC-protein adduct 
formation, suggesting involvement of the 2',3'-unsaturated bond in adduct formation. 
 
 
 
Figure 1.17:  Compounds:  Aldehyde 16a; ‘trapping’ product of 16a with methoxylamine to form 
compound 19 and DH-ABC 20.  DH-ABC, dihydro-ABC. 
 
α,β-Unsaturated aldehydes can react via two mechanisms with proteins:  Schiff base 
or 1,4-Michael addition.  Both mechanisms would form a protein–drug metabolite 
conjugate leading to a possible T-cell mediated immune response.4 The work 
presented by Walsh and co-workers supported a hapten hypothesis.  
 
1.8.5 The hapten hypothesis vs. p-i mechanism for ABC toxicity. 
Chessman et al. conducted a thorough immunological investigation into ABC-HSR.  
Chessman and co-workers found that CD8+ T-cells were activated by ABC, 
measured by an increase in cytokine release, interferon-γ (IFN-γ) and tumour 
necrosis factor-α (TNF-α).  This study was conducted using CD8+ T-cells from both 
HLA-B*57:01 ABC naïve patients and those patients who had previously 
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experienced ABC-HSR.95 Further to this, Chessman et al. were able to eliminate any 
involvement from the HIV-1 virus from use of T-cells obtained from healthy, normal 
individuals.  It has been proposed that for an immune response, the MHC-I antigen 
presentation pathway is required95 suggesting relation to the hapten hypothesis and 
as shown by Chessman et al., unmodified ABC was insufficient to stimulate the T-
cells. 
 
Chessman et al. found slight amino acid variations, namely 114 Asp-Asn and 116 
Ser-Tyr (HLA-B*57:03) within the HLA-B*57:01 allele altered MHC presentation 
and affected the T-cell response.  A >50% reduction in IFN-γ release was observed 
with 114 Asp-Asn, and a T-cell response from 116 Ser-Tyr was completely 
eliminated.  Amino acid 116 was of particular interest as it has key involvement in 
the structure of the F-pocket and influences the peptides that bind within the HLA-
B*57:01 protein.  This residue will only accommodate peptides with a particular C-
terminal amino acid, namely Trp or Phe.  Further to this, HLA-B*57:01 has 
previously shown to allow the binding of peptides with Tyr at the C-terminus 
showing that polymorphism within the F-pocket can alter the peptide repertoire.96 
These amino acid alterations (residues 114 and 116) could affect both covalent and 
non-covalent binding leading to postulate that both the hapten and p-i hypotheses are 
applicable.  At the onset of this work, no in vivo haptenated-ABC product had been 
isolated. 
 
The p-i mechanism for ABC-HSR is also yet to be proven:  The residues that differ 
HLA-B*57:01 from HLA-B*57:03 (an allele that does not induce ABC-HSR) do not 
interact with the TCR directly so the p-i mechanism may not be appropriate.  Further 
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to this, McCluskey et al. have shown that ABC undergoes the antigen-processing 
pathway:  It is TAP and tapasin protein dependent demonstrating that the p-i 
mechanism is not applicable.97 
 
The work undertaken by Chessman and co-workers led them to postulate that 6-
cyclopropylamine had involvement in ABC-HSR due to the lack of T-cell response 
against CBV, didanosine and guanosine.  They concluded that ABC, or a derivative 
of ABC, conjugates with a self-peptide to form a haptenated immunogenic 
compound and either this immunogen, ABC itself or a metabolite of ABC is 
accommodated within the F-pocket of HLA-B*57:01. 
 
1.8.6 Altered repertoire mechanism. 
A mechanism, newly proposed while this study was in progress, has been applied to 
both ABC, and less so to CBZ, toxicity.29 The proposal suggests that ABC binds 
directly within the HLA-B*57:01 allele and exhibits several stabilising interactions 
within a number of pockets of the protein.98,99 These hydrogen bonding and van der 
Waals interactions allow ABC to bind well within the HLA protein and in doing so, 
the normal selection of peptides presented to the TCR cannot bind and an altered set 
of peptides are displayed, initiating an immune response.100 This mechanism is 
discussed further in Chapter 5. 
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1.8.7 Synthesis of ABC analogues.  
To probe the suggested mechanisms of ABC-HSR, it would be essential to 
synthesise a range of ABC analogues using a SAR approach.  Research and reviews 
of all possible total synthetic routes used to synthesise carbocyclic nucleosides is 
therefore key for this approach. 
 
1.9 Carbocyclic Nucleoside Analogues 
There is much interest for the use of nucleoside analogues as drug therapy, especially 
as antiviral and anticancer drugs.101 However, several issues can develop with the use 
of this class of drugs:  Problems with triphosphorylation to the active drug 
(nucleoside analogues are invariably administered as pro-drugs) and instability of the 
N-glycosidic bond in the presence of phosphorylases.101,102 The latter problem has 
been overcome with the design and synthesis of carbocyclic nucleosides; where the 
furanose oxygen is replaced with a methylene group.  This replacement much 
improves the metabolic stability of carbocyclic nucleosides in comparison to their 
glycosidic equivalents.102-105 However, carbocyclic nucleosides are less active than 
their furanose equivalents.106,107 
 
1.9.1 Synthesis of cyclopentyl carbocyclic nucleosides. 
There has been vast research into the synthetic production of carbocyclic 
nucleosides.  The formation of these compounds is achieved using three main 
methods108,109 (Figure 1.18):  Nucleophilic substitution of hydroxycyclopentane with 
a nucleoside base;110-112 palladium-catalysed allylic reactions between a cyclopentene 
pseudosugar and nucleoside base113-115 and addition of a heterocycle to an 
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aminocyclopentane followed by further construction of the heterocycle moiety, 
forming a nucleoside base.116-118 
 
 
 
 
 
Figure 1.18:  Three major methods used to synthesise nucleosides:  Substitution of 
hydroxycyclopentane with a nucleoside base (A); palladium-catalysed allylic reactions between a 
pseudosugar and nucleobase (B) and addition of a heterocycle to an aminocyclopentane (C). 
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The synthesis of carbocyclic derivatives and analogues can be achieved using any of 
the aforementioned methods.  The following discussion of these methods involves 
the synthesis of guanosine carbocyclic analogues only.  The literature precedent for 
the synthesis of carbocyclic nucleoside analogues, in particular cyclopentyl 
analogues are vast and only a select number of examples are discussed here within.  
The synthesis of these compounds can be divided into two parts:  Synthesis of 
carbocyclic pseudosugar and coupling/construction of the nucleoside base. 
 
  1.9.1.1 Construction of cyclopentene carbocycle. 
The formation of the cyclopentene structure can be achieved via two methods:  Ring 
closing of a linear structure using either the Wittig reaction or ring-closing 
metathesis (RCM) or alternatively using cyclopentadiene as the starting material. 
 
Both Wittig and RCM conditions can be utilised to form the basic pseudosugar 
structure.  The chiral starting materials are often carbohydrates119-122 e.g. D-ribose, L-
tartrate123 or chiral auxiliaries.124,125 RCM has become the most popular method for 
synthesising the pseudosugar compounds over using the Wittig reaction (Figure 
1.19).102 This has been demonstrated by Choi et al.,121 where D-isoascorbic acid was 
converted to lactol 21 over 4 steps.  This compound was subjected to Wittig reaction 
conditions, using methyltriphenylphosphonium bromide and dimethylsulfoxide 
(DMSO) anion, to give exclusively stereoisomer 22.  Compound 22 underwent 
RCM, using Grubbs catalyst, to yield 23, which was further oxidised using 
manganese oxide (MnO2) forming cyclopentenone 24.  This target compound, 
compound 24, can be used in carbocyclic nucleoside synthesis.  In these RCM 
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reactions, it is often Grubbs catalyst (ruthenium-based) that is of choice, rather than 
Schrok catalyst (molybdenum) or Nugent & Jacobsen catalyst (tungsten). 
 
 
 
Figure 1.19:  The synthesis of a pseudosugar intermediate can be achieved using a RCM approach 
from carbohydrate starting materials e.g. D-isoascorbic acid.121 RCM is usually achieved using a 
ruthenium-based Grubbs catalyst. RCM, ring-closing metathesis. 
 
Although scarcely used, other ring closing methods have been used to synthesise 
cyclopentene carbocycles.  Such methods include aldol reactions,126 radical 
cyclisation reactions127 and transition metal-catalysed reactions using rhodium128 or 
cobalt.129 
 
Other than ring closing methods, cyclopentene carbocycles can be synthesised from 
cyclopentadiene.  The most widely used methods are [4+2] Diels–Alder 
cycloaddition reactions, through use of molecular oxygen as the dienophile, to form 
cyclopent-4-ene-1,3-diol or formation of bicyclic lactams from addition of sulfonyl 
cyanides and isocyanate or nitrosocarbonyls.102 The formation of cyclopent-4-ene-
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1,3-diol from cycloaddition of O2 is followed by reduction with thiourea and 
protection of the diol (acetate, benzoate or carbonate) to yield an intermediate 25 
which is ideal for enzymatic catalysis.130 This is followed by a Mitsunobu reaction 
with a nucleobase to yield compound 26.  Alternatively, the required product can be 
achieved using a palladium(0)- (Pd0)-catalysed allylic substitution method utilising 
chiral ligands (Figure 1.20).  This has been shown to occur with retention of 
configuration 131,132 and has been applied in the synthesis of CBV 8.131 
 
 
 
Figure 1.20:  Cyclopentadiene will react with molecular oxygen to form cyclopent-4-ene-1,3-diol 
which can be di-protected, and this pseudosugar 25 can in turn undergo Pd0-catalysed allylic 
substitution with a nucleobase to yield compound 26.  Relative stereochemistry is achieved with the 
use of chiral ligands.  Application of this pathway has been shown by Trost et al. in the formation of 
CBV 8.132 
 
Although commercially available, Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-
one) 28 (Figure 1.21) can be synthesised from cyclopentadiene using toluene 
sulfonyl cyanide (TsCN) and chlorosulfonyl isocyanate via a thermodynamically 
controlled aza Diels–Alder cycloaddition to yield racemic compound 27.102 This is 
followed by enzymatic resolution using a γ-lactamase enzyme to yield Vince lactam 
28.  Compound 28 has extended use in the synthesis of carbocyclic nucleosides.  It is 
a particularly good intermediate for carbocyclic nucleosides where functionalisation 
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at the 2'- and 3'-positions of the pseudosugar is necessary.  Hydrolysis of 28 would 
yield amino-alcohol cyclopentene compound 29 (Figure 1.21), which can undergo 
further coupling with 2,5-diamino-4,6-dichloropyrimidine (DADCP) 30 to yield 
compound 31.  A ring-closing reaction of 31 with triethylorthoformate (TEOF) 
yields chloro-ABC (Cl-ABC) 32.133 This method is particularly useful for the 
synthesis of purine carbocyclic nucleosides,134 although through Pd0-catalysed allylic 
substitution, pyrimidine carbocyclic nucleosides synthesis is also possible.135 The use 
of nitrosocarbonyl compounds in the hetero Diels–Alder cycloaddition reactions with 
cyclopentadiene can also yield a bi-lactam intermediate that has valuable use, 
especially in the synthesis of 5'-nor carbocyclic nucleosides.  
 
 
 
Figure 1.21:  Synthesis of Vince lactam 28 can be achieved from cyclopentadiene via racemic 27.102 
Hydrolysis of lactam 28 would yield amino-alcohol cyclopentene 29.  Following this, a heterocycle 
coupling of 29 with 30 to yield intermediate 31 and ring-closing of 31 with TEOF can be utilised to 
yield carbocyclic nucleoside 32.133 TEOF, triethylorthoformate. 
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Although less well utilised, [2+2] cycloaddition reactions also yield bi-lactam 
intermediates obtained through kinetic control of reactions of cyclopentadiene with 
chlorosulfonyl isocyanate.136 The pseudosugar moieties can also be obtained from 
cyclopentadiene from an asymmetric hydroboration reaction137 or through resolution 
of cyclopentene epoxides.138 
 
  1.9.1.2 Methods to couple cyclopentyl carbocycle and nucleobase 
moieties. 
The addition of a nucleoside base to a carbocycle essentially occurs via an SN2 
mechanism.  This process can be achieved via two major routes:  A direct 
nucleophilic route, or construction of the nucleobase from a heterocycle base 
following addition into an aminocyclopentene intermediate. 
 
Nucleophilic substitution of a hydroxy carbocycle with a nucleobase can be achieved 
using Mitsunobu reaction conditions or alternatively an alcohol-protected allylic 
carbocycle can be coupled with a nucleobase using a Pd0 allylic substitution reaction 
(Figure 1.22).  Both methods are prevalent in nucleoside synthesis.  The Mitsunobu 
method requires the presence of diethyl azodicarboxylate (DEAD) and 
triphenylphosphine (PPh3) and substitution of a carbocyclic alcohol with either a 
pyrimidinic or purinic base occurs with inversion of configuration.  Conversely, 
palladium-mediated coupling occurs with retention of configuration. 
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Figure 1.22:  Example construction of carbocyclic nucleoside 34 from carbocycle 33 using the 
Mitsunobu reaction with inversion of configuration (A).  Alternatively, this can be achieved using 
palladium(0)- (Pd0)-allylic substitution with retention of configuration, where di-protected alcohol 35 
can be coupled with 6-Cl purine to form compound 36 (B).102 
 
Construction of pyrimidinic and purinic bases can be achieved from addition of a 
heterocycle to an amino carbocycle (Figure 1.23).  The assembly of the nucleobase is 
dependent upon the carbocycle starting material.  Using a carbocyclic amine, 
guanine bases can be constructed from coupling amine 37 to 5-amino-4,6-
dichloropyrimidine to yield intermediate 38.  Following this, the addition of an 
amine group at the 2-position is achieved using benzene diazonium chloride (4-
ClC6H4N2+Cl–) and this is followed by reduction with Zn and acetic acid (AcOH) 
yielding compound 39.  The 6-Cl position can be modified as required to synthesise 
the required analogue.  Alternatively, a ring-closing reaction of 39 creating the 
imidazole ring using TEOF in the presence of catalytic H+, can yield product 40.   
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Figure 1.23:  Linear construction of a purine carbocyclic nucleoside from an amino-alcohol 
pseudosugar 37 and a heterocycle, 5-amino-4,6-dichloropyrimidine.  Following addition of the 
heterocycle to the carbocycle yielding 38, NH2 is placed at the 2-position using 4-ClC6H4N2+Cl– and 
Zn/AcOH to yield intermediate 39.  Ring-closing of compound 39 with TEOF followed by hydrolysis 
yields the guanine nucleobase 40.139 
 
Alternatively, the guanine-based moiety can be synthesised from coupling of 
DADCP 30 (Figure 1.21) with a 1,4-disubstituted amino-alcohol carbocycle obtained 
from hydrolysis of Vince lactam.  Formation of the imidazole ring is again achieved 
using TEOF and catalytic H+.  The applications of a variety of these synthetic routes 
to ABC are discussed in Chapter 4. 
 
1.10 In Vitro Immunological Assays 
Drugs or compounds that illicit, or are thought to induce, a CD8+ mediated T-cell 
response can undergo a series of in vitro immunological assays to confirm or check 
induction of an immune response, as depicted and applied to ABC, in Figure 1.24. 
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 1.10.1 Lymphocyte transformation test. 
One such assay that can utilised is the lymphocyte transformation test (LTT) which 
is used to check for DTH.140 Cells, from a patient who has experienced a drug-
induced idiosyncratic reaction, are incubated with this drug along with APCs and 
radiolabelled thymidine ([3H]-thymidine).  Should these T-cells be specific for this 
drug, proliferation will occur which can be monitored by uptake of [3H]-thymidine 
into replicating lymphocyte DNA.  These results can then be quantified, using a 
scintillation counter, to monitor the extent of proliferation, which is usually 
expressed as stimulation index (ratio of the proliferative response ± drug). 
 
  
 
Chapter 1 – General Introduction 
54 
 
 
 
 
Figure 1.24:  An APC displays an immunogenic molecule via the MHC to a T helper cell.  The 
formation of such a complex causes the T-cell to become stimulated and such activation will result in 
cytokine release from Th1 cells.  One such cytokine, IFN-γ, can be detected using the ELISpot assay.  
The T helper cells will also proliferate once stimulated.  The addition of radiolabelled thymidine to 
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   Figure 1.24 continued: 
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proliferating T-cells will cause the uptake of  [3H]-thymidine into replicating DNA.  The extent of 
proliferation can be quantified using a scintillation counter. 
 
1.10.2 Enzyme-linked immunosorbent spot. 
Alongside the LTT assay, a cytokine release assay (enzyme-linked immunosorbent 
spot (ELISpot)) can be used.141 This assay allows the visualisation of cytokine 
release, where CD8+ cytotoxic T-cells that have been stimulated will be shown as 
blue-black spots.  The cells are incubated with the antigenic compound and should 
the Th1 cells be stimulated, released cytokine (IFN-γ, TNF-α or IL-2) will be 
captured using a specific antibody.142 Following this, a biotinylated monoclonal 
antibody and a chromogenic substrate are added.142 The visualised spots can be 
counted, using an ELISpot reader, allowing the data to become quantitative with 
higher numbers of spot forming cells per well representing a larger cytokine release. 
 
Both immunological assays will be used throughout this research to help probe the 
mechanism of ABC toxicity. 
 
1.11 In Vitro Cytotoxicological and Pharmacological Assays 
In addition to immunological assays pharmacological assays, in which the 
cytotoxicity and antiviral efficacy of the compounds will be measured.  The 
assessment will involve the use of the spectrophotometric thiazolyl blue tetrazolium 
bromide (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT) assay 
in MT4 cells.  MT4 cells are a T-cell leukaemia cell line transformed by human T-
cell lymphotropic virus-I (HTLV-I), is highly sensitive to infection by HIV-1 
infection and routinely used to test efficacy of antiretroviral drugs.143 MTT, a yellow 
colour, can be reduced to MTT formazan, a purple colour, in isolated cells and 
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tissues by mitochondrial enzymes and electron carriers144,145 and this indicator of 
‘cell redox activity’ can be used to determine cell viability (Figure 1.25).146  
 
 
Figure 1.25:  Diagram depicting the HIV life cycle in a monocyte (e.g. MT4 cell), through 7 main 
stages:  Binding (1); fusion (2); reverse transcription (3); integration (4); transcription and translation 
(5); assembly (6) and budding (7).  The 6 classes of anti-HIV drugs are also depicted, in particular, it 
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is at stage 3 (reverse transcription) that ABC 7 acts (as an NRTI), once it has been metabolised to the 
active compound, CBV-TP 15.  In the MTT assay, the compounds to be tested will act at this stage (3) 
and inhibit the replication of the virus.  NRTI, nucleoside reverse transcriptase inhibitor.  Adapted 
from National Institute of Allergy and Infectious Disease.147 
 
Once MTT is metabolised to MTT formazan the colour change can be measured 
spectrophotometrically, as absorbance values or optical density detection, at a 
wavelength of 570 nm (Figure 1.26 A).  This is a direct measure of cell viability:  A 
reduced number of MT4 cells results in less conversion of MTT to MTT formazan.  
This basic concept and methodology can be applied to assessing cell cytotoxicity and 
antiviral efficacy assays.  For the latter, the MT4 cells are infected with the HIVIIIB 
strain and incubated with the respective test compounds.  Should the compounds 
possess efficacy against the virus, the MT4 cells will remain viable and turnover of 
MTT to MTT formazan should be higher than those compounds with poor potency 
(Figure 1.26 B) where the virus replicates resulting in increased MT4 cell death. 
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Figure 1.26:  MTT (yellow) is metabolised to MTT formazan (purple) by mitochondrial reductases, 
and such metabolism can be used as a direct indicator of cell (MT4) viability.  MT4 cells are a virally 
transformed human T-cell leukaemia line.  The spectrophotometric MTT assay can be used to 
determine a compounds cytotoxicity and antiviral efficacy with a colour change of yellow to purple 
(A).  Should the cell viability decrease, through presence of cytotoxic compounds or a virus, this 
N
NN
S
N
Me
Me
Br
H
N
N N
N
N
S
Me
Me
MTT
(Yellow)
MTT formezan
(Purple)
Mitochondrial
reductase
MTT MTT formazan
Mitochondrial
reductase
MT4 cell
MTT MTT formazan
MT4 cell
A 
B 
HIVIIIB 
Cytotoxic 
compound 
Figure 1.26 continued: 
Chapter 1 – General Introduction 
59 
would be reflected in the spectrophotometric reading, with less MTT conversion to MTT formazan.  
The efficacy of compounds against the HIV virus will be determined using the HIVIIIB strain (B).  
MTT, thiazolyl blue tetrazolium bromide. 
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1.12 Overall Aims 
 
Although much research has been conducted, along with proposed mechanisms to 
probe ABC toxicity, a conclusive hypothesis to understand the chemical basis of 
ABC-HSR remains unidentified.  It was therefore the overall aim of this study to 
design and synthesise analogues of ABC, which could not only be used to probe its 
oxidative metabolism, but to determine the immunogenic mechanism of ABC-HSR. 
 
The overall aims are as follows: 
• To develop a synthesis for a deuterated form of ABC to probe 5'-OH 
oxidative ABC metabolism  
• To undertake a series of metabolism experiments to determine contribution of 
ABC metabolism to its associated toxicity 
• To synthesise a range of ABC analogues using a SAR approach to block 
metabolism and/or binding within HLA-B*57:01 
• To use synthesised analogues in a range of toxicological assays to further 
probe its toxicity 
• To use all chemical, metabolic and toxicology results to deduce or validate a 
mechanism of ABC toxicity. 
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2.1 Introduction 
 
As discussed in Chapter 1, oxidative metabolism of ABC 7 may contribute to its 
toxicity.1 This major oxidative pathway occurs on the 5'-C to yield ABC-aldehyde 
(ABC-CHO) isomers 16a–16c and ABC-carboxylic acid (ABC-COOH) isomers 
17a–17c.  It was of great interest to have synthetic standards of compounds that 
would assist in probing this pathway further. 
 
2.1.1 Chemical oxidation methods applied to purine nucleosides. 
There are a wide variety of methods to oxidise primary alcohols to their respective 
aldehydes and carboxylic acids.  Many of the methods available use strong oxidising 
conditions, often resulting from metal-based reagents.  Milder oxidation conditions 
are always highly sought after as they often ease work-up procedures and enable 
easy removal of excess oxidant.  There is much published literature for the oxidation 
at 5'-C of purine based nucleoside 5'-primary alcohols to their carboxylate 
compounds.2-6 Comparatively, less literature can be found for aldehyde products.7-9 It 
is necessary to find an oxidation procedure that will oxidise the 5'-C atom in ABC to 
its corresponding aldehyde and carboxylic acid, using an oxidising reagent, which 
will not react with the other functional groups present within the molecule. 
 
 2.1.1.1 Oxidation of 5'-primary alcohols to 5'-carboxylate products. 
The most common method for oxidising 5'-primary alcohols to their COOH products 
is via a 2,2,6,6-tetramethylpiperidinyloxy/[bis(acetoxy)iodo]benzene 
(TEMPO/BIAB) route.  This mild oxidation method has been employed for a variety 
of purine nucleoside substrates.2,3,10-12 An example of such an oxidation is shown in 
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Scheme 2.1.  In the presence of 1:1 H2O−acetonitrile (ACN), the COOH product will 
be formed.  In anhydrous conditions, the aldehyde would be formed.  This method 
often achieves very good yields, and with precipitation of the final product, 
purification is often not required.2 Another well-utilised method uses potassium 
permanganate (KMnO4) and potassium hydroxide (KOH) as reagents.5,13,14 
 
Other less utilised methods include sodium periodate/ruthenium (IV) oxide 
(NaIO4/RuO2) oxidations6,15 (Scheme 2.1) and enzymatic oxidations using 
nucleoside oxidase isolated from S. maltophilia.4 This enzyme has a wide substrate 
range, within which it can accommodate non-biological nucleosides. 
 
 
 
Scheme 2.1:  Examples of nucleoside substrates and the conditions used for primary alcohol 
oxidation to carboxylic acid products.  Reagents and conditions used:  TEMPO, BIAB, 1:1 
H2O−ACN, r.t.;3 KMnO4, KOH, H2O, r.t.13 and Ru (IV) oxide, NaIO4, K2CO3, 1:1:2 
ACN−CHCl3−H2O.6 TEMPO, 2,6,6-tetramethylpiperidinyloxy; BIAB, [bis(acetoxy)iodo]benzene; 
ACN, acetonitrile. 
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2.1.1.2 Oxidation of 5'-primary alcohols to 5'-aldehyde products. 
Due to the highly reactive nature of aldehydes, there is little literature precedent for 
oxidation methods of purine nucleoside alcohols to aldehyde products.  The two 
major methods use a Dess–Martin periodinane procedure7,9 or the Moffatt oxidation.8 
 
2.1.2 Introduction to deuterium and its use in drug therapeutics. 
Deuterium is a naturally occurring non-radioactive isotope of hydrogen to which it 
has very similar properties, notably its size and shape.  Of recent interest for a 
hydrogen (protium) substitute, it is known to reduce toxicological and PK issues in 
certain approved drugs as well as being used as a probe to determine mechanisms of 
drug bioactivation.16 Most importantly, it has no intrinsic toxicological problems and 
has equivalent efficacy to hydrogen. 
 
2.1.2.1 Deuterated drugs in clinical trials. 
There are several deuterated forms of existing drugs currently or recently in clinical 
trials, four of which include:  CTP-347 (deuterated paroxetine),17 CTP-518 
(deuterated atazanavir),18 SD-254 (deuterated venlafaxine)19 and BDD-10103 
(deuterated tolperisone)20 (Figure 2.1).  These drugs have been designed to eliminate 
and/or address toxicity and PK issues and are discussed within. 
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Figure 2.1:  Proposed structures of existing drugs and their deuterated equivalents, which have been 
designed in order to combat toxicity or PK issues:  Paroxetine and CTP-347 (deuterated paroxetine) 
(A);17 atazanavir and CTP-518 (deuterated atazanavir) (B);18 venlafaxine and SD-254 (deuterated 
venlafaxine) (C)19 and tolperisone and BDD-10103 (deuterated tolperisone) (D).20 PK, 
pharmacokinetic. 
 
  2.1.2.1.1 CTP-347 (deuterated paroxetine). 
CTP-347, a deuterated form of paroxetine (Figures 2.1 and 2.2), is a Concert 
Pharmaceuticals compound.  Paroxetine, a serotonin re-uptake inhibitor, can cause 
serious DDIs, which are thought to arise from reactive metabolite formation, 
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followed by deactivation of a cytochrome P450, CYP2D6 (Figure 2.2).19 Deuteration 
of paroxetine has been shown to reduce irreversible CYP2D6 inactivation in pre-
clinical trials.21 By reducing the rate of reactive metabolite formation, CTP-347 can 
preclude the DDIs normally found with paroxetine.21 It is currently in clinical trials. 
 
 
 
Figure 2.2:  Proposed mechanism of paroxetine’s DDIs via selective P450 inhibition, with carbene 
formation and irreversible reactivity with CYP2D6.  The structure of CTP-347 is undisclosed but a 
proposed structure of CTP-347 is shown.  DDI, drug–drug interaction.  Adapted from Concert 
Pharmaceuticals IPT32.17  
 
  2.1.2.1.2 CTP-518 (deuterated atazanavir). 
CTP-518, a GSK and Concert Pharmaceuticals compound, was designed as a 
deuterated form of atazanavir (an HIV protease inhibitor), which is administered 
with ritonavir to boost its PK properties.  The compound, whose official structure has 
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not yet been released (but the structure of D15-atazanavir has been released in a 
patent, Figure 2.1)18 entered phase I clinical trials in 2010.22 In pre-clinical trials it 
was found that due to the presence of the deuterium atoms, the drugs metabolism 
was greatly reduced, with increased liver microsomal stability18 and half-life.23 
Consequently, combination therapy with ritonavir would not be required. 
 
  2.1.2.1.3 SD-254 (deuterated venlafaxine). 
Venlafaxine is a selective serotonin re-uptake inhibitor that is used for the treatment 
of a variety of anxiety disorders.  It is metabolised largely by CYP2D6 enzymes to 
its active major metabolite, O-desmethylvenlafaxine (ODV) (Figure 2.3).24-26 Further 
to this, it is also metabolised, mainly by CYP3A4 enzymes, to an inactive metabolite 
N-desmethylvenlafaxine (NDV) (Figure 2.3).25 Due to the genetic variability with 
CYP2D6 enzymes, and as ODV is equally as active as the parent compound,27 the 
consequence for both poor and extensive metabolisers can be high plasma 
concentration levels of an active compound.26 SD-254, designed by Auspex 
Pharmaceuticals and having completed phase I clinical trials, is such as to retard the 
metabolism to ODV, preventing high plasma concentrations of the active compound.  
The structure has also not been revealed, and limited clinical data is available, 
however a proposed structure is shown in Figures 2.1 and 2.3.19 
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Figure 2.3:  Venlafaxine, a selective serotonin re-uptake inhibitor, is used in the treatment of a variety 
of anxiety disorders.  Venlafaxine is principally metabolised to an equally active metabolite ODV27 by 
CYP2D6 enzymes and to an inactive metabolite NDV by CYP3A4 enzymes.24-26 The inter-patient 
variability associated with CYP2D6 enzymes has resulted in high plasma concentrations levels in both 
poor and extensive metabolisers of either the parent compound venlafaxine or ODV.  SD-254 
(deuterated venlafaxine) has completed phase I clinical trials and was been designed to slow the 
metabolism to ODV, reducing plasma concentration levels.  ODV, O-desmethylvenlafaxine; NDV, N-
desmethylvenlafaxine. 
 
  2.1.2.1.4 BDD-10103 (deuterated tolperisone). 
Tolperisone is an orally administered drug used as a centrally acting muscle 
relaxant.28 There is low toxicity associated with the drug and it is largely metabolised 
by CYP2D6 (with minor CYP2C19 and CYP1A2 contribution) to an inactive aryl 
methyl hydroxylated metabolite (Figure 2.4).29 As previously mentioned, there is 
high genetic variability associated in particular with CYP2D6 enzymes, and as a 
consequence, tolperisone is associated with low bioavailability in extensive 
metabolisers resulting in the requirement of high daily doses.28 Although the 
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structure of its deuterated equivalent, BDD-10103 is undisclosed, the structure of D7-
tolperisone (Figures 2.1 and 2.4) has been revealed in a patent.20 Little clinical data 
has been revealed for BDD-10103, but this deuterated compound has shown to 
exhibit a 10-fold decrease (in pre-clinical trials) in the hydroxylated metabolite 
compared to its non-deuterated equivalent.19 Should BDD-10103 be successful in 
further clinical trials, it has the potential to reduce the first-pass metabolism effect 
and the inter-patient variability linked with tolperisone would be reduced. 
 
 
 
Figure 2.4:  Tolperisone, a centrally acting muscle relaxant, is associated with low bioavailability and 
as a result, in certain patients, high daily doses are required.  Tolperisone is extensively metabolised, 
largely by CYP2D6 enzymes, to a pharmacologically inactive aryl methyl hydroxylated product.29 
The structure of BDD-10103 has not been disclosed, but D7-tolperisone has been released.20 Although 
limited clinical data is available, it has been shown that there is a 10-fold decrease in plasma 
concentration of the hydroxylated metabolite from BDD-10103 compared to tolperisone.19 The 
deuterated equivalent has the potential of reducing the first-pass metabolism effect and the inter-
patient PK variation can be reduced. 
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2.1.3 Investigation into ABC metabolism. 
With the suggestion that the aldehyde metabolite could contribute to ABC’s 
toxicity,30 it would be advantageous if the production and fate of this metabolite were 
characterised thoroughly.  However, 16, a short-lived, highly reactive intermediate, 
is notoriously difficult to isolate.1 There is little documented data for the oxidation 
chemistry of ABC, however, in 2011, Charneira et al. published the chemical 
synthesis of 16c (and its β,γ-unsaturated isomer 16a/16b), using Swern oxidation 
conditions (Scheme 2.2).31 The base used in the reaction determined which isomer 
was formed:  Triethylamine (NEt3) formed the isomer 16c and N,N-
diisopropylethylamine (DIEA) formed predominantly the β,γ-unsaturated isomers 
16a and 16b.  The stereochemistry of the isomers formed from using DIEA as the 
base could not be determined and with 16a able to undergo epimerisation to 16b, 
they used this pathway solely to form the β,γ-unsaturated collectively.  They did 
however discover that 16a/16b were able to isomerise to 16c and these samples were 
often contaminated with these isomers.  With isomerisation to the more 
thermodynamically stable product, NEt3 is known to assist in the formation of α,β-
unsaturated aldehyde.31 
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Scheme 2.2:  The aldehyde products (16a–16c) that Charneira et al. had previously synthesised from 
ABC using standard and modified Swern conditions.31 The formation of two β,γ-unsaturated products 
(16a and 16b) is hypothetical; the stereochemistry of the β,γ-unsaturated aldehyde at 4'-C was not 
determined.  The synthesis of 16a/16b, always a low yielding reaction, also formed compound 16c as 
a by-product through isomerisation.31 DMSO, dimethylsulfoxide; DIEA, N,N-diisopropylethylamine, 
THF, tetrahydrofuran. 
 
Further studies with the synthetic aldehyde isomers 16a/16b and 16c have shown 
that covalent protein binding can occur in vitro to haemoglobin (Hb),31 HSA32 and 
glutathione S-transferase Pi (GSTP).32 In vivo, the aldehyde metabolites bind 
covalently and form protein adducts with Hb in rats33 and human,34 and with HSA in 
humans.32 Through use of the N-alkyl Edman procedure (Figure 2.5), it was found 
that 16c can bind to the N-terminal valine residue of Hb using a Schiff base 
mechanism,31-33 through detection of product 41 in vitro and in vivo, although further 
in vivo studies are required on a larger cohort of patients to determine the frequency 
of adduction accurately.  Further to this reactivity, 16c reacts with cysteine, via a 1,4-
Michael addition mechanism.  The in vitro studies on reactions of 16c with HSA and 
GSTP found that the aldehyde covalently bonded through Michael addition or via 
cross-linking mechanisms with Cys, His, and Lys in HSA and Cys 47 in GSTP.32 In 
vitro reactions with 16a/16b found no adduct formation with this isomer, confirming 
the isomerisation of 16a to 16c.31 Furthermore, research conducted within the 
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Liverpool group has shown that ABC can undergo oxidative metabolism in the 
cytosolic fraction of human APCs.35 
  
 
Figure 2.5:  N-Alkyl Edman degradation product 41 can be synthesised and detected both in vitro and 
in vivo from covalent binding of 16c with Hb.31,33 Hb, haemoglobin. 
 
The mechanisms of ABC’s enzymic oxidations are not fully understood and the 
synthesis of di-deuterated ABC 42 (D2-ABC, Figure 2.6), initially designed as an 
improved drug to ABC, could be used as an investigational reagent in the discussed 
oxidation pathway.  Two deuterium atoms will replace the 5'-methylene protons, and 
in doing this it will be possible to determine whether isotopic substitution at this 
carbon can alter metabolic turnover, effectively comparing oxidative metabolism 
between the non-deuterated and deuterated form.  Deuteration of ABC should slow 
the rate of oxidative metabolism due to the slower abstraction of 5'-D atoms when 
the drug is metabolised to the carboxylic acid via the aldehyde.  Further to this, the 
toxicity and antiviral activity of D2-ABC can be determined with comparison to 
ABC.  In principle, the metabolic data will allow research of the hapten mechanism 
and its involvement with ABC-associated hypersensitivity and whether isotopic 
substitution at 5'-C can eliminate or reduce ABC’s toxicity. 
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Figure 2.6:  ABC 7 shown with its designed di-deuterated analogue, D2-ABC 42; where two 5'-H 
(ABC) atoms have been replaced with 2 5'-D atoms (D2-ABC).  D2-ABC, deuterated-ABC. 
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2.2 Aims 
 
• To develop a synthetic route to D2-ABC 42 
• To synthesise and isolate ABC-CHO (16a/16b and 16c) 
• To synthesise and isolate ABC-COOH (17a) using a variety of synthetic 
methods and/or routes. 
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2.3 Results & Discussion 
 
2.3.1 Synthesis of ABC-aldehyde 16. 
The initial focus of the chemical research was to synthesise ABC aldehyde 16.  The 
isolation of this intermediate would be very useful in further immunology and 
proteomic experiments to determine any T-cell stimulation and protein binding. 
 
Previous research has highlighted the difficulty in obtaining the aldehyde due to its 
reactive nature with either a molecule of itself or other reagents present.1,31 Also, 
16a, the primary product of the chemical and enzymic oxidation of ABC, rearranges 
to 16c spontaneously.  Consideration had to be made that the alkene must be 
unaffected by the oxidant. 
 
Before the Charneira paper was published in 2011,31 several oxidation reactions were 
attempted.  The first attempt used pyridinium chlorochromate (PCC) in 
dichloromethane (DCM) (Figure 2.7).  PCC is a stable, well-utilised chromium (VI) 
oxidising agent, used for selectively oxidising primary alcohols to aldehydes.36-38 
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Figure 2.7:  Attempted oxidation of ABC 7 using the following oxidising reagents:  PCC or 
TEMPO/BIAB or BaMnO4 to synthesise aldehyde 16a (A) and oxidation of DH-ABC 20 using PCC 
as the oxidising agent to theoretically yield 43 (B).  PCC, pyridinium chlorochromate. 
 
The reaction was attempted several times with varying reaction times (2–24 h), and 
equivalents of PCC (1.5–3.0 equiv).  Analysis of the crude reactions using 1H NMR 
showed the presence of an aldehyde product (9.96 ppm), but due to the crude nature 
of the mixture, confirmation of aldehyde stereochemistry and formation was 
difficult.  It was evident that side reactions were occurring, shown by thin layer 
chromatography (TLC) and 1H NMR.  These reactions were either pre- or post- 
aldehyde formation, and following simple work-up and purification by column 
chromatography, no aldehyde product could be obtained via this method.  The 
formation of the aldehyde appeared to be short-lived and even liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) also failed to detect 
product formation, with significant side-product formation being detected instead.  
The crude nature of the mixture hindered analysis and confirmation of side-
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products/products.  It was likely, from the presence of several nucleophilic groups on 
ABC and the likelihood of double bond migration and further reactivity through a 1,4 
mechanism, that the formation of side products was certain to occur (Figure 2.8). 
 
  
 
 
 
 
 
 
 
Figure 2.8:  During the oxidation process, the α,β-unsaturated aldehyde 16c becomes susceptible to 
1,4 nucleophilic attack (A).  The β,γ-unsaturated aldehyde 16a/16b is also able to react via a 1,2 
nucleophilic addition (B). 
 
With this consequence in mind, the oxidation of DH-ABC 20 (see Chapter 4 for 
synthesis of 20) to its aldehyde 43 was attempted under the same conditions (Figure 
2.7).  Due to lack of a carbocyclic alkene, no double bond migration and/or 1,4 
nucleophilic addition could occur.  Unfortunately, analysis of the crude reaction 
detected no aldehyde formation and no product was isolated by silica gel column 
chromatography.  Nucleophilic attack of the aldehyde could occur immediately after 
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it had been formed (Figure 2.8).  Side reactions of this nature are applicable to both 7 
and 42. 
 
Following this attempt, further research was carried out into milder oxidising 
methods and so barium manganate (BaMnO4)39 was employed.  This agent is capable 
of selectively oxidising primary alcohols to their respective aldehydes without 
oxidising alkenes.  The BaMnO4 reaction was heated to reflux (in DCM) for 48 h, 
and although only very few side reactions occurred, starting material (80%) was 
recovered. 
 
Although often used for complete oxidation of primary alcohols to their respective 
carboxylic acids, TEMPO/BIAB reagent was used in an attempt to synthesise 16 
(Figure 2.7).  The oxidation was attempted with one equivalent of TEMPO in 
anhydrous ACN.  The desired aldehyde was not isolated and starting material was 
observed. 
 
After the failure to obtain 16 via the traditional Swern oxidation method, a paper 
published in 2011 reported an application of modified Swern oxidation reagents, for 
the synthesis of 16a/16b and its isomer 16c (Scheme 2.2) as previously discussed.31 
 
By following this procedure, isomer 16c (Scheme 2.3) was synthesised and 
successfully isolated via silica gel column chromatography.  The instability of 16c 
was noticeable after purification, with apparent degradation products observed by 1H 
NMR.  This was likely to occur due to the instability of compound 16c.  Further 
work conducted within the Liverpool group has shown that this impurity yielded 
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[M+H]+ at m/z 271 and the generic purine fragment at m/z 191, deducing the 
impurity to be ABC cyclopentenone.  Minimal contact of 16c with solvents and 
storing the aldehyde at −20 °C reduced the rate of product degradation.  This 
compound could be used to further investigate covalent protein binding.31 
 
  
 
Scheme 2.3:  Reagents and conditions:  DMSO (2.5 equiv), C2O2Cl2 (1 equiv), ABC 7 (1 equiv), NEt3 
(4.5 equiv), THF, −78 °C  r.t., N2, 2 h, 18%. 
 
Future work will involve the synthesis of aldehyde 16a/16b under the conditions 
stated by Charneira et al.31 although, Charneira and co-workers found the isolation of 
this aldehyde difficult with 16c often contaminating the samples.  With successful 
purification, both compound 16a/16b and its isomer 16c could be used in further 
studies. 
 
2.3.2 Synthesis of ABC-carboxylic acid 17a. 
ABC-COOH (17a) was required as a standard metabolite in future metabolic studies. 
GSK initially supplied this compound, namely standard compound 2269W93,1 but 
due to limited supply additional material was required and attempts to synthesise it 
chemically from ABC itself are detailed below. 
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An oxidation method using KMnO4 was discarded due to non-selective oxidation, as 
the alkene is also susceptible to oxidation.  Other possible oxidation methods 
considered were ruthenium tetraoxide (RuO4), pyridinium dichromate (PDC), Jones 
reagent, and TEMPO/BIAB oxidation.  The first oxidation procedure attempted 
utilised freshly prepared Jones reagent (Figure 2.9).  Although ABC has limited 
solubility in organic solvents, the Jones oxidation was performed conventionally in 
acetone, in which ABC is moderately soluble.  However, upon cooling to 0 °C in 
preparation for addition of Jones reagent, some precipitation was evident.  After 
addition of the oxidising agent, rapid salt formation was observed.  The equivalents 
of the reagent were reduced but the precipitate formation still occurred and through 
analysis via TLC, there was no conversion of starting material.  The salt formation 
was likely due to the formation of ABC sulfate (sulfate originating from sulfuric acid 
in Jones reagent).  In an attempt to overcome this problem, the succinate salt of ABC 
was used.  However, using ABC succinate completely prevented any material 
dissolving in acetone, and although the reaction was attempted with solubility issues, 
no product was formed. 
 
  
 
Figure 2.9:  Direct formation of ABC-COOH 17a from ABC 7 using three oxidising agents:  Jones 
reagent, TEMPO/BIAB and molecular O2 with Pd/C. ABC-COOH, abacavir carboxylic acid. 
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TEMPO oxidation was also attempted.  Rather than anhydrous conditions, as seen 
with TEMPO oxidation to afford the corresponding aldehyde, a 1:1 mixture of ACN 
and H2O was used. This procedure has been the method of choice for many 
oxidations of nucleoside 5'-primary alcohols to carboxylic acids.2,3,10-12 The 
formation of these carboxylic acids is typically high yielding, using mild reaction 
conditions with no lengthy purification procedures:  Products frequently precipitate 
and are obtained via filtration.2 However, even with varying TEMPO equivalents (1–
2 equiv), reaction times (4–24 h) and solvent volumes, no carboxylic acid product 
was obtained or detected.  Although the reagents are relatively mild, in comparison 
to metallic oxidising agents, side reactions were still evident and seen within 1H 
NMR analysis.  The low solubility of ABC in most organic solvents was overcome 
in this reaction by using water, which readily solubilises ABC.  Therefore, it is 
concluded that the solubility of ABC is not an issue in these reaction conditions, 
rather the problem lies with the reactivity of ABC itself. 
 
The final direct oxidation method attempted utilised oxygen, palladium on carbon 
(Pd/C), sodium borohydride (NaBH4) and KOH.  This method, although relatively 
unemployed as a common oxidation procedure, has been applied to a variety of 
substrates.40 ABC succinate was used rather than ABC itself due to solubility issues, 
but unfortunately no reaction occurred and only starting material was recovered. 
 
Due to the problems of forming 17a from ABC, an alternative route was designed.  
The procedure was adapted from a patent, published by GSK, for the efficient large-
scale synthesis of ABC.  The original route, a three-step method, used a chiral 
amino-alcohol and DADCP 30.41 The adapted route (Scheme 2.4) consisted of five 
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steps and began with ring-opening chiral lactam 28, followed by coupling with 
pyrimidine 30. 
 
 
 
Scheme 2.4:  Proposed route to synthesise 17a.  Reagents and conditions:  a) SOCl2 (2.2 equiv), 
MeOH, 0 °C, 1 h, 95%; b) DADCP 30 (2.0 equiv), NaHCO3 (3.5 equiv), t-BuOH, 95 °C, 14 h, 42%; 
c) TEOF (1.2 equiv), H2SO4 (0.05 equiv), n-BuOH, 65 °C; d) Cyclopropylamine (1.2 equiv), MeOH, 
60 °C; e) 2 M LiOH, MeOH, r.t.  (Steps c–e were not fully completed).  DADCP, 2,5-diamino-4,6-
dichloropyrimidine. 
 
At the initial step, ring opening of bi-cyclic lactam 28 using thionyl chloride (SOCl2) 
and methanol (MeOH), formed the cyclopentyl portion of ABC with appropriate 
functionality and stereochemistry in excellent yields.  By using MeOH in this step, 
the methyl ester at 5'-C was obtained.  The ester, replacing the 5'-OH group in ABC, 
could be hydrolysed to the desired carboxylic acid at the end of the synthesis. 
 
Compound 44 was coupled with DADCP 30 under conditions similar to those 
patented.41 This step proved problematic, and in the first instance it was thought that 
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reduced electrophilicity and steric clashes with pyrimidine 30 were responsible for 
lack of product formation; nucleophilic substitution occurs more easily at positions 2, 
4 and 6.  To circumvent this problem, it was proposed that mono/di-protecting the 
amino groups on 30 would allow for easier nucleophilic substitution of either 
chlorine atom. 
 
  
 
Figure 2.10:  Attempts to di-protect compound 30 using Boc2O and Ac2O. 
 
Di-amino protection of pyrimidines is notoriously difficult, with mono protection 
only likely at position 5.42 Amine moieties at position 2 have the greatest electron 
density in comparison to the other positions and therefore protection of this position 
is much lower.  Two reactions were attempted:  Protection with a t-butyloxycarbonyl 
(Boc) and an acetyl group using di-tert-butyl dicarbonate (Boc2O) and acetic 
anhydride (Ac2O), respectively (Figure 2.10).  However, even with a large excess of 
reagents in both experiments, no reactions occurred, and the initial method using 
non-protected DADCP was revisited.  Therefore, the focus of this step was the need 
to optimise the original reaction conditions (Table 2.1). 
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Table 2.1:  Table representing the set of reactions completed (A–G) to optimise conditions for the 
coupling reaction (step 2, Scheme 2.4) of compound 44 with 30.  DBU, 1,8-diazabicyclo[5.4.0]undec-
7-ene. 
 
 
Reagents and Reaction Conditions* 
 
 
 
Reaction 
  
Solvent 
 
 
Base (equiv) 
 
Temperature (°C) 
 
 
Yield (%) 
 
A 
 
 
n-BuOH 
 
NaHCO3  
(3.5) 
 
 
70 
 
36 (crude) 
 
B 
 
 
MeOH (sealed 
tube or reflux) 
 
 
K2CO3 
 (2.5) 
 
80 (sealed tube / 
reflux) 
 
Not 
obtained 
 
C 
 
 
t-BuOH  
(sealed tube) 
 
 
NaHCO3 
(2.5) 
 
85 
 
42 
 
D 
 
 
EtOH 
 
NEt3 
(2.5) 
 
 
Reflux 
 
Not 
obtained 
 
 
E 
 
 
t-BuOH 
 
NEt3 
(2.5) 
 
80 then 95 
 
Not 
obtained 
 
 
F 
 
 
t-BuOH 
 
DIEA & 
DBU 
(2.5) 
 
 
85 
 
15 
 
G 
 
 
EtOH 
 
NaHCO3 
(2.5) 
 
 
Microwave at 100 °C 
 
Not isolated 
 
 
* All reactions were completed on a 200 mg scale (of compound 44). 
 
The choice of base and solvent appeared critical to affording the desired product.  
Less hindered polar aliphatic solvents such as MeOH and ethanol (EtOH) proved 
problematic due to their aromatic nucleophilic tendencies to substitute chlorine at the 
6-position.  t-Butanol (t-BuOH), a more hindered protic solvent, was therefore 
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chosen.  The base required for the reaction was also altered, so as to use an organic 
or inorganic base.  Under organic base conditions, (reactions D, E and F) fewer side 
reactions were evident but product formation was slower.  In reaction E, where NEt3 
was used, nucleophilic addition at the 6-position yielded the undesired product 48 
(Figure 2.11 A).  To prevent this from occurring, a more hindered organic base, in 
this case DIEA followed by 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), was used.  
Although fewer side reactions occurred, the yield achieved was lower than that in 
reaction C.  Under microwave (MW) conditions, reaction E, the greatest amount of 
side products was observed and no desired product was obtained.   
 
 
 
 
 
Figure 2.11:  Diethylamine product 48 formed during reaction E (Table 2.1), using NEt3 as the base 
(A).  The equilibrium between compounds 28 and 44 at step 2 may have contributed to low reaction 
yields (B). 
 
The original conditions that have been adapted to this synthesis were taken from a 
patent for the synthesis of ABC.41 The initial step in this patent, was coupling of a 
cyclopentyl amino-alcohol with DADCP 30, rather than with the amino-ester 44 as 
used within this synthesis.  The problems experienced in this coupling step are 
therefore thought to arise from a reversible reaction between lactam 28 and amino-
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ester 44 (Figure 2.11 B).  Increased temperatures would favour this equilibrium:  A 
condition that is essential in this step.  Therefore it is postulated that the low yields 
experienced are as a result of this equilibrium.  Nevertheless, reaction C conditions 
were chosen, and by using a sealed tube the temperature of the reaction could be 
increased, if necessary beyond the boiling point of the solvent. 
 
The third step, ring closing to form purine 46, also proved problematic.  Purification 
of the step 2 product was extremely difficult and often resulted in low yields.  To 
eliminate this problem, crude mixtures were used without purification in step 3.  The 
number of side reactions also increased in step 3, and consequently compound 46 
could not be isolated.  Due to time constraints, these conditions were not optimised 
and the final two steps are yet to be completed.  These steps would be a focus for 
future work. 
 
2.3.3 Synthesis of D2-ABC 42. 
An efficient, high yielding total synthesis of D2-ABC 42 was essential for this 
research.  There are a variety of methods that can be adapted to incorporate D atoms.  
A synthetic route using chiral auxiliaries, as developed by Crimmins and co-
workers,43 was chosen as the optimal route.  The two D atoms are introduced at step 
4 and are placed on the 4'-C.  The synthetic route is shown in Scheme 2.5. 
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Scheme 2.5:  Total synthetic route for synthesising D2-ABC.  Reagents and conditions:  a) n-BuLi (1 
equiv), pivaloyl chloride (1 equiv), NEt3 (1 equiv), 4-pentenoic acid (1 equiv), t-BME, THF, −78 °C 
 r.t., N2, 2 h, 85%; b) DIEA (2.2 equiv), DBBT (2.2 equiv), acrolein (2.1 equiv), DCM, −78 °C  
r.t., N2, 16 h, 87%; c) Grubbs catalyst 1st generation (5 mol %), DCM, r.t., Ar, 15 h, 70%; d) LiAlD4 
(2.2 equiv), THF, 0 °C, 2 h; e) Ac2O (3 equiv), NEt3 (3 equiv), DMAP (cat.), DCM, r.t., N2, 16 h; f) 2-
amino-6-chloro purine (1.5 equiv), NaH (1.5 equiv), Pd(PPh3)4 (10 mol %), THF, 50 °C, Ar, 16 h, 
32%; g)  Cyclopropylamine (1.2 equiv), MeOH, 60 °C, 16 h, 77%; h) 1 M NaOH (excess), EtOH, r.t., 
48 h, 64%. t-BME, t-butylmethyl ether; DBBT, dibutylboryl triflate; DCM, dichloromethane; DMAP, 
4-dimethylaminopyridine; cat., catalytic. 
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The initial step synthesised compound 51 from an enantiomerically pure benzyl 
oxazolidinone auxiliary 49.  Intermediate 50 was prepared from 4-pentenoic acid and 
pivaloyl chloride.  It was used without purification, and upon reaction with the 
oxazolidinone auxiliary, compound 51 was obtained in high yields (78–85%).  A 
terminal alkenyl side chain obtained from acrolein was added to 51 using 
dibutylboryl triflate (DBBT) to form the appropriate syn aldol geometry, yielding 
compound 52. 
 
The two terminal alkenes were now positioned ideally for RCM to form the 
cyclopentyl ring, compound 53.  Relatively near the start of the complete synthesis, it 
was paramount that this step achieved a good yield.  Olefin metathesis was achieved 
using the ruthenium-based Grubbs catalyst.  Four commonly used catalysts are 
Grubbs catalysts 1st and 2nd generation and Hoveyda-Grubbs catalysts 1st and 2nd 
generation.  The catalyst chosen initially was Grubbs catalyst 1st generation.  
 
The initial difficulties encountered with this reaction were low yield and removal of 
the catalyst.  The conditions required optimisation; the results of which can be seen 
in Table 2.2.  Increasing the mol % of the catalyst from 0.5 (reaction A) to 2 mol % 
(reaction B) resulted in an increased yield of 35%.  Increasing the mol % further to 5 
or 7 mol % (reaction C) increased the yield further to 50%.  Under an atmosphere of 
nitrogen, Hoveyda-Grubbs 2nd generation catalyst (reaction D) gave the best yields 
(62%) but this relatively new catalyst is expensive to use on a larger scale.  Yields 
were improved further when the reaction was carried out under an argon atmosphere 
as opposed to nitrogen (reactions E and F). 
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Ruthenium-based catalysts have been shown to act as a catalyst in the reduction of 
alkene functional groups in the presence of NaBH4.44 It was therefore vital that all 
the Ru catalyst was removed prior to the following reduction step using lithium 
borodeuteride (LiBD4).  Tris(hydroxymethyl)phosphine (THP) (1 M) has proved an 
efficient Ru scavenger.45,46 THP readily complexes with Ru, and in doing so, the 
metallic complex becomes water-soluble.  The catalyst was then removed in a simple 
organic–water work-up.  The optimised yield (70%), forming compound 53, was 
achieved using conditions shown in reaction F. 
 
Table 2.2:  Table representing the set of reactions completed (A–F) in order to optimise conditions 
for the RCM of compound 53.  THP, tris(hydroxymethyl)phosphine. 
 
 
Reagents and Reaction Conditions* 
 
 
 
Reaction 
  
Grubbs Catalyst 
 
 
Atmosphere 
 
 
 
 
Yield (%) 
 
A 
 
 
1st generation (0.5 mol %) 
 
Nitrogen 
 
10 
 
B 
 
 
1st generation (2 mol %) 
 
 
Nitrogen 
 
 
45 
 
C 
 
 
1st generation (5 / 7 mol %) 
 
 
Constant flow of nitrogen 
 
 
50 / 51  
 
D 
 
 
Hoveyda-Grubbs 2nd 
generation (5 mol %) 
 
 
Nitrogen 
 
55 
 
 
E 
 
 
1st generation (5 mol %) 
 
Argon 
 
 
62 
 
F 
 
 
1st generation (5 mol %) 
 
Argon (with THP to 
remove catalyst) 
 
 
58–70 
 
* All reactions were left for 16 h at r.t. and trial experiments were completed on 50–100 mg scales. 
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Commercially available LiBD4 was used to reduce 53 and in doing so, two D atoms 
were placed at the 5'-C position.  1H NMR analysis showed a mixture of three 
products (Figure 2.12):  Non-deuterated, mono-deuterated and di-deuterated 
products. 
 
 
 
Figure 2.12:  Mixture of three products formed (2.5:1:0.5 di-deuterated−mono-deuterated−non-
deuterated) when using LiBD4 as the reducing agent to reduce intermediate 53. 
 
To dispel the uncertainty as to why three products were formed, a test reaction using 
3,5-dibromomethylbenzoate was attempted (Figure 2.13).  It was found that again, a 
mixture of three products were formed.  From this finding, it was concluded that the 
reagent, LiBD4, was contaminated with lithium borohydride (LiBH4).  The reducing 
agent was changed and commercially available lithium aluminum deuteride (LiAlD4) 
was used.  Although the yields using this reagent were low, a compromise was 
accepted as the reagent eliminated the mixture of products and only the required di-
deuterated product 54 was formed.  Due to the high water solubility and relative 
volatility of 54, it was often taken on crude to the next step, after removal of 
inorganic salts.  The following step was a simple diacetylation of the alcohol groups 
with Ac2O to yield compound 55 in moderate yields (50–60%). 
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Figure 2.13: 3,5-Dibromomethylbenzoate was the compound used to test the purity of the reducing 
agent, LiBD4.  The reaction was conducted using LiBD4 (2.2 equiv) with the formation of three 
products (di-deuterated, mono-deuterated and non-deuterated compound) showing some 
contamination of the deuterated reducing agent with LiBH4. 
 
The optimised conditions for step 6 were previously established for the non-
deuterated route (see Chapter 4) and compound 56 was achieved with a 38% yield.  
The N9 isomer was almost exclusively synthesised with very little N7 isomer 
formation observed.  Using NMR and reference standards, it was clear that the 
isomer N9 was obtained.  In 1H NMR the C-8 proton of this isomer is usually upfield 
(approx. 7.9 ppm) compared to the C-8 proton of the N7 isomer (approx. 8.1 ppm).47 
Subsequent nucleophilic aromatic substitution under standard conditions with 
cyclopropylamine, displacing chlorine at the 6-position, yielded compound 57 with 
good yields.  The final step, deprotection of 5'-OH using 1 M sodium hydroxide 
(NaOH), yielded the desired compound, D2-ABC 42, in 63% yield.  This material 
was used in metabolism studies (Chapter 3). 
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2.4 Conclusions & Future Work 
 
Uncertainties remain in determining the contribution of the oxidative metabolites of 
ABC to its toxicity, although this pathway has been greatly researched.1,23 To probe 
the oxidative pathway further, synthetic standards of both metabolites under 
investigation, ABC-CHO 16 and ABC-COOH 17 were required. 
 
A variety of methods used in the attempted synthesis of either ABC-16 or ABC-17 
have proven difficult to apply using a variety of oxidising agents.  A modified Swern 
method used to synthesise two isomers of ABC-16 was published recently31 and this 
method has been utilised successfully to form an ABC-16 isomer (isomer 16c). The 
difficulties in forming ABC-17 remain, however a 5-step synthetic route to the 
product has been started, with steps 1 and 2 successfully completed.  Further work is 
needed to improve this route and to complete the final three steps.  The α,β-
unsaturated aldehyde and its isomers will be useful for testing possible haptenation 
reactions and for other research into protein modification.34 The carboxylic acid, an 
in vivo metabolite, will be valuable as an assay standard, as seen in Chapter 3, for 
further metabolic studies on ABC. 
 
D2-ABC 42 was successfully synthesised using an 8-step synthesis.  It was 
synthesised not only as an internal standard (IS) for quantitative metabolic studies on 
ABC (Chapter 3), but principally to probe the metabolic activation of ABC as a 
means of assessing the potential of the isotopically substituted compound to deliver 
enhanced drug safety.  In respect of the initial hypothesis of ABC toxicity, namely 
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the hapten hypothesis, 42 was the ideal compound to probe this phenomenon, 
provided the rate of the major metabolic activation route was slowed (Chapter 3). 
  
To further probe the oxidative metabolic pathway of ABC, the secondary isotope 
effect could be investigated.  This would require synthesis of the 4'-D analogue of 
ABC (Figure 2.14 A).  Investigation of the secondary isotope effect will also probe 
the reaction mechanism and in particular, the rate determining step (RDS) of this 
oxidative pathway. 
 
 
 
Figure 2.14:  Structure of an alternative deuterated form of ABC, where the 4'-H is replaced with a D 
atom, rather than at the 5'-H position, as synthesised within this research (A).  An alternative 5'-C 
analogue:  An analogue that bears a methyl group at the 5'-C position.  This analogue would prevent 
the oxidative pathway allowing for further probing of the mechanistic pathway (B). 
 
Further to this, analogues at the 5'-C position could also be synthesised, such as the 
substitution of a 5'-H for a methyl group (Figure 2.14 B).  This would prevent the 
formation of both the aldehyde and carboxylic acid compounds.  This analogue, 
under subjection to the same metabolic experiments as described in Chapter 3, would 
allow the oxidative mechanistic pathway to be explored further. 
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2.5 Experimental 
 
2.5.1 General chemical methods. 
All reagents were purchased from Sigma Aldrich (Poole, Dorset), Alfa Aesar 
(Heysham, Lancashire) or Apollo Scientific (Bredbury, Stockport, Cheshire) unless 
otherwise stated.  Air and moisture sensitive reactions were carried out using oven-
dried glassware and rubber septa.  Such reactions were carried out under a positive 
pressure of a nitrogen or argon atmosphere and air or moisture sensitive liquids were 
transferred via syringe.  All reactions were stirred using Teflon-coated magnetic 
stirrer bars and all organic solvents were removed using a Buchi rotary evaporator, 
unless otherwise stated.  Anhydrous solvents were either obtained from commercial 
sources (Sigma Aldrich or Alfa Aesar) or distilled under an inert atmosphere prior to 
immediate use.  Tetrahydrofuran (THF) was distilled from Na and DCM from 
calcium hydride (CaH2).  All other reagents were used without further purification 
unless stated otherwise. 
 
All 1H and 13C NMR analyses were run on a Bruker ARX 400 (400 MHz) NMR 
spectrometer and all deuterated solvents were as stated within the text for each 
compound.  Chemical shifts (δ) are in parts per million (ppm).  Tetramethylsilane 
(TMS) was used as the internal reference.  Multiplicities are recorded as singlet (s), 
doublet (d), triplet (t), multiplet (m) and broad (br).  All J couplings are recorded in 
Hertz (Hz).  Mass spectra were recorded on a Micromass LCT mass spectrometer 
using electron spray ionisation (ESI), a Fisons TRIO spectrometer or Agilent QTOF 
700 spectrometer, using chemical ionisation (CI).  Accurate mass values are stated 
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within ± 5 ppm.  Infrared spectra (IR) were recorded using a Jasco FT/IR-4200 
spectrometer and samples were run neat.  Elemental analyses (C, H and N) were 
completed within the University of Liverpool Microanalysis Laboratory and values 
are stated within a ± 0.5% error.  Melting points were determined on a Gallenkamp 
melting point apparatus. TLC was performed on silica gel 60-F254 (Merck) and 
visualised via ultraviolet (UV) light or by staining with p-anisaldehyde stain (p-
anisaldehyde (3.7 mL), AcOH (1.5 mL), conc. H2SO4 (5 mL) in EtOH (135 mL)) or 
KMnO4 stain (KMnO4 (1.5 g), K2CO3 (10 g) and 10% NaOH (1.25 mL) dissolved in 
H2O (200 mL)) followed by gentle heating.  Silica gel 60 (Merck, 63–200 m) was 
used for flash column chromatography. 
 
2.5.2 Synthesis. 
 
 
 
(S)-4-Benzyl-3-(pent-4-enoyl)oxazolidin-2-one 51:47 To a solution of 4-pentenoic 
acid (7.7 mL, 0.08 mol) in t-butylmethyl ether (t-BME) (220 mL) cooled to −78 °C 
was added NEt3 (10.5 mL, 0.08 mol) and the solution was allowed to stir for 5 min.  
Pivaloyl chloride (9.4 mL, 0.08 mol) was added, and after a further 15 min, the 
solution was allowed to warm to 0 °C and stirred for 1 h.  In a separate flask, (S)-4-
benzyl-2-oxazolidinone 49 (6.36 g, 0.04 mol) in THF (100 mL) was allowed to cool 
to −78 °C and n-butyl lithium (n-BuLi) (15.0 mL, 2.5 M in hexane) was added 
dropwise.  The solution was allowed to stir for 20 min.  The anhydride flask was 
HN
O
O
Ph
N
O
OO
Ph
51 49 
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cooled back to −78 °C and the white auxiliary solution added.  The resulting mixture 
was allowed to stir for 15 min at −78 °C and for 30 min at 0 °C, whereupon the 
reaction was quenched with saturated aqueous ammonium chloride (NH4Cl).  The 
mixture was extracted with DCM (4 × 500 mL) and the resulting organic extracts 
were washed with brine and dried over magnesium sulfate (MgSO4).  The solvent 
was removed in vacuo.  The crude product was purified by column chromatography 
(1:4 ethyl acetate−n-hexane (EtOAc−n-hex)) to yield 51 (7.90 g, 85%) as a clear and 
colourless oil.47 1H NMR (CDCl3): δ 7.36–7.20 (m, 5H), 5.90–5.87 (m, 1H), 5.19–
4.97 (m, 2H), 4.71–4.65 (m, 1H), 4.27–4.11 (m, 2H), 3.30 (dd, J = 13.3, 3.3 Hz, 1H), 
3.08–3.04 (m, 2H), 2.76 (dd, J = 13.4, 9.7 Hz, 1H), 2.54–2.39 (m, 2H).  13C NMR 
(CDCl3): δ 173.0, 153.9, 137.1, 135.7, 129.8 (2C), 129.4 (2C), 127.8, 116.2, 66.6, 
55.6, 38.3, 35.2, 28.6.  m/z (ES+) 282.1110 calculated for C15H17NO3Na:  [M+Na]+ 
282.1106.  Anal. calc. for C15H17NO3:  C, 69.48; H, 6.61; N, 5.40.  Found:  C, 69.34; 
H, 6.70; N, 5.49.  IR (cm-1):  2978 (C−H), 1778 (C=O), 1581 (C=C aromatic), 1203 
(C−O). 
 
 
 
(S)-3-((2S,3R)-2-Allyl-3-hydroxypent-4-enoyl)-4-benzyloxazolidin-2-one 52:47 To 
a solution of compound 51 (5.52 g, 0.02 mol) in DCM (20 mL) at −78 °C was added 
DIEA (8.2 mL, 0.05 mol) followed by DBBT (42.6 mL, 1 M solution in DCM).  The 
mixture was allowed to stir at room temperature for 1 h.  After re-cooling to −78 °C, 
a solution of acrolein (3.2 mL, 0.05 mol) in DCM (5 mL) was added dropwise.  The 
N
O
OO
Ph
N
O
OO
Ph
OH
51 52 
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resulting mixture was allowed to stir at −78 °C for 2 h and then allowed to warm to 
room temperature overnight.  The solution was quenched with saturated aqueous 
sodium hydrogen carbonate (NaHCO3) and extracted into DCM (4 × 100 mL).  The 
combined organic extracts were washed with brine and dried over MgSO4.  The 
solvent was removed in vacuo.  The resulting crude product was purified by column 
chromatography (1:4 to 2:5 EtOAc−n-hex) to yield 52 (5.82 g, 87%) as a pale yellow 
oil.47 1H NMR (CDCl3): δ 7.33–7.19 (m, 5H), 5.91–5.87 (m, 2H), 5.36–5.04 (m, 4H), 
4.72–4.61 (m, 1H), 4.47–4.45 (m, 1H), 4.37–4.25 (m, 1H), 4.18–4.11 (m, 2H), 3.30–
3.24 (m, 1H), 2.76–2.64 (m, 1H), 2.63–2.52 (m, 1H), 2.51–2.35 (m, 1H).  13C NMR 
(CDCl3): δ 174.9, 153.8, 137.4, 135.6, 129.8, 129.3, 127.8, 117.8, 116.7, 73.7, 66.4, 
56.0, 47.6, 38.4, 32.4.  m/z (ES+) 338.1379 calculated for C18H21NO4Na:  [M+Na]+ 
338.1368.  IR (cm-1): 2970 (C−H), 1774 (C=O), 1697 (C=C), 1207 (C−O). 
 
 
 
(S)-4-Benzyl-3-((1S,2R)-2-hydroxycyclopent-3-enecarbonyl)oxazolidin-2-one 
53:47 To a solution of 52 (2.75 g, 9.0 mmol) in anhydrous DCM (15 mL), in a 
degassed flask under argon, was added 1st generation Grubbs catalyst (0.26 g, 5 mol 
%) at room temperature.  The reaction was allowed to stir overnight.  Freshly 
prepared THP (8.0 mL, 1 M in isopropyl alcohol (IPA)) was added and the mixture 
was extracted into DCM (3 × 30 mL).  The combined organic extracts were washed 
with brine and dried over MgSO4.  The solvent was removed in vacuo.  The crude 
product was purified by column chromatography (1:1 EtOAc−n-hex) to yield 53 
N
O
OO
Ph
OH
N
O
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(1.74 g, 70%) as a colourless crystalline solid.47 mp:  81–83 °C.  1H NMR (CDCl3): δ 
7.40–7.16 (m, 5H), 6.11–6.00 (m, 1H), 5.85–5.73 (m, 1H), 5.19–5.05 (m, 1H), 4.78–
4.72 (m, 1H), 4.52–4.47 (m, 1H), 4.19–4.15 (m, 2H), 3.35 (dd, J = 13.3, 3.3 Hz, 1H), 
3.22–3.08 (m, 1H), 2.79 (dd, J = 13.4, 9.8 Hz, 1H), 2.54–2.50 (m, 1H).  13C NMR 
(CDCl3): δ 172.6, 154.0, 135.8, 135.3, 131.5, 129.9 (2C), 129.4 (2C), 127.8, 66.6, 
60.8, 56.0, 47.5, 38.5, 33.7.  m/z (ES+) 310.1057 calculated for C16H17NO4Na:  
[M+Na]+ 310.1055.  Anal. calc. for C16H17NO4:  C, 66.89; H, 5.96; N, 4.88.  Found: 
C, 66.59; H, 5.99; N, 4.76.  IR (cm-1):  3471 (br, O−H), 2966 (C−H), 1781 (C=O), 
1693 (C=C), 1207 (C−O). 
 
 
 
d2-(1R,5R)-5-(Hydroxymethyl)cyclopent-2-enol 54:  To a solution of 53 (1.16 g, 
4.0 mmol) in THF (30 mL) at 0 °C was added LiAlD4 (0.27 g, 7.0 mmol) slowly.  
The resulting suspension was stirred at 0 °C for 2 h and at 0 °C, H2O (0.27 mL) was 
added dropwise.  After stirring for 5 min, 15% aqueous NaOH (0.27 mL) was added 
and the solution was stirred for a further 5 min and finally water (0.81 mL) was 
added and the solution stirred for 15 min.  MgSO4 was added, and the suspension 
was stirred for 15 min before filtering the solution and removing the solvent in 
vacuo.  The crude product (yellow liquid) was used without purification.  1H NMR 
(CDCl3): δ 6.03–6.01 (m, 1H), 5.85–5.82 (m, 1H), 4.95–4.93 (m, 1H), 2.52–2.48 (m, 
1H), 2.42–2.35 (m, 1H), 2.27–2.20 (m, 1H), 2.04 (br s, 1H), 1.64 (br s, 1H).  13C 
N
O
OO
Ph
HO
HO
HO
DD
54 53 
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NMR (CDCl3): δ 135.9, 132.7, 78.5, 42.7, 34.0.  m/z (CI) 116.08 calculated for 
C6H8D2O2:  [M+[NH4]+–H2O]+ 116.1. 
 
 
 
d2-((1R,2R)-2-Acetoxycyclopent-3-en-1-yl)methyl acetate 55:  To a stirred 
solution of crude 54 (0.93 g) and 4-dimethylaminopyridine (DMAP, 0.08 g, 0.7 
mmol) in DCM (10 mL) at 0 °C was added NEt3 (1.6 mL, 11.0 mmol) and Ac2O (1.1 
mL, 12.0 mmol) dropwise.  The resulting mixture was allowed to warm to room 
temperature overnight whereupon it was quenched with water.  The solution was 
extracted into DCM (3 × 20 mL) and the combined organic extracts were dried over 
MgSO4 and the solvent removed in vacuo.  The crude product was purified by 
column chromatography (2:3 EtOAc−n-hex) to yield 55 (0.27 g) as a pale yellow oil.  
1H NMR (CDCl3): δ 6.11–6.08 (m, 1H), 5.88–5.83 (m, 1H), 5.76–5.72 (m, 1H), 
2.72–2.66 (m, 1H), 2.52–2.45 (m, 1H), 2.29–2.21 (m, 1H), 2.04 (s, 3H), 2.02 (s, 3H).  
13C NMR (CDCl3): δ 171.4, 171.0, 137.1, 129.8, 78.5, 63.8–63.2 (q), 39.8, 35.0, 
21.4, 21.3.  m/z (CI) 200.10 calculated for C10H12D2O4:  [M+H]+ 200.1.  IR (cm-1):  
2924 (C−H), 1734 (C=O), 1236 (C−O). 
 
AcO
AcO
DD
HO
HO
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d2-((1S,4R)-4-(2-Amino-6-chloro-9H-purin-9-yl)cyclopent-2-en-1-yl)methyl 
acetate 56:  Sodium hydride (NaH, 60% dispersed in mineral oil, 0.11 g, 2.9 mmol) 
and 2-amino-6-chloro-purine (0.49 g , 2.5 mmol) in THF (10 mL) were stirred for 30 
min at room temperature in the dark.  The pale yellow solution was added to a flask, 
equipped with reflux apparatus, containing tetrakis(triphenylphosphine)palladium(0) 
(Pd(PPh3)4) (0.22 g, 10 mol %) and 55 (0.38 g, 1.9 mmol) in THF (10 mL), and the 
resulting solution was degassed and heated under argon at 60 °C overnight in the 
dark.  The solution was cooled to room temperature whereupon H2O (5 mL) was 
added, the mixture was extracted with DCM (2 × 30 mL) and the combined organic 
extracts were dried over MgSO4.  The solvent was removed in vacuo.  The crude 
material was purified by column chromatography (1:4 to 3:2 EtOAc−n-hex) to yield 
56 (0.19 g, 32%) as an off-white solid.  mp:  120–123 °C.  1H NMR (CDCl3): δ 7.83 
(s, 1H), 6.15 (ddd, J = 5.6, 2.1, 2.0 Hz, 1H), 5.91 (ddd, J = 5.6, 2.2, 2.1 Hz, 1H), 
5.58–5.56 (br m, 1H), 3.19–3.15 (m, 1H), 2.85 (ddd, J = 14.2, 8.9, 8.5 Hz, 1H), 2.06 
(s, 3H), 1.70 (ddd, J = 14.2, 5.7, 5.5 Hz, 1H).  13C NMR (CDCl3): δ 171.4, 159.5, 
153.8, 151.6, 140.9, 138.3, 130.2, 125.9, 59.9, 44.7, 34.9, 21.3.  m/z (ES+) 332.09 
calculated for C13H12D235ClN5O2Na:  [M+Na]+ 332.1.  IR (cm-1):  3428 (N−H), 3301 
(N−H), 1716 (C=N), 1612 (C=O), 1558 (C=C aromatic), 1257 (C−O). 
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d2-((1S,4R)-4-(2-Amino-6-(cyclopropylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methyl acetate 57:  To a solution of 56 (0.12 g,  0.4 mmol) in MeOH (10 mL) 
was added cyclopropylamine (0.07 mL, 1.0 mmol) at 0 °C and the solution was 
heated to 55 °C overnight.  The reaction was allowed to cool and the solvent 
removed in vacuo to obtain 57 (0.10 g, 77%) as an off-white solid.  1H NMR 
(CDCl3): δ 7.52 (s, 1H), 6.10 (ddd, J = 5.6, 2.1, 2.1 Hz, 1H), 5.92–5.88 (m, 2H), 
5.57–5.53 (br m, 1H), 4.83 (br s, 2H), 3.16–3.11 (m, 1H), 3.03–2.97 (m, 1H), 2.84 
(ddd, J = 14.0, 8.8, 8.7 Hz, 1H), 2.07 (s, 3H), 1.64 (ddd, J = 14.0, 6.0, 5.8 Hz, 1H), 
0.88–0.83 (m, 2H), 0.64–0.60 (m, 2H).  13C NMR (CDCl3): δ 171.4, 160.4, 156.7, 
137.3, 135.7, 131.2, 115.3, 59.1, 44.6, 35.5, 24.1, 21.3, 7.8 (2C).  m/z (ES+) 
331.1854 calculated for C16H19D2N6O2:  [M+H]+ 331.1852.   IR (cm-1):  3301 (N−H), 
3201 (N−H), 2927 (C−H), 1731 (C=N), 1597 (C=C aromatic), 1477 (CH2), 1257 
(C−N). 
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d2-((1S,4R)-4-(2-Amino-6-(cyclopropylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 42:  To a solution of 57 (0.09 g, 0.3 mmol) in EtOH (10 mL) was added 
1 M NaOH (1.0 mL, 1.0 mmol) dropwise and the solution was allowed to stir at 
room temperature for 6 h.  The solvent was removed in vacuo and the crude product 
was purified by column chromatography (1:19 MeOH−DCM) to yield 42 (0.05 g, 
64%) as a colourless solid.  mp:  136–140 °C.  1H NMR (CDCl3): δ 7.70 (s, 1H), 
6.13 (ddd, J = 5.6, 2.1, 2.0 Hz, 1H), 5.86 (ddd, J = 5.6, 2.1, 2.0 Hz, 1H), 5.52–5.44 
(br m, 1H), 3.29–3.25 (m, 2H), 3.01–2.93 (m, 1H), 2.73 (ddd, J = 13.9, 8.8, 8.5 Hz, 
1H), 1.65 (ddd, J = 13.9, 5.8, 5.6 Hz, 1H), 0.87–0.74 (m, 2H), 0.61–0.51 (m, 2H).  
13C NMR (CDCl3): δ 160.4, 156.2, 138.2, 136.0, 129.5, 113.4, 59.3, 48.3, 34.2, 23.0, 
6.3 (2C).  m/z (ES+) 289.1738 calculated for C14H17D2N6O:  [M+H]+ 289.1746.  IR 
(cm-1):  3332 (N−H), 1592 (C=C aromatic), 1481 (CH2), 1392 (CH3), 1261 (C−N), 
1103 (C−O).  The LC-MS/MS chromatogram for compound purity can be found in 
Supplementary Information Figure S1. 
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(S)-4-(2-Amino-6-(cyclopropylamino)-9H-purin-9-yl)cyclopent-1-
enecarbaldehyde 16c:32 To anhydrous DMSO (33 µL, 0.5 mmol) was added oxalyl 
chloride (20 µL, 0.2 mmol) in anhydrous THF (3 mL) under nitrogen at −78 °C.  The 
mixture was stirred for 5 min and ABC 7 (0.05 g, 0.2 mmol) in anhydrous THF (5 
mL) was added and stirring continued at −78 °C for 1 h.  NEt3 (127 µL, 0.9 mmol) 
was then added and the temperature allowed to rise to 0 °C over 1 h.  Water (5 mL) 
was added to quench the reaction and the mixture extracted into diethyl ether (3 × 20 
mL).  The organic extracts were dried over MgSO4 and the solvent removed in 
vacuo.  The crude mixture was purified by column chromatography (1:99 to 1:24 
MeOH−DCM) to yield 16c (8 mg, 16%) as an off-white cloudy oil.31 1H NMR 
(CDCl3): δ 9.84 (s, 1H), 7.49 (s, 1H), 6.11–6.09 (m, 1H), 5.92–5.85 (m, 1H), 5.52–
5.48 (m, 1H), 3.19–3.12 (m, 1H), 2.89–2.72 (m, 3H), 0.79–0.71 (m, 2H), 0.59–0.51 
(m, 2H).  m/z (ES+) 285.1475 calculated for C14H17N6O:  [M+H]+ 285.1464.  
N
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(1R,4S)-4-(Methoxycarbonyl)cyclopent-2-enaminium chloride 44:48 SOCl2 (1.5 
mL, 0.02 mol) was added to MeOH (15 mL) dropwise at 0 °C.  The solution was 
allowed to stir for 5 min and (1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-one 28 (1.14 g, 
0.01 mol) was added.  The resulting mixture was allowed to stir at 0 °C under 
nitrogen for 1 h.  SOCl2 and MeOH were removed in vacuo to yield 44 (1.73 g, 95%) 
as a colourless crystalline solid.  mp:  94–98 °C (lit.48 mp:  91.1–94.2 °C).  1H NMR 
(DMSO-d6): δ 8.40 (s, 3H), 6.08 (ddd, J = 5.5, 2.0, 1.9 Hz, 1H), 5.96–5.83 (m, 1H), 
4.25–4.09 (m, 1H), 3.70 (ddd, J = 7.2, 5.9, 2.3 Hz, 1H), 3.65 (s, 3H), 2.58–2.51 (m, 
1H), 2.04–1.83 (m, 1H).  13C NMR (DMSO-d6): δ 173.2, 134.7, 130.9, 55.7, 52.4, 
49.4, 31.7.  m/z (CI) 141.08 calculated for C7H11NO2:  [M+H]+ 142.  IR (cm-1):  3102 
(N−H), 3066 (N−H), 1700 (C=O), 1203 (C−O). 
 
 
 
(1S,4R)-Methyl-4-((2,5-diamino-6-chloropyrimidin-4-yl)amino)cyclopent-2-
enecarboxylate 45:  To DADCP 30 (0.70 g, 4.0 mmol) and 44 (0.70 g, 4.0 mmol) in 
t-BuOH (10 mL) was added NaHCO3 (1.20 g, 14.0 mmol) and the dark red solution 
was stirred in a sealed tube at 90 °C for 14 h.  The mixture was allowed to cool and 
was filtered under suction.  The solvents were removed in vacuo and the crude 
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product was purified by column chromatography (1:49 to 1:19 MeOH−DCM) to 
yield 45 (0.71 g, 42%) as a dark brown solid.  1H NMR (CDCl3): δ 6.00–5.95 (m, 
1H), 5.94–5.92 (m, 1H), 5.28–5.26 (m, 1H), 3.74 (s, 3H), 3.58–3.53 (m, 1H), 2.74–
2.67 (m, 1H), 2.57–2.50 (m, 1H).  m/z (ES+) 284.0911 calculated for 
C11H15N5O235Cl:  [M+H]+ 284.0914 and 286.0888 calculated for C11H15N5O237Cl:  
[M+H]+ 286.0885.  
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2.6 Supplementary Information 
 
 
 
 
 
Figure S1:  LC-MS/MS chromatogram (elution time 12.8 min) (A) and an EPI spectrum (precursor 
ion of m/z 289 and product ion of m/z 191) (B) for D2-ABC. LC-MS/MS, liquid chromatography-
tandem mass spectrometry; EPI, enhanced product ion. 
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3.1 Introduction 
 
Many marketed drugs undergo an oxidative bioactivation;1 a process that can be 
associated with adverse reactions in a small minority of patients.2,3 Through 
theoretical study and applied research, the mechanisms leading to the bioactivation 
of drugs can be determined, and this knowledge can in turn serve to deliver a better 
design of drugs that might produce a lower or no incidence of ADRs.4 
 
Oxidation of ABC in humans occurs on the 5'-C primary alcohol function, where it is 
metabolised inter alia by ADH isozymes ADH1A (αα) and ADH2C2 (γγ) to the 
major carboxylic acid isomer 17a via a highly reactive aldehyde intermediate 16a.5 
Alternatively, ABC can undergo phase II metabolism by UGT, to its 
pharmacologically inactive glucuronide metabolite 18 (Figure 3.1).6 This is the major 
clearance route, as discussed in Chapter 1.  Aldehyde 16a is able to undergo 
epimerisation to aldehyde 16b or isomerisation to aldehyde 16c and these 
compounds can undergo further oxidation by ADH1A to their respective carboxylic 
acid metabolites 17b and 17c.  Further to this, 16b and 16c can undergo reduction 
reactions by ADH2C2 to form isomeric parent compounds 7b and 7c respectively. 
 
Although this oxidative metabolic route is known, it is not fully understood, with a 
lack of knowledge of the enzymology and stereochemistry of the products and the 
contribution of 16 to ABC’s toxicity is unknown.  Deuterated analogues of drugs or 
deuterated substrates are well known to probe metabolic activities, pharmacokinetics 
or bioactivation.  Examples of these include, 1-methyl-4-phenyl-1,2,3,6-
Chapter 3 – Probing the Oxidative Metabolism of Abacavir 
121 
tetrahydropyridine (MPTP), a neurotoxin,7 domiodol, a mucolytic drug8 and semi-
synthetic artemisinin-based drugs.9 
 
 
 
Figure 3.1:  Biochemical oxidation of ABC 7 to its stereo-equivalent aldehyde intermediate 16a by 
ADH and further metabolism of 16a to the major carboxylic acid isomer 17a in vitro by ADH1A 
(αα)/ALDH.  At the beginning of this work, the involvement of ALDH in this oxidation pathway was 
unknown and ADH1A was shown to oxidise ABC to 17a.5 Aldehyde 16a can undergo epimerisation 
to 16b, which in turn is oxidised by ADH1A to carboxylic acid 17b or reduced to an isomer of ABC, 
7b.  Alternatively, 16a can undergo isomerisation to aldehyde 16c, which has shown to undergo in 
vitro and in vivo protein adduct formation.  Isomer 16c can also undergo further oxidation to 
carboxylic acid 17c or reduction to an isomeric parent compound 7c.  Through a phase II pathway, 
ABC can be metabolised to its pharmacologically inactive glucuronide metabolite 18 by UGT.  This is 
the major phase II clearance route, as discussed in Chapter 1.  UDP, uridine diphosphate; UGT, UDP-
glucuronosyl transferase.  Adapted from Walsh et al.5 and Charneira et al.10 
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3.1.1 ADH and ALDH inhibitors. 
To probe the oxidative metabolism of ABC, the ADH inhibitor, 4-MP (Figure 3.2) 
would be required.  This would allow investigation into this pathway and has been 
shown to be effective in blocking this oxidative metabolism.5,11 With no research 
available for the involvement of ALDH and its isozymes in ABC’s metabolism, an 
effective ALDH inhibitor is unknown.  The inhibitors cyanamide and disulfiram 
(DSF) were trialled.  
 
 
 
Figure 3.2:  Inhibitor of ADH, 4-MP (A) and inhibitors of ALDH, cyanamide (B) and DSF (C) will 
be required to probe ABC’s oxidative metabolism pathway.  4-MP has shown to be an effective ADH 
inhibitor in blocking ABC-17 formation5,11 but the involvement of ALDH in the metabolism pathway 
is unknown, resulting in the trialling of ALDH inhibitors cyanamide and DSF.  4-MP, 4-
methylpyrazole; DSF, disulfiram. 
 
3.1.1.1 ADH inhibitor:  4-MP. 
4-MP (fomepizole) (Figure 3.2 A) is a competitive inhibitor, with respect to EtOH, 
of ADH isozymes ADH1A, ADH1B1, ADH1B2, ADH1C1 and ADH1C2 and a non-
competitive inhibitor of ADH1B3, ADH2 and ADH4.12 It is known that ADH1A and 
ADH2C2 are involved in ABC metabolism however, whether 4-MP would act as a 
competitive or non-competitive inhibitor with respect to ABC is unknown.  It is clear 
however, that 4-MP would inhibit the desired isozymes.  4-MP, acting as an enzyme 
N
H
N H2N
C
N SN
S
S
S
N
C B A 
Chapter 3 – Probing the Oxidative Metabolism of Abacavir 
123 
inhibitor, is often used as an antidote in the treatment of ethylene glycol and 
methanol poisoning.12,13 
 
3.1.1.2 ALDH inhibitors:  Cyanamide and DSF. 
  3.1.1.2.1 Cyanamide. 
Cyanamide (Figure 3.2 B), a pro-drug that once metabolised to a nitroxyl 
intermediate (Figure 3.3) is an irreversible inhibitor of ALDH isozyme ALDH2,14 
and it is often used as a second-line treatment to treat alcoholism.15 Furthermore, it is 
a catalase inhibitor.16 Cyanamide is activated by catalase and hydrogen peroxide 
(H2O2) to a N-hydroxycyanamide intermediate,16 which readily decomposes to 
cyanide and the active nitroxyl metabolite (Figure 3.3).17 This metabolite can act as 
both a reversible (via disulfide formation) and non-reversible inhibitor (via 
sulfinamide formation) (Figure 3.3), depending on the environmental pH.18 
 
 
 
Figure 3.3:  Cyanamide is metabolised by catalase and H2O2 to form an N-hydroxycyanamide 
intermediate,16 which decomposes to cyanide and the active nitroxyl metabolite.17 This intermediate 
will act as a non-reversible inhibitor through sulfinamide formation (pathway a) or as a reversible 
inhibitor through disulfide formation (pathway b).  Adapted from Koppaka et al.14 
 
 
H2N
C
N
HN
C
N
OH
HC
N
HN
O
ba
Cys302
SH
Cys302
SS
Cys302
Cys302
S
H
HN
OH
– H2O
Cys302
SHN
Cys302
S
H2N O + H2O
Catalase, H2O2
Nitroxyl intermediateN-HydroxycyanamideCyanamide
Chapter 3 – Probing the Oxidative Metabolism of Abacavir 
124 
3.1.1.2.2 DSF. 
DSF (tetraethylthioperoxydicarbonic diamide) (Figure 3.2 C) is an irreversible 
inhibitor of ALDH isozymes ALDH1A1 and ALDH2 although, it is a more efficient 
ALDH1A1 inhibitor.19 DSF, marketed as Antabuse, is used to treat alcoholism.  It is 
metabolised to a variety of substrates (Figure 3.4), all of which are capable of 
inhibiting the ALDH enzyme20-23 via the Cys 302 residue.20 The first metabolism 
step, reduction of DSF, yields N,N-diethyldithiocarbamate (DDC).  Further 
metabolism, by hepatic thiol methyltransferases, produces S-methyl-DDC (MeDDC).  
This intermediate can be metabolised by CYP P450 and flavin monooxygenase 
(FMO) enzymes23 to a MeDDC sulfine and a MeDDC sulfoxide metabolite.  
MeDDC sulfine can be further oxidised to S-methyl-N,N-diethylthiocarbamate 
(MeDTC) followed by oxidation to MeDTC sulfoxide and then MeDTC sulfone 
(Figure 3.4). 
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Figure 3.4:  DSF is an irreversible ALDH (isozymes ALDH1A1 and ALDH2) inhibitor acting at the 
Cys 302 residue.  It is metabolised, by a variety of, namely CYP P450, enzymes, to a number of 
substrates, all of which have been shown to possess ALDH inhibitory properties.20,22 DDC, N,N-
diethyldithiocarbamate; MeDDC, S-methyl-DDC; MeDTC, S-methyl-N,N-diethylthiocarbamate;  
FMO, flavin monooxygenase.  Adapted from Koppaka et al.,14 Pike et al.23 and Mays et al.22 
 
3.1.2 Kinetic isotope effect. 
When comparing deuterated substances to their protium equivalents, the kinetic 
isotope effect (KIE) can explain altered rates of reactions/metabolism pathways. 
Where an atom, involved in the RDS step of a molecule, is replaced by an isotope, a 
primary KIE is seen.  Thus, the KIE is defined as the observed rate change within a 
reaction where one of the atoms contributing to the rate mechanism is isotopically 
substituted.24 The KIE can be expressed as a ratio of its rates: 
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The KIEs for hydrogen are larger than those for other elements due to the high mass 
ratios:  H:D:T ≈ 1:2:3.  For a KIE to be present, the ratio of the rate constants must 
be greater than one:  The larger the ratio, the greater the KIE.  In terms of H and D, 
the KIE can be explained by the difference between the energies of the reactant and 
transition states (Figure 3.5).  The C−D bond is of a lower zero point energy than the 
C−H bond, therefore more energy is required to break the C−D bond and form the 
transition state.  The zero point energy difference between the transition states for 
both H and D reduces so overall more energy is required to break the C−D bond.  
The resulting effect is slower bond cleavage, and therefore the KIE can also be 
defined as the ratio of the rate constants of bond cleavage. 
 
The KIE exists in two major forms:  The primary and secondary KIE.  The primary 
KIE, of most interest in this research, is such that the isotopically substituted atom is 
involved in the breaking or making of a covalent bond during the reaction.24 When 
an isotopic effect is still observed, even though the isotopic atom is not involved in 
the bond breaking/making, it is termed the secondary kinetic isotope effect.25 KIEs 
have been shown in several studies to develop and explain mechanisms of drug 
metabolism.26-28 
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Figure 3.5:  The zero point energy difference for C−D is less than that for C−H due to the heavier 
mass of deuterium.  The zero point energy differences at the transition state levels for both                
[C---D---B]‡ and [C---H---B]‡ reduces so the energy values become comparable.  Therefore overall, 
more energy is required to break the C−D bond compared to the C−H bond. 
 
3.1.3 Michaelis–Menten parameters. 
In order to determine any KIE for an enzymic reaction and to compare rates of 
metabolism between isotopically substituted compounds and their parent 
isotopologues, the Michaelis–Menten parameters, Vmax and Km, should be 
determined.  They are defined as follows:  Vmax is the maximum rate at the saturating 
substrate concentration and Km is the substrate concentration at the rate, which is half 
of Vmax.  They can both be determined by conducting rate experiments:  The rate is 
calculated over increasing substrate concentrations.  From this calculation, via 
graphical methods (plotting 1/v vs. 1/[S]) as depicted in Figure 3.6, the parameters 
can be determined. 
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Figure 3.6:  Graph showing enzymic reaction rate vs. [substrate], with the Michaelis–Menten 
parameters, Vmax and Km shown (A).  Graph showing 1/v vs. 1/[S]:  The Michaelis–Menten parameters 
can be calculated from the gradient and the y- or x-axis intercepts (B). 
 
In this research, the Vmax parameters were used to determine any KIE according to 
the following equation: 
€ 
KIE = VmaxHVmaxD  
 
Two aspects of ABC’s oxidation in biological systems are unresolved: The 
isomerisation of 16a (invoked to explain the formation of multiple carboxylate 
isomers but never characterised definitively) and the contribution of ALDH to the 
oxidation of ABC aldehyde. The following research conducted aims to further 
investigate these uncertainties.  The Michaelis–Menten values will be calculated 
measuring product formation (ABC-17) as demonstrated by Patanella et al.29 
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3.2 Aims 
 
• To determine the metabolic fate of D2-ABC in human liver cytosol 
• To determine the Michaelis–Menten parameters, Km and Vmax, and use their 
values to calculate whether a KIE is present with D2-ABC in comparison with 
ABC 
• To determine if oxidative metabolism of D2-ABC can be retarded compared 
to ABC and investigate how deuteration of ABC at the 5'-position affects 
ABC toxicity. 
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3.3 Results & Discussion 
 
3.3.1 Comparative metabolism of ABC and D2-ABC in human liver cytosol. 
3.3.1.1 Quantification of the formation of carboxylic acid. 
For all experiments, the formation of ABC-17 (Figure 3.7 A) was used as the end-
point.  Although substrate or NAD(P)+ has been shown to be a well utilised method 
for enzymatic metabolism experiments, product formation has also been shown to be 
effective as used by Patanella et al. when applied to CBV.29 As three carboxylic acid 
isomers were formed (17a–17c), (Figure 3.7 B) the peak areas of the isomers were 
combined and the analyte:IS ratio was then calculated.  Results are therefore reported 
as the formation of collective carboxylic acid products. 
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Figure 3.7:  ABC 7 and D2-ABC 42 are metabolised via aldehyde intermediates to their respective 
carboxylic acid metabolites with the formation of ABC-COOH 17a–17c as the end-point for both 7 
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and 42 (A).  The formation of three carboxylic acid metabolites was evident from the LC-MS/MS 
chromatograms for both ABC (B) and D2-ABC (C).  The three COOH isomers eluted at 8.5, 8.8, and 
9.2 min and 8.4, 8.7 and 9.0 min for ABC and D2-ABC respectively.  Carboxylic acid 17a was the 3rd 
eluted isomer for both compounds and this was determined through comparison with the authentic 
standard 2269W93, supplied by GSK.  Both chromatograms are taken from the inhibitor experiments, 
experiment 7 (Table 3.1). GSK, GlaxoSmithKline. 
 
Linear calibration curves, with concentration ranges determined previously,11 were 
used to estimate analyte concentrations from LC-MS/MS data.  A curve was 
generated by plotting the ratio of the peak areas of analyte:IS against concentration 
of analyte (nM).  For experiments where ABC was the compound assayed, D2-ABC 
(200 nM) was used as the IS.  And conversely, ABC (200 nM) was used as the IS 
when D2-ABC was the compound assayed.  Representative calibration curves for 
ABC, D2-ABC and ABC-17 are shown in Figure 3.8. 
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  A        ABC   B     D2-ABC 
     
      
  C         ABC-COOH (ABC as IS)  D      ABC-COOH (D2-ABC as IS) 
     
 
Figure 3.8:  Representative calibration curves for ABC (R2 = 0.9999) (A), D2-ABC (R2 = 0.9992) (B), 
ABC-COOH (R2 = 1.0000) with ABC as the IS (C) and ABC-COOH (R2 = 0.9992) with D2-ABC as 
the IS (D).  The range of analyte concentrations for ABC and D2-ABC was 5–2000 nM and 10–4000 
nM for ABC-COOH.  Each graph represents data with the line of best fit not forced through the 
origin. 
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3.3.1.2 Linearity of the oxidation of ABC and D2-ABC with respect to 
cytosolic protein concentration. 
To determine the appropriate protein concentration for incubations of ABC and D2-
ABC with liver cytosol, and to ensure linearity of ABC-17 formation with respect to 
protein concentration, the substrates (10 mM) were incubated with the following 
concentrations of cytosolic protein:  0.1, 0.25, 0.5, 0.75, 1.0, 1.25 and 1.5 mg/mL.  
The duration of each incubation was 2 h:  After this length of time, the 
concentrations of carboxylic acid were sufficient for quantification by LC-MS/MS.  
Representative multiple reaction monitoring (MRM) chromatograms for ABC and 
D2-ABC incubations at a protein concentration of 0.75 mg/mL are shown in Figure 
3.9.  For both compounds, the COOH formation was linear at protein concentrations 
from 0.1–1.5 mg/mL and these results can be seen in Figure 3.10. 
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Figure 3.9:  MRM chromatograms obtained after 2 h incubations of ABC (10 mM) at 0.75 mg/mL 
cytosolic protein (A) and D2-ABC (10 mM) at 0.75 mg/mL cytosolic protein (B). 
 
The mid-point concentration of liver cytosol protein, 0.75 mg/mL, was chosen as the 
concentration for all subsequent incubations. 
 
 
ABC (m/z 287/191) 
D2-ABC (m/z 289/191) 
ABC-COOH (m/z 301/191) 
A 
B 
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Figure 3.10:  Graph representing the formation of ABC-COOH 17 (µM) from ABC (R2 = 0.967) and 
D2-ABC (R2 = 0.963) against liver cytosolic protein concentrations (0.1–1.5 mg/mL) after 2 h 
incubations.  The substrate concentration was 10 mM.  The NAD+ concentration was 7.5 mM.  Data 
were obtained from two separate experiments over two days and are shown as the mean value (n = 2) 
± standard deviation (ns = not significant, * p < 0.05, ** p < 0.01, *** p < 0.0001; ABC vs. D2-ABC; 
unpaired t-test). 
 
3.3.1.3 Formation of 17a from ABC and D2-ABC with respect to time. 
Preliminary work within the Liverpool group had shown that there was a statistically 
significant difference between the rate of formation of ABC-17 from ABC and D2-
ABC by human liver cytosol over time.  This observation was further investigated 
within this research.  Using a fixed protein concentration of 0.75 mg/mL and 
ABC/D2-ABC at 10 µM, the COOH formation was measured over 1, 4, 8, 16, 20 and 
24 h.  An early study of ABC’s oxidation in human liver cytosol noted that a long 
incubation time (20 h) was required to yield detectable quantities of the carboxylic 
acids.5 MRM chromatograms for both substrates over the individual times can be 
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seen in Supplementary Information S1A and S1B.  The chromatograms obtained at 
24 h can be seen in Figure 3.11. 
 
 A 
 
B 
         
 
Figure 3.11:  MRM chromatograms showing ABC-17 formation after a 24 h incubation of ABC (10 
µM) (A) or D2-ABC (10 µM) (B) with human liver cytosol (protein concentration, 0.75 mg/mL). 
ABC (m/z 287/191) 
D2-ABC (m/z 289/191) 
ABC-COOH (m/z 301/191) 
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Figure 3.12:  Formation of ABC-COOH 17 (µM) by human liver cytosol, with samples taken at 1, 4, 
8, 16, 20 and 24 h for both ABC (R2 = 0.9797) and D2-ABC (R2 = 0.9821).  The substrate 
concentration was 10 mM. The protein concentration was 0.75 mg/mL.  The NAD+ concentration was 
7.5 mM.  Data were obtained from three separate experiments on different days.  Data represent mean 
(n = 3) ± standard deviation (ns = not significant, ** p < 0.01; ABC vs. D2-ABC; unpaired t-test). 
 
Three COOH isomers are formed (Figure 3.7 B), although there is one major isomer 
(Figure 3.11):  Compound 17a, identified by chromatographic comparison with an 
authentic standard (compound 2269W93 supplied by GSK).  This compound remains 
the major isomer over time.  It can also be seen that the concentration of ABC-17 
formed is lower for D2-ABC compared to ABC:  At 24 h, 1.03 µM and 2.07 µM, 
respectively.  This difference can be consistently seen throughout the experiments 
when comparing COOH formation over time (Figure 3.12 and Supplementary 
Information S1A and S1B).  Both ABC and D2-ABC oxidation follows the same 
pattern, albeit ABC-17 is formed from D2-ABC at a lower concentration.  The slower 
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bond cleavage of both D atoms would be slower, leading to a slower COOH 
formation.  This overall comparable relationship (linear increase of COOH formation 
over time) was essential to obtain accurate data for comparison of the rate of COOH 
formation from ABC-17 vs. D2-ABC-17.  
 
3.3.1.4 Determination of the oxidative metabolic fate of D2-ABC compared 
to ABC. 
To conduct enzymatic rate experiments, it was vital that ABC and D2-ABC had the 
same oxidative metabolic fate in human liver cytosol.  This was determined using 
two enzyme inhibitors, namely 4-MP5,30 and DSF31 for ADH and ALDH, 
respectively, and an aldehyde trapping agent, methoxylamine.5 The two selective 
dehydrogenase inhibitors would enable confirmation of a two-step metabolic 
pathway for both compounds and the trapping agent would confirm that the aldehyde 
intermediate was formed during the oxidation process.   
 
The initial metabolism of ABC by ADH has been documented5 but the oxidation 
from aldehyde to carboxylic acid has received little research attention.  Previous 
work completed within the Liverpool group has shown, using 4-MP (600 µM), that 
approximately 90% inhibition of ABC-17 formation from ABC can be achieved in 
human liver cytosol, but no such experiments have been conducted with DSF, or any 
other ALDH inhibitor, in human liver cytosol.11 
 
3.3.1.4.1 Identification of a suitable ALDH inhibitor. 
Without knowing whether ALDH contributes to the oxidation of ABC-16 in human 
liver cytosol,5 it was decided that cyanamide, an irreversible inhibitor of human 
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ALDH2, would be used.14 Cyanamide is known to inhibit the oxidation of carbovir 
to its carboxylic acid in rat liver cytosol.32 However, ALDH2, which is highly 
expressed in human liver,32 is a mitochondrial enzyme.33 ALDH1 is expressed in 
human liver cytosol.33 Therefore it seemed unlikely cyanamide would inhibit ABC’s 
oxidation in human liver cytosol.  Initial experiments were conducted with 10 mM 
ABC and cyanamide concentrations between 0.05–10 mM, cyanamide 
concentrations based upon those used by Patanella et al.,29 but reproducible 
inhibition could not be obtained.  Following this result, DSF, an irreversible inhibitor 
of isoforms ALDH1A1 and ALDH2, was the ALDH inhibitor of choice. 
Methoxylamine (10 mM) was used to trap the aldehyde intermediate,5 and thereby 
inhibit the oxidation of ABC to the carboxylic acid.  This agent provided 
confirmation that oxidation of ABC was occurring via the aldehyde. 
 
 3.3.1.5 Investigation into the oxidative metabolic fate of ABC and D2-ABC. 
The final experiments were completed as shown in Table 3.1, with results shown in 
Figure 3.13.  Mass chromatograms obtained for ABC and D2-ABC for all the 
incubations are shown in Supplementary Information S2A and S2B.  
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Table 3.1:  Experiments using an ADH inhibitor (4-MP), an ALDH inhibitor (DSF) and an aldehyde 
trapping agent (methoxylamine) to confirm that the oxidative metabolic pathways of both ABC and 
D2-ABC in human liver cytosol include an aldehyde intermediate.* 
 
Experiment Inhibitor/Trapping Agent  
(Final Concentration) 
+/−  NAD  
(7.5 mM) 
1 - - 
2 4-Methylpyrazole (600 µM) 
Disulfiram (500 µM) 
+ 
3 - + 
4 Methoxylamine (10 mM) + 
5 4-Methylpyrazole (600 µM) + 
6 Disulfiram (500 µM) + 
7 Methoxylamine (10 mM) 
Disulfiram (500 µM) 
+ 
* Each experiment consisted of two incubations of substrate (10 µM) with human liver cytosol (protein 
concentration, 0.75 mg/mL):  One containing D2-ABC and the other containing ABC. 
 
For experiment 1 (Table 3.1), a negative control, it was predicted that no COOH 
formation would occur due to the absence of co-factor NAD+, which is required for 
ADH to oxidise its substrates.  The activities of most ALDH enzymes are optimal 
with NAD+ as co-factor, and both human cytosolic ALDH1 and human 
mitochondrial ALDH2 use NAD+.34 It can be seen from mass chromatogram A in 
Figures S2A and S2B (Supplementary Information), and from Figure 3.13, that a 
small amount of COOH formation occurred:  ABC-17 formation from ABC, 0.11 
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µM (8% formation), and ABC-17 formation from D2-ABC, 0.06 µM (7% formation), 
compared to 1.44 µM and 0.88 µM in the positive control, respectively (Figure 3.12).  
All three isomers were formed.  This unexpected COOH formation might have been 
due to minute amounts of NAD+ present in the liver cytosol supplied (Sigma Aldrich, 
UK).  
 
In experiment 2 (Table 3.1), both ADH (4-MP, 600 µM) and ALDH (DSF, 500 µM) 
inhibitors were used to block COOH formation.  This combination of inhibitors 
blocked the COOH formation by a 97% decrease for ABC (0.04 µM) and D2-ABC 
(0.02 µM) compared to the positive control (Figure 3.13).  Although complete 
inhibition was not achieved, turnover of the compounds was inhibited to the same 
extent. 
 
Experiment 3 (Table 3.1), a positive control, was used to compare the formation of 
COOH from both ABC and D2-ABC and to ensure that this product was being 
formed.  The COOH formation from ABC and D2-ABC was 1.44 µM and 0.88 µM, 
respectively (Figure 3.13). 
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Figure 3.13:  Metabolic experiments conducted with ABC and D2-ABC to confirm the compounds 
undertook the same oxidative metabolic pathway in human liver cytosol.  Values shown are the 
combined formation (µM) of three isomeric carboxylic acids. Incubations were conducted over 20 h in 
the presence of ABC (10 µM) or D2-ABC (10 µM).  The protein concentration was 0.75 mg/mL. The 
NAD+ concentration was 7.5 mM.  Data derived from two separate experiments conducted over two 
days.  Data represent mean values (n = 2) ± standard deviation (ns = not significant, ** p < 0.01; ABC 
vs. D2-ABC; unpaired t-test).  Methoxy, methoxylamine. 
 
Methoxylamine (10 mM) was used to trap the aldehyde through imine (oxime) 
formation (Figure 3.14).  Only the imine product for ABC was detected, but a 
reduction in ABC-17 formation from D2-ABC provides evidence that aldehyde 
formation is occurring. Methoxylamine was used at saturating concentrations but 
COOH formation was still observed (Figures 3.13, S2A and S2B) with 0.09 µM 
(94% decrease) being detected for ABC and 0.04 µM (95% decrease) for D2-ABC 
compared to the positive control.  The nucleophilic tendencies of methoxylamine 
  **               ns          ns              ns              **              ns               ns 
n = 2 
ABC 
D2-ABC 
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allow it to react with a variety of compounds, and due to the crude nature of the 
pooled human liver cytosol used, it could have reacted with numerous compounds 
within the cytosol, resulting in by-product formation. 
 
Evidently only small amounts of compounds 19a and 19b were produced, so it was 
not possible to detect either compound by conventional LC-MS/MS.  An EPI LC-
MS/MS scan was used to search selectively for the products of m/z 314 ([M+H]+) 
(compound 19a) and the products of m/z 315 ([M+H]+) (compound 19b).  A peak at 
m/z 191 is the characteristic fragment of both molecules (Figure 3.14).  As can be 
seen from the mass spectra in Figure 3.15, the detection of predicted parent and 
fragment masses led to the conclusion that formation of ABC aldehyde was 
occurring.  For D2-ABC, a parent ion of m/z 314 was detected, with no m/z 315 
found.  The reason for this unexpected molecular ion peak could be due to 
contamination from ABC.  The slower rate of D2-ABC dehydrogenation may have 
resulted in the preparation of D2-ABC yielding more 19a than 19b, hence the 
dominant detection of the parent ion m/z 314.  The mass spectra from the EPI scan 
for this experiment can be found in Supplementary Information S2C. 
 
Nevertheless, from these experiments, it was clear that ADH and ALDH were key 
enzymes in this oxidation process for both ABC and D2-ABC.  Methoxylamine’s 
inhibition of ABC-17 from D2-ABC provided enough evidence that D2-ABC also 
yielded a discrete aldehyde species and therefore the oxidation pathway to the 
aldehyde is similar and the final product formation is the same. 
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Figure 3.14:  Structures of imine (oxime) products:  19a, formed from trapping the aldehyde of ABC 
7 with methoxylamine, and 19b, formed from trapping the aldehyde of D2-ABC 42 with 
methoxylamine.  The key diagnostic ions were m/z 314 ([M+H]+) and 191 (purine residue of 
molecule, as indicated in blue) for 19a and m/z 315 ([M+H]+) and 191 for 19b. 
 
In experiment 5, 4-MP (600 µM) was used to inhibit ADH enzymes.  4-MP is a 
selective inhibitor of class I ADH isoforms,12,35 and previous research has shown that 
up to 90% of ABC-17 formation from ABC can be prevented using this inhibitor in 
human liver cytosol at a concentration of 600 µM.11 Carboxylic acid formation was 
reduced but 0.62 µM and 0.38 µM ABC-17 were produced from ABC and D2-ABC, 
respectively, representing a 56% and 57% decrease of ABC-17 formation, 
respectively, compared to the positive control (Figure 3.13).  It was expected that a 
greater percentage decrease would be seen, so repeats of the experiments would seek 
to confirm this expectation with increased concentration of 4-MP.  Chromatograms 
for these experiments can be seen in Supplementary Information Figures S2A and 
S2B. 
 
DSF (500 µM) was used as the ALDH inhibitor, as previously discussed.  It had not 
been used before to inhibit the oxidation of ABC.  For experiment 6 (Table 3.1), DSF 
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was co-incubated in human liver cytosol.  Chromatograms for this experiment can be 
seen in Supplementary Information Figures S2A and S2B.  From these assays, 1.3 
µM ABC-17 was formed from ABC and 0.77 µM from D2-ABC, which represented 
an 8% and 13% decrease in the formation of ABC-17, respectively, compared to the 
positive control (1.44 µM and 0.88 µM for ABC and D2-ABC, respectively) (Figure 
3.13).  The COOH formation was not completely suppressed.  However, solubility 
issues did occur with DSF and these may have contributed to inconsistent results.  
Nevertheless, these results are not surprising:  As discussed previously, and as 
demonstrated by Walsh et al.,5 human ADH1A is able to oxidise ABC to the COOH 
product without the involvement of ALDH.  Due to this activity, COOH formation 
would not be stopped without the additional presence of an ADH inhibitor.  
However, the formation of COOH from both compounds was affected and so ALDH 
appeared to contribute approximately equally to the metabolic fate of these 
compounds. 
 
Finally, in experiment 7 (Table 3.1), both DSF (500 µM) and methoxylamine (10 
mM) were used.  This experiment was conducted to ensure that both substrates were 
largely oxidised via the ADH and ALDH pathways.  The formation of COOH in 
these incubations was found to be 0.36 µM (75% decrease) and 1.77 µM (80% 
decrease) for ABC and D2-ABC, respectively, compared to the positive control (1.44 
µM and 0.88 µM for ABC and D2-ABC respectively) (Figure 3.13).  The formation 
of carboxylic acids was greatly reduced in comparison with incubations containing 
exclusively DSF (experiment 5), but greater than that seen in experiment 3, where 
methoxylamine was used.  It might be expected that COOH formation would be 
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reduced even further, but a possible reason for this not occurring could be reactivity 
between DSF and methoxylamine. 
 
From the results of the seven experiments, it was concluded that ABC and D2-ABC 
underwent the same oxidative metabolic fate in human liver cytosol, and so the final 
set of experiments, to determine the rates of metabolism, could be conducted. 
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Figure 3.15:  MRM chromatograms obtained from experiments 3 (positive control, + NAD) (A), 4 
(co-incubation with methoxylamine) (B) and 7 (co-incubation with methoxylamine and DSF) (C) for 
the characterisation of the pathway of ABC oxidation by human liver cytosol (Table 3.1). EPI scan for 
fragments of m/z 314 ([M+H]+ for the oxime derivative of the ABC aldehyde intermediate) can be 
seen in diagrams D and E for experiments 4 and 7, respectively.  The corresponding spectra are 
presented in diagrams F and G, with the predominant fragment of m/z 314 at m/z 191.  MRM, 
multiple reaction monitoring. 
 
 
 
 
 
 
 
 
 
  
 
Figure 3.16:  MRM chromatograms obtained from experiments 3 (positive control, + NAD) (A), 4 
(co-incubation with methoxylamine) (B) and 7 (co-incubation with methoxylamine and DSF) (C) for 
the characterisation of the pathway of D2-ABC oxidation by human liver cytosol (Table 3.1). 
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3.3.1.6 Experimental determination of Michaelis–Menten parameters. 
Once it was ensured that both ABC and D2-ABC were metabolised in the same 
manner with respect to protein concentration, time and metabolic pathway, it was 
possible to conduct rate vs. substrate concentration experiments with human liver 
cytosol.  By completing these experiments, the Michaelis–Menten parameters, Km 
and Vmax, were determined, and the difference of rate of D2-ABC oxidation 
compared with ABC oxidation was calculated. 
 
Following on from work published by Walsh et al.5 and previous work within the 
Liverpool group,11 a final concentration of 10 µM was used for ABC and D2-ABC.  
To determine the saturating substrate concentration, it was decided to conduct 
experiments as described in Section 3.5.1.4, where samples were taken every 10 min 
up to and including 60 min and every 30 min thereafter up to 120 min over a range of 
concentrations.  Initially, the substrate concentrations attempted were ranging from 
10 nM to 10 µM.  Due to relatively slow turnover of substrate to COOH product, it 
was extremely difficult to detect product formation at the lowest concentrations (10–
250 nM).  However, at 500 nM to 10 µM, COOH product, isomer 17a, was detected.  
Using these results to plot rate vs. substrate concentration, it was found that the 
saturating substrate concentration was not reached.  This was determined due to the 
linearity of the Michaelis–Menten graph.  At saturating substrate concentrations, the 
reaction rate should remain constant at increasing substrate concentration.  Substrate 
concentrations greater than 10 µM were therefore required.   
 
The second set of experiments completed were over the higher substrate 
concentrations, 50 µM to 1 mM.  Product formation was easier to quantify with these 
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concentrations, but again, rate vs. substrate concentration showed linearity.  In order 
to determine the required concentrations, the experiments were repeated with 
substrate concentrations ranging from 2.5–10 mM but similar results were obtained.  
Experiments conducted at two concentrations, 20 and 50 mM, gave positive results, 
with the graph showing saturating substrate concentration levels at 20 mM (Figure 
3.17).  Representative mass chromatograms for concentrations 500 µM and 20 mM 
at 0 and 120 min can be seen in Supplementary Information Figures S3A and S3B. 
 
 
 
 
 
 
 
Figure 3.17:  Michaelis–Menten graphs representing incubations of 500 µM to 20 mM substrate 
(ABC or D2-ABC) in human liver cytosol vs. rate of reaction (µM/min).  The protein concentration 
was 0.75 mg/mL.  The concentration of NAD+ was 7.5 mM.  Data were derived from two separate 
experiments over two days.  Data represent the mean values obtained (n = 2) ± standard deviation. 
 
Due to solubility difficulties of ABC/D2-ABC in the incubation buffer, it was 
decided that the most reliable results could only be obtained at the maximum 
substrate concentration of 20 mM.  The results obtained at 50 mM were discarded.  
The experiments were completed for concentrations of 0.5, 1, 2.5, 5, 7.5, 10 and 20 
ABC 
D2-ABC 
n = 2 
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mM for both ABC and D2-ABC with the total formation of COOH as the analytical 
end-point.  The rate data were obtained initially from plotting product formation 
[ABC-17] (µM) vs. time (min).  Representative graphs at the 0.5 mM concentrations 
for both compounds can be seen in Figure 3.18. 
 
 
 
 
 
Figure 3.18:  Representative graphs of ABC-17 production for ABC (A) and D2-ABC (B) obtained 
for the 0.5 mM substrate concentration from 0 to 120 min.  The gradient of the graph (ABC:  0.083, 
R2 = 0.985 and D2-ABC:  0.0165, R2 = 0.975) was the rate value for that specific concentration.  The 
protein concentration in the human liver cytosol was 0.75 mg/mL.  The concentration of NAD+ was 
7.5 mM. 
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After confirming these individual graphs were linear, the gradient of each graph was 
calculated.  This value represented the reaction rate (v).  Finally, these v (µM min-1) 
values were plotted against substrate concentration (mM) (Table 3.2) and the 
Michaelis–Menten parameters were calculated using GraphPad Prism® Version 6 
software (GraphPad Inc, La Jolla, CA, USA) (Table 3.3). 
 
Table 3.2:  The final rate values for the oxidation of ABC and D2-ABC in human liver cytosol over 
the range of 0.5–20 mM substrate concentrations.  The rate values were obtained from the gradients of 
plots of [ABC-17 formation] (µM) vs. time (min).  Experiments were completed on two days and data 
are presented as the mean (n = 2) ± standard deviation.* 
 
Substrate 
Concentration 
(mM) 
Mean Rate for ABC 
 (µM/min)  
± SD 
Mean Rate for D2-ABC 
 (µM/min)  
± SD 
0.5 0.815 ± 0.020 0.023 ± 0.000 
1 1.815 ± 0.304 0.42 ± 0.028 
2.5 3.985 ± 0.954 1.485 ± 0.181 
5 6.227 ± 0.078 2.88 ± 0.526 
7.5 7.52 ± 0.484 3.265 ± 0.310 
10 7.362 ± 1.245 3.618 ± 0.578 
20 7.545 ± 1.823 3.69 ± 0.495 
 
* The protein concentration in the human liver cytosol was 0.75 mg/mL.  The concentration of NAD+ 
was 7.5 mM. 
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Table 3.3:  Michaelis–Menten parameters (Vmax and Km) for the oxidation of ABC and D2-ABC to 
ABC-17 in human liver cytosol.  The data represent values obtained from two separate experiments, 
completed on two days.  Mean values (n = 2) are stated ± standard deviation.  The values were 
calculated using GraphPad Prism® Version 6 software. 
 
Substrate  Vmax Value ± SD Km Value ± SD 
ABC 9.56 ± 0.88 3.19 ± 0.90 
D2-ABC 5.09 ± 0.62 5.08 ± 1.60 
 
It can be seen from Table 3.3 that the Vmax and Km values differ appreciably between 
ABC and D2-ABC.  Using the equation as stated below to determine the KIE,25 the 
kinetic effect can be calculated and the KIE for ABC:D2-ABC was found to be 1.88. 
 
                           = 1.88 
 
For a KIE to be present, it must be that the isotopically substituted atom is directly 
involved in determining the rate of the overall reaction.  This would be the 
abstraction of both D atoms from D2-ABC over both oxidation steps (Figure 3.19). 
 
 
 
Figure 3.19:  Abstraction of two D atoms from D2-ABC 42 over both major oxidation steps to form 
intermediate 58 followed by carboxylic acid 17a.  ADH and/or ALDH would complete this oxidation 
pathway, with the use of the co-factor, NAD+. 
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Practically, it is essential that the KIE value is greater than 1, with a larger value 
representing a larger effect.  Therefore it can be concluded that as the ratio calculated 
for ABC:D2-ABC is 1.88, there is a deuterium isotopic effect on the oxidative 
metabolism of ABC to its carboxylic acid metabolites. Whether both of the 
metabolic oxidation steps are subject to a KIE is yet to be determined. 
 
3.3.2 Cross-reactivity of ABC-specific human T-cell clones with D2-ABC. 
ABC is known to stimulate CD8+ T-cells from HLA-B*57:01 positive 
individuals,11,36,37 therefore in addition to the metabolism studies, the ability of D2-
ABC to stimulate T-cells was also probed.  The chemical cross-reactivity 
experiments were conducted within the University of Liverpool, with full details of 
all methodological protocols available.11 In order to determine whether a D2-ABC-
stimulated T-cell response occurred, cytokine release (IFN-γ, ELISpot assay, Chapter 
1, Section 1.10.2) was examined. 
 
T-cells isolated from HLA-B*57:01-positive individuals were cloned and used 
within all assays.  These T-cells were incubated over 48 h with irradiated autologous 
Epstein–Barr Virus (EBV)-transformed B-cells in the presence of either ABC or D2-
ABC at concentrations of 10, 50 and 100 µM, and it was found that these 
concentrations of D2-ABC stimulated T-cells to the same extent as ABC itself 
(Figure 3.20). 
 
As previously discussed in this chapter, D2-ABC is metabolised oxidatively by 
human liver cytosol at a slower rate in comparison to ABC over 24 h.  Whether this 
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difference continues to be statistically significant over 48 h is unknown.  Due to the 
long incubation times (48 h) of both compounds in the ELISpot assay, it is also 
unknown whether a slower rate of drug metabolism would affect T-cell stimulation.  
The mechanism of T-cell stimulation by ABC remains uncertain, as it is still unclear 
whether the parent drug or a metabolite is responsible for the activation.  However, it 
is known that cytosol from EBV-transformed B-cells can metabolise ABC to its 
carboxylic acids during a 16 h incubation.30 
 
 
   
    
 
Figure 3.20:  Cross-reactivity results for ABC and D2-ABC after a 48 h incubation with four 
individual ABC-specific T-cell clones isolated from HLA-B*57:01-positive individuals and 
autologous EBV-transformed B-cells.  Data shown are results obtained from an ELISpot assay.  IFN-γ 
was measured as spot-forming cells (SFC)/well.  EBV, Epstein–Barr virus; IFN-γ, interferon-γ; 
ELISpot, enzyme-linked immunospot; SFC, spot-forming cells. 
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3.3.3 Cytotoxicological and pharmacological studies with D2-ABC. 
The cytotoxicity of ABC and D2-ABC was determined in MT4 cells, using the MTT 
viability assay at 24 h and 5-day intervals.  The theory and discussion of these assays 
are discussed in Chapter 1, Section 1.11.  Viable cells, with active redox 
metabolism,38 reduce MTT to a purple formazan product that can be measured 
spectrophotometrically.39 The MTT assay has been used previously with MT4 
cells.40 For both ABC and D2-ABC, statistically significant cytotoxicity was seen in 
MT4 cells at 200 µM (p = 0.0013 and p = 0.0021, respectively), 1 mM and 5 mM 
concentrations (Figure 3.21).  In addition to this result, comparable IC50 values were 
obtained for ABC and D2-ABC (370.4 µM and 397.2 µM, respectively).  As at 24 h, 
significant cytotoxicity was also observed after 5 days for both compounds at 200 
µM (p < 0.0001 for ABC and D2-ABC), 1 mM and 5 mM concentrations (Figure 
3.21).  Additionally, the IC50 values generated at this time point were 240.2 µM 
(ABC) and 255.7 µM (D2-ABC).  The cytotoxicity of ABC has been assessed in 
other cell types.41  
 
In addition to cytotoxicity assays, the antiretroviral activities of both compounds 
were determined using HIVIIIB virus replicating in MT4 cells (Figure 3.21). ABC 
exhibits potent in vitro antiviral activity against wild-type HIV-1 in MT4 cells.42,43 
The EC50 values for ABC and D2-ABC were 7.5 µM and 13.4 µM, respectively.  
Comparing these values, it can be seen that D2-ABC maintains potency with 
comparison to ABC.  It should be noted that the drugs countered the cytotoxicity 
caused by viral infection notwithstanding they were themselves somewhat toxic to 
MT4 cells. 
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The evaluations of both IC50 and EC50 values for D2-ABC against ABC indicated D2-
ABC retained pharmacological potency without any change of toxicity in the same 
cell type.  It can be concluded from these data that the placement of two deuterium 
atoms at the 5'-C position does not affect the antiretroviral activity compared to 
ABC.  Specifically, it appears deuteration does not significantly affect the 
metabolism of ABC in T-cells to its pharmacologically active derivative, namely (–)-
CBV-TP; the first step of the pathway being formation of ABC 5'-MP.44 
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Figure 3.21:  Determination of cytotoxicity after 24 h exposure to ABC (A) and D2-ABC (B) and 
after 5-day exposure to ABC (C) and D2-ABC (D) in MT4 cells.  Cell viability was assessed using the 
spectrophotometric MTT assay.  Antiretroviral activity of ABC (E) and D2-ABC (F) against HIVIIIB 
in MT4 cells was assessed indirectly using the spectrophotometric MTT assay, which visualises the 
viral cytotoxicity.  All data are given as the mean ± standard deviation of four experiments conducted 
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Figure 3.21 continued: 
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on different days.  All data were normally distributed.  Statistical analysis was conducted using an 
unpaired t-test and two-tailed p values are given (* p < 0.05; ** p < 0.01; *** p < 0.001).  IC50 (µM) 
data were generated using GraphPad Prism 3.0 statistical analysis software.  0.1% Meth, 0.1% 
methanol. 
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3.4 Conclusions & Future Work 
 
Although the biochemical oxidation of ABC has been widely studied,5,45-47 the 
contribution of the intermediate/metabolite products of this pathway to ABC’s 
toxicity is still unknown.  The possibility ABC-16 mediates the cytotoxicity of ABC 
in MT4 cells cannot be assessed because neither ADH expression by these cells nor 
the effect of ADH inhibitors has been investigated.  ABC-16, an α,β-unsaturated 
aldehyde, has been shown to covalently bind to proteins both in vitro and in vivo, 
although a method for direct detection of this aldehyde intermediate in in vivo 
samples has yet to be discovered.  Within this research, the oxidative metabolism 
was probed further. 
 
To investigate the metabolism of D2-ABC further, sets of experiments were designed 
to confirm that D2-ABC undertook the same metabolic pathway as ABC.  Related 
experiments proved linearity of ABC oxidation with respect to cytosolic protein 
concentration and time.  By inhibiting the two enzymes involved in hepatic oxidation 
of ABC, ADH and ALDH, and trapping the aldehyde intermediate, it was possible to 
confirm that the compounds undertook the same metabolic pathway in human liver 
cytosol. 
 
Finally, the Michaelis–Menten parameters (Vmax and Km) were obtained from a set of 
rate experiments, where the measure of product generation was cumulative COOH 
formation.  Both values were calculated for ABC and D2-ABC, and the Vmax values 
have been used to determine whether an isotopic effect is present in the oxidative 
metabolism of ABC vs. D2-ABC.  This value was calculated at 1.88, illustrating that 
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the oxidative metabolism of the 5'-C OH group in human liver is significantly 
affected by isotopic substitution at this position.  However, it should be noted that 
there might not be a KIE on ABC oxidation in all human cell types:  The NAD-
dependent oxidation of ABC to carboxylic acids in cytosol from EBV-transformed 
B-cells does not involve a 4-MP-sensitive enzyme, i.e. a class I ADH.30 
 
There are limits within the work presented in this thesis and further metabolic studies 
are required in order to determine whether a KIE is present between ABC and D2-
ABC with respect to the rate constants k.  For this analysis, crude liver cytosol 
cannot be used; purified forms of liver ADH and ALDH are required.  Before this 
work can be undertaken, further research into the involvement of individual isoforms 
of both ADH and ALDH is also required and the exact ALDH isoform involved in 
the oxidation would need to be determined.  This identification would also assist in 
choosing a more suitable inhibitor for these experiments. 
 
Also, it will be important to extend the metabolic investigations with D2-ABC to 
non-hepatic cell types, and especially skin cells because the major adverse reactions 
associated with ABC in HIV patients are cutaneous hypersensitivity reactions.48 
 
It was clear from the T-cell cross-reactivity, cytotoxicity and pharmacological assays 
that deuteration of ABC had no ameliorating effect on T-cell activation or MT4 cell 
cytotoxicity but neither did it reduce antiviral activity in MT4 cells.  The mechanism 
of ABC’s toxicity in MT4 cells is unknown; in particular, whether it is an action of 
the parent drug or a metabolite.  Notably, the possibility that the cytotoxicity of D2-
ABC is caused by (–)-D2-CBV-TP or an intermediate of its biosynthesis cannot be 
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excluded because D2-ABC retains the potent antiretroviral activity that is mediated 
exclusively by the anabolic triphosphate.44 Due to the long incubations times of these 
assays, it is difficult to determine whether the slower metabolism of D2-ABC would 
have a significant effect on the pharmacological activity or T-cell activation over a 
shorter period of time.  The likely effect of D2-ABC in vivo is also unclear, and the in 
vivo effects of deuterium substitution of drugs are much less documented.  Although, 
initial studies on a corticotropin-releasing hormone receptor 1 (CRF1) antagonist 
have shown that H replacement with D can slow its oxidative pathway, resulting in 
altered PK parameters.49 By blocking one metabolic pathway in vivo, the metabolism 
of this drug was diverted to other metabolic routes.  In the case of ABC, this 
switching effect would divert drug to the other major, but reversible, deactivating 
pathway, namely O-glucuronidation.6 
 
Further work should include a repeat of the experiments with substrate disappearance 
measured, rather than product formation.  Further to the primary isotope effect, it 
would be interesting to use another deuterated form of ABC, such as the product of 
mono-deuteration of the 4'-C position (Chapter 2, Figure 2.14), which would allow 
for investigation into any possible secondary KIEs.   
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3.5 Experimental 
 
Immunology (cross-reactivity) experiments were conducted and obtained at the 
University of Liverpool by Dr. Catherine Bell and John Farrell (Dr. Dean Naisbitt’s 
research group).  Cytotoxicity/efficacy experiments were also conducted and 
obtained at the University of Liverpool by Dr. Philip Martin (Prof. Andrew Owen’s 
research group). 
 
3.5.1 ABC and D2-ABC metabolism in human liver cytosol. 
All reagents were purchased from Sigma Aldrich, Fisher Scientific (Loughborough, 
UK) and Romil Ltd (Cambridge, UK) unless otherwise stated.  ABC succinate, ABC 
sulfate and ABC carboxylic acid 17a were kind gifts from GSK. 
 
 3.5.1.1 Determination of linearity of ABC/D2-ABC oxidation in human 
liver cytosol with respect to protein concentration. 
Reactions were conducted in sodium pyrophosphate buffer (50 mM, pH 8.8, 500 
µL).  ABC (10 µM) or D2-ABC (10 µM) was incubated with human liver cytosol 
(pooled cytosol from human liver, Sigma Aldrich, UK) (protein concentration, 0.1, 
0.25, 0.5, 0.75, 1.0, 1.25 and 1.5 mg/mL) and NAD (7.5 mM) at 37 °C in a shaking 
water bath for 2 h, whereupon the incubation vials were placed on ice for 5 min.  An 
aliquot (10 µL) of the reaction mixture was taken, and to this, ACN (100 µL) was 
added.  The samples were vortexed and the IS (ABC or D2-ABC, 100 µL, 200 nM) 
was added.  The precipitated protein was sedimented by centrifugation (14,000 × g, 
20 min, 4 °C), and the supernatant was removed and evaporated to dry residue at 30 
°C.  The residues were re-dissolved in the mobile phase (100 µL, 10 mM ammonium 
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acetate (NH4OAc, pH 3.8)) containing 5% ACN, filtered through 0.45 µM filter pore 
plates and transferred to high-performance liquid chromatography (HPLC) vials for 
LC-MS/MS analysis. 
 
 3.5.1.2 Comparative oxidation of ABC and D2-ABC in human liver cytosol 
with respect to time. 
Reactions were conducted in sodium pyrophosphate buffer (50 mM, pH 8.8, 500 
µL).  ABC (10 µM) or D2-ABC (10 µM) was incubated with human liver cytosol 
(protein concentration, 0.75 mg/mL) and NAD (7.5 mM) at 37 °C in a shaking water 
bath for 1, 4, 8, 16, 20, and 24 h, whereupon the incubation vials were placed on ice 
for 5 min.  An aliquot (10 µL) was taken, and to this ACN (100 µL) was added.  The 
samples were vortexed and the IS (ABC or D2-ABC, 100 µL, 200 nM) was added.  
The precipitated protein was sedimented by centrifugation (14,000 × g, 20 min, 4 
°C), and the supernatant was removed and evaporated to dry residue at 30 °C.  The 
residues were re-dissolved in the mobile phase (100 µL, 10 mM NH4OAc, pH 3.8) 
containing 5% ACN, filtered through 0.45 µM filter pore plates and transferred to 
HPLC vials for LC-MS/MS analysis. 
   
 3.5.1.3 Enzyme inhibition and aldehyde trapping experiments for 
comparison of ABC and D2-ABC oxidation in human liver cytosol. 
Reactions were conducted in sodium pyrophosphate buffer (50 mM, pH 8.8, 500 
µL).  ABC (10 µM) or D2-ABC (10 µM) was incubated with human liver cytosol 
(protein concentration, 0.75 mg/mL), +/– NAD (7.5 mM) (Table 3.1, Section 3.3.1.5) 
and where used, the following compounds (Table 3.1, Section 3.3.1.5) at 37 °C in a 
shaking water bath for 20 h.  Following the incubation, the vials were placed on ice 
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for 5 min.  An aliquot (10 µL) was taken, and to this ACN (100 µL) was added.  The 
samples were vortexed and the IS (ABC or D2-ABC, 100 µL, 200 nM) was added.  
The precipitated protein was sedimented by centrifugation (14,000 × g, 20 min, 4 
°C), and the supernatant was removed and evaporated to dry residue at 30 °C.  The 
residues were re-dissolved in the mobile phase (100 µL, 10 mM NH4OAc, pH 3.8) 
containing 5% ACN, filtered through 0.45 µM filter pore plates and transferred to 
HPLC vials for LC-MS/MS analysis. 
 
 3.5.1.4 Determination of COOH formation with respect to substrate 
concentration and determination of deuterium isotope effects for D2-ABC 
vs. ABC. 
Reactions were conducted in sodium pyrophosphate buffer (50 mM, pH 8.8, 500 
µL). ABC (500 µM, 1, 2.5, 5, 7.5, 10 and 20 mM) or D2-ABC (500 µM, 1, 2.5, 5, 
7.5, 10 and 20 mM) was incubated with human liver cytosol (protein concentration, 
0.75 mg/mL) and NAD (7.5 mM) at 37 °C in a shaking water bath, and aliquots (10 
µL) were taken at 0, 10, 20, 30, 40, 50, 60, 90 and 120 min from each incubation.  
The samples were placed on ice for 5 min and ACN (100 µL) was added.  The 
samples were vortexed and the IS (ABC or D2-ABC, 100 µL, 200 nM) was added.  
The precipitated protein was sedimented by centrifugation (14,000 × g, 20 min, 4 
°C), and the supernatant was removed and evaporated to dry residue at 30 °C.  The 
residues were re-dissolved in the mobile phase (100 µL, 10 mM NH4OAc, pH 3.8) 
containing 5% ACN, filtered through 0.45 µM filter pore plates and transferred to 
HPLC vials for LC-MS/MS analysis. 
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3.5.1.5 LC-MS/MS conditions. 
All samples were analysed on a 4000 QTRAP system (AB Sciex, Foster City, CA, 
USA).  An Eclipse XBD C18 column (2.1 × 150 mm, 5 µm) (Agilent, Cheshire, UK) 
was used for chromatographic separation at 30 °C.  An Ultimate 3000 liquid 
chromatography system (Dionex, CA, USA) was interfaced to the mass 
spectrometer.  The sample injection volume was 5 µL.  The mobile phases were as 
follows:  Mobile phase A – NH4OAc (10 mM, pH 3.8), mobile phase B – ACN.  The 
compounds, including all metabolites, were eluted from the chromatographic column 
using a linear gradient (5–20% ‘B’) over 15 min and 20% ‘B’ for the remaining 5 
min (20 min total) using a flow rate of 0.3 mL/min.  The mass spectrometer was 
operated in positive-ion mode.  Nitrogen was used as both the nebulising and drying 
gas.  The source was operated at 500 °C.  The electrospray voltage was set to 5 kV 
and analyses were performed in MRM mode.  Compound-dependent parameters are 
shown in Table 3.4. 
 
Table 3.4:  Compound dependent parameters for ABC 7, D2-ABC 42 and ABC-COOH 17. 
 
Compound  Precursor 
Ion  
(m/z) 
Product 
Ion  
(m/z) 
Declustering 
Potential 
(V) 
Entrance 
Potential 
(V) 
Collision 
Energy 
(eV) 
Exit 
Potential 
(V) 
ABC 7 287 191 66 10 27 10 
D2-ABC 42 289 191 66 10 27 10 
COOH 17 301 191 63 10 29 10 
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Where EPI scans were used, the mass spectrometer was targeted to scan for product 
ions of m/z 314 for ABC and m/z 315 for D2-ABC.  Data were analysed using 
Analyst software (AB Sciex). 
 
3.5.1.6 Quantification of parent drug and carboxylic acid metabolite. 
Standard samples (S1–S10) were prepared from stock solutions of ABC, D2-ABC 
and ABC-17.  The stock solutions were as follows:  ABC and D2-ABC:  0.1, 1, 10 
and 100 µM, and ABC-17:  1 and 10 µM.  They were prepared in distilled water, and 
stored at −20 °C.  The solutions were used to generate the required concentrations for 
LC-MS/MS calibration as stated in Table 3.7.  Stock solutions were diluted with 
sodium pyrophosphate buffer (50 mM, pH 8.8).  ABC and ABC-17 were standard 
compounds obtained from GSK and D2-ABC was synthetically produced (see 
Chapter 2). 
 
Where ABC was analyte or substrate, D2-ABC was the IS, and when D2-ABC was 
the analyte or substrate, ABC was the IS.  Once the standard samples (S1–S10) (90 
µL) were generated, bovine serum albumin (BSA) (0.75 mg/mL, 10 µL), used as a 
substitute for blank human liver cytosol, dissolved in sodium pyrophosphate buffer 
(50 mM, pH 8.8)) was added to each sample and vortexed.  The protein was 
precipitated with ACN (100 µL) and sedimented by centrifugation (14,000 × g, 20 
min, 4 °C).  The supernatant was removed and evaporated to dry residue at 30 °C.  
The residues were re-dissolved in the mobile phase (100 µL, 10 mM NH4OAc, pH 
3.8) containing 5% ACN, filtered through 0.45 µM filter pore plates and transferred 
to HPLC vials for LC-MS/MS analysis.  The lower limits of detection (signal-to-
noise ratio ≥3) and quantification (cross-validation (CV) error ≤20%) of ABC-17 
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under these conditions were 2.5 nM and 10 nM, respectively as determined 
previously.11 Blank human liver cytosol processed in the same way did not yield 
MRM signals that interfered with those of ABC, D2-ABC and ABC-17. 
 
Table 3.5:  Final concentrations of the calibration standards (ABC, D2-ABC and ABC-17) and the IS 
(ABC or D2-ABC) used to create a calibration curve. 
 
  
Standard 
 
ABC or D2-ABC 
[nM] 
 
ABC-17  
[nM] 
 
Internal Standard 
(ABC/D2-ABC) [nM] 
S10 5 10 200 
S9 10 20 200 
S8 25 50 200 
S7 50 100 200 
S6 100 200 200 
S5 250 500 200 
S4 500 1000 200 
S3 1000 2000 200 
S2 2000 4000 200 
S1 4000 8000 200 
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 3.5.1.7 Carboxylic acid formation, statistical analysis and kinetic 
parameters 
The values of ABC-17 production shown in figures and graphs present the total 
COOH formation as its concentration (µM), with values calculated as the sum of all 
three COOH isomers.  Where percentage decrease/increase of COOH formation 
values are stated, this was calculated such that: 
 
% COOH change = difference between positive control and expt. sample (µM) 
   positive control (µM) 
 
Statistical tests were conducted and Michaelis–Menten kinetic parameters were 
calculated using GraphPad Prism® Version 6 software.  The statistical significance of 
a difference, where appropriate, was determined using an unpaired t-test. 
 
3.5.2 Immunology studies. 
Cells from three HLA-B*57:01-positive individuals were selected from our cell bank 
containing peripheral blood mononuclear cells (70–150 × 106; stored in vials of 10 × 
106 cells) from 1000 HLA-typed donors.  The demographics of the first 400 study 
subjects and HLA allele frequencies have been reported previously.50 Ethical 
approval for the study was obtained from the local research ethics committee and all 
volunteers were consented prior to blood donation.  Confidentiality was maintained 
throughout the study. 
 
All reagents were supplied by Sigma Aldrich (UK) unless otherwise stated. ABC-
specific human T-cell clones were generated as described previously:11,30 1 × 106 
* 100 
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peripheral blood mononucleated cells (PBMCs) from a HLA-B*57:01-positive 
volunteer were incubated with 50 µM ABC in RPMI medium supplemented with 
10% human AB serum (Innovative Research, Novi, MI, USA), 1000 U/mL 
penicillin, 0.1 mg/mL streptomycin, HEPES and transferrin.  On days 6 and 9, IL-2 
(Peprotech, London) was added to the cultures.  CD8+ T-cells were isolated by 
magnetic separation (Multisort kit, Milteny Biotec, Surrey) and serially diluted 
according to established protocols.51 Autologous EBV-transformed human B-cell 
lines were also generated from PBMCs, by transformation with supernatant from the 
virus-producing cell line B9.58.  ABC-specificity of T-cell clones (5 × 104 cells/well) 
was determined by addition of 50 µM ABC and 1 × 104 irradiated autologous EBV-
transformed B-cells to serve as APCs.  
 
Cross-reactivity of ABC-specific T-cell clones was assessed by IFN-γ ELISpot assay 
(Mabtech, Stockholm, Sweden).  T-cell clones (5 × 104 cells/well) were incubated 
with 10, 50 or 100 µM ABC or D2-ABC in the presence of 1 × 104 irradiated 
autologous EBV-transformed B-cells.  The ELISpot was developed after 48 h.  SFCs 
were quantified using an AID ELISpot microplate reader (Cadama Medical, 
Stourbridge, UK). 
 
3.5.3 Pharmacological studies. 
3.5.3.1 Routine cell culture/cell maintenance. 
MT4 cells were supplied by the EU programme’s EVA Centre for AIDS Reagents, 
NIBSC (South Mimms, Hertfordshire, UK), and routinely maintained in RPMI-1640 
supplemented with 10% sterile filtered foetal bovine serum (FBS; BioWhittaker, 
Berkshire, UK).  They were incubated at 37 °C and 5% CO2, and subcultured every 
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four days prior to use.  Cell viability was determined by Trypan Blue exclusion assay 
and was typically <97%. 
 
3.5.3.2 Determination of ABC and D2-ABC cytotoxicity in MT4 cells by 
MTT assay. 
MT4 cells were seeded at a density of 2.5 × 104 cells / 100 µL of RPMI-1640 and 
10% sterile filtered FBS into each well of a 96-well plate (NunclonTM, Denmark), 
and incubated for 24 h at 37 °C and 5% CO2.  The medium was then aspirated and 
replaced with medium containing a range of concentrations (0.0026, 0.0128, 0.064, 
0.32, 1.6, 8, 40, 200, 1000 or 5000 µM) of ABC or D2-ABC dissolved in 0.1% 
MeOH (final concentration) and routine culture medium.  The plates were then 
incubated for 24 h or 5 days at 37 °C and 5% CO2.  Plates were removed from the 
incubator and 20 µL of a 5 mg/mL solution of MTT (Sigma, UK) in Hanks balanced 
salt solution (HBSS; Sigma, UK) was added to each well.  The plates were further 
incubated for 2 h at 37 °C and 5% CO2.  Finally, lysis buffer (100 µL) containing 
50% v/v dimethylformamide (DMF, Sigma, UK) and 20% v/v sodium dodecyl 
sulfate (SDS; Sigma, UK) was added to each well and incubated for 24 h at 37 °C 
and 5% CO2.  Absorbance readings were taken at 570 nm using a Tecan Genesis 
plate reader (Tecan Magellan, Austria).  
 
3.5.3.3 Inhibition of HIVIIIB replication in MT4 cells. 
The HIVIIIB strain of virus was provided by the EU programmes EVA Centre for 
AIDS Reagents, National Institute for Biological Standards and Control (NIBSC, 
South Mimms, Hertfordshire, UK).  MT4 cells and viral isolates (multiplicity of 
infection, 0.01) were dispensed into a 50 mL Falcon tube and centrifuged (2000 × g, 
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15 min, 25 °C) in a Galaxy 170R incubator (Sanyo, Japan).  The Falcon tube 
containing the MT4/HIVIIIB pellet was then incubated at 37 °C and 5% CO2.  After 
2 h, the supernatant was aspirated and the pellet resuspended in RPMI-1640 
supplemented with 10% sterile filtered FBS.  MT4 cells containing virus particles 
were then seeded at a density of 1 × 104 cells / 80 µL into each well of a 96-well 
plate also containing 20 µL of a range of concentrations (5 × concentrate) of ABC or 
D2-ABC dissolved in 0.5% MeOH and RPMI-1640 supplemented with 10% sterile 
filtered FBS resulting in final concentrations 0.0128, 0.064, 0.32, 1.6, 8, 40, 200, 
1000 or 5000 µM.  The plates were then incubated for 5 days at 37 °C and 5% CO2 
prior to the MTT assay as described above.  Inhibitory effects of drugs on HIV 
replication can be assessed indirectly through the inhibition of virus-induced 
cytotoxicity to the MT4 cells, estimated using an MTT assay.39,52 
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3.6 Supplementary Information 
 
 
 
 
 
Figure S1A:  MRM chromatograms for the formation of ABC-COOH 17 from ABC (10 µM) in 
human liver cytosol at the following hours:  1 h (A); 4 h (B); 8 h (C); 16 h (D); 20 h (E) and 24 h (F). 
Protein and NAD+ concentrations were 0.75 mg/mL and 7.5 mM, respectively. 
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Figure S1B:  MRM chromatograms for the formation of ABC-COOH 17 from D2-ABC (10 µM) in 
human liver cytosol at the following hours:  1 h (A); 4 h (B); 8 h (C); 16 h (D); 20 h (E) and 24 h (F).  
Protein and NAD+ concentrations were 0.75 mg/mL and 7.5 mM, respectively. 
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Figure S2A:  MRM chromatograms representing experiments measuring COOH formation from 
ABC (10 µM) in human liver cytosol under a variety of compromised metabolic conditions:  Without 
NAD (Experiment 1) (A); magnified image of the formation of 3 COOH isomers (Experiment 1) (B); 
with 4-MP (600 µM) and DSF (500 µM) (Experiment 2) (C); with NAD (Experiment 3) (D); with 4-
MP (600 µM) (Experiment 5) (E); with DSF (500 µM) (Experiment 6) (F).  Protein and NAD+ 
concentrations were 0.75 mg/mL and 7.5 mM, respectively.  Comparing experiments 3 (D) and 6 (F) 
there is a marked increase in the proportions of the lesser carboxylic acids 17b and 17c.  Under the 
circumstances of ALDH inhibition, by DSF, when aldehyde oxidation might be catalysed principally 
by ADH1A, the selectivity of oxidation of the isomeric aldehydes is altered. 
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Figure S2B:  MRM chromatograms representing experiments measuring COOH formation from D2-
ABC (10 µM) in human liver cytosol under a variety of compromised metabolic conditions:  Without 
NAD (Experiment 1) (A); magnified image of the formation of 3 COOH isomers (Experiment 1) (B); 
with 4-MP (600 µM) and DSF (500 µM) (Experiment 2) (C); with NAD (Experiment 3) (D); with 4-
MP (600 µM) (Experiment 5) (E); with DSF (500 µM) (Experiment 6) (F).  Protein and NAD+ 
concentrations were 0.75 mg/mL and 7.5 mM, respectively.  Comparing experiments 3 (D) and 6 (F) 
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there is a marked increase in the proportions of the lesser carboxylic acids 17b and 17c.  Under the 
circumstances of ALDH inhibition, by DSF, when aldehyde oxidation might be catalysed principally 
by ADH1A, the selectivity of oxidation of the isomeric aldehydes is altered. 
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Figure S2C:  EPI scans for fragments m/z 315 ([M+H]+ for the oxime derivative of the D2-ABC 
aldehyde intermediate) from experiments 4 (co-incubation with methoxylamine) and 7 (co-incubation 
with methoxylamine and DSF) for D2-ABC (A and B respectively).  The corresponding spectra are 
presented for experiments 4 and 7 (C and D respectively).  The imine product 19b (m/z 315) was not 
detected and the sample may have been contaminated with ABC, hence the detection of the precursor 
ion for 19a.  The slow dehydrogenation of D2-ABC might have precluded production of detectable 
amounts of oxime 58. 
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Figure S3A:  MRM chromatograms obtained from the rate-substrate concentration experiments when 
ABC (10 µM) was incubated with human liver cytosol.  Diagrams show representative 
chromatograms at the following concentrations and times:  500 µM at 0 min (A), 500 µM at 120 min 
(B), 20 mM at 0 min (C) and 20 mM at 120 min (D).  Protein and NAD+ concentrations were 0.75 
mg/mL and 7.5 mM, respectively. 
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Figure S3B:  MRM chromatograms obtained from the rate-substrate concentration experiments when 
D2-ABC (10 µM) was incubated with human liver cytosol.  Diagrams show representative 
chromatograms at the following concentrations and times:  500 µM at 0 min (A), 500 µM at 120 min 
(B), 20 mM at 0 min (C) and 20 mM at 120 min (D).  Protein and NAD+ concentrations were 0.75 
mg/mL and 7.5 mM, respectively.  
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4.1 Introduction 
 
4.1.1 Synthesis of ABC. 
The total and formal synthesis of ABC and its precursors has been well studied with 
all established routes using methods discussed in Chapter 1.  The application of three 
of these syntheses is discussed herein. 
 
 4.1.1.1 Synthesis from Vince lactam and heterocycle construction. 
Daluge et al. reported the first large-scale synthesis of ABC in 2000,1 shortly after its 
initial release onto the market.  The large-scale route was initiated with Vince lactam 
28 (Scheme 4.1).1,2 This forms the basic structure of the stereoselective 
cyclopentenyl moiety of the final carbocyclic nucleoside.  The bicyclic system 
underwent ring opening by water, reduction and work-up to provide the amino-
alcohol cyclopentenyl 29.  Compound 29 was subsequently N-Boc protected to form 
compound 59.  2,5-Diamino-4,6-dihydroxypyrimidine, compound 60, underwent 
chlorination using Vilsmeier reagent to form compound 61, which was subjected to 
acidic hydrolysis, neutralisation and precipitation to form 62.  Amide formation 
(compound 63), was achieved through hydrolysis of 62 using phosphate buffer, 
ensuring the pH was below 4 to prevent the formation of unwanted N,N-
dimethylamine pyrimidine by-products.  The following steps:  Addition of the chloro 
pyrimidine intermediate 63 to 59, followed by ring closure of the pyrimidine formed 
the purine base and finally nucleophilic substitution of 6-Cl with cyclopropylamine 
yielded ABC.  This route has also been shown to be effective on a research scale.1 
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Scheme 4.1:  Reagents and conditions:  a) i) MsOH hydrated, H2O, THF, 60 °C, 3 h, 97%; ii) LiAlH4, 
THF; iii) NaF, 30 min, H2O, 90%; b) Boc2O, DMAP, THF, quant.; c) i) [Me2NCHCl+]Cl, CHCl3, 
reflux, 2 days; ii) 5 N NaOH to pH 7, 81–92%; d) Conc. HCl, EtOH−H2O, 55 °C, 30 min, 95%; e) 
Phosphate buffer, pH 3.2, reflux, 4 h, 72%; f) i) Conc. HCl, EtOH, reflux, 90 min; ii) 63, 84–88%; g) 
TEOF, conc. HCl, 85–92%; h) Cyclopropylamine, EtOH, reflux, 3 h, 70–90%. 
 
Vince & Hua have developed a slightly modified route, although still utilising the 
linear construction route of the purinic base after coupling with Vince lactam 28 
(Scheme 4.2).3 Vince lactam, as demonstrated by Evans et al.,4 can be prepared from 
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toluene-p-sulfonyl cyanide and cyclopentadiene to form racemic Vince lactam 27.  
Resolution of this racemic compound was achieved using Pseudomonas 
solanacearum to give the unreacted chiral lactam and the ring opened product, an 
amino acid.4 However, lactam 28 is also commercially available in its desired chiral 
form.  
 
Vince lactam 28 underwent a series of reactions:  Hydrolysis, amine protection, 
reduction and finally alcohol protection to yield di-protected intermediate 65.  
Following this, 29 was coupled with 5-amino-4,6-dichloropyrimidine to yield 66.  As 
discussed in Chapter 1, Section 1.9.2.2, an amine group is incorporated at the 2-
position of 66 via diazonium cation formation, using p-chloroaniline, hydrochloric 
acid (HCl) and sodium nitrite (NaNO2).  This was followed by reduction using 
Zn/AcOH to form compound 31.  TEOF/catalytic (cat.) H+ forms the imidazole ring 
(compound 32) and substitution of 6-Cl with cyclopropylamine yields ABC in 14% 
yield over 10 steps. 
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Scheme 4.2:  Reagents and conditions:  a) i) 1 N HCl, reflux, 1 h, 88%; ii) Ac2O, pyridine, r.t., o/n, 
83%; iii) NaBH4, CaCl2, THF, r.t., 18 h; iv) Ac2O, pyridine, r.t., o/n, 73%; b) 0.5 N Ba(OH)2, reflux, 
o/n; c) 2-Amino-4,6-dichloropyrimidine, NEt3, n-BuOH, reflux, 48 h, 76%; d) p-Chloroaniline, 3 N 
HCl, NaNO2, AcOH, NaOAc.3H2O, r.t., o/n, 94%; e) Zn, AcOH, H2O, EtOH, reflux, 3 h, 66%; f) 
TEOF, 12 N HCl, r.t., o/n, 80%; g) Cyclopropylamine, EtOH, 55 °C, 25 h, 68%. 
 
4.1.1.2 Pd0 mediated allylic substitution of purinic base and cyclopentyl 
carbocycle.   
Crimmins and co-workers described an efficient asymmetric synthesis of both CBV 
and ABC (Scheme 4.3):5,6 A synthesis that has been utilised by other researchers in 
the formation of carbocyclic analogues.7,8  
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Scheme 4.3:  Reagents and conditions:  a) n-BuLi, 4-pentenoic acid, NEt3, pivaloyl chloride, THF,  
−78 °C  0 °C, 2 h, 99%; b) TiCl4, (–)-sparteine, DCM, acrolein, −78 °C  0 °C, 1 h, 82%; c) 
Benzylidine(bistricyclohexylphosphine)ruthenium(II) chloride, DCM, r.t., 30 min, 97%; d) LiBH4, 
MeOH, THF, 0 °C, 1 h, 78%; e) Ac2O, NEt3, DMAP, DCM, 0 °C, 2 h, 90%; f) Cyclopropylamine, 
DMSO, 55 °C, 16 h; g) NaH, 70, Pd(PPh3)4, 1:1 THF−DMSO, 45 °C, 65%; h) NaOH, H2O, r.t., o/n, 
81%. 
 
As an alternative method to using cyclopentadiene as the initial material and 
introducing asymmetry via enzymatic or chiral ligand methods, a chiral 
oxazolidinone 49 was used with Grubbs mediated RCM to form the cyclopentyl 
carbocyclic moiety.  Acylation of 49 with 4-pentenoic acid and pivaloyl chloride 
anhydride afforded intermediate 51, which underwent an asymmetric syn aldol 
addition with acrolein along with titanium tetrachloride (TiCl4) and (–)-spartenine 
determining the relative stereochemistry.  RCM with 1st generation Grubbs catalyst 
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followed by reduction with LiBH4 yielded diol 68.  Di-protection of this diol yields 
intermediate 69 and Crimmins and co-workers used established Trost Pd0 allylic 
substitution methods to couple this carbocycle with 2-amino-6-
(cyclopropylamino)purine 70 (Figure 4.1).  Removal of the acetyl group was 
achieved using NaOH to yield ABC.  Compound 69 was coupled with 70, rather than 
2-amino-6-chloropurine, to maximise the N9:N7 ratio from 85:15 to 95:5.  
Synthesising ABC in this manner allows for carbocyclic modifications. 
 
 
 
Figure 4.1:  Mechanism depicting the coupling of di-protected diol 69 with 2-amino-6-
(cyclopropylamino)purine 70 using Trost Pd0 allylic substitution:  Pd coordinates with the double 
bond of the allylic acetate and this occurs on the less hindered face.  The acetate (leaving group) is 
lost and the π-allyl Pd complex is formed.  The nucleophile (deprotonated 2-amino-6-
(cyclopropylamino)purine will then attack from the less hindered face and Pd will become 
uncoordinated.  The net result is retention of configuration. 
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Crimmins et al. have also reported a solid-phase synthesis of ABC, using a Pd-
catalysed allylic coupling of a resin-bound carbocyclic sugar with a purine base.9 
 
4.1.1.3 Enzymatic resolution and [2+2] cycloaddition. 
The final route to be discussed is a recent enantioselective synthesis of ABC 
(Scheme 4.4).  Unlike the other methods previously mentioned, cyclopentadiene is 
used as the starting material.  A hetero Diels–Alder [2+2] cycloaddition of 
cyclopentadiene with chlorosulfonyl isocyanate (CSI) followed by isomeric 
resolution using Lipase B10 formed the correct bi-lactam intermediate 72.  Lipase B 
(also widely known as Lipolase from Candida antarctica) resolves racemic β-
lactams through hydrolysis.   The racemic mixture is hydrolysed in H2O (1 equiv) 
and diisopropyl ether at 60 °C to form the β-amino acid product and the unreacted β-
lactam.11 These compounds are then easily separated. 
 
Chiral 72 underwent amine protection using a highly electron withdrawing group:  4-
methylbenzenesulfonic anhydride.  Coupling of 73 with 2,6-dichloropurine was 
achieved using either Pd2(dba)3 or Pd(OAc)2 with phosphorus-based ligand P(i-OPr)3 
and high N9:N7 regioselectivity was achieved.  This mechanism is likely to occur via 
a π-allyl Pd coupling using the tosylate (Ts) group to stabilise the charge during ring 
opening.  Following N-methylation of 74 and subsequent reduction and nucleophilic 
aromatic substitution with cyclopropylamine yielded 76.  Addition of the 2-amino 
group was achieved using 4-methoxybenzylamine and the p-methoxybenzyl ether 
group was removed using trifluoroacetic acid (TFA).  All steps were high yielding 
(>70%).  The synthesis was achieved in 24% yield over 9 steps.  Bi-lactam 72 would 
serve as a key starting material for a wide range of ABC analogues. 
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Scheme 4.4:  a) i) CSI ii) Lipase B;10 b) 4-Methylbenzenesulfonic anhydride, NEt3, DMAP, DCM, 
r.t., 48 h, 75–81%; c) 2,6-Dichloropurine, tetrabutylammonium salt, Pd2(dba)3, P(i-OPr)3, THF, r.t., 90 
min, 75% d) PPh3, DIAD, MeOH, 1:1 DCM–THF, r.t., 30 min, 94%; e) i) NaBH4, i-PrOH, THF, 0 °C 
to r.t., 3 h, 86%; ii) Cyclopropylamine, EtOH, 50 °C, 5 h, 73%; f) 4-Methoxybenzylamine, DMSO, 
150 °C, 16 h, 90%; g) TFA, reflux, 72 h, 73%.  CSI, chlorosulfonyl isocyanate; DIAD, diisopropyl 
azodicarboxylate. 
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4.1.2 ABC analogue synthesis. 
A range of ABC analogues have been synthesised from a variety of synthetic routes, 
often using the pathways discussed within this chapter and Chapter 1, Section 1.9.  
Synthesis of analogues for ABC has been of interest to reduce associated 
toxicological issues, to modulate lipophilicity and anti-HIV activity.  Modifications 
of the cyclopentyl moieties are often the most common structure alterations in the 
synthesis of such analogues; a selection of previously synthesised analogues is 
discussed below. 
 
Crimmins and co-workers synthesised (–)-2'-methyl ABC using a slight variation of 
their established synthesis (see Scheme 4.3).5 The usual addition of acrolein at step 2 
of this synthesis is altered with the addition of methylacrolein.  The result of this is a 
methyl substituent at the 2'-position (Figure 4.2 A), eventually yielding the required 
analogue. 
 
Other modified total synthetic routes to produce analogues of ABC include the 
synthesis of; 5'-homo-ABC from a bicyclic α-hydroxy lactone intermediate (Figure 
4.2 B);12 racemic nor-ABC from a cyclopentene epoxide starting material (Figure 4.2 
C);13 3'-methyl-ABC from [(1S,4S)-4-hydroxy-2-methylcyclopent-2-enyl]methyl 
acetate (Figure 4.2 D)14 and 5'-homo-dihydroxy-ABC from cyclopentadiene (Figure 
4.2 E).15 Although there is little literature precedent for the synthesis of analogues 
from direct ABC modification, one example, using microwave-assisted reactions to 
produce N2 analogues is reported (Figure 4.2 F).16 
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Figure 4.2:  Series of ABC analogues synthesised via total synthetic routes (A–E) or through direct 
ABC modification (F).  Their corresponding starting materials are shown within the dotted circles. 
 
There are well-established routes to synthesise ABC and a number of its analogues.  
These routes will be utilised to synthesise analogues of ABC and such compounds 
will be used to probe mechanisms of ABC toxicity. 
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4.2 Aims 
 
• To synthesise a range of 5'-OH and alkene analogues of ABC to block 
metabolism 
• To synthesise N2 analogues to block its metabolism and to disrupt binding 
within HLA-B*57:01 
• To synthesise the enantiomer of ABC and to test this enantiomer in ABC-
positive HLA-B*57:01 T-cells to probe its toxicity 
• To develop a synthetic route to form intermediates for use within ABC 
analogue synthesis. 
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4.3 Results & Discussion 
 
The following section describes the design and synthesis of a range of ABC 
analogues that can and have been used to probe its ABC-associated immune-
mediated toxicity. 
 
4.3.1 Design and synthesis of 5'-OH analogues to block O-oxidation. 
As initially proposed by Walsh et al.,17 the oxidation of the primary alcohol of ABC 
to its aldehyde (Figure 4.3 A) could potentially contribute to its toxicity.  Blocking 
this oxidation pathway would reduce ABC bioactivation through prevention of 
aldehyde formation (Figure 4.3 B). 
 
 
 
Figure 4.3:  Oxidation of ABC 7 to its corresponding aldehyde 16a by ADH and co-factor NAD+ (A).  
Aldehyde formation can be prevented through blocking the 5'-OH group with an ester moiety (B). 
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Acetylation of the primary alcohol appeared to be the most logical route (Scheme 
4.5).  This was attempted using a variety of reagents. 
 
 
 
Scheme 4.5:  Reagents and conditions:  Ac2O (1.3 equiv), NEt3 (1.2 equiv), DCM, 0 °C, 4 h, 69%. 
 
Initially, the method of acetylation using acetyl chloride (AcCl) and pyridine was 
employed, but this led to the formation of several side products and the desired 
product was difficult to obtain.  The formation of side products was likely to stem 
from the nucleophilic amine groups at positions 2 and 6 on ABC.  Following this, 
reaction of ABC with benzoyl chloride (BzCl) and pyridine was attempted but 
similar problems were encountered, with the formation of side products and little 
product formation.  Finally, a successful method was found using Ac2O and NEt3.  
This yielded the desired product 71, in a 69% yield. 
 
The loss and/or replacement of the 5'-OH functional group would also prevent 
oxidation at this position.  Without synthesising ABC itself, it would have been 
difficult to directly replace the hydroxyl group from the parent drug.  Primary 
alcohols often undergo functional group interconversion to halides, carboxylic acids, 
esters and ethers but many of these groups would be unsuitable due to maintaining 
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oxidation ability and/or nucleophilicity.  It was therefore decided to synthesise 
compound 78 using XtalFluor-E® (Scheme 4.6). XtalFluor-E® is a deoxyfluorinating 
reagent that is relatively easy to handle and has improved air stability compared with 
other fluorinating reagents such as diethylaminosulfur trifluoride,18 where toxic 
hydrogen fluoride is a side product. 
 
 
 
Scheme 4.6:  The 5'-OH present within ABC can be substituted with fluorine using XtalFluor-E® 
reagent.  The mechanism for this reaction is shown.  Reagents and conditions:  XtalFluor-E® (1.4 
equiv), NEt3.3HF (2.2 equiv), reflux, 3 h, 3%. 
 
The reaction conditions, XtalFluor-E® (1.5 equiv) with DBU (1.5 equiv) were 
initially used.  No desired product was obtained from this reaction, and after further 
research on the reagent, triethylamine trihydrofluoride (NEt3.3HF) in replacement of 
DBU was used, as demonstrated by L’Heureux et al.19 Overall, this improved the 
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reaction and although very low yields were achieved, enough of compound 78 was 
obtained for future immunological testing. 
 
4.3.2 N2 analogues to block N-oxidation. 
Extending the focus beyond 5'-OH analogues, analogues preventing N-oxidation 
were also considered.  These analogues mainly consisted of small functional groups 
so to limit any considerable disruption of binding with the HLA molecule.  Acylation 
was chosen as the main method of formation of these analogues (Figure 4.4). 
 
 
 
Figure 4.4:  Attempted reactions of N2 protection using several different reagents:  AcCl, Ac2O, BzCl, 
Boc, Fmoc, pivaloyl chloride (1.2–2.0 equiv).  All attempted reactions required NEt3 (1.5–2.0 equiv). 
 
Although primary amine groups are known to exhibit stronger nucleophilic 
properties during acetylation compared to their alcohol equivalents, it was likely to 
be the reverse for ABC due to the purine aromatic system.  This system would 
reduce the nucleophilic tendencies of the N2 amine so protection of the 5'-OH was 
initially required.  This was completed using t-butyldimethylsilyl chloride 
N
N
N
NH2N
HN
OR1
N
N
N
N
H
N
HN
OR1
R2
R1 = TBDMS/TMS
R2 = Ac / Bz / Boc / Fmoc / COi-Pr
Chapter 4 – Using Asymmetric Synthetic Methods to Synthesise Analogues of Abacavir 
203 
(TBDMS−Cl) (Scheme 4.7).  This reaction was carried out with TBDMS−Cl (1.5 
equiv) and imidazole (2 equiv) in DMF with achievement of good yields (65%). 
 
 
 
Scheme 4.7:  Reagents and conditions:  TBDMS−Cl (1.5 equiv), imidazole (2.1 equiv), DMF, r.t., 24 
h, 65%. TBDMS, t-butyldimethylsilyl ether. 
 
Following alcohol protection, acetylation, using acetyl chloride (AcCl, 1.5 equiv) 
was attempted.20 Although, some product was formed, a very low yield was obtained 
(24%).  The reaction was repeated with BzCl (1.5 equiv)20 and the yield was again, 
extremely poor.  Further reactions included acetylation with isobutyric anhydride 
using conditions applied by Challa et al. on nucleoside analogue, 2'-
deoxyguanosine,21 Boc and fluorenylmethyloxycarbonyl chloride (Fmoc−Cl) 
reactions with the latter demonstrated previously with guanosine nucleosides22,23 
(Figure 4.4).  When these reactions were applied to ABC, no product was obtained, 
with solvent solubility issues and significant side product formation occurring. 
 
A slightly different approach was subsequently used:  A peptide coupling reaction 
(Figure 4.4) using benzoic acid (1.2 equiv), 1-hydroxybenzotriazole (HoBt) (0.001 
equiv) and dicyclohexylcarbodiimide (DCC) (1 equiv) in DCM.  Upon purification, 
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the required product was not formed.  Again, this was likely to be the result of ABC 
insolubility within the solvent. 
 
The final reactions attempted were acetylation reactions using Ac2O and NEt3 in a 
large excess of DCM (Scheme 4.4).  The conditions used to form O-acetylated ABC 
71 were employed.  Alcohol protection at the 5' position using TBDMS was first 
required.  Following this, the acetylation reaction was attempted.  It was found that a 
mixture of three products was formed:  Mono-, di- and tri-acetylation had occurred 
and with the acidic conditions generated during the reaction, the TBDMS group was 
removed during the reaction (Figure 4.5).  All three products were separated via 
silica gel chromatography to yield compounds 71, 80 and 81 – although compound 
71 was the major product, which was isolated in a 53% yield. 
 
 
 
Figure 4.5:  Formation of three acetylated products, 71, 80 and 81.  These products were formed 
during the acetylation reaction of 79 with Ac2O and NEt3 in DCM. 
 
During further repeats of this reaction where TBDMS was not removed (achieved 
through use of freshly distilled Ac2O), intermediate 82 was formed (Scheme 4.8).  
This compound was deprotected using ‪tetra-n-butylammonium fluoride (TBAF) in 
THF to yield the desired compound 83 in a 71% yield. 
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Scheme 4.8:  Reagents and conditions:  a) Ac2O (1.2 equiv), NEt3 (1.2 equiv), DCM, 0 °C, 4 h, 53%; 
b) TBAF (1 M in THF, 1 equiv), r.t., o/n, 71%.  TBAF, tetra-n-butylammonium fluoride. 
 
4.3.3 Cyclopentane analogues to block 1,4-Michael addition. 
A set of analogues was designed to inhibit alkene migration:  A potential 
contributing factor in ABC toxicity, through a 1,4-Michael addition, as discussed in 
Chapter 2.  Elimination of the cyclopentyl alkene group would prevent this 
mechanism from occurring. 
 
Using the most logical approach in designing these analogues, removal of the alkene 
to form DH-ABC 20 was the starting analogue (Scheme 4.9).  This compound was 
formed through reduction of ABC with H2, using catalytic Pd/C and a good yield of 
67% was achieved.  It was clear from 1H NMR that the desired product was formed, 
through disappearance of the alkene proton shifts at δ 6.11 and 5.76 ppm. 
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Scheme 4.9:  Reagents and conditions:  10% Pd/C (cat.), H2, MeOH, r.t., 4 h, 67%. 
 
Following the success of synthesising 20, analogues designed to replace the alkene 
group were attempted.  These analogues included cyclopropanation, di-fluoro 
substituted cyclopropanation (Figure 4.6 A) and di-hydroxylation (Figure 4.6 B).   
 
 
 
Figure 4.6:  Carbocyclic alkene manipulations:  Cyclopropanation using Simmons–Smith conditions 
on compounds 7, 61 and 62, or di-fluoro cyclopropanation using TFDA/NaH also on compounds 7, 79 
and 80 (A) and dihydroxylation of 7 using AD-mix-β (B).  TFDA, trimethylsilyl 
fluorosulfonyldifluoroacetate. 
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The cyclopropanation reaction used Simmons–Smith conditions (diethyl zinc (2 
equiv) and diiodomethane (4 equiv) in DCM) and such conditions have been applied 
to nucleosides.24,25 Several polar side products were formed and significant starting 
material remained after 20 h.  ABC, as discussed in Chapter 2, is only partially 
soluble in DCM at room temperature and less so at 0 °C:  The temperature required 
for these reaction conditions.  This insolubility may have been a contributing factor 
to lack of product formation.  To overcome this insolubility issue, cycloproponation 
was attempted using O-TBDMS protected intermediate 79 (Figure 4.6 A):  A 
compound with high solubility in DCM compared to ABC.  Under the same 
conditions, a considerable number of side reactions occurred with decomposition of 
starting material.  The reasons for this unsuccessful reaction are not known although, 
the nucleophilic primary amine, N2 may have been responsible for side product 
formation.  To eliminate this factor, di-acetate compound 80 was used, and the 
reaction was repeated under the same conditions (Figure 4.6 A).  As before, similar 
results were obtained with no formation of desired product.  No further reactions 
using these reaction conditions were attempted. 
 
With no successful reactions using Simmons–Smith conditions, a new reagent, 
trimethylsilyl fluorosulfonyldifluoroacetate (TFDA) was used with catalytic sodium 
fluoride (NaF) in toluene (Figure 4.6 A) as used by Wang et al.26 
 
TFDA forms a difluorocarbene intermediate, which is able to undergo electrophilic 
reactions with alkenes.  This reaction was attempted using both ABC and compound 
79:  Both of which resulted in no desired product formation, and recovered starting 
material.  The difluorocarbene intermediate is highly reactive and has shown to react 
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successfully with nucleoside analogues.27 However, a number of side reactions with 
this reactive intermediate and the purine moiety were reported.  To limit possible 
side reactions occurring, the reaction was repeated using di-protected compound 80 
(Figure 4.6 A).  Unfortunately, significant side product formation remained and this 
is thought to occur from the highly reactive nature of the carbene intermediate, 
particularly at the high temperature used in this reaction.  Further attempts with these 
reaction conditions were not pursued. 
 
Substitution of the cyclopentyl alkene with hydroxyl groups was an analogue also 
attempted.  Di-hydroxylation in this manner was attempted using Sharpless 
asymmetric hydroxylation conditions:  AD-mix β (potassium carbonate (K2CO3), 0.5 
mol; potassium ferricyanide, 0.5 mol; potassium osmate dihydrate, 0.0007 mol; 
(DHQD)2PHAL, 0.002 mol) in 1:1 H2O−t-BuOH (Figure 4.6 B).  This analogue was 
of particular interest due to the specific stereochemical nature of the reaction and the 
use of H2O and t-BuOH was also encouraging as ABC is highly soluble in these 
solvents at room temperature.  Although no side reactions occurred, the desired 
product was not formed.  The reaction was left for a significant period of time (7 
days) with gentle heating (40 °C) for 24 h and no product was formed.  Starting 
material was recovered (95%).  The lack of formation of product could be a result of 
steric hindrance exhibited by AD-mix β.  For future work, and to either eliminate or 
confirm this hypothesis, AD-mix α could be used to form the enantiomer (Figure 4.7) 
and directly using osmium tetraoxide (OsO4).  The reactions with AD-mix β were not 
explored further. 
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Figure 4.7:  The possible formation of the alternative 2',3'-dihydroxylated analogue using AD-mix α. 
   
4.3.3.1 Cross-reactivity and proliferation of ABC-specific human T-cell 
clones with DH-ABC 20. 
Following success with compounds 20, 71 and 83, they were further utilised in 
immunological assays to measure the toxicity in T-cells.  The chemical cross-
reactivity experiments were conducted within the University of Liverpool, with full 
details of all methodological protocols available28 and for details of these assays see 
Chapter 1, Section 1.10.  The cross-reactivity and proliferation results obtained from 
compound 20 are presented and discussed within.  Over increasing concentrations of 
both ABC and DH-ABC 20 (0–100 µM), it was found that DH-ABC stimulated a 
select number of clones to proliferate at higher concentrations (50 and 100 µM) only, 
although this was still significantly less than ABC itself (Figure 4.8 A).  This was 
also found to be the case for cytokine release (ELISpot IFN-γ assay), where DH-
ABC, at 50 and 100 µM, stimulated IFN-γ release (Figure 4.8 B).  In these two 
assays, it has been found that the removal of the cyclopentyl double bond has an 
effect on the stimulation of ABC-specific T-cell clones.  There are two possible 
explanations for the lack of immunogenicity of DH-ABC.  The cyclopentane ring is 
less rigid than its cyclopentenyl equivalent and this perturbation could result in 
altered binding within the HLA-B*57:01 protein.  Alternatively, without a C=C, 20 
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will not be able to be oxidised to an aldehyde by ADH and should ABC-16 be 
responsible for T-cell stimulation, this would not be observed with 20.  ABC-16 has 
been shown to undergo protein binding resulting in an immunogen, as discussed in 
Chapter 2.  This would not be possible with 20.  However, should this be a valid 
rationale for reduced immunogenicity, it fails to explain why DH-ABC stimulates T-
cell clones at higher concentrations. 
 
 
Figure 4.8:  Cross-reactivity results obtained from ABC-specific T-cell clones in the presence of 
ABC 7 and DH-ABC 20.  Results obtained show proliferation of T-cell clones over increasing 
compound concentrations of 0–100 µM (A) and IFN-γ cytokine release, visualised using an ELISpot 
assay (B).  The ELISpot wells were obtained after 48 h incubation of ABC-specific T-cell clones in 
the presence of ABC (50 µM) and DH-ABC (50 µM).  Adapted from Bell, 2013.28 
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4.3.4 Synthesis of ABC enantiomers. 
As reported in Section 3.1, a synthesis of ABC was reported by MacKeith et al.,29 
where the absolute stereochemistry of ABC was achieved using an enzyme, 
Pseudomonas fluorescens lipase.  Due to the problems associated with modifying 
ABC directly, this synthetic route was adapted to synthesise intermediates that could 
be used to form ABC analogues.  During the synthesis, it became apparent that the 
enantiomer of ABC would be an interesting analogue.  Although it is widely 
documented that a large proportion of enzymes are selective for one isomeric 
substrate only – the formation of ABC’s enantiomer would allow an investigation of 
the selectivity of the enzymes involved in ABC metabolism.  The synthesis was 
adapted as originally reported by MacKeith et al. (Scheme 4.9).29 
Chapter 4 – Using Asymmetric Synthetic Methods to Synthesise Analogues of Abacavir 
212 
 
 
Scheme 4.10:  Reagents and conditions:  a) Cyclopentadiene (1 equiv), glyoxylic acid (1 equiv), H2O, 
r.t., 4 days, 18%; b) LiAlH4 (1 equiv), THF, r.t., o/n; c) i) Sodium metaperiodate (1 equiv), diethyl 
ether, H2O, 0 °C, 2 h; ii) Ethylene glycol (0.4 equiv), 0 °C, 1 h; iii) NaBH4 (1 equiv), NEt3 (1 equiv), 
DCM, r.t., o/n, 59%; d) Trityl chloride (1 equiv), NEt3 (1 equiv), DMAP (0.1 equiv), DCM, r.t., o/n, 
72%; e) Ac2O (excess), pyridine (excess), r.t. o/n, 39%; f) NaH (60% dispersed in mineral oil, 3.5 
equiv), 2-amino-6-chloro purine (2 equiv), Pd(PPh3)4 (10 mol %), DMF, Ar, 50 °C, o/n, 17%; g) 
Cyclopropylamine (excess), MeOH, 50 °C, o/n, 72%; h) 80% Acetic acid (excess), 50 C, 48 h, 52%. 
 
The initial step was the cycloaddition of glyoxylic acid and freshly prepared 
cyclopentadiene.  This reaction yielded diastereoisomers 84a and 84b (Figure 4.10), 
which were successfully separated by fractional crystallisation:  The required 
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racemic isomer 84a crystallised, whilst racemic isomer 84b remained in the diethyl 
ether solution as an oil. 
 
 
 
Figure 4.9:  Formation of diastereoisomers 84a and 84b from cycloaddition of glyoxylic acid and 
cyclopentadiene in H2O. 
 
Ring opening of lactam product 84a was achieved using lithium aluminium hydride 
(LiAlH4) to yield 85, which was used in the following step without further 
purification.  Conversion of triol 85 to diol 68 was achieved using NaIO4 (1 equiv) 
and ethylene glycol (0.4 equiv), followed by addition of NaBH4 (1 equiv) to yield the 
required product 68.  The primary alcohol intermediate was selectively protected 
with trityl chloride (CPh3Cl) to yield 86 (72%) and the secondary alcohol was further 
protected with Ac2O to yield intermediate 87 with a 39% yield. 
 
Step 6 consisted of coupling the di-protected intermediate 87 with 2-amino-6-
chloropurine to yield 88.  Although reaction conditions were optimised, the best 
yield achieved was 17%.  A common problem with this reaction is the formation of 
the N7 isomer as well as the required N9 isomer.5,30 Although, use of 2-amino-6-
chloropurine rather than other purine compounds can increase the N9:N7 ratio to 
99:1.31 It was also essential that this reaction was maintained under an inert 
atmosphere and fresh Pd(PPh3)4 catalyst (10 mol %) was used.  The following step 
was nucleophilic aromatic substitution of 6-chloro with cyclopropylamine to form 
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compound 89 and excellent yields of 72% were achieved.  The final step, removal of 
O-protecting trityl group, was completed using 80% AcOH over 48 h to yield 
racemic ABC 7 with a 52% yield (Figure 4.10). 
 
 
 
Figure 4.10:  Synthetic formation of ABC enantiomers (1S,4R)-ABC (ABC 7) and (1R,4S)-ABC (ent-
ABC) using an 8-step synthetic route – a route adapted from MacKeith et al.29 
 
The racemic mixture was separated using HPLC and a Chiracel OD-H analytical 
column.  The conditions were used as published by Seshachalam et al.32 ABC was 
the first isomer to elute from the column (Rt = 27 min) followed closely by its 
enantiomer, ent-ABC (Rt = 32 min).  A representative chromatogram can be seen in 
Supplementary Information Figure S1. 
 
 4.3.4.1 Cross-reactivity and proliferation of ABC-specific human T-cell 
clones with ent-ABC. 
The chemical cross-reactivity experiments were conducted within the University of 
Liverpool, with full details of all methodological protocols available28 and for details 
of these assays see Chapter 1, Section 1.10.  The cross-reactivity results for ent-ABC 
were obtained and measured using both a proliferation and IFN-γ ELISpot assay 
(Figure 4.11).  At increasing concentrations of ent-ABC (0–100 µM), no 
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proliferation of ABC-specific T-cell clones was seen (Figure 4.11 A).  This was also 
reflected in the IFN-γ ELISpot assay, where little IFN-γ release was observed 
(Figure 4.11 B).  As discussed in Section 4.3.3.1, there are again two possible 
explanations for the lack of immunogenicity of ent-ABC.  The first possible reason is 
that ent-ABC will not bind within the HLA-B*57:01 protein due to its 
stereochemistry resulting in possible steric clashes with the protein, inhibiting 
binding.  Alternatively, ent-ABC may not be a substrate for ADH, again due to its 
stereochemistry.  Enzymes are highly substrate specific and this has been observed 
with CBV.33 If ent-ABC is not a substrate for ADH, no 5'-OH oxidation will occur 
and therefore the suspected aldehyde immunogen will not be formed, resulting in 
reduced T-cell clone stimulation. 
 
 
 
 
Figure 4.11:  Cross-reactivity results obtained from ABC-specific T-cell clones in the presence of 
ABC and ent-ABC.  Results obtained show proliferation of T-cell clones over increasing compound 
concentrations of 0–100 µM (A) and IFN-γ cytokine release, visualised using an ELISpot assay (B).  
The ELISpot wells were obtained after 48 h incubation of ABC-specific T-cell clones in the presence 
of ABC (50 µM) and ent-ABC (50 µM).  Adapted from Bell, 2013.28 
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4.3.5 Synthesis of ABC intermediates for use in analogue synthesis. 
 4.3.5.1 Asymmetric synthesis I. 
Although useful to yield ABC enantiomers, the inefficient and time-consuming 
synthesis discussed in Section 4.3.4 is not ideal to use for adaption to ABC 
analogues.  The lack of stereochemical control and several low-yielding steps in this 
synthesis would prove problematic.  A 12-step asymmetric synthesis was designed 
(Figure 4.12).  The third step establishes the absolute stereochemistry and from step 
6, the scheme follows the non-selective synthesis. 
 
 
 
Figure 4.12:  The designed 12-step synthesis of ABC and its intermediates using the conditions 
shown within the figure.  Such intermediate compounds could assist in ABC analogue synthesis.  
THAB, tetrahexylammonium bromide; MoOPD, oxodiperoxymolybdenum (pyridine) (1,3-dimethyl-
3,4,5,6-tetrahydro-2-pyrimidinone). 
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The first six steps of this synthesis can be seen in Scheme 4.11.  The first step is a 
Luche reduction; where cyclopentenone is reduced using NaBH4 and cerium (III) 
chloride heptahydrate (CeCl3.7H2O) in MeOH.  This reaction was successful, 
yielding compound 90, which was used directly in the following step.  CeCl3.7H2O 
was used to direct reduction of the ketone to alcohol, rather than reduction of the 
alkene group.  The following step, alcohol protection, was completed using Ac2O 
and NEt3 in DCM to yield 91.  The volatility of products 90 and 91 was a key factor 
in the choice of reagents and conditions for both reactions.  This was particularly the 
case in the formation of 91, where low yields were initially a problem.  Alternative 
conditions were attempted but without improvement.  After significant optimisation 
of both the original reaction conditions and purification procedure, yields of 58% 
could be reliably obtained. 
 
 
 
Scheme 4.11:  Reagents and conditions:  a) 2-Cyclopenten-1-one (1 equiv), CeCl3.7H2O (1.3 equiv), 
NaBH4 (1.2 equiv), MeOH, 0 °C, 1 h; b) Ac2O (1.5 equiv), NEt3 (1.4 equiv), DMAP (0.1 equiv), 
DCM, 0 °C  r.t., o/n, 58%; c) Dimethyl malonate (3 equiv), CsCO3 (4 equiv), THAB (2.5 equiv), 
allyl palladium (II) chloride dimer (0.0025 equiv), (R,R)-DACH-phenyl Trost ligand (0.065 equiv), 
DCM, r.t., 4 h; 88%; d) KOH (2.5 M, excess), reflux, 4 h, 72%; e) I2 (2.2 equiv), KI (excess), sat. 
NaHCO3, THF, r.t., 4 h, 94%; f) DBU (2.5 equiv), THF, reflux, o/n, 48%. 
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The absolute stereochemistry, in step 3, was achieved using 
allylpalladium(II)chloride dimer and (R,R)-DACH-phenyl Trost ligand:   
 
 
This step involved the palladium mediated coupling of dimethyl malonate and 
acetate 91 to form compound 92 with excellent yields (88%, [α]D = −74.0°, c = 
3.0).34 This is a well-studied reaction with specific emphasis on gaining high 
enantiomeric excess (ee).35 Based on this previous research, reaction conditions used 
by Trost and co-workers were utilised.34,35 The base, NaH was replaced by caesium 
carbonate (Cs2CO3) to improve product ee.35 Slow addition (over 1.5 h) of the 
deprotonated dimethyl malonate solution to the Pd0 catalyst was also essential in 
achieving high ee values. 
 
Di-ester 92 was hydrolysed to its di-carboxylate product using 2.5 M KOH and once 
acidified, the dicarboxylic acid was heated to 160 °C, promoting decarboxylation to 
form intermediate 93 in a 72% yield.  Compound 93 underwent iodolactonisation 
with iodine/potassium iodide (I2/KI) in H2O–THF to form intermediate 94 with 
excellent yields of 94%.36 The iodo-compound 94 was converted to unsaturated 
lactone 95 in a 48% yield using DBU in THF at reflux.36 
 
The following step was α-oxidation of lactone 95 to yield hydroxylactone 84. 
Although α-oxidation of lactones is not well reported, an oxidant and strong 
nucleophilic base are always required (Figure 4.13).37,38 
NH HN
OO
PPh2Ph2P
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Figure 4.13:  α-Hydroxylation of lactone 95 using an oxidant and a strongly nucleophilic base in THF 
to form compound 84. 
 
A common reagent used for such oxidations is Vedej’s reagent (a MoO5 complex).39-
42 The reagent was freshly prepared as shown in Scheme 4.11 and 1,3-dimethyl-
3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU) was used in replacement of the 
highly toxic hexamethylphosphoramide (HMPA) reagent in accordance with a 
procedure developed by Anderson et al.43 
 
 
 
Scheme 4.12:  Reagents and conditions:  a) i) MoO3 (1 equiv), 30% H2O2, 35–40 °C, 4 h; ii) DMPU 
(1 equiv), 10 °C, 20 min, 52%; b) i) P2O5 under vacuum, 24 h; ii) Pyridine (1 equiv), r.t., 10 min, 
51%.  DMPU, 1,3-dimethyl-3,4,5,6-tetrahydro-2-pyrimidinone. 
 
The formation of the oxidising agent utilises a 2-step procedure, in which initially, 
molybdenum (VI) oxide (MoO3) complexes with a molecule of water.  This step 
required very careful heating, at 35 °C, with 30% H2O2 and following this, the 
resulting compound was further reacted with a molecule of DMPU to yield complex 
96.  Following dehydration of this complex over phosphorus pentoxide (P2O5) in a 
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vacuum desiccator, the final reaction was completed with dropwise addition of 
pyridine to yield the active oxidant oxodiperoxymolybdenum (pyridine) (1,3-
dimethyl-3,4,5,6-tetrahydro-2-pyrimidinone) (MoOPD), compound 97.  Care was 
taken when using and storing the reagent as stipulated by Anderson et al. due to the 
instability of complex 97 with light and heat.  
 
To test the efficiency of the freshly prepared oxidant, two test reactions were 
performed on γ-butyrolactone (due to its similarity to the starting material 95) 
(Scheme 4.13 A) and camphor (an inexpensive substrate that gives excellent yields 
with this oxidant) (Scheme 4.13 B).43 Under optimised conditions, both substrates 
were converted to their corresponding α-hydroxylated products in excellent yields. 
 
 
 
Scheme 4.13:  Reagents and conditions for α-oxidation of camphor (A) and γ-butyrolactone (B):  
LDA (1.5 equiv), MoOPD (1.1 equiv), THF, −78 °C, 2 h, 72% (A) and 81% (B).  LDA, lithium 
diisopropylamide. 
 
Applying these optimised conditions to 95, the reaction yielded very little product 
with a significant number of side reactions occurring.  After purification via silica gel 
chromatography, it was clear from 1H NMR that diastereoisomers were forming 
(Figure 4.14).  The formation of diastereoisomers should not interfere with future 
O O
OH
O
O
O
O
HO
A 
B 
Chapter 4 – Using Asymmetric Synthetic Methods to Synthesise Analogues of Abacavir 
221 
analogue synthesis as the stereochemistry at this quaternary carbon would be lost 
during analogue synthesis at step 8, Figure 4.12.  However, the yields from this 
reaction were very poor. 
 
 
 
Figure 4.14:  Formation of diastereoisomers from α-hydroxylation of 95 using LDA and MoOPD. 
 
A series of test reactions were carried out in an attempt to optimise the yield of 84a 
and 84b (Table 4.1). 
 
Extended reaction times and increasing the number of equivalents of base proved 
detrimental, with increased side product formation (reactions B and C).  Increasing 
the temperature, rigorous drying on MoOPD and increasing MoOPD equivalents, 
also had little effect on the reaction profile (reactions D and E).  Finally, potassium 
bis(trimethylsilyl)amide (KHMDS), in replacement of lithium diisopropylamide 
(LDA), was used in reaction F and no reaction occurred, with starting material 
recoverable.  For further work within this area, alternative oxidants, N-
sulfonyloxaziridines could be used.  These have found to be a higher yielding 
alternative to using metal based oxidants for lactone substrates.44 
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Table 4.1:  Experiments A–F showing the optimisation of reactions conditions for α-hydroxylation of 
lactone 95.  KHMDS, potassium bis(trimethylsilyl)amide.  SM, starting material. 
 
 
Reagent Conditions* 
 
 
 
Reaction 
  
Base (equiv)  
 
 
Temperature 
(°C)  
 
 
Other Conditions 
 
 
Yield (%) 
 
A 
 
 
LDA (1.5) 
 
−78 
 
MoOPD (1.1 equiv),  
2 h 
 
 
Diastereoisomers 
obtained – low 
yield (<20%) 
 
 
B 
 
 
LDA (1.5) 
 
−78 
 
MoOPD (1.1 equiv), 
3 h 
 
Increased 
number of side 
products – no 
yield obtained 
 
 
C 
 
 
LDA (2.0) 
 
−78 
 
MoOPD (1.1 equiv), 
2 h 
 
 
As reaction B 
 
D 
 
 
LDA (1.5) 
 
−78 to −30 
 
MoOPD (1.1 equiv), 
2 h (with initial 
drying of SM over 
P2O5) 
 
 
As reaction A 
 
E 
 
 
LDA (1.5) 
 
−78 to −30 
 
 
MoOPD (2 equiv), 
2 h 
 
 
As reaction A 
 
F 
 
 
KHMDS  
(1.5) 
 
 
−78 to −30 
 
MoOPD (1.1 equiv), 
2 h 
 
No reaction 
 
* All reactions were completed on a 100–150 mg scale. 
 
Following the problems with the aforementioned step 7, a slightly altered step 4 of 
the original synthesis was attempted (Figure 4.15).  This involved an oxidation of 
compound 92 in an open air flask with caesium fluoride (CsF) in DMF.45 The 
addition of a hydroxyl group at this point would eliminate the need for lactone α-
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hydroxylation.  However, no reaction occurred and starting material was recovered.  
This same step was repeated using the LDA/MoOPD conditions and again, no 
product was formed and starting material recovered. 
 
 
 
Figure 4.15:  The design of an alternative pathway for the formation of intermediate 84, where α-
hydroxylation of an earlier intermediate 92 occurs rather than lactone 95 (Figure 4.14). 
 
Subsequently, the synthesis was redesigned slightly as shown in Figure 4.16.  The 
synthesis was initially tested using racemic intermediates, as not to use the expensive 
(R,R)-DACH-phenyl Trost ligand.  Diethylbromomalonate was initially converted to 
compound 100 with excellent yields (93%) and this compound underwent further Pd0 
mediated coupling with intermediate 91.  This reaction originally used Cs2CO3 as the 
base, but no product was formed.  Substitution of Cs2CO3 for NaH gave a 23% yield 
of 101 but significant starting material was recovered.  Further optimisation revealed 
that the base, N,O-bis(trimethylsilyl)acetamide46 improved the yield slightly to 37%. 
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Figure 4.16:  Design of an alternative synthetic pathway to yield ABC 7.  This pathway circumvents 
the need for α-hydroxylation of the bicyclic lactone intermediate 95. 
 
Along with the low yields, once step 3 was repeated using chiral (R,R)-DACH-
phenyl Trost ligand, to form chiral 99, diastereoisomers were formed.  With all the 
problems experienced in the above syntheses, this asymmetric pathway was 
discarded and an alternative synthesis was found and developed. 
 
4.3.5.2 Asymmetric synthesis II. 
It was essential that intermediates for ABC analogues were found, and having 
experienced difficulties with previous syntheses, the synthetic route shown in 
Scheme 4.14 was researched and developed.5,7 This synthesis was used to synthesise 
D2-ABC and the initial 3 steps are the identical to those discussed in Chapter 2. 
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Scheme 4.14:  Reagents and conditions:  a) n-BuLi (1 equiv), pivaloyl chloride (1 equiv), NEt3 (1 
equiv), 4-pentenoic acid (1 equiv), t-BME, THF, −78 °C  r.t., N2, 2 h, 85%; b) DIEA (2.2 equiv), 
DBBT (2.2 equiv), acrolein (2.1 equiv), DCM, −78 °C  r.t., N2, 16 h, 87%; c) Grubbs catalyst 1st 
generation (5 mol %), DCM, r.t., Ar, 15 h, 70%; d) LiBH4 (5 equiv), MeOH (excess), THF, 0 °C  
r.t., 1 h; e) Ac2O (1.6 equiv), NEt3 (1.6 equiv), DMAP (0.1 equiv), DCM, 0 °C  r.t., o/n; f) NaH 
60% dispersed in mineral oil, 1.2 equiv), 2-amino-6-chloro purine (1.1 equiv), Pd(PPh3)4 (10 mol %), 
DMF, THF, Ar, 65 °C, o/n, 34%.  DMF, dimethylformamide. 
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Intermediate 68 was obtained by reduction of compound 53 with LiBH4 and MeOH 
in THF.  It was found to be preferential to use 68 without further purification due to 
compound loss associated with its volatility.  The di-protection of 68 with Ac2O and 
NEt3 in DCM yielded di-acetate 69, which underwent a further Pd0 mediated reaction 
with 2-amino-6-chloropurine.  This step is notoriously difficult, as previously 
discussed, with strict reaction conditions required for successful product formation.5 
Such reaction conditions included an inert atmosphere and absence of light.  The 
reaction conditions were optimised as shown in Table 4.2. 
 
Table 4.2:  Experiments A–D showing the optimisation of Pd0 mediated coupling step of compound 
69 with 2-amino-6-chloropurine. 
 
 
Reaction 
 
Reaction Conditions*  
(Reagents (equiv), Solvent,  
Temperature (°C), Time, Atmosphere) 
 
 
Yield (%) 
 
 
A 
 
NaH (1.3), Purine (1.1),  
Pd(PPh3)4 (0.05), DMF, 50 °C, 3 h, N2 
 
 
No reaction 
 
(82% acetate SM 
(69) recovered 
 
 
B 
 
 
NaH (1.5), Purine (1.3),  
Pd(PPh3)4 (0.1), DMF/THF, 50 °C,  
3 h, N2 
 
29  
 
(slight 
triphenylphosphine 
impurity) 
 
 
C 
 
 
NaH (1.5), Purine (1.3), Pd(PPh3)4 (0.1), 
DMF/THF, 50 °C, o/n, Argon 
 
 
30  
 
D 
 
 
NaH (1.5), Purine (1.3), Pd(PPh3)4 (0.1), 
DMF/THF, 60 °C, o/n, Argon 
 
 
34 
 
* All reactions were completed on a 150–200 mg scale. 
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With such low yields obtained in step 6 of the non-stereoselective synthesis (Section 
4.3.4), the palladium mediated coupling step was optimised further.  The reaction 
conditions used in reaction A were not successful and no reaction occurred, with 
82% of starting material recovered.  In reaction B, the number of equivalents of NaH 
and 2-amino-6-chloropurine were increased to 1.5 and 1.3 equivalents respectively.  
The mole equivalent of Pd catalyst was also increased from 5 to 10 mol %.  
Alongside this, Pd(PPh3)4 and 69 were stirred for 20 min in THF rather than DMF.  
The NaH/purine solution remained in DMF and this was added dropwise to the 
palladium solution.  The desired product was obtained in a 29% yield, but with slight 
triphenylphosphine oxide impurity:  A by-product that proved difficult to remove by 
silica gel column chromatography.  The conditions were optimised further as seen in 
reaction C.  The reaction was stirred overnight, rather than for 3 h and under an 
argon atmosphere, rather than nitrogen.  The yield increased to 30%.  Finally, in 
reaction D, all previous conditions remained the same but the temperatures of the 
reactions were altered.  Before addition to the palladium mixture, the NaH/purine 
solution was heated to 45 °C, shielded from light, for 30 min.  Once both solutions 
were combined, the overnight temperature was increased from 50 to 65 °C.  Again, 
the yield increased slightly to 34%. 
 
With compound 102 in hand, the synthetic route was halted.  The availability of this 
intermediate would allow for the synthesis of ABC analogues, particularly 6-position 
analogues.  These analogues could be synthesised as depicted in Figure 4.17, where 
102 would undergo nucleophilic aromatic addition with amine, thiol or alcohol 
substrates, followed by 5'-OH deprotection in 1 M NaOH to yield a range of 
analogues.  The synthesis and use of these analogues is discussed in Chapter 5.  
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Furthermore, compound 102 could be used to form other analogues of ABC, such as 
cyclopentyl and N2 analogues. 
 
 
 
Figure 4.17:  Using acetylated Cl-ABC 102, a range of 6-position amine analogues can be 
synthesised, followed by 5'-OH deprotection using 1 M NaOH.  The reactions conditions employed 
are shown within the figure. 
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4.4 Conclusions & Future Work 
 
There has been significant research into the synthesis of carbocyclic nucleosides:  
The group of compounds to which ABC belongs.  There are a range of synthetic 
protocols to synthesise ABC and its analogues.  In order to probe the mechanism of 
ABC toxicity, it was essential that a synthetic route was utilised and/or modified to 
produce a suitable ABC intermediate that could be easily employed in the chemical 
synthesis of ABC analogues. 
 
The initial research conducted did not use a total synthetic route but utilised a route 
from the parent drug itself.  The lack of solubility of ABC in a wide range of solvents 
significantly hampered synthetic endeavours.  However, compounds 20, 71 and 83 
were synthesised, with DH-ABC 20 of most interest.  In immunological studies, it 
was found that only at high concentrations of DH-ABC (50 and 100 µM), did T-cell 
proliferation and cytokine release occur.  The reason for this reduced immunological 
response is unknown, but it can be suggested that either DH-ABC binds in a different 
manner to ABC within the HLA-B*57:01 protein.  Although still in a non-covalent 
manner or, due to the lack of the cyclopentyl ring, metabolism to an aldehyde 
intermediate cannot occur resulting in no further covalent protein/peptide binding.  
The latter does not explain why at higher concentrations of DH-ABC, T-cells are 
activated. 
 
With only a small number of analogues synthesised from ABC itself, a de novo 
synthesis was evaluated.  MacKeith et al. developed a synthetic route from 
cyclopentadiene, using an enzyme to produce enantiomerically pure material.29 This 
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route was modified slightly to synthesise racemic ABC and the enantiomers were 
separated using chiral HPLC.  As with DH-ABC, the enantiomer of ent-ABC was 
subjected to cross-reactivity assays.  It was found that the enantiomer did not cause 
the ABC-specific T-cell clones to proliferate or release cytokine IFN-γ.  Again, the 
reason for reduced immunogenicity could be due to either altered binding with the 
HLA-B*57:01 protein or the enantiomer ent-ABC may not be a substrate for ADH, 
and so metabolism to the reactive aldehyde intermediate would not occur. 
 
Additional synthetic routes were probed – those that did not require enzymatic or 
chiral HPLC resolution.  An asymmetric synthesis using (R,R)-DACH-phenyl Trost 
ligand was designed.  The first 5 steps of this route worked well, but problems 
became apparent during α-oxidation of the lactone 95.  A variety of reaction 
conditions were attempted but isolation of the required product was not achieved, 
with consistently low yields.  The synthetic route was also slightly modified, but 
again, the desired product was not obtained. 
 
Crimmins and co-workers developed an efficient synthetic route to produce ABC, 
starting with a commercially available chiral oxazolidinone auxiliary.  This synthetic 
route was ideal as several intermediates in this synthesis could be utilised to form 
ABC analogues, namely acetylated chloro-ABC 102.  Good to excellent yields were 
achieved for the majority of the synthesis but the Pd0 mediated allyl coupling proved 
problematic.  Optimisation of the conditions required for this step was conducted and 
compound 102, a required intermediate for 6-position analogue synthesis (see 
Chapter 5) was obtained. 
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Further research into the successful synthesis of ABC analogues is required so a 
larger range of analogues (2-, 6-, 2'-, 3'- 4'- and 5'-position) can be synthesised 
(Figure 4.18 A).   
 
                               
 
Figure 4.18:  Possible positions on ABC 7 where modifications can be made for the synthesis of a 
wide range of analogues (A) and compound 78 which will require further immunological studies to 
establish any T-cell stimulatory effects in comparison to ABC. 
 
This will allow for a thorough investigation into the mechanisms surrounding ABC 
toxicity and the moiety contributing to its toxicity can be deduced.  Further to this, 
fluoro compound 78 (Figure 4.18 B) will need to undergo immunological testing to 
further investigate the contribution of the primary alcohol to ABC toxicity. 
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4.5 Experimental 
 
Immunology (cross-reactivity) experiments were conducted and obtained at the 
University of Liverpool by Catherine Bell and John Farrell (Dr. Dean Naisbitt’s 
research group). 
 
4.5.1 HPLC conditions for separation of ABC enantiomers. 
4.5.1.1 Processing of samples for HPLC. 
A stock solution (5 mg/mL) of ABC enantiomers was prepared and diluted to its 
working concentration of 1 mg/mL when required for analysis.  These final solutions 
were injected onto the HPLC column without further processing.   
 
4.5.1.2 Analysis of compounds. 
The enantiomers were chromatographed at room temperature using a Chiracel OD-
H analytical column and a fixed eluent system of n-hex−EtOH−TFA, 92:8:0.1 (v/v) 
over 40 min, injecting 0.5 mL for each analysis.  The eluent flow rate was 1 mL/min.  
The LC system consisted of a Gilson Gradient Manual Prep System with 2 × 306 
pumps and 118 UV/Vis detector. 
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4.5.2 Synthesis. 
 
 
 
9-((1R,4S)-4-(((tert-Butyldimethylsilyl)oxy)methyl)cyclopent-2-en-1-yl)-N6-
cyclopropyl-9H-purine-2,6-diamine 79:47 To a solution of ABC (0.60 g, 2.10 
mmol) and imidazole (0.30 g, 4.40 mmol) in DMF (10 mL) was added TBDMS−Cl 
(0.48 g, 3.20 mmol) and the reaction was allowed to stir at room temperature under 
nitrogen for 24 h.  Water was added (5 mL) and the resulting mixture was extracted 
into EtOAc (3 × 30 mL).  The combined organic extracts were washed with H2O (4 × 
120 mL), brine (1 × 100 mL), dried over MgSO4 and the solvent removed in vacuo.  
The crude product was purified by column chromatography (1:24 MeOH−DCM) to 
yield 79 (0.55 g, 65%) as a bright yellow solid.47 mp:  91–93 °C.  1H NMR (CDCl3): 
δ 7.55 (s, 1H), 6.12 (ddd, J = 5.6, 2.1, 2.1 Hz, 1H), 5.82 (ddd, J = 5.6, 2.1, 2.1 Hz, 
1H), 5.75 (br s, 1H), 5.57–5.51 (br m, 1H), 4.78 (br s, 2H), 3.69 (dd, J = 9.9, 5.4 Hz, 
1H), 3.60 (dd, J = 9.9, 5.4 Hz, 1H), 3.03–2.95 (m, 2H), 2.74 (ddd, J = 13.8, 8.6, 8.5 
Hz, 1H), 1.61 (ddd, J = 13.7, 6.3, 6.0 Hz, 1H), 0.89 (s, 9H), 0.87–0.83 (m, 2H), 
0.64–0.59 (m, 2H), 0.05 (s, 6H).  13C NMR (CDCl3): δ 163.1, 160.4, 156.7, 151.3, 
138.8, 136.0, 130.4, 115.1, 66.3, 59.0, 48.2, 36.9, 35.3, 31.8, 26.3 (3C), 24.0, 18.8, 
7.8 (2C), −4.9 (2C), −6.2.  m/z (ES+) 401.2481 calculated for C20H33N6OSi:  [M+H]+ 
N
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401.2485.  IR (cm-1):  3302 (N−H), 3197 (N−H), 1597, 1581 (C=C aromatic), 1238 
(C−O), 837 (Si−O). 
 
 
 
N-(9-((1R,4S)-4-(((tert-Butyldimethylsilyl)oxy)methyl)cyclopent-2-en-1-yl)-6-
(cyclopropylamino)-9H-purin-2-yl)acetamide 82:  To a solution of 79 (0.36 g, 
0.90 mmol) in DCM (20 mL) was added NEt3 (0.2 mL, 1.10 mmol) followed by 
Ac2O (0.1 mL, 1.10 mmol) dropwise at 0 °C.  The reaction was allowed to stir at 
room temperature over 4 h whereupon excess DCM (50 mL) was added.  The 
mixture was washed with H2O (1 × 50 mL) and the organic layer dried over MgSO4 
and the solvent removed in vacuo.  The crude product was purified by column 
chromatography (1:99 to 1:24 MeOH−DCM) to yield 82 (0.21 g, 53%) as an off-
white solid.  mp:  153–156 °C. 1H NMR (CDCl3): δ 8.22 (s, br, 1H), 7.74 (s, 1H), 
6.15 (ddd, J = 5.6, 2.0, 2.0 Hz, 1H), 5.85 (ddd, J = 5.6, 2.1, 2.0 Hz, 1H), 5.63–5.59 
(br m, 1H), 3.70 (dd, J = 10.0, 5.6 Hz, 1H), 3.60 (dd, J = 10.0, 5.5 Hz, 1H), 3.04–
2.97 (m, 1H), 2.76 (ddd, J = 14.0, 7.0, 6.6 Hz, 1H), 2.65 (s, 3H), 2.05–1.99 (m, 1H), 
1.65 (ddd, J = 14.0, 6.6, 6.6 Hz, 1H), 0.88 (s, 9H), 0.87–0.85 (m, 2H), 0.68–0.61 (m, 
2H), 0.05 (s, 6H).  13C NMR (CDCl3): δ 170.1, 156.4, 153.3, 139.2, 138.0, 130.0, 
117.0, 66.2, 59.6, 48.3, 35.3, 26.3 (3C), 25.6, 18.8, 7.7, −4.94 (2C).  m/z (ES+) 
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443.2601 calculated for C22H35N6O2Si:  [M+H]+ 443.2591.  IR (cm-1):  2931 (C−H), 
1620, 1466 (C=C aromatic), 1373 (C−N), 1249 (C−O), 833 (Si−O). 
 
 
 
N-(6-(Cyclopropylamino)-9-((1R,4S)-4-(hydroxymethyl)cyclopent-2-en-1-yl)-
9H-purin-2-yl)acetamide 83:  To a solution of 82 (76 mg, 0.20 mmol) in anhydrous 
THF (5 mL) was added TBAF (0.2 mL, 1 M in THF) and the reaction was stirred 
overnight at room temperature.  The solvent was removed in vacuo and the crude 
product purified by column chromatography (3:97 MeOH−DCM) to yield 83 (40 mg, 
71%) as a colourless solid.  mp:  130–133 °C.  1H NMR (CDCl3): δ 8.58 (br s, 1H), 
7.76 (s, 1H), 6.75 (br s, 1H), 6.15 (ddd, J = 5.5, 2.1, 2.1 Hz, 1H), 5.86 (ddd, J = 5.5, 
2.1, 2.1 Hz, 1H), 5.59–5.55 (br m, 1H), 3.76 (dd, J = 10.7, 4.9 Hz, 1H), 3.67 (dd, J = 
10.7, 4.7 Hz, 1H), 3.07–3.06 (m, 1H), 3.02–2.99 (m, 1H), 2.95 (br s, 1H), 2.78 (ddd, 
J = 14.0, 5.7, 5.5 Hz, 1H), 2.60 (s, 3H), 1.84 (ddd, J = 14.0, 5.7, 5.5 Hz, 1H), 0.86–
0.81 (m, 2H), 0.64–0.60 (m, 2H).  13C NMR (CDCl3): δ 170.6, 156.0, 152.9, 138.5, 
138.1, 130.2, 116.8, 64.9, 60.2, 53.6, 47.8, 34.1, 25.3, 7.33 (2C).  m/z (ES+) 
328.3690 calculated for C16H20N6O2:  [M+H]+ 329.1726.  IR (cm-1):  3209 (N−H), 
2978 (C−H), 1736 (C=N), 1608 (C=O), 1462 (C=C aromatic), 1369 (C−N), 1238 
(C−O). 
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N6-Cyclopropyl-9-((1R,4S)-4-(fluoromethyl)cyclopent-2-en-1-yl)-9H-purine-2,6-
diamine 78:  To a solution of NEt3.3HF (3.2 mL, 2.0 mmol) in DCM (15 mL) was 
added XtalFluor-E® (0.30 g, 1.3 mmol) followed by ABC 7 (0.27 g, 0.9 mmol) at 
room temperature under nitrogen.  The reaction mixture was heated to reflux for 3 h 
and after cooling, the reaction was quenched with 5% aqueous NaHCO3.  The 
mixture was extracted with DCM (3 × 30 mL) and the combined organic extracts 
were dried over MgSO4 and the solvent removed in vacuo.  The crude product was 
purified by column chromatography (1:99 to 1:19 MeOH−DCM) to yield 78 (8 mg, 
3%) as a colourless solid.  mp:  140–143 °C.  1H NMR (CDCl3): δ 7.61 (s, 1H), 
6.14–6.12 (m, 1H), 5.94–5.92 (m, 1H), 5.52–5.48 (br m, 1H), 4.42 (dddd, J = 47.6, 
29.2, 9.0, 4.9 Hz, 2H), 3.59–3.56 (m, 1H), 3.12–3.10 (m, 1H), 2.94–2.91 (m, 1H), 
2.79 (ddd, J = 14.0, 8.9, 8.7 Hz, 1H), 1.65 (ddd, J = 12.0, 8.0, 8.0 Hz, 1H), 0.81–0.79 
(m, 2H), 0.59–0.56 (m, 2H).  m/z (ES+) 289.1586 calculated for C14H18N6F:  [M+H]+ 
289.1577.  IR (cm-1):  3309 (N−H), 3191 (N−H), 1691 (C=N), 1477 (C−H), 1029 
(C−F). 
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((1S,4R)-4-(2-Amino-6-(cyclopropylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methyl acetate 71:5 To a solution of ABC 7 (0.72 g, 2.5 mmol) in DCM (30 mL) 
was successively added NEt3 (0.4 mL, 3.0 mmol) and Ac2O (0.3 mL, 3.2 mmol) 
dropwise at 0 °C.  The reaction was allowed to stir for 4 h and was quenched with 
saturated aqueous NH4Cl.  The mixture was extracted into DCM (3 × 20 mL) and the 
combined organic extracts were dried over MgSO4.  The solvent was removed in 
vacuo.  The material was purified by column chromatography (1:99 to 3:97 
MeOH−DCM) to yield 71 (0.57 g, 69%) as a colourless solid.5 mp:  119–121 °C.  1H 
NMR (CDCl3): δ 7.52 (s, 1H), 6.11–6.09 (m, 2H), 5.90 (ddd, J = 5.6, 2.2, 2.1 Hz, 
1H), 5.56–5.53 (br m, 1H), 4.20 (dd, J = 11.0, 5.8, 1H), 4.10 (dd, J = 10.9, 5.5 Hz, 
1H), 3.16–3.12 (m, 1H), 2.99 (br s, 1H), 2.84 (ddd, J = 14.0, 8.8, 8.7 Hz, 1H), 2.07 
(s, 3H), 1.64 (ddd, J = 14.0, 6.0, 5.9 Hz, 1H), 0.85–0.82 (m, 2H), 0.63–0.60 (m, 2H).  
13C NMR (CDCl3): δ 171.4, 160.4, 156.6, 151.1, 137.4, 135.6, 131.1, 115.1, 66.9, 
59.1, 44.8, 35.6, 24.1, 21.3, 7.8 (2C).  m/z (ES+) 329.1724 calculated for 
C16H21N6O2:  [M+H]+ 329.1726.  IR (cm-1):  3320 (N−H), 3197 (N−H), 2943 (C−H), 
1732 (C=O), 1585 (C=C aromatic), 1458 (CH2), 1389 (C−N), 1234 (C−O). 
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 ((1S,4R)-4-(2-Acetamido-6-(cyclopropylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methyl acetate 80:  A colourless solid (23%).  mp:  135–137 °C.  1H NMR 
(CDCl3): δ 7.68 (s, 1H), 6.14 (ddd, J = 5.5, 2.1, 2.1 Hz, 1H), 5.94 (ddd, J = 5.6, 2.2, 
2.1 Hz, 1H) 5.64–5.59 (br m, 1H), 4.19 (dd, J = 11.0, 5.8 Hz, 1H), 4.11 (dd, J = 11.0, 
5.7 Hz, 1H), 3.21–3.14 (m, 1H), 3.09–3.01 (m, 1H), 2.98 (br s, 1H), 2.87 (ddd, J = 
14.0, 8.8, 8.7 Hz, 1H), 2.06 (s, 3H), 1.77 (s, 3H), 1.66 (ddd, J = 14.0, 6.0, 5.9 Hz, 
1H), 0.90–0.85 (m, 2H), 0.66–0.62 (m, 2H).  13C NMR (CDCl3): δ 171.3, 169.6, 
156.7, 153.5, 138.4, 137.8, 137.6, 130.7, 117.2, 66.8, 59.5, 44.8, 35.7, 26.8, 25.7, 
21.3, 7.7.  m/z (ES+) 371.1830 calculated for C18H23N6O3:  [M+H]+ 371.1832.  Anal. 
calc. for C18H22N6O3:  C, 58.37; H, 5.99; N, 22.69.  Found: C, 57.97; H, 6.00; N, 
22.21.  IR (cm-1):  2974 (C−H), 1736 (C=N), 1608 (C=O), 1462 (C=C aromatic), 
1230 (C−O). 
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((1R,3S)-3-(2-Amino-6-(cyclopropylamino)-9H-purin-9-yl)cyclopentyl)methanol 
20:1 To a solution of ABC 7 (0.55 g, 2.0 mmol) in MeOH (10 mL) was added 10% 
Pd/C (cat.).  A vacuum was applied to the flask and ensuring the solution was under 
a hydrogen atmosphere, it was allowed to stir for 4 h at room temperature.  The 
mixture was filtered through celite and the solvent was removed in vacuo to obtain 
compound 20 (0.37 g, 67%) as a yellow solid.  mp:  151–153 °C (lit.1 mp as 
succinate salt:  170–175 °C).  1H NMR (MeOD): δ 7.81 (s, 1H), 4.76–4.61 (m, 1H), 
3.55 (dd, J = 6.2, 2.4 Hz, 1H), 3.31–3.21 (m, 1H), 2.86 (dd, J = 6.7, 3.3 Hz, 1H), 
2.38–2.10 (m, 3H), 2.03–1.90 (m, 1H), 1.90–1.78 (m, 1H), 1.76–1.62 (m, 2H), 0.83–
0.75 (m, 2H), 0.58–0.52 (m, 2H).  13C NMR (MeOD): δ 161.7, 157.5, 152.0, 137.3, 
114.9, 66.7, 56.5, 41.4, 36.7, 32.6, 27.6, 24.3, 7.6 (2C).  m/z (ES+) 289.1781 
calculated for C14H21N6O:  [M+H]+ 289.1777.  IR (cm-1):  3330 (N−H), 3213 (N−H), 
2955 (C−H), 1580 (C=C aromatic), 1390 (C−N), 1230 (C−O). 
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(±)-4-Hydroxy-2-oxabicyclo-[3.3.0]oct-7-en-3-one 84a:48 Cyclopentadiene (22.0 
mL, 0.26 mol) was added to a flask containing glyoxylic acid (20.30 g, 0.27 mol) in 
H2O (70 mL) and allowed to stir for 4 days at room temperature.  The solution was 
washed with n-hexane (4 × 100 mL).  The aqueous layer was saturated with sodium 
chloride (NaCl) and extracted with EtOAc (12 × 150 mL).  The organic layer was 
reduced to approximately 200 mL and washed with NaHCO3 at 0 °C (2 × 150 mL).  
The aqueous layer was extracted with EtOAc (4 × 150 mL) and the organic layers 
were dried over MgSO4 and the solvent removed in vacuo.  The crude mixture was 
recrystallised from diethyl ether to yield diastereoisomer 84a (5.49 g, 18%) as a 
colourless crystalline solid.  Diastereoisomer 84b remained in solution.  mp:  82–87 
°C (lit.48 mp:  83–85 °C).  1H NMR (CDCl3): δ 6.29–6.26 (m, 1H), 5.96–5.93 (m, 
1H), 5.35 (dd, J = 6.4, 2.2 Hz, 1H), 4.75 (d, J = 9.4 Hz, 1H), 3.64 (s, br, 1H), 3.27–
3.19 (m, 1H), 2.81–2.73 (m, 1H), 2.51–2.43 (m, 1H).  13C NMR (CDCl3): δ 178.0, 
142.6, 128.0, 87.9, 69.7, 41.0, 31.3.  m/z (CI) 158.0820 calculated for C7H12NO3:  
[M+NH4]+ 158.0816.    Anal. calc. for C7H8O3:  C, 59.99; H, 5.75; Found: C, 60.03; 
H, 5.71.  IR (cm-1):  3405 (br, O−H), 1735 (C=O), 1137 (C−O). 
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(±)-2-(1,2-Dihydroxyethyl)cyclopent-4-en-1-ol 85:15 LiAlH4 (1.60 g, 0.04 mol) in 
THF (40 mL) was cooled to 0 °C.  Compound 84a (5.40 g, 0.04 mol) in THF (20 
mL) was added dropwise to the hydride solution and left to stir overnight under 
nitrogen.  The mixture was stirred under reflux for 2 h and allowed to cool to room 
temperature.  Diethyl ether (60 mL) was added dropwise to quench the reaction 
followed by water (10 mL).  The aqueous solution was heated under reflux for a 
further hour, allowed to cool and filtered through celite.  THF (70 mL) and H2O (10 
mL) were added to the remaining precipitate and stirred under reflux for another 
hour.  The hot solution was filtered through celite and the combined extracts were 
concentrated in vacuo to yield crude 85  (5.10 g) as a brown oil.15 1H NMR (CDCl3): 
δ 6.06–6.05 (m, 1H), 5.92–5.90 (m, 1H), 4.90–4.88 (m, 1H), 3.93–3.89 (m, 1H), 
3.79–3.75 (m, 1H), 3.64–3.60 (m, 1H), 2.34–2.24 (m, 3H). 13C NMR (CDCl3): δ 
136.0, 132.7, 76.1, 73.2, 66.2, 44.6, 33.9.  m/z (CI) 144.17 calculated for C7H12O3:  
[M+NH4]+ 162 Da and [(M+NH4)–H2O] + 144 Da.   
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(±)-2-Hydroxymethylcyclopent-4-en-1-ol 68:29 NaIO4 (2.40 g, 11.0 mmol) was 
added to a vigorously stirred solution of the crude triol 85 (1.30 g) in a mixture of 
diethyl ether (50 mL) and H2O (50 mL) at 0 °C.  After stirring for 2 h, ethylene 
glycol (0.3 mL, 4.4 mmol) was added and the mixture was continued to be stirred at 
0 °C for an hour.  The yellow/orange solution was concentrated in vacuo to remove 
diethyl ether and EtOH (15 mL) was added.  The mixture was cooled to 0 °C and 
NaBH4 (0.40 g, 12.0 mmol) were added.  The solution was allowed to stir for 1 h at 0 
°C and the EtOH then removed.  The orange solution was saturated with NaCl and 
extracted with EtOAc (6 × 60 mL).  The organic extracts were washed with brine, 
dried over MgSO4 and the solvent removed in vacuo.  The crude product was 
purified by column chromatography (2:1 EtOAc−petroleum ether) to yield 0.56 g 
(59%) of 68 as a clear and colourless oil.29 1H NMR (CDCl3): δ 6.02–6.00 (m, 1H), 
5.85–5.82 (m, 1H), 4.93–4.91 (m, 1H), 3.85–3.76 (m, 2H), 3.11 (s, br, 1H), 2.81 (s, 
br, 1H), 2.53–2.44 (m, 1H), 2.41–2.34 (m, 1H), 2.25–2.18 (m, 1H).  13C NMR 
(CDCl3): δ 135.7, 132.8, 78.3, 63.2, 42.9, 34.0.  m/z (CI) 113.9962 calculated for 
C6H12NO:  [(M+NH4)–H2O]+ 114.0683.  IR (cm-1):  3305 (br, O−H), 2929 (C−H). 
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(±)-2-(Triphenylmethyloxymethyl)cyclopent-4-en-1-ol 86:29 A solution of the diol 
68 (0.50 g, 4.5 mmol), CPh3Cl (1.30 g, 4.6 mmol), DMAP (0.06 g, 0.5 mmol), NEt3 
(0.6 mL, 4.6 mmol) in DCM (25 mL) was stirred under nitrogen at room temperature 
overnight.  The mixture was washed with saturated aqueous NH4Cl (1 × 30 mL), 
brine and dried over MgSO4.  The solvent was removed in vacuo.  The crude product 
was purified by column chromatography (1:4 EtOAc−n-hex) to afford 86 (1.16 g, 
72%) as a colourless solid.29 mp: 97–100 °C.  1H NMR (CDCl3): δ 7.46–7.44 (m, 
6H), 7.26–7.22 (m, 9H), 5.98–5.95 (m, 1H), 5.87–5.85 (m, 1H), 4.95–4.92 (m, 1H), 
3.43–3.39 (m, 1H), 3.20 (t, J = 9.0 Hz, 1H), 2.61–2.53 (m, 1H), 2.38–2.30 (m, 1H), 
2.17 (s, br, 1H), 2.13–2.05 (m, 1H).  13C NMR (CDCl3): δ 144.3, 135.2, 133.0, 
128.9, 128.1, 127.5, 87.2, 78.1, 63.7, 42.2, 34.6.  m/z (ES+) 379.1681 calculated for 
C25H24O2Na:  [M+Na]+ 379.1674.  IR (cm-1):  3405 (br, O−H), 2931 (C−H), 1490 & 
1446 (C=C aromatic). 
 
 
 
(±)-1-Acetoxy-2-(triphenylmethyloxymethyl)cyclopent-2-en-1-yl 87:29 Mono-
protected diol 86 (1.20 g, 3.2 mmol) was allowed to stir overnight at room 
temperature in a mixture of pyridine (2.0 mL, 25.0 mmol) and Ac2O (2.4 mL, 25 
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mmol).  Saturated aqueous NH4Cl (10 mL) was added and the solution extracted 
with diethyl ether (2 × 15 mL).  The combined organic layers were washed with 
sodium bicarbonate (NaHCO3) and brine.  The organic layer was dried over MgSO4 
and the solvent removed in vacuo to yield 87 (0.77 g, 39%) as a pale yellow solid.29 
mp:  121–124 °C. 1H NMR (CDCl3): δ 7.44–7.41 (m, 6H), 7.25–7.21 (m, 9H), 6.09–
6.07 (m, 1H), 5.86–5.83 (m, 1H), 5.80–5.77 (m, 1H), 3.24–3.14 (m, 2H), 2.74–2.65 
(m, 1H), 2.50–2.42 (m, 1H), 2.19–2.13 (m, 1H), 1.78 (s, 3H).  13C NMR (CDCl3): δ 
171.0, 144.6, 137.8, 130.0, 129.1, 128.1, 127.3, 86.8, 78.8, 62.8, 41.8, 35.3, 21.5.  
m/z (ES+) 421.1779 calculated for C27H26O3Na:  [M+Na]+ 421.1780.  IR (cm-1):  
1724 (C=O), 1488 & 1444 (C=C aromatic), 1375 (C−O). 
 
 
 
(±)-2-Amino-6-chloro-9-((4-(triphenylmethyloxymethyl)-cyclopent-2-en-1-
yl)purine 88:4 NaH (washed in anhydrous n-hex, 30 mg, 1.1 mmol) was dissolved in 
DMF (2 mL) and 2-amino-6-chloropurine (0.10 g, 0.6 mmol) in DMF (2 mL) was 
added to the NaH solution.  The reaction was allowed to stir at room temperature in 
the dark, under argon, for 30 min.  Acetate 87 (0.10 g, 0.3 mmol) was dissolved in 
DMF (5 mL) and Pd(PPh3)4 (0.30 g, 0.3 mmol) was added.  The hydride mixture was 
added to this flask via a cannula and the mixture was allowed to stir overnight at 50 
°C, in the dark, under argon.  The reaction mixture was allowed to cool to room 
(±)
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N
N
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OCPh3
AcO
Ph3CO N
NNH
N
Cl
NH2
87                  88 
Chapter 4 – Using Asymmetric Synthetic Methods to Synthesise Analogues of Abacavir 
245 
temperature and extracted with EtOAc (6 × 15 mL), dried over MgSO4 and the 
solvent removed in vacuo.  The crude product was purified by column 
chromatography (1:1 EtOAc−n-hex) to yield 88 (0.17 g, 17%) as a colourless solid.  
mp:  85–89 °C ((–)-enantiomer lit.4 mp:  82–90 °C).  1H NMR (CDCl3): δ 7.65 (s, 
1H), 7.43–7.40 (m, 6H), 7.27–7.21 (m, 9H), 6.27–6.25 (m, 1H), 5.84–5.83 (m, 1H), 
5.56–5.52 (br m, 1H), 5.20 (s, 2H), 3.18–3.13 (m, 3H), 2.80–2.72 (m, 1H), 1.62–1.56 
(m, 1H).  13C NMR (CDCl3): δ 159.3, 153.9, 151.5, 144.3, 143.8, 141.9, 140.9, 
129.3, 129.0, 128.9, 128.7, 87.0, 66.5, 60.8, 46.1, 35.7.  m/z (ES+) 530.1729 
calculated for C30H26ClN5ONa:  [M+Na]+ 530.1724.  IR (cm-1):  3316 (N−H), 3239 
(N−H), 2919 (C−H), 1608 (C=N), 1450 & 1403 (C=C aromatic), 1203 (C−O), 701 
(C−Cl). 
 
 
 
(±)-2-Amino-6-(cyclopropylamino)-9-(4-(triphenylmethyloxymethyl)-cyclopent-
2-en-1-yl)purine 89:  To an ice cold solution of the purine 89 (0.10 g, 0.2 mmol) in 
MeOH (5 mL) was added cyclopropylamine (0.1 mL, 1.4 mmol) and the resulting 
solution was stirred at 50 °C overnight.  After removal of the solvent, the crude 
product was purified by column chromatography (7:3 EtOAc−n-hex) to afford 89 (60 
mg, 72%) as an off-white solid.  mp:  119–123 °C. 1H NMR (CDCl3): δ 7.43–7.41 
(m, 6H), 7.36 (s, 1H), 7.31–7.23 (m, 9H), 6.22–6.19 (m, 1H), 5.84–5.82 (m, 1H), 
(±) (±)
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5.54–5.50 (br m, 1H), 3.15–3.12 (m, 2H), 3.09–3.05 (m, 1H), 3.03–2.96 (m, 1H), 
2.77 (ddd, J = 13.9, 8.3, 8.2 Hz, 1H), 1.59–1.52 (m, 1H), 0.88–0.82 (m, 2H), 0.62–
0.58 (m, 2H).  13C NMR (CDCl3): δ 156.6, 144.4, 138.8, 130.2, 128.9, 128.2, 127.5, 
115.2, 86.9, 66.8, 59.1, 46.1, 36.1, 30.1, 24.1, 7.8.  m/z (ES+) 529.2720 calculated 
for C33H33N6O:  [M+H]+ 529.2716. 
 
 
 
(±)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl 
methanol 7:49 A solution of the purine 89 (0.10 g, 0.2 mmol) in 80% AcOH (2.0 
mL, 35.0 mmol) was allowed to stir for 48 h at 50 °C.  The solvent was removed in 
vacuo and the crude product purified by column chromatography (1:19 
MeOH−DCM) to yield racemic 7 (28 mg, 52%) as an off-white powder.  mp: 155–
159 °C ((–)-enantiomer lit.49 mp:  165 °C).  1H NMR (DMSO-d6): δ 7.48 (s, 1H), 
6.12–6.10 (m, 1H), 5.77–5.74 (m, 1H), 5.44–5.39 (br m, 1H), 3.92 (dd, J = 11.0, 3.7 
Hz, 1H), 3.81 (dd, J = 11.0, 2.9 Hz, 1H), 3.16–3.10 (m, 1H), 3.01–2.94 (m, br, 1H), 
2.79 (ddd, J = 14.7, 9.8, 8.5 Hz, 1H), 2.22 (ddd, J = 14.6, 5.6, 5.0 Hz, 1H), 0.87–0.82 
(m, 2H), 0.62–0.58 (m, 2H). 13C NMR (DMSO-d6): δ 160.4, 156.3, 138.3, 135.2, 
130.4, 113.9, 64.5, 58.5, 55.3, 48.0, 34.7, 6.8 (2C).  m/z (ES+) 287.1618 calculated 
for C14H18N6O:  [M+H]+ 287.1620.  IR (cm-1):  3328 & 3250 (O−H & N−H), 2977 
(C−H), 1592 (C=N), 1481 & 1427 (C=C aromatic). 
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Cyclopent-2-enol 90:50 To an ice-cold solution of the 2-cyclopenten-1-one (5.1 mL, 
0.06 mol) and CeCl3.7H2O (29.80 g, 0.08 mol) in MeOH (100 mL) was added 
NaBH4 (2.50 g, 0.07 mol) slowly over 30 min with vigorous stirring.  The mixture 
was allowed to stir at room temperature for 1 h followed by dropwise addition of 
water.  The mixture was extracted with diethyl ether (3 × 100 mL) and the organic 
layer was dried over MgSO4.  The solvent was removed in vacuo to yield crude 90 
(4.10 g) as an off-white volatile liquid.50 1H NMR (CDCl3): δ 6.00–5.97 (ddd, J = 
5.5, 2.1, 2.1 Hz, 1H), 5.85–5.81 (ddd, J = 5.5, 2.2, 2.1 Hz, 1H), 4.87–4.86 (m, br, 
1H), 2.55–2.46 (m, 1H), 2.32–2.22 (m, 2H), 1.73–1.65 (m, 1H).  m/z (CI) 84.12 
calculated for C5H8O: [(M+NH4)–H2O] + 84.  
 
 
 
Cyclopent-2-en-1-yl acetate 91:50 Cyclopent-2-enol 90 (2.20 g, 26.0 mmol) and 
DMAP (0.30 g, 2.8 mmol) were dissolved in DCM (60 mL) and cooled to 0 °C.  
NEt3 (5.1 mL, 37.0 mmol) and Ac2O (3.6 mL, 38.0 mmol) were added at 0 °C and 
the solution were allowed to stir overnight at room temperature.  The mixture was 
diluted with diethyl ether (100 mL) and washed with 2 M HCl (2 × 60 mL) and 
NaHCO3 (1 × 60 mL).  The organic layer was dried over MgSO4 and the solvent 
removed in vacuo.  The crude product was purified by column chromatography 
(100% diethyl ether) to yield 91 (1.90 g, 58%) as a clear and colourless volatile 
OHO
OAcOH
90 
91 90 
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liquid.50 1H NMR (CDCl3): δ 6.12–6.09 (m, 1H), 5.84–5.81 (m, 1H), 5.72–5.67 (m, 
1H), 2.57–2.47 (m, 1H), 2.37–2.24 (m, 2H), 2.03 (s, 3H), 1.87–1.78 (m, 1H).  13C 
NMR (CDCl3): δ 171.4, 137.9, 129.6, 80.8, 31.4, 30.1, 21.7.  m/z (CI) 126.15 
calculated for C7H14NO2:  [M+NH4]+ 144.0. IR (cm-1):  2977 (C−H), 1731 (C=O), 
1241 (C−O). 
 
 
 
(S)-Dimethyl-2-(cyclopent-2-en-1-yl)malonate 92:34 To a suspension of CsCO3 
(51.30 g, 0.16 mol) in anhydrous DCM (125 mL) was added dimethyl malonate 
(13.6 mL, 0.12 mol) and solution was allowed to stir at room temperature for 1 h 
under nitrogen. Tetrahexylammonium bromide (THAB, 42.90 g, 0.10 mol) was 
added and the solution was allowed to stir for a further 20 min.  Anhydrous DCM 
(50 mL) was added to allylpalladium(II)chloride dimer (0.40 g, 0.1 mmol) and (R,R)-
DACH-phenyl Trost ligand (1.80 g, 2.6 mmol) under nitrogen and stirred for 10 min.  
Compound 91 (5.00 g, 0.04 mol) in DCM (5 mL) was added and the solution was 
allowed to stir for a further 10 min.  The dimethyl malonate solution was added to 
the palladium mixture over 1.5 h and the solution were allowed to stir under nitrogen 
at room temperature for a further hour.  The reaction was quenched with water and 
extracted with diethyl ether (4 × 200 mL), dried over MgSO4 and the solvent 
removed in vacuo.  The crude product was purified by column chromatography (1:9 
EtOAc−n-hex) to obtain 92 (6.83 g, 88%) as a clear volatile liquid.  1H NMR 
(CDCl3): δ 5.85–5.82 (m, 1H), 5.67–5.64 (m, 1H), 3.74 (s, 6H), 3.42–3.35 (m, 1H), 
3.28 (d, J = 9.6 Hz, 1H), 2.42–2.27 (m, 2H), 2.18–2.09 (m, 1H), 1.64–1.55 (m, 1H).  
CO2Me
CO2Me
MeO2C CO2MeOAc
91 92 
Chapter 4 – Using Asymmetric Synthetic Methods to Synthesise Analogues of Abacavir 
249 
13C NMR (CDCl3): δ 169.5, 133.5, 131.7, 57.0, 52.7, 45.8, 32.1, 28.2.  m/z (CI) 
199.22 calculated for C10H16O4:  [M+H]+ 199.3.  IR (cm-1):  2954 (C−H), 1735 
(C=O), 1149 (C−O).  [α]D −74.0° (c = 3.0 in DCM), lit. [α]D −71.65° (c = 3.09 in 
DCM).34 
 
 
 
(R)-2-(Cyclopent-2-en-1-yl)acetic acid 93:51 The di-ester 92 (6.40 g, 30.0 mmol) in 
KOH (15 mL, 2.5 M) was heated under reflux for 4 h.  The resulting solution was 
cooled to room temperature then to 0 °C and acidified to pH 1 with 3 M HCl.  The 
acidified solution was extracted with diethyl ether (4 × 50 mL), dried over MgSO4 
and the solvent removed in vacuo to obtain the crude dicarboxylic acid as a 
colourless solid.  This solid was heated (130–140 °C) until a liquid was obtained and 
this was further heated at 160 °C for 1 h.  The crude product was purified via column 
chromatography (100% diethyl ether) to yield 93 (2.95 g, 72%) as a clear and 
colourless slightly volatile liquid. (For (S)-enantiomer).51 1H NMR (CDCl3): δ 5.80–
5.77 (m, 1H), 5.70–5.68 (m, 1H), 3.14–3.06 (m, 1H), 2.46–2.41 (m, 2H), 2.40–2.27 
(m, 2H), 2.20–2.11 (m, 1H), 1.53–1.45 (m, 1H).  13C NMR (CDCl3): δ 179.8, 133.8, 
132.2, 42.2, 40.6, 32.2, 30.0.  m/z (CI) 126.15 calculated for C7H10O2:  [M+NH4]+ 
144.   
CO2H
CO2Me
CO2Me
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(1R,5S,8S)-8-Iodo-2-oxabicyclo-[3.3.0]-oct-3-one 94:52 To a mixture of 93 (0.60 g, 
4.4 mmol) and saturated aqueous NaHCO3 (9.0 mL) in THF (10 mL) was added a 
solution of I2 (2.40 g, 9.6 mmol) and KI (4.80 g, 29.0 mmol) in H2O (13 mL) and the 
solution was stirred for 4 h at room temperature.  The resulting mixture was 
quenched dropwise with saturated aqueous sodium sulfite (Na2SO3) solution until the 
dark brown solution became clear and colourless.  The solution was then extracted 
with diethyl ether (4 × 50 mL), dried over MgSO4 and the solvent removed in vacuo.  
The resulting crude oil was recrystallised from 1:1 EtOAc−pentane to yield 94 (1.05 
g, 94%) as an off-white solid.  mp:  62–65 °C (lit.52 mp for (1S,5R,8R)-enantiomer:  
69–70 °C).  1H NMR (CDCl3): δ 5.21 (d, J = 6.0 Hz, 1H), 4.48 (d, J = 5.0 Hz, 1H), 
3.21–3.13 (m, 1H), 2.90 (dd, J = 18.1, 9.7 Hz, 1H), 2.49–2.42 (m, 1H), 2.41 (d, J = 
2.1 Hz, 1H), 2.36 (d, J = 2.1 Hz, 1H), 2.20–2.02 (m, 2H), 1.62–1.57 (m, 1H).  13C 
NMR (CDCl3): δ 177.0, 92.8, 36.5 (2C), 35.0, 32.6, 29.8.  m/z (ES+) 274.9544 
calculated for C7H9IO2Na:  [M+H]+ 274.9545.  Anal. calc. for C7H9IO2:  C, 33.36; H, 
3.60.  Found: C, 33.79; H, 3.59.  IR (cm-1):  2965 (C−H), 1770 (C=O), 1168 (C−O). 
 
 
 
 
 
O O
ICO2H
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(1R,5S)-2-Oxabicyclo-[3.3.0]oct-7-en-3-one 95:53 To a solution of iodo-lactone 94 
(5.30 g, 20.0 mmol) in THF (60 mL) was added DBU (7.8 mL, 50.0 mmol) and the 
solution was refluxed under nitrogen overnight.  The remaining solution was cooled 
to room temperature, diluted with diethyl ether (60 mL) and cooled to 0 °C 
whereupon saturated aqueous NH4Cl solution (60 mL) was added slowly.  The layers 
were separated and the aqueous layer was extracted with diethyl ether (3 × 60 mL).  
The combined organic extracts were dried over MgSO4 and the solvent removed in 
vacuo.  The crude product was purified by column chromatography (1:1 EtOAc−n-
hex) to yield 95 (1.24 g, 48%) as a clear and colourless oil.53 1H NMR (CDCl3): δ 
6.10–6.08 (m, 1H), 5.90–5.87 (m, 1H), 5.55–5.51 (m, 1H), 3.19–3.10 (m, 1H), 2.95–
2.85 (m, 1H), 2.82–2.73 (m, 1H), 2.36–2.28 (m, 2H).  13C NMR (CDCl3): δ 177.6, 
137.3, 129.5, 90.0, 60.8, 40.0, 36.5, 35.5.  m/z (CI) 124.14 calculated for C7H8O2:  
[M+NH4]+ 142.  IR (cm-1):  2962 (C−H), 1770 (C=O), 1164 (C−O), 1002 (=C−H). 
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MoO5.DMPU.H2O 96:  MoO3 (10.05 g, 0.07 mol) was dissolved in 30% H2O2 (40 
mL) and heated slowly, ensuring the internal temperature was consistently kept 
between 30–40 °C, for 4 h.  The yellow solution was cooled to room temperature and 
filtered though celite, washing with H2O.  The filtrate was cooled to 10 °C and 
DMPU (8.4 mL, 0.07 mol) was added over 10 min.  Stirring at 10 °C was continued 
for a further 10 min and the solid filtered under suction.  The solid material was 
recrystallised with MeOH to yield the product 96 (11.60 g, 52%) as a partially 
suspended yellow solid. 
 
 
 
MoO5.DMPU.Py 97:43 Complex 96 was dried for 24 h over P2O5 in a vacuum 
dessicator, shielded from light.  The remaining product (MoO5.DMPU, 7.50 g, 0.02 
mol) was dissolved in THF (50 mL) and under vigorous stirring, pyridine (1.6 mL, 
0.02 mol) was added dropwise over 10 min at room temperature.  The product was 
filtered and washed with anhydrous THF and dried in a vacuum desiccator shielded 
from light to yield the product 97 (4.80 g, 51%) as a fine yellow crystalline solid.  
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mp:  93–94 °C (lit.43 mp:  93.5–94.5 °C).  Anal. calc. for C11H17MoN3O6:  C, 34.47; 
H, 4.47; N, 10.64.  Found: C, 34.32; H, 4.44; N, 10.64.  IR (cm-1):  1595 (C=N), 
1542 (C=C aromatic), 955 (Mo=O), 866 (O−O). 
 
 
 
Diethyl-2-acetoxymalonate 100:54 To a solution of diethylbromomalonate (0.7 mL, 
4.0 mmol) in DMF (15 mL) was added to NaOAc (0.51 g, 6.0 mmol) and the 
solution was stirred at room temperature for 2 h whereupon water (2 mL) was added.  
The mixture was extracted with EtOAc (3 × 20 mL) and the combined organic 
extracts were washed with H2O (3 × 40 mL), brine and dried over MgSO4.  The 
solvent was removed in vacuo.  The crude product was purified by column 
chromatography (1:3 EtOAc−n-hex) to yield 100 (0.85 g, 93%) as a colourless 
liquid.54 1H NMR (CDCl3): δ 5.52 (s, 1H), 4.33–4.26 (m, 4H), 2.23 (s, 3H), 1.31 (t, J 
= 6.8 Hz, 6H).  m/z (CI) 218.2 calculated for C9H14O6:  [M+[NH4]+ 236.3.  IR (cm-1):  
2966 (C−H), 1766 (C=O), 1165 (C−O). 
 
 
 
(1R,5R)-5-(Hydroxymethyl)cyclopent-2-enol 68:5 To a suspension of LiBH4 (6.3 
mL, 0.19 mol) in THF (20 mL) cooled to 0 °C was added to a solution of 53 (1.20 g, 
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4.0 mmol) in THF (20 mL) and MeOH (0.5 mL, 0.01 mol) dropwise.  The resulting 
solution was stirred at 0 °C for 1 h and allowed to warm to room temperature 
whereupon 10% NaOH (6.3 mL) was added and stirring was continued until the 
solution became clear.  The mixture was extracted with diethyl ether (3 × 30 mL) and 
the aqueous layer was acidified with 1 M HCl and further washed with diethyl ether.  
The combined organic extracts were dried over MgSO4.  The solvent was removed in 
vacuo and the crude product 68 (yellow liquid) was used without purification.5 1H 
NMR (CDCl3): δ 5.94–5.92 (m, 1H), 5.87–5.84 (m, 1H), 5.10–5.06 (m, 1H), 4.03 
(dd, J = 10.8, 7.1 Hz, 1H), 3.78 (dd, J = 10.8, 6.9 Hz, 1H), 2.66–2.58 (m, 1H), 2.51–
2.42 (m, 1H), 2.27–2.20 (m, 1H).  13C NMR (CDCl3): δ 135.7, 132.8, 78.1, 63.9, 
43.0, 34.0.  m/z (CI) 114.07 calculated for C6H10O2:  [M+[NH4]+–H2O ] 114.1.  
 
 
 
((1R,2R)-2-Acetoxycyclopent-3-en-1-yl)methyl acetate 69:5 To a solution of 68 
(0.50 g) in DCM (25 mL) was added DMAP (0.11 g, 0.8 mmol), NEt3 (1.8 mL, 13.0 
mmol) and Ac2O (1.2 mL, 13.0 mmol) at 0 °C.  The solution was allowed to stir 
overnight at room temperature whereupon saturated aqueous NH4Cl was added.  The 
quenched mixture was extracted into DCM (3 × 30 mL) and the combined organic 
extracts were dried over MgSO4.  The crude product was purified by column 
chromatography (1:9 EtOAc−n-hex) to yield compound 69 (0.34 g) as a yellow oil.5 
1H NMR (CDCl3): δ 6.12–6.09 (m, 1H), 5.87–5.84 (m, 1H), 5.78–5.70 (m, 1H), 4.22 
(dd, J = 10.9, 8.3 Hz, 1H), 4.14 (dd, J = 11.0, 7.1 Hz, 1H), 2.75–2.66 (m, 1H), 2.53–
2.46 (m, 1H), 2.29–2.21 (m, 1H), 2.05 (s, 3H), 2.03 (s, 3H).  13C NMR (CDCl3): δ 
AcO
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171.5, 171.1, 137.2, 129.8, 78.5, 63.8, 39.9, 35.0, 21.5, 21.4.  m/z (ES+) 221.08 
calculated for C10H14O4Na:  [M+Na]+ 221.1.  IR (cm-1):  1735 (C=O), 1373 (C−H), 
1241 (C−O). 
 
 
((1S,4R)-4-(2-Amino-6-chloro-9H-purin-9-yl)cyclopent-2-en-1-yl)methyl acetate 
102:5 To a stirred solution of NaH (60% dispersed in mineral oil, 0.07 g, 1.6 mmol) 
in DMF (3 mL) was added 2-amino-6-chloropurine (0.23 g, 1.4 mmol).  The 
resulting mixture was allowed to stir at 45 °C under argon for 30 min and then 
cooled to room temperature.  In a separate flask, compound 69 (0.25 g, 1.3 mmol) 
was added to a solution of Pd(PPh3)4 (0.14 g, 10 mol %) in THF (3 mL) and was 
allowed to stir at room temperature under argon for 20 min.  This solution was added 
dropwise to the NaH solution and heated to 65 °C overnight under argon, shielded 
from light.  The resulting solution was extracted into DCM and the combined organic 
extracts were washed with brine and dried over MgSO4.  The solvent was removed in 
vacuo.  The crude product was purified by column chromatography (1:1 EtOAc−n-
hex) to yield 102 (0.13 g, 34%) as a colourless solid.5 mp:  119–121 °C.  1H NMR 
(CDCl3): δ 7.83 (s, 1H), 6.16 (ddd, J = 5.6, 2.2, 2.2 Hz, 1H), 5.91 (ddd, J = 5.6, 2.2, 
2.1 Hz, 1H), 5.62–5.56 (br m, 1H), 4.23 (dd, J = 10.0, 5.6 Hz, 1H), 4.16 (dd, J = 
10.0, 5.5 Hz, 1H), 3.22–3.16 (m, 1H), 2.87 (ddd, J = 14.0, 6.4, 6.4 Hz, 1H), 2.08 (s, 
3H), 1.71 (ddd, J = 14.0, 6.4, 6.3 Hz, 1H).  13C NMR (CDCl3): δ 170.3, 159.6, 153.5, 
151.4, 141.9, 138.9, 130.1, 128.5, 65.1, 59.7, 45.0, 34.5, 21.3.  m/z (ES+) 330.0729 
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calculated for C13H14N5O2Na35Cl:  [M+Na]+ 330.0734.  IR (cm-1):  3340 (N−H), 
1720 (C=O), 1615, 1560 & 1471 (C=C aromatic), 1261 (C−O). 
 
4.5.3 Immunology studies. 
For generation of ABC-specific T-cell clones and assessment of cross-reactivity of 
ABC, ent-ABC and 20 using the IFN-γ ELISpot assay, the procedure in Chapter 3, 
Section 3.5.2 was followed. 
 
 4.5.3.1 Cross-reactivity of ABC-specific T-cell clones using LTT assay. 
ABC-specific T-cell clones were generated according to Section 3.5.2.  ABC-
specificity of T-cell clones (5 × 104 cells/well) was determined by addition of 50 µM 
abacavir and 1 × 104 irradiated autologous EBV-transformed B-cells to serve as 
APCs.  [3H]-Thymidine (0.5 µCi/well) was added after 48 h and proliferation 
determined via scintillation counting. Clones with a stimulation index (cpm in drug 
treated wells/cpm in control wells) of greater than 2 were expanded by repeated 
mitogen stimulation and were maintained in IL-2 containing medium for several 
weeks.  
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4.6 Supplementary Information 
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5.1 Introduction 
 
Recently published research proposed a new potential mechanism of ABC toxicity.  
This new concept is known as the ‘altered repertoire mechanism.’1-4 Although it has 
been suggested as a theory to specifically explain the toxicity associated with ABC, 
initial research has also shown it can be applied to CBZ hypersensitivity.1 
 
5.1.1 Altered repertoire mechanism. 
It was suggested that the altered repertoire mechanism can be applied to those 
molecules that stimulate the immune system via the antigen processing and MHC 
class I pathway.4 The antigens bind within the MHC molecule and in doing so, it 
alters the self-peptides that bind (Figure 5.1).  The self-peptides that bind within the 
MHC are highly specific and by changing the range of peptides that bind, from those 
that would normally be presented, the CD8+ T-cells will detect a neo-peptide and in 
turn will be activated.  
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Figure 5.1:  Mechanism for the altered repertoire concept.  A normal self-peptide (Peptide 1) will 
bind within the HLA molecule and this will not induce an immune response (A).  Peptide 2, a neo 
self-peptide cannot bind within the HLA molecule in the absence of ABC.  Once ABC binds, it 
facilitates the binding of Peptide 2 within HLA-B*57:01 resulting in the stimulation of CD8+ T-cells, 
causing an immune response (B). 
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5.1.2 Altered repertoire mechanism applied to ABC. 
Three papers published recently, hypothesised that ABC-HSR arose from the altered 
repertoire mechanism.1-3 The research presented showed that ABC bound within the 
F-pocket of the peptide-binding grove of the MHC and in doing so, altered the self-
peptide repertoire, and subsequently stimulated a T-cell response (Figure 5.1). 
 
ABC does not induce an immune response in patients who bear the HLA-B*57:02, 
HLA-B*57:03, HLA-B*57:11 and HLA-B*58:01 alleles.  The amino acid residues 
that differ in these alleles from HLA-B*57:01 are shown in Table 5.1 with 
differences ranging from two to four amino acids.  Using this knowledge, Illing et al. 
had deduced that ABC specifically bound at the C-terminal end of the HLA-B*57:01 
protein within the C, D, E and F-pockets.1 
 
In experiments analysing the repertoire of peptides binding within cell lines 
expressing either HLA-B*57:01 or HLA-B*57:03 alleles, no ABC metabolites were 
detected, rather ABC itself; suggesting the parent drug, ABC, was responsible for T-
cell stimulation.  Within these experiments, Illing et al. detected a change of self-
peptides eluting from cells bearing HLA-B*57:01.  A large number of these peptides, 
in the presence of ABC, were found to contain Ile or Leu at the C-terminus (PΩ) of 
the peptide.  This was a contrast compared to self-peptides that normally bind within 
this allele or HLA-B*57:03. These peptides were often found to terminate with the 
more bulky Trp or Phe amino acids.5 This led the authors to postulate that, along 
with ABC undertaking the normal antigen processing pathway, a large proportion of 
normal self-peptides were unable to bind within HLA-B*57:01 during peptide 
loading in the presence of ABC.  This was due to steric hindrance and as a 
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consequence, a new repertoire of peptides, bearing smaller C-terminal amino acids 
were found to bind. 
 
Table 5.1:  Amino acid differences in HLA allotypes:  HLA-B*57:02, -B*57:03, -B*57:11 and  
-B*58:01 in comparison with HLA-B*57:01. 
 
 
HLA Allotype 
 
 
 
Amino Acid Difference 
with respect to  
HLA-B*57:01 
 
 
HLA-B*57:02 
 
 
Asp114Asn 
Ser116Tyr 
Leu156Arg 
 
 
HLA-B*57:03 
 
 
Asp114Asn 
Ser116Tyr 
 
 
HLA-B*57:11 
 
 
Ile94Thr 
Ile95Leu 
Val97Trp 
 
 
HLA-B*58:01 
 
 
Met45Thr 
Ala46Glu 
Val97Arg 
Val103Leu 
 
 
X-ray structures of HLA-B*57:01 bearing neo self-peptides and ABC were obtained, 
and from this data, the interactions of ABC and the peptide were determined.  The 
cyclopentyl, purinyl and cyclopropyl moieties of ABC were situated in the D, E and 
F-pockets respectively.  Several van der Waals interactions and H-bonds were 
discovered to form in this immunogenic complex and those with particular interest 
were Ser 116 and Val 97, which were involved in H-bonding and van der Waals 
interactions respectively.  These interactions explain why alleles such as HLA-
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B*57:02 and HLA-B*57:03 do not initiate a T-cell response in the presence of ABC.  
In alleles HLA-B*57:02 and HLA-B*57:03, Tyr replaces Ser 116, an amino acid 
located in the F-pocket of the allele.  Tyr is a large bulky amino acid and would 
disfavour ABC binding.  This is similar for HLA-B*58:01, where Val 97 is replaced 
by charged Arg, again resulting in unfavoured binding of ABC.  The position and 
interactions of the cyclopropyl group were found to be responsible for the altered PΩ 
amino acids, with smaller amino acids being favoured. 
 
In support of the research by Illing et al., Ostrov et al. also postulated that ABC, as 
the parent drug, was present whilst peptide loading was occurring within the ER.  
Following vast combinatorial library research, they designed a synthetic peptide, 
pep-V (sequence HSITYLLPV), and this peptide exhibited a high affinity for HLA-
B*57:01.  This only occurred in the presence of ABC in a dose-dependent manner.2 
The researchers obtained an X-ray crystal structure of pep-V and ABC bound within 
HLA-B*57:01.  From this, the H-bonding and van der Waals interactions of ABC 
within the complex were obtained (Figure 5.2).  Pep-V was shown to contribute to 
two of the van der Waals interactions. 
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Figure 5.2:  Interactions of ABC within the C, D, E and F-pockets of HLA-B*57:01.  ABC undergoes 
H-bonding with four amino acids (Tyr 74, Asp 114, Ser 116 and Ile 124, as shown in blue) and in 
addition to this, several van der Waals interactions (Tyr 9, Val 97, Tyr 99, Tyr 123 and Trp 147, as 
shown in red) are present.  Three of these van der Waals interactions appear from pep-V (amino acids 
Ile 3, Leu 7 and Val 9). Adapted from Ostrov et al.2  
 
Ostrov et al. also demonstrated an altered repertoire of bound peptides within HLA-
B*57:01 in ABC-treated cells compared to non-treated cells.2 High levels of peptides 
eluted from ABC-treated cells were found to encompass a Val (and Ile) amino acid at 
PΩ, and conversely, in untreated cells, no recovered peptides possessed a Val at the 
this position.  In ABC-treated cells, it was also found a lower number of peptides 
with Trp or Phe at this PΩ position:  This was consistent with Illing et al.1 Further to 
this and previous work conducted in 2008,6 no eluted peptides possessed an Ala 
residue at the C-terminus, confirming that ABC becomes involved in intracellular 
antigen processing:  A process which disfavours peptides bearing an Ala residue at 
the C-terminus.  The presence of ABC during antigen processing results in the 
structure binding within the antigen-binding cleft of the HLA molecule.  This 
complex would result in the binding of a new repertoire of peptides. 
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Further to this, Norcross et al. supported this hypothesis:3  ABC induced the loading 
of peptides that favoured an Ile or Leu amino acid at the PΩ position, in a dose-
dependent manner.  In addition, it was found that the P2 anchor amino acids (Ala, 
Thr or Ser)5 of the neo self-peptides remained the same as those peptides found in 
untreated cells.  Interestingly, two drug-induced peptides, HSLPALIQI and 
STIRLLTSL had high affinity binding for HLA-B*57:01, not only in the presence of 
ABC, but also in its absence.  These neo self-peptides in vivo would ordinarily have 
a low affinity for this HLA protein but upon ABC exposure, ABC may assist in the 
stabilisation of these peptides within the HLA complex. 
 
The ABC-associated findings assisted the authors in postulating that ABC is able to 
alter the structure of the HLA complex directly, by either remaining within the HLA 
protein or modifying the peptide processing pathway and as a result, affect peptide 
loading and/or binding.  Along with this, the role of tapasin is to stabilise MHC 
complexes and to promote binding of high affinity peptides,7 thereby, modification 
of the tapasin/TAP pathway may also alter the repertoire of peptides, and ABC is 
known to undertake this pathway.6 
 
In initial research, Illing et al. also demonstrated this mechanism with CBZ.1 CBZ, 
an anti-epileptic drug, is strongly associated with an HLA-specific CBZ-induced 
SJS/TEN in patients whom possess the HLA-B*15:02 allele.  Applying the same 
experimental techniques as used with ABC, Illing et al. found an altered set of 
peptides bound within the HLA-B*15:02 allele in the presence of CBZ.  HLA-
B*15:02, in the presence of CBZ, preferred peptides with increased hydrophobicity 
Chapter 5 – Using Structure–Activity Relationships to Investigate Abacavir Toxicity 
270 
and smaller residues at the P4 and P6 positions, but the response was 15% smaller 
than that generated by ABC.  Further work is required to support these findings. 
 
Whilst, collectively, the above data provides a solid understanding to ABC-HSR, it 
fails to explain why only 50% of HLA-B*57:01 positive patients develop the 
toxicity.  In order to investigate and develop this research further, ABC analogues 
were designed to probe and further understand its interactions specifically within the 
F-pocket of HLA-B*57:01. 
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5.2 Aims 
 
• To synthesise a range of amine and oxy analogues of ABC at the 6-position 
using an SAR approach 
• To investigate whether synthesised 6-position analogues can reduce T-cell 
stimulation in HLA-B*57:01 ABC-stimulated T-cells 
• To determine whether replacement of 6-cyclopropyl amine will eliminate 
ABC toxicity. 
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5.3 Results & Discussion 
 
 5.3.1 Synthesis of Cl-ABC 32. 
To synthesise any 6-position analogues of ABC, Cl-ABC intermediate 32, was 
required.  The two-step method for this synthesis was taken from a large-scale 
patent, originally used to synthesise ABC (Scheme 5.1).8 
 
 
 
Scheme 5.1:  Reagents and conditions:  a) (1S,4R)-4-Amino-2-cyclopentene-1-methanol tartrate salt 
29 (1 equiv), 2,5-diamino-4,6-dichloropyrimidine 30 (1 equiv), NaHCO3 (3.5 equiv), n-BuOH, 95 °C, 
16 h, 53%; b) TEOF (1.2 equiv) and conc. H2SO4 (0.05 equiv), n-BuOH, 70 °C, 20 h, 87%. 
 
Both commercially available starting materials 29 and 30 were coupled together in n-
butanol (n-BuOH), using the inorganic base, NaHCO3 (3.5 equiv).  The optimum 
temperature used was 95 °C and a 53% yield achieved.  The ring closing reaction of 
31 was completed using TEOF (1.2 equiv) and concentrated sulfuric acid (H2SO4, 
0.05 equiv).  The strict addition of reagent equivalents was vital for the formation of 
32.  It was found that excess addition of either reagent, resulted in an unwanted side 
product.  This side product was difficult to remove by silica gel column 
chromatography due to the comparable polarity to the desired product 32.  This 
reaction proceeded with 87% yield. 
 
NH2
HO
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N NH2
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N
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32   29   30 31 
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5.3.2 Synthesis of 6-position 1° and 2° amine analogues (compounds 103–118). 
The synthesis for the majority of the 1° and 2° amine analogues was straightforward, 
providing there were no steric clashes or hindering groups.  Most of the reactions 
were completed using standard nucleophilic aromatic substitution conditions 
(Scheme 5.2) for this type of compound.  These conditions comprised of heating the 
1°/2° amine in MeOH to 60/70 °C overnight.9 Compounds 115–118 were 
synthesised within the group at the University of Liverpool.  The structures and 
yields of the compounds can be found in Table 5.2. 
 
  
 
Scheme 5.2:  General procedure for formation of 6-position 1° and 2° amine analogues.  Reagents and 
conditions:  1°/2° Amine (1.5, 10 or 20 equiv), MeOH, 60–70 °C, o/n, 31–94%. 
 
The reaction of 32 with t-butylamine to form compound 109 required excess amine 
(10 equiv) as the reaction proceeded extremely slowly at lower stoichiometrics.  This 
was likely to be due to steric reasons as the t-Bu alkyl group is more hindered.  A 
57% yield was achieved from this reaction.  Yields from all other reactions ranged 
from 31–94%.  Excess amine reagent, N-methylcyclopropanamine (20 equiv), was 
also required for the synthesis of compound 114.  For the synthesis of compound 
N
N
N
NH2N
Cl
OH
N
N
N
NH2N
R1
OH
R1 = 1o / 2o Amine
32 
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118, the reaction time was 3 days rather than overnight.  All other conditions were as 
previously mentioned. 
 
Table 5.2:  The formation of 6-position 1° and 2° amine analogues using standard nucleophilic 
aromatic substitution conditions, forming compounds 103–118.  Compounds 117 and 118 were 
synthesised within the group at the University of Liverpool. 
 
 
Compound 
Number 
 
 
R1 Group* 
 
Yield (%) 
 
 
103 
 
 
 
 
 
62 
 
104 
 
 
 
 
 
85 
 
105 
 
 
 
 
 
71 
 
 
106 
 
 
 
 
 
81 
 
107 
 
 
 
 
 
73 
 
108 
 
 
 
 
 
71 
 
109 
 
 
 
 
 
57 
 
NH
NH
NH
NH
NH
NH
NH
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Table 5.2 continued: 
 
110 
 
 
 
 
 
70 
 
111 
 
 
 
 
 
81 
 
112 
 
 
  
 
 
94 
 
113 
 
 
 
 
 
74 
 
114 
 
 
 
 
 
77 
 
115 
 
 
 
 
 
68 
 
116 
 
 
 
 
 
65 
 
117 
 
 
 
 
 
81 
 
118 
 
 
 
 
 
31 
 
* All reactions were completed on a 50–250 mg scale. 
 
The compounds synthesised were designed in a SAR manner, so as to disrupt 
binding and intermolecular bonding within the F-pocket of the HLA-B*57:01 allele.  
NHN
O
NH
NHMe
N Me
N Me
NH
NH
NH
NH
Ph
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By disrupting this binding, neo self-peptides would not be able to bind, resulting in 
reduced or no T-cell activation.  Substituting the cyclopropyl substituent with larger 
alkyl rings:  Cyclobutyl, cyclopentyl and cyclohexyl (compounds 103–105) moieties 
should subtly disrupt the binding in the F-pocket itself, whereas those with larger, 
substitutions e.g. compounds 106, 110, 117 and 118, would almost certainly cease 
the analogue from binding in a manner similar to ABC.  The substitutions of the 
cyclopropyl ring with n-alkyl, isopropyl (i-Pr) or t-Bu groups (compounds 108, 109, 
111, 113, 115 and 116) produce very slight changes to the structure but these could 
significantly reduce binding.  This would be expected with the i-Pr and t-Bu 
analogues due to the increased steric bulk of the methyl groups.  The final 
cyclopropyl analogues, 107, 112 and 114, have only very slight variations in 
comparison to ABC but are capable of interrupting van der Waals bonding in and 
around the F-pocket. 
 
 5.3.2.1 Synthesis of compound 121. 
With no commercially available amine reagent needed to synthesise compound 121, 
N-methylcyclopropanamine was itself synthesised.  This three-step synthesis was 
completed as seen in Scheme 5.3.  The starting material, cyclopropylamine, was 
protected with Boc in quantitative yields.  Following this, the Boc protected amine 
119 underwent deprotonation with NaH and subsequent addition of methyl iodide 
(MeI) to form intermediate 120 with a 73% yield.  The final step posed more issues 
due to the volatility of the desired methylated amine compound 120, but yields of 
58% were achieved.  The product, compound 121, was stored at −20 °C until it was 
used as a reagent under nucleophilic aromatic substitution conditions with 32 to form 
compound 114. 
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Scheme 5.3:  Reagents and conditions: a) Cyclopropylamine (1 equiv), Boc2O (1 equiv), DCM, 0 °C 
 r.t., o/n, 92%; b) NaH (1.5 equiv), MeI (1 equiv), DMF, 0 °C  r.t., o/n, 73%; c) AcCl (5 equiv), 
MeOH, r.t., o/n, 58%. 
 
5.3.3 Synthesis of 6-position 1° amine analogues (compounds 122–126). 
A select number of analogues could not be synthesised using the nucleophilic 
aromatic conditions as stated in Section 5.3.2.  This was due to volatility of the 
amine reagent or for electronic reasons.  Rather than directly heating the reaction 
mixtures in a standard flask, a sealed tube was required (Table 5.3). 
 
NH2 NH
Boc
N
Boc
Me
H
N Me
a b c
  120 119 121 
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Table 5.3:  Synthesis of 1° amine analogues, compounds 122–126.  The compounds were synthesised 
using nucleophilic aromatic substitution of 6-Cl (compound 32) with the respective amine reagent. 
 
 
Compound 
Number 
 
 
Analogue  
(R1 Group) 
 
Conditions* 
 
Yield (%) 
 
 
122 
 
 
 
 
7 N NH3 (excess), MeOH 
 
 
96 
 
124  
 
 
 
 
 
(123) 
 
 
  
  
 via  
 
 
 
 
 
 
 
 
 
 
(1-Boc-3-(amino)azetidine 
(1 equiv), MeOH) 
 
53  
 
 
 
 
 
(57) 
 
125 
 
 
 
 
 
3-amino-oxetane (5 
equiv), EtOH 
 
80 
 
126 
 
 
 
 
 
2,2-
dimethylcyclopropylamine 
(1 equiv), K2CO3 (1.5 
equiv),  
t-BuOH 
 
 
54 
 
* All reactions were carried out in a sealed tube and were completed on a 50–300 mg scale. 
 
During the synthesis of compound 122, the volatility of ammonia (NH3) proved to be 
problematic, but once the reaction was completed in a sealed tube and with a large 
excess of NH3, the issue was corrected.10 To synthesise compound 124, 1-Boc-3-
(amino)azetidine was used.  The reaction was carried out in MeOH and once the 
intermediate product 124 was formed, the Boc group was removed using TFA in 
DCM to yield the azetidine product 124 with a 53% yield.  The reaction to form 
compound 125 was conducted in EtOH.  This improved the yield of the reaction, as 
NH2
NH
HN
NH
BocN
NH
O
NHMe
Me
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the temperature of the reaction in the sealed tube could be increased compared to 
using MeOH as the solvent.  This increased temperature improved the reaction yield 
(from 42% to 80%).  Compound 126 was synthesised using 2,2-
dimethylcyclopropylamine hydrochloride.  Under standard conditions (Scheme 5.2), 
no product was observed.  The difficulty in obtaining the product was likely due to 
steric reasons.  Two methyl groups on the cyclopropyl ring would greatly hinder the 
amine to undergo nucleophilic attack.  To overcome this problem, K2CO3 was used 
with t-BuOH and the reaction was carried out in a sealed tube.  The inorganic base, 
K2CO3 was used as it would not interfere with the nucleophilic substitution:  A 
common problem observed when using organic bases such as NEt3.  The solvent t-
BuOH was also used, rather than EtOH or MeOH, as it again allowed for an 
increased temperature to be used but with no possibility of itself acting as a 
nucleophile.  Under these conditions, the product 126 was obtained with a 54% yield. 
 
Compound 122 was synthesised for comparative purposes against the n-alkyl amino 
chains (i.e. compounds 111, 115 and 116).  Modifications of the cyclopropyl amino 
group were of great interest as they maintained the fundamental structure of ABC but 
slight changes on the cyclopropyl ring would produce analogues that have the 
potential of reducing or eliminating toxicity but maintaining a high level of antiviral 
activity and PK parameters.  Examples of this include compounds 112 and 126:  
These compounds bear either mono- or di-methyl groups on the cyclopropyl ring.  
These methyl groups could disrupt the binding sufficiently within the F-pocket so as 
to reduce a T-cell response. 
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Two further compounds 124 and 125 were designed to test the H-bonding effects 
within the HLA-B*57:01 molecule.  Both compounds bear ring structures that are 
small enough to not deviate far from ABC’s structure with both containing 
heteroatoms.  The O-atom on the amino oxetane group (compound 125) would act as 
an H-bond acceptor and therefore there would be potential interactions with amino 
acids present within the F-pocket region of the protein.  Conversely, the N-atom in 
compound 124, which bears an amino azetidine group, would act as an H-bond 
donor.  But again, the amino acid interactions within the F-pocket would be 
interesting to investigate.  This compound was synthesised via Boc-protected 
azetidine 123 and removal of the Boc-protecting group using TFA yielded 124 as the 
TFA salt. 
 
5.3.4 Synthesis of fluoro-substituted cyclopropyl amine analogues (compounds 
127–130). 
Four substituted compounds 127–130 could not be synthesised.  These are shown in 
Figure 5.3.  Ranges of conditions were attempted for these reactions as depicted in 
Table 5.4.  All substituted cyclopropyl amine reagents were used as salts and all 
reactions were completed on either 50 or 100 mg scales. 
 
 
 
Figure 5.3:  Substituted cyclopropylamine compounds 127–130 that could not be synthesised via 
nucleophilic aromatic substitution of 6-Cl. 
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Table 5.4:  Varying conditions used in attempt to synthesise the fluorinated compounds 127–130. 
 
 
Compound/ 
R1 Group 
 
 
Conditions* 
 
 
Yield 
(%) 
 
 
A1 
 
 
K2CO3 (1.5 equiv), MeOH, 60 °C, 16 h 
 
 
- 
 
A2 
 
DIEA (1.2 equiv), DMF, 70 °C, 16 h 
 
 
- 
 
A3 
 
NEt3 (1.1 equiv), DMF, 60 °C, 16 h 
 
 
- 
 
A4 
 
K2CO3 (1.5 equiv), Dioxane, 150 °C, 20 min, MW 
 
 
- 
 
A5 
 
NEt3 (1.1 equiv), Dioxane, 170 °C, 30 min, MW 
 
 
- 
 
A6 
 
NEt3 (2 equiv), DMSO, 180 °C, 60 min, MW 
 
 
- 
 
A7 
 
Pd(dba)2 (0.1 equiv), K3PO4 (3.2 equiv), XPhos (0.5 
equiv), DME, 20 min, 100 °C, MW 
 
 
- 
 
A8 
 
 
K2CO3 (2 equiv), t-BuOH, 100 °C, 1 h, MW 
 
- 
 
 
 
 
 
 
 
 
 
 
 
127 
 
 
 
 
(Ts)  
(1.1 equiv) 
 
 
 
A9 
 
K2CO3 (2 equiv), t-BuOH, 100 °C, 3 days, Sealed Tube 
 
 
1 
 
128 
 
 
 
(Ts)  
(1.1 equiv) 
 
 
B1 
 
 
K2CO3 (2 equiv), t-BuOH, 100 °C, 3 days, Sealed Tube 
 
- 
 
 
NHF
NHF
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Table 5.4 continued: 
 
C1 
 
K2CO3 (3 equiv), t-BuOH, 100 °C, 2 days, Sealed Tube 
 
 
- 
 
129 
 
 
 
C2 
 
K2CO3 (2.5 equiv), EtOH, 80 °C, 24 h, Sealed Tube 
 
 
- 
 
130 
 
 
 
 
D1 
 
K2CO3 (2.5 equiv), EtOH, 80 °C, 24 h, Sealed Tube 
 
- 
 
* All reactions were completed on a 50–100 mg scale. 
 
Compound 127 was used as the test compound to determine optimum reaction 
conditions.  Conditions A1 used for this compound proved unsuccessful, with no 
product formation and starting material was recovered.  With the presumption that 
the inorganic base was contributing to no product formation, conditions A2 and A3 
were attempted using DIEA and NEt3 respectively in DMF.  Using DMF would 
allow the temperature of the reaction to be increased, should it have required this.  
Unfortunately, no desired product was formed, with some side reactions evident.  It 
was apparent that the fluorine atom was having a major influence on the substitution 
reaction:  This is likely to be due to electronic reasons.  
 
To force the reaction further, microwave conditions were used (conditions A4–A6, 
Table 5.4).  Reactions were completed in either DMSO or dioxane with varying base, 
temperature and reaction times.  For all reactions, the formation of side products was 
vast and it was difficult to determine any product formation.  For reaction A6, a 
major product was formed and once isolated, this was found to be compound 131 
(Figure 5.4).  NEt3 under these conditions had reacted with the starting material.  
NHF
F
NHF
MeF
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From this, no organic base was used for future aromatic substitution reactions.  
DMSO and N-methyl-2-pyrrolidone (NMP) were also unable to be used as solvents 
due to similar polarities with the starting material and required products. 
 
 
 
Figure 5.4:  Major side product formed during reaction A6 Table 5.4, forming compound 131, with 
no desired product obtained. 
 
A palladium-coupling reaction was attempted (reaction A7), using C−N cross-
coupling reaction conditions.  This has been seen to assist in the coupling of aryl 
halides with a range of amine substrates.11-13 More notably, these cross-coupling 
reactions have been demonstrated with deoxynucleoside halides.14,15 Although 
significantly less side reactions occurred, no product was obtained.   Finally, using 
K2CO3 as the base and t-BuOH as the solvent (a hindered solvent with no possibility 
to act as a nucleophile itself) reactions A8 and A9 were attempted.  A sealed tube has 
been shown to be advantageous with previous difficult aromatic substitution 
reactions (see Section 5.3.3) and some product formation was apparent.  Once 
isolated, mass spectrometry analysis showed a product with the desired accurate 
mass (m/z (ES+) 305.1526 calculated for C14H18N6OF:  [M+H]+ 305.1527) but due to 
a low mass obtained, further analysis was not possible. 
 
N
N
N
NH2N
OH
NEt3
131 
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Using these reaction conditions (B1, Table 5.4), the synthesis of the enantiomer was 
attempted (compound 128).  Some product was formed but no pure 128 were 
obtained.  Compound 129 was also attempted with these conditions (C1, Table 5.4), 
but again, no product was obtained.  This was expected due to the difluoro 
substitution.  The reaction was repeated using EtOH, a solvent found to previously 
assist with difficult substitution reactions, but this was also unsuccessful (C2, Table 
5.4).  The same outcome was observed with compound 130, with no product 
formation.  The difluoro substitution would not only slow the reaction significantly, 
but the additional methyl group would also hinder nucleophilic addition.  With a 
range of conditions attempted for these compounds and very little or no product 
obtained, they were not pursued further.  
 
5.3.5 Synthesis of oxy 6-position analogues (compounds 132–139). 
SAR design of the analogues was not limited solely to 6-position amines.  Six oxy-
analogues were synthesised as shown in Table 5.5.  The reaction conditions varied 
slightly to their amine equivalents (Scheme 5.4). 
 
  
 
Scheme 5.4:  General procedure used to synthesise 6-position oxy analogues.  Reagents and 
conditions:  Alcohol (excess, as solvent), NaH (3 equiv), 80 °C, 4 h, 51–85% yields. 
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N
N
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Initially, DMF was used as the reaction solvent and reactions were extremely slow 
with very little or no product formation evident after 24 h.  Along with this, the 
number of side products increased over time and purification of products posed many 
problems, often with no successful results.  After further research into alternative 
methods Vince et al.16 had successfully synthesised similar analogues using the 
alcohol itself as the reagent and solvent.  The synthesis of 7 oxy analogues proceeded 
well using this method (using the alcohol reagent as the solvent), giving yields of 
51–85%.  NaH was used as the base and a temperature of 80 °C over 4 h was 
required.  The reactions occurred more rapidly than their amine equivalents and with 
generally good yields. 
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Table 5.5:  The formation of 6-position oxy analogues using nucleophilic aromatic substitution 
conditions (alcohol (excess), NaH (3 equiv), 80 °C, 4 h) to form compounds 132–139. 
 
 
Compound 
 
 
R2 Group* 
 
Yield (%) 
 
 
132 
 
 
 
 
 
70 
 
133 
 
 
 
 
 
 
73 
 
134 
 
 
 
 
 
57 
 
 
135 
 
 
 
 
 
75 
 
 
136 
 
 
 
 
 
85 
 
137 
 
 
 
 
 
51 
 
138 
 
 
 
 
 
0 
 
139 
 
 
 
 
 
80 
 
* All reactions were completed on a 50–500 mg scale. 
 
O
O
O
OMe
O
O
ON
O
O
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Problems were only encountered with one analogue, compound 138.  The reaction 
conditions used were those as previously described (Scheme 5.4).  It was clear from 
early analysis that reaction yields for this reaction were poor due to significant 
formation of side products and remaining starting material.  Difficulties arose during 
purification (via silica gel chromatography); excess morpholine reagent was difficult 
to remove using this method and polarities of starting material, desired product and 
side products were very similar and so contributed to difficult purification.  With no 
successful results via this method, short-path vacuum distillation using Kugelrohr 
apparatus was attempted.  Although this method was successful at removing excess 
morpholine reagent, the issues with removing starting material and side products 
remained.  The synthesis of this analogue was not pursued further due to time 
constraints. 
 
5.3.6 Cross-reactivity of ABC-specific human T-cell clones with 6-position 
analogues. 
The cross-reactivity studies were carried out within the University of Liverpool and 
for details of these assays see Chapter 1, Section 1.10.2.  The cross-reactivity results 
for a select number of N- and O- 6-position analogues, as depicted in Figure 5.5, 
were determined by both proliferation and ELISpot IFN-γ assays.  The ELISpot 
assay results are discussed within. 
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Figure 5.5:  The select number of 6-position amine and oxy analogues that were investigated in the 
ELISpot assay (results shown in Figures 5.6 and 5.7). 
 
Over increasing compound concentrations (10–250 µM), it can be seen that 
analogues 107, 111, 115, 136 and 137 stimulated IFN-γ release to the same extent as 
ABC, where all other analogues did not (Figure 5.6 A–D).  The analogues that 
resulted in T-cell stimulation have 6-position alkyl moieties.  Interestingly, these 
analogues have less bulky, non-heteroatom, longer chained 6-position substituents 
compared to those analogues that did not stimulate T-cell clones (Figure 5.5).  These 
analogues are likely to stimulate T-cells as a result of binding within the HLA-
B*57:01 protein – in a similar manner to ABC.  This is visualised within Figure 5.8, 
where ABC, or one of the aforementioned analogues, can bind within HLA-B*57:01 
and alter the set of peptides that are normally displayed by this allele.  It is probable 
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that these analogues will undergo comparable amino acid, namely van der Waals, 
interactions within the protein as seen with ABC, mainly within the F-pocket region. 
 
 
    
     
 
Figure 5.6:  Cross-reactivity results for compounds 103–107 (A); 132 and 133 (B); 108, 110, 113 and 
115 (C); 111, 135–137 (D) showing IFN-γ release, over increasing compound concentrations of 10–
250 µM after a 48 h incubation with ABC-specific T-cell clones.  Data was visualised using an 
ELISpot assay and is represented as SFC/well. 
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The two most notable analogues were compounds 108 and 113.  These analogues 
bear remarkable similarity to ABC and yet do not result in cytokine release (Figures 
5.6 C and 5.7).  Both compounds 108 and 113 are likely to experience increased 
steric interactions whilst binding within the protein, resulting in unfavourable 
binding and no stimulation of T-cells. 
 
 
 
 
Figure 5.7:  ELISpot assay data showing cytokine IFN-γ release for compounds 108, 113 and 115, 
against the positive control ABC, over concentrations of 10–250 µM.  Compound 115 stimulates 
cytokine release, whereas compounds 108 and 113 do not. 
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Figure 5.8:  In the absence of ABC, self-peptides are displayed within the HLA-B*57:01 allele to T-
cells (A).  In the presence of ABC, and other selected analogues 107, 111, 115, 136 and 137, the T-
cells are stimulated, in in vitro experiments.  Adapting the altered repertoire mechanism, ABC and 
these analogues are able to form stable interactions within HLA-B*57:01, most notably within the F-
pocket, resulting in an altered set of peptides binding, stimulating T-cells.  The stimulation of T-cells 
will result in cytokine IFN-γ release, which is detected and visualised via the ELISpot assay (B). 
 
5.3.7 In silico molecular docking studies with 6-position analogues. 
In silico studies were conducted within the University of Liverpool.  Molecular 
docking can be used to predict the binding orientation of a ligand within a proteins 
binding site, and establish its potential binding interactions in this preferred 
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conformation.17,18 It is a key tool for use in structure-based drug design.  The 
computer program GOLD19 can be used to generate docking solutions, as well as 
evaluate the results.  By assigning a quantitative measure of binding affinity to each 
generated pose, this can be completed.  One such measure, which can be applied, is 
the GOLDScore fitness function.  Values obtained from GOLDScore consider the 
key interactions between the ligand and protein:  H-bonding, van der Waals 
interactions, lipophilic interactions and internal strain energy.20,21  
 
The HLA-B*57:01 protein crystal structure was obtained from the Protein Data Bank 
(accession code 3UPR).  Firstly, removing ABC from the protein and then docking it 
back in developed a suitable docking protocol.  This was to ensure the docking 
protocol was capable of reproducing the native binding pose.  Using rigid docking 
the native binding pose of ABC was found to be highly reproducible.  This rigid 
protocol was then applied to the 6-position analogues to observe their potential 
binding interactions in the HLA-B*57:01 protein, specifically the F-pocket, in 
comparison to ABC. The resulting GOLDScore values are shown in Table 5.6.  
These results, together with data obtained from T-cell assays (Section 5.3.6), would 
be used to develop a correlation between GOLDScore values and T-cell stimulation. 
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Table 5.6:  Qualitative T-cell response results and quantitative GOLDScore values, for a select 
number of 6-position amino and oxy analogues, obtained using the rigid docking protocol.  
GOLDScore values were obtained using GOLD 5.1.  A general trend was observed, where analogues 
generating GOLDScore values of >50 showed a positive T-cell response. 
 
 
Compound 
 
 
 
R1/R2 Group 
 
 
T-Cell Response 
 
 
GOLDScore 
 
 
ABC 7 
 
 
 
 
 
Yes 
 
 
64.1 
 
103 
 
 
 
 
 
No 
 
34.4 
 
104 
 
 
 
 
 
No 
 
46.0 
 
105 
 
 
 
 
 
No 
 
31.4 
 
106 
 
 
 
 
 
No 
 
28.1 
 
107 
 
 
 
 
 
Yes 
 
55.7 
 
 
108 
 
 
 
 
 
No 
 
48.4 
 
110 
 
 
 
 
 
No 
 
−175.1 
 
113 
 
 
 
 
 
No 
 
24.1 
 
NH
NH
NH
NH
NH
NH
NH
NHN
O
N Me
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Table 5.6 continued: 
 
115 
 
 
 
 
 
Yes 
 
64.3 
 
132 
 
 
 
 
 
No 
 
29.0 
 
133 
 
 
 
 
 
No 
 
45.2 
 
Using the developed rigid docking protocol, there was found to be a positive 
relationship between T-cell stimulation and GOLDScore values (Table 5.6).  Those 
analogues with higher GOLDScore values, particularly above 50, were shown to be 
more likely to exhibit T-cell activation.  After further examination of analogues 
within the protein it can be seen that those with lower GOLDScore values interact 
unfavourably with certain amino acids.  These steric clashes would inhibit the altered 
repertoire of peptides binding within HLA-B*57:01 and so preventing T-cell 
stimulation.  It was therefore decided that the arbitrary value 50, would be used a 
cut-off point to predict whether analogues, in in silico studies, could cause a T-cell 
response. 
 
The key protein–substrate interactions can be seen in Figure 5.9 A–F.  The 
cyclopropyl moiety of ABC (Figure 5.9 A) undergoes van der Waals interactions 
with Ser 116, Tyr 123 and Ile 124, and N2 interacts with Asp 114.  Intermolecular 
bonding occurs with a range of protein amino acid residues beyond these 4 amino 
acids.  After docking compound 108 into the protein (Figure 5.9 B), it was observed 
that almost identical amino acid interactions, as seen with ABC, occurred, although 
NH
O
O
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one distinct steric clash occurred between an i-Pr methyl group and Tyr 123.  This 
one interaction was significant enough to disrupt a stable protein–substrate complex 
from forming and the consequence was seen not only in the lower GOLDScore value 
(48.4, Table 5.6), but also with a negative T-cell response.  These observations were 
not only limited to compound 108 but were also seen for compound 113 (Figure 5.9 
C).  As before, steric interactions also occurred with an i-Pr methyl moiety and Tyr 
123, resulting in unfavourable substrate binding. Compound 110 gave a very low 
GOLDScore result (−175.1, Table 5.6) and no in vitro T-cell activation occurred.  
Studying this compound further (Figure 5.9 D), a large proportion of interactions 
exhibited by ABC binding are disrupted by the large 6-aminoethyl morpholine 
group.  Most notable is the considerable steric interaction of the morpholine moiety 
with Tyr 123.  With the steric clashes evident in the binding of these 3 compounds, 
the lower GOLDScore values and eliminated T-cell activation can be explained. 
 
Conversely, when compounds 107 and 115 (Figure 5.9 E and F) were docked into 
the protein, a large proportion of favourable protein interactions were maintained.  
The 6-amino propyl or the 6-amino methylene cyclopropyl moiety were able to 
additionally improve binding due to further stable interactions within the F-pocket of 
the HLA-B*57:01.  No detrimental steric interactions occurred with either 
compound.  These compounds docked with GOLDScore values of 55.7 and 64.3 
respectively, and T-cell activation was evident from the cross-reactivity T-cell assays 
(Figure 5.6 A and C). 
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Figure 5.9 A:  Protein represented as a cartoon. Pep-V is shown in red, ABC (2D structure also 
shown) is shown in blue and key amino acid residues (Asp 114, Ser 116, Tyr 123 and Ile 124) in 
yellow.  Amino acid residues Ser 116, Tyr 123 and Ile 124, present within the F-pocket, interact with 
the cyclopropyl moiety of ABC and N2 interacts with Asp 114.  These interactions stabilise the 
binding of ABC within HLA-B*57:01. 
 
            
 
Figure 5.9 B:  Protein represented as a cartoon. Pep-V is shown in red, ABC is shown in blue, and 
compound 108 (2D structure also shown) has been overlaid in green and key amino acid residues 
(Asp 114, Ser 116, Tyr 123 and Ile 124) in yellow.  The steric interaction of a methyl group from the 
i-Pr moiety with Tyr 123 is highlighted within the figure and this is responsible for an altered binding 
within the F-pocket of the protein, disrupting its binding within the protein, giving a lower 
GOLDScore value (48.4) compared to ABC. 
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Figure 5.9 C:  Protein represented as a cartoon. Pep-V is shown in red, ABC is shown in blue, and 
compound 113 (2D structure also shown) has been overlaid in green and key amino acid residues 
(Asn 77, Asp 114, Ser 116, Tyr 123 and Ile 124) in yellow.  There is a visible interaction of a methyl 
group with Tyr 123 from N6, leading to altered binding within the F-pocket and resulting in a lower 
GOLDScore value (24.1).  
 
        
 
Figure 5.9 D:  Protein represented as a cartoon. Pep-V is shown in red, ABC is shown in blue, and 
compound 110 (2D structure also shown) has been overlaid in green and key amino acid residues 
(Asp 114, Ser 116, Tyr 123 and Ile 124) in yellow.  As depicted within the figure, there is a large 
steric clash between the morpholine moiety and Tyr 123.  The large morpholine group is unable to 
securely bind within the F-pocket due to these steric interactions, resulting in a large negative 
GOLDScore value (−175.1). 
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Figure 5.9 E:  Protein represented as a cartoon. Pep-V is shown in red, ABC is shown in blue, and 
compound 107 (2D structure also shown) has been overlaid in green and key amino acid residues 
(Asp 114, Ser 116, Tyr 123 and Ile 124) in yellow.  Although 107 bound with a slightly different 
conformation to ABC, the CH2–cyclopropyl group is able to interact favourably with Tyr 123, leading 
to a high GOLDScore value (55.7). 
 
           
 
Figure 5.9 F:  Protein represented as a cartoon. Pep-V is shown in red, ABC is shown in blue, and 
compound 115 (2D structure also shown) has been overlaid in green and key amino acid residues 
(Asp 114, Ser 116, Tyr 123 and Ile 124) in yellow.  Compound 115 bound with a very similar 
conformation to ABC within the F-pocket and in particular, it maintains the van der Waals 
interactions with Tyr 123, assisting with its binding within HLA-B*57:01, giving a higher 
GOLDScore value (64.3). 
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HN
  107 
E 
111 
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As presented in Section 5.3.6, cross-reactivity data (presented as ELISpot (IFN-γ) 
data) were obtained from a select number of 6-position analogues (following 
incubation of each compound with ABC-specific T-cell clones), generated within the 
University of Liverpool.  Not all analogues underwent these cross-reactivity 
experiments, but GOLDScore values have been generated for these outstanding 
compounds (Table 5.7). 
 
Without reactivity data for the compounds as depicted in Table 5.7, it is difficult to 
confirm whether these compounds would elicit a T-cell response.  However, the rigid 
docking protocol could be used in a predictive manner, with careful consideration of 
the GOLDScore values allowing us to predict if a response will occur. Should the T-
cell data for these compounds reflect the GOLDScore values, docking can therefore 
be used to direct the synthesis of future compounds. 
 
Table 5.7: Table representing quantitative GOLDScore values for outstanding 6-position amine and 
oxy analogues.  The data were obtained using a rigid docking protocol.  GOLDScore values were 
obtained using GOLD 5.1.  The GOLDScore values will be compared to the T-cell cross-reactivity 
results and docking can eventually be used to direct future analogue synthesis. 
 
 
Compound 
 
 
R1/R2 Group 
 
 
GOLDScore 
 
 
109 
 
 
 
 
 
18.9 
 
112 
 
 
 
 
 
22.3 
 
 
NH
NHMe
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Table 5.7 continued: 
 
114 
 
 
 
 
 
34.4 
 
116 
 
 
 
 
 
57.2 
 
117 
 
 
 
 
 
−59.8 
 
 
122 
 
 
 
 
 
51.9 
 
124 
 
 
 
 
 
42.0 
 
125 
 
 
 
 
 
47.6 
 
126 
 
 
 
 
 
−5.6 
 
 
134 
 
 
 
 
 
−52.6 
 
135 
 
 
 
 
 
55.1 
 
 
As shown in Table 5.7, it can be seen that those compounds that are likely to 
stimulate T-cell clones possess smaller 6-position moieties (compounds 116, 122 and 
135).  These compounds bear groups at this position small enough to maintain the 
relevant van der Waals interactions (as with ABC) and bind easily within the F-
pocket of HLA-B*57:01.  Conversely, three compounds have generated negative 
N Me
NH
NH
NH2
NH
HN
NH
O
NH
Me
Me
O
OMe
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GOLDScore values:  Compounds 117 (−59.8), 126 (−5.6) and 134 (−52.6).  The 
values for compounds 117 and 134 are not surprising due to the large aromatic 
substituents at the 6-position and such large groups at this position have shown to 
generate low GOLDScore values (Table 5.7).  Compound 126 has two additional 
methyl groups at the β-position on the cyclopropylamine ring.  These methyl groups 
are likely to have a significant impact in the binding of 126 within the F-pocket due 
to large steric interactions with the neighbouring amino acids. 
 
The remaining five analogues, compounds 109, 112, 114, 124 and 125 have also 
generated lower GOLDScore values than the threshold used to analyse these data.  
The steric bulk of the t-Bu group within compound 109, as with compound 126, is 
likely to exhibit steric interactions when binding within the protein.  This is also 
likely to be a similar reason for lower GOLDScore values for compounds 112 (22.3) 
and 114 (34.4).  The additional methyl group on both these compounds, either on the 
cyclopropyl ring (112) or on N-methyl, will add to the steric hindrance of the group 
at this position.  Finally, the amino azetidine and oxetane moieties, compounds 124 
and 125 respectively, have also generated lower GOLDScore values, although, these 
values are close to the threshold, 50.  However, they are predicted to not elicit a T-
cell response.  Further molecular docking analysis of these analogues would be 
interesting due to the small nature of the group and the presence of a heteroatom 
within the ring structures.  The possible H-bonding of these heteroatoms to 
neighbouring amino acids within the HLA-B*57:01, in particular within and 
surrounding the F-pocket would be interesting to investigate. Also, the threshold at 
which the docking defines a compound as having the potential to generate a T-cell 
response or not may require modification, depending upon the new results, with 50 
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currently being used as the most obvious cut-off.  This value can be subject to 
change:  The molecular docking studies are in their infantry, and as our 
understanding of analogue binding within HLA-B*57:01 develops it will help define 
a more accurate and permanent value. 
 
5.3.8 Cytotoxicological and pharmacological studies with 6-position analogues  
The antiviral and cytotoxicity studies were carried out at the University of Liverpool.  
The theory and discussion of these assays is discussed in Chapter 1, Section 1.11.  To 
probe the pharmacological activity of a select number of the synthesised 6-position 
analogues, cytotoxicity and efficacy of these analogues was tested.  The results of 
these assays can be seen in Table 5.8.  Assays measuring cytotoxicity (IC50) in MT4 
cells was measured over 24 h and 5 days and antiviral (EC50) values were obtained 
after 5-day incubations.  All comparisons are made with the control, ABC. 
 
After 24 h and 5 days, the cytotoxicity for ABC was found to be 301.8 µM and 199.2 
µM respectively.  The IC50 values for compounds 103–106, 110, 132 and 133 ranged 
from 10.2–44.5 µM over 24 h and 2.4–12.2 µM over 5 days.  These compounds 
exhibited significant toxicity compared to ABC over both time points.  The most 
notable analogues 107, 108, 113 and 115 gave comparable cytotoxicity values to 
ABC at 24 h and 5 days.  Interestingly, compounds 108 and 113 did not stimulate T-
cells in cross-reactivity experiments.  The disparity in toxicity is likely to be due to 
variation of cell types used, within the cytotoxicity (mitochondrial toxicity) and T-
cell experiments.  Compound 115 showed the most promise with IC50 values of 
295.4 µM and 197.9 µM at 24 h and 5 days respectively but this was shown to 
exhibit significant stimulation of T-cells (Figure 5.5). 
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For all analogues, the cytotoxicity values increased in samples taken after 5 days, 
compared to those obtained after 24 h.  A possible reason being the generation of a 
toxic intermediate metabolite and the nature of this metabolite would lead to 
decreased MT4 cell viability.  Due to the lower number of MT4 cells there would be 
less conversion of MTT to MTT formazan, resulting in increased IC50 values.  This 
toxic compound could possibly be the aldehyde intermediate, generated from 
oxidation of 5'-OH to its corresponding carboxylic acid. 
 
The antiviral EC50 value generated for ABC was 3.8 µM.  Most analogues proved to 
be much less potent than ABC EC50 values >5 µM, with 108, 113 and 115 presenting 
comparable efficacy values:  2.7, 2.4 and 5.3 µM respectively (Table 5.8).  
Comparing the selectivity index (IC50/EC50) of these analogues (Table 5.8), it can be 
seen that the most significant compounds are 107, 108, 113 and 115 – analogues 
presenting high IC50 and low EC50 values as with ABC.  The structures of these 
compounds are very subtly different to ABC but as discussed in Section 5.3.2, they 
exhibit slight steric interactions with the HLA-B*57:01 protein resulting in subtly 
different levels of T-cell activation. 
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Table 5.8:  Cell viability was assessed using the spectrophotometric MTT assay.  Cytotoxicity (IC50) 
values generated in MT4 cells over 24 h and 5 days and efficacy (EC50) values generated against 
HIVIIIB in MT4, using the spectrophotometric MTT assay; which visualises the viral cytotoxicity.  
These data were completed for select 6-position amine and oxy analogues.  The selectivity index is 
shown within the table (IC50/EC50).  All data are given as the mean ± standard deviation of four 
independent experiments, performed on different days.  IC50 values were generated using GraphPad 
Prism 3.0 software. 
 
 
Cytotoxicity 
IC50 (µM) ± 
SD 
 
 
Cytotoxicity 
IC50 (µM) ± 
SD 
 
 
Efficacy 
EC50 (µM) 
± SD 
 
Selectivity 
Index 
(IC50/EC50) 
 
 
Compound 
 
 
R1/R2 
Group 
 
24 h 5 days 5 days 5 days 
 
7 
 
 
 
 
301.8 ± 17.00 
 
 
199.2 ± 11.80 
 
3.8 ± 0.19 
 
52.56 
 
103 
 
 
 
 
30.2 ± 1.21 
 
11.5 ± 0.75 
 
12.6 ± 0.17 
 
0.91 
 
104 
 
 
 
 
44.5 ± 3.71 
 
12.2 ± 0.74 
 
11.6 ± 0.51 
 
0.10 
 
105 
 
 
 
 
12.0 ± 2.36 
 
9.9 ± 0.66 
 
15.0 ± 0.33 
 
0.66 
 
106 
 
 
 
 
34.6 ± 3.26 
 
11.7 ± 0.39 
 
17.9 ± 3.31 
 
0.65 
 
107 
 
 
 
 
233.3 ± 9.00 
 
171.2 ± 5.20 
 
6.8 ± 0.89 
 
25.18 
 
108 
 
 
 
 
 
126.4 ± 12.20 
 
77.7 ± 3.63 
 
2.7 ± 0.03 
 
28.70 
 
110 
 
 
 
 
 
11.7 ± 0.45 
 
 
2.8 ± 0.14 
 
 
8.5 ± 0.86 
 
 
0.33 
 
NH
NH
NH
NH
NH
NH
NH
NHN
O
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Table 5.8 continued: 
 
113 
 
 
 
 
 
 
95.8 ± 8.88 
 
 
65.3 ± 5.18 
 
 
2.4 ± 0.02 
 
 
27.20 
 
115 
 
 
 
 
 
295.4 ± 28.30 
 
197.9 ± 7.46 
 
5.3 ± 0.77 
 
37.34 
 
132 
 
 
 
 
12.7 ± 0.43 
 
3.0 ± 0.09 
 
6.4 ± 0.48 
 
0.47 
 
133 
 
 
 
 
 
10.2 ± 0.34 
 
2.4 ± 0.07 
 
5.9 ± 0.42 
 
0.41 
 
5.3.9 Initial PK screening for ABC and compound 108. 
With compound 108 showing promise in pharmacological and immunological 
studies showing low cytotoxicity, comparable efficacy to ABC and no T-cell 
activation, initial PK experiments were conducted. 
 
5.3.9.1 Plasma concentration–time relationship for ABC and compound 
108. 
Mean plasma concentration–time graphs (Figure 5.10 A and B) were obtained using 
male SD rats (n = 3) via intravenous (IV, 1 mg/kg) and oral (PO, 10 mg/kg) 
administration over selected times points. 
 
N Me
NH
O
O
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Figure 5.10:  Graph showing the plasma concentration–time curves for ABC and compound 108 
following IV administration with dosage of 1 mg/kg (A) and PO administration with dosage of 10 
mg/kg (B) in male SD rats. Samples were taken over 24 h and unquantifiable data (<1 ng/mL) was 
excluded  (samples obtained between 12–24 h).  Data represents the mean value ± SD (n = 3).  IV, 
intravenous; PO, per os (oral). 
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From Figure 5.10, it can be seen that the relationship of compound plasma 
concentrations over time (5 min to 4 h) via IV and PO administration for ABC and 
compound 108 are similar for both means of administration.  Data obtained from >4 
h was below the quantifiable limit (BQL). 
 
5.3.9.2 PK parameter relationships for ABC and compound 108. 
PK parameters (Table 5.9) were obtained using male SD rats (n = 3) via an IV (1 
mg/kg) and PO (10 mg/kg) dose administration.  Four PK parameters (clearance, CL; 
Tmax; Cmax; bioavailability, F) for both ABC and 108 are shown in Table 5.9.  CL and 
Cmax values for 108 are very similar to ABC, and although F for 108 is lower than for 
ABC, it still shows excellent bioavailability (~ 80%). 
 
Table 5.9:  PK parameters for ABC and compound 108.  IV and PO doses were administered to 6 
male SD rats (3 rats for each route of administration) at a dose of 1 mg/kg and 10 mg/kg respectively.  
Data is represented as the mean ± SD (n = 3). 
 
 
PK Parameter 
(ABC) 
 
 
Mean ± SD (n = 3) 
 
IV dose at 1 mg/kg in male SD rats 
 
 
CL (L/h/kg) 
 
 
2.20 ± 0.33 
 
PO dose at 10 mg/kg in male SD rats 
 
 
Tmax (h) 
 
 
0.50 ± 0.00 
 
Cmax (ng/mL) 
 
 
1653 ± 146 
 
F (%) 
 
 
124 ± 6.82 
 
PK Parameter 
(108) 
 
 
Mean ± SD (n = 3) 
 
IV dose at 1 mg/kg in male SD rats 
 
 
CL (L/h/kg) 
 
 
2.23 ± 0.28 
 
 
PO dose at 10 mg/kg in male SD rats 
 
 
Tmax (h) 
 
 
0.50 ± 0.00 
 
Cmax (ng/mL) 
 
 
1407 ± 170 
 
 
F (%) 
 
 
79.90 ± 19.70 
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Comparing the initial PK data, it shows that compound 108 over a 24 h time-course 
has a comparable rat PK profile following IV and PO administration compared to 
ABC.  These initial experiments show that the replacement of 6-cyclopropylamine 
with 6-isopropylamine does not appear to have a significant impact on overall 
disposition. 
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5.4 Conclusions & Future Work 
 
It was proposed by two independent research groups that ABC toxicity arose from 
the non-covalent binding of ABC within the HLA-B*57:01 protein.  Upon binding, 
ABC was exposed to several van der Waals interactions with a number of amino 
acids, resulting in assisted stabilised binding within the protein.  Such binding 
resulted in an altered repertoire of peptides displayed by the protein, the consequence 
being an immunological response.  Notably, the binding of ABC was assisted by the 
6-position cyclopropyl moiety within the F-pocket of the protein.  It was therefore 
the aim of this research to synthesise a range of 6-position analogues of ABC in an 
attempt to inhibit binding within HLA-B*57:01 and probe this suggested mechanism 
of toxicity further. 
 
A series of N- and O- 6-position analogues were synthesised from Cl-ABC 32 using 
standard aromatic nucleophilic substitution.  Such analogues bore n-, i-alkyl chains, 
alkyl ring structures with or without the incorporation of heteroatoms, and aromatic 
groups.  Most desired analogues were achieved with excellent yields.  Those 
analogues that bore cyclic heteroatom or sterically hindered alkyl moieties proved 
the most difficult to synthesise, but most difficulties were overcome with slightly 
modified reaction conditions.  Fluoro-cyclopropyl starting compounds were 
problematic, and although a range of reaction conditions was attempted, these 
analogues could not be synthesised. 
 
A select number of both N- and O- analogues were chosen to undergo 
immunological testing, where proliferation and IFN-γ release of ABC-specific T-
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cells was monitored.  The majority of analogues did not stimulate the T-cell clones, 
with compounds 107, 111, 115, 136 and 137 resulting in a positive response.  Further 
molecular modelling studies of these analogues illustrated that they too underwent 
similar binding to ABC, with all van der Waals interactions with key amino acids 
maintained.  Conversely, two notable compounds 108 and 113 did not stimulate the 
T-cell clones, although they both bear a remarkable similarity to the structure of 
ABC.  Further docking studies of these compounds revealed that although both 
compounds bound in a similar manner to ABC, steric interactions of the i-Pr methyl 
group with the bulky Tyr 123 amino acid within the F-pocket of the HLA-B*57:01 
protein made this binding unfavourable.  In silico studies revealed that the larger the 
6-position substituent, the more unfavourable the binding was within the protein – 
likely to be due to steric interactions.  Analogues that bore n-alkyl 6-position 
moieties were more likely to stimulate a T-cell response through favourable binding 
of these groups within the F-pocket of the protein. 
 
Along with the immunological and molecular modelling studies, pharmacological 
testing was also conducted on these same analogues.  The antiviral testing was 
conducted using the HIVIIIB virus.  Most analogues were shown to be less active 
than ABC, although compounds 108 and 113 had comparable efficacy results to 
ABC.  It was further noted that as well as these compounds having similar antiviral 
activity to ABC, they did not stimulate cytokine release or proliferation of T-cell 
clones in the immunological assays.  Compound 108 was selected for initial PK 
profiling and plasma concentration–time data and PK parameters were obtained.  All 
values for 108 were similar to ABC (namely plasma concentration–time data, Cmax 
and bioavailability). 
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For future studies, there are many potential avenues available for the development of 
a safer alternative to ABC.  Although 108 shows much promise in vitro and in initial 
in vivo studies, further PD studies will be required.  The remaining 6-position 
analogues require immunological, in silico, and pharmacological testing.  This will 
not only allow for further probing and understanding of ABC toxicity, and to 
determine whether a compound with equivalent pharmacological and PK parameters 
to ABC can be discovered, but most importantly, with no immunogenic properties.  
Further to these biological studies, additional chemical synthesis of 6-position 
analogues can be conducted.  Further studies into the synthesis of 6-
fluorocyclopropyl compounds, the 6-oxycyclopropyl analogue, and 6-position thiol 
compounds should be investigated. 
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5.5 Experimental 
 
Compounds 115, 117, 118, 135–137 and 139 were synthesised at the University of 
Liverpool by Matthew Pye.  Dr. Alex Lawrenson performed molecular docking 
studies and generated GOLDScore values at the University of Liverpool.  
Immunology (cross-reactivity) experiments and pharmacological 
(cytotoxicity/efficacy) experiments were also conducted and obtained at the 
University of Liverpool by Mohammad Alhaidari and John Farrell (Dr. Dean 
Naisbitt’s research group) and Dr Philip Martin (Prof. Andrew Owen’s research 
group) respectively. 
 
5.5.1 Synthesis. 
 
 
((1S,4R)-4-((2,5-Diamino-6-chloropyrimidin-4-yl)amino)cyclopent-2-en-1-
yl)methanol 31:22 To (1S,4R)-4-amino-2-cyclopentene-1-methanol tartrate salt 29 
(1.00 g, 4.0 mmol) in n-BuOH (10 mL) was added DADCP 30 (0.69 g, 4.0 mmol) 
and NaHCO3 (1.12 g, 13.0 mmol) and the mixture was allowed to stir for 16 h at 95 
°C.  The mixture was cooled and filtered under vacuum.  The resulting solvent from 
the filtrate was removed in vacuo.  The crude product was purified by column 
chromatography (1:49 to 1:24 MeOH−DCM) to yield 31 (0.52 g, 53%) as a pale 
brown solid.  mp:  157–159 °C (lit.22 mp:  158.5–160.5 °C).  1H NMR (MeOD): δ 
5.87 (ddd, J = 5.5, 2.0, 1.9 Hz, 1H), 5.80 (ddd, J = 5.6, 2.0, 2.0 Hz, 1H), 5.15–5.07 
NH2
HO
N
N NH2
H2N
Cl
Cl N
N
Cl
NH2
H2N
N
H
HO
31  30   29 
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(m, 1H), 3.56–3.47 (m, 1H), 3.28 (m, 1H), 2.83–2.79 (m, 1H), 2.53 (ddd, J = 13.4, 
6.4, 6.4 Hz, 1H), 1.36 (ddd, J = 13.4, 6.3, 5.9 Hz, 1H).  13C NMR (MeOD): δ 158.2, 
157.3, 143.2, 135.8, 133.9, 114.4, 66.4, 57.8, 57.7, 35.8.  m/z (ES+) 256.0955 
calculated for C10H15N5O35Cl:  [M+H]+ 256.0965 and 258.0928 calculated for 
C10H15N5O37Cl:  [M+H]+ 258.0936.  IR (cm-1):  3451 (N−H), 3324 (N−H), 3125 (br, 
O−H), 2931 (C−H), 1570 (C=C aromatic), 1430 (CH2), 690 (C−Cl). 
 
 
 
((1S,4R)-4-(2-Amino-6-chloro-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol 32:23 
To a solution of 31 (0.50 g, 2.0 mmol) in n-BuOH (15 mL) was added TEOF (0.4 
mL, 2.4 mmol) and H2SO4 (0.05 µL, 0.1 mmol).  The brown solution was allowed to 
stir for 20 h at 70 °C.  The solution was allowed to cool whereupon the solvent was 
removed in vacuo and the crude mixture was purified by column chromatography 
(1:99 to 5:95 MeOH−DCM) to yield 32 (0.45 g, 87%) as a brown solid.  mp:  158–
161 °C (lit.23 mp:  160–162 °C).  1H NMR (CDCl3): δ 7.95 (s, 1H), 6.18 (ddd, J = 
5.5, 2.2, 2.1 Hz, 1H), 5.82 (ddd, J = 5.5, 2.2, 2.0 Hz, 1H), 5.56–5.52 (br m, 1H), 3.85 
(dd, J = 10.7, 4.2 Hz, 1H), 3.76 (dd, J = 10.7, 3.9 Hz, 1H), 3.48 (MeOH), 3.13–3.09 
(m, 1H), 2.81 (ddd, J = 14.4, 6.4, 6.2 Hz, 1H), 1.98 (ddd, J = 14.4, 6.2, 5.3 Hz, 1H).  
13C NMR (CDCl3): δ 159.1, 153.5, 151.6, 142.2, 139.5, 130.0, 115.9, 65.0, 61.1, 50.4 
(MeOH), 48.1, 33.6.  m/z (ES+) 288.0626 calculated for C11H12N5O23Na35Cl:  
[M+Na]+ 288.0628 and 290.0603 calculated for C11H12N5O23Na37Cl:  [M+Na]+ 
N
N
Cl
NH2
H2N
N
H
HO
N
NN
N
OH
Cl
NH2
 32 31 
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290.0599.  IR (cm-1):  3325 (N−H), 3205 (N−H), 1581 (C=C aromatic), 1246 (C−O), 
640 (C−Cl). 
 
 
 
tert-Butyl cyclopropylcarbamate 119:24 To a solution of cyclopropylamine (1.00 g, 
0.02 mol) in DCM (35 mL) was added Boc2O (3.68 g, 0.02 mol) at 0 °C.  The 
reaction mixture was allowed to stir overnight at room temperature.  Following this, 
the solvent was removed in vacuo to yield 119 (2.76 g, 92%) as a pale yellow 
crystalline solid.  mp:  63–65 °C (lit.24 mp:  62.5–64 °C).  1H NMR (CDCl3): δ 4.75 
(br s, 1H), 2.54–2.52 (m, 1H), 1.44 (s, 9H), 0.69–0.66 (m, 2H), 0.48–0.46 (m, 2H).  
13C NMR (CDCl3): δ 157.1, 79.7, 28.8 (3C), 23.3, 7.1 (2C).  m/z (CI) 157.11 
calculated for C8H15NO2:  [M+H]+ 158.1.  Anal. calc. for C8H15NO2:  C, 61.12; H, 
9.62; N, 8.91.  Found: C, 61.00; H, 9.66; N, 8.95.  IR (cm-1):  3359 (N−H), 2970 
(C−H), 1693 (C=O), 1207 (C−O). 
 
 
 
tert-Butyl cyclopropyl(methyl)carbamate 120:24 To a solution of 119 (2.52 g, 0.02 
mol) in DMF (50 mL) was added NaH (60% dispersed in mineral oil, 0.77 g, 0.03 
mol) at 0 °C.  The solution was allowed to stir for 30 min and MeI (1.2 mL, 0.02 
mol) was added dropwise at 0 °C.  The solution was allowed to stir for a further 5 h 
HN
BocNH2
HN
Boc
N
BocMe
119 
 119     120 
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at room temperature and was quenched with saturated aqueous NH4Cl.  The mixture 
was extracted with EtOAc (3 × 50 mL) and the combined organic extracts were 
washed with water (4 × 200 mL), brine and dried over MgSO4.  The solvent was 
removed in vacuo.  The crude product was purified by column chromatography (3:17 
EtOAc−n-hex) to yield 120 (2.00 g, 73%) as a pale yellow viscous oil.24 1H NMR 
(CDCl3): δ 2.83 (s, 3H), 2.53–2.48 (m, 1H), 1.46 (s, 9H), 0.72–0.69 (m, 2H), 0.61–
0.57 (m, 2H).  13C NMR (CDCl3): δ 157.1, 79.2, 34.7, 30.5, 28.6 (3C), 7.9 (2C).  m/z 
(CI) 171.13 calculated for C9H17NO2:  [M+H]+ 172.2.  IR (cm-1):  2978 (C−H), 1700 
(C=O), 1153 (C−O). 
 
 
 
N-Methylcyclopropanamine 121:24 To an ice-cold solution of 120 (1.45 g, 8.0 
mmol) in MeOH (30 mL) was added AcCl (3 mL, 42.0 mmol) dropwise.  The 
solution was allowed to stir at room temperature overnight.  The reaction was 
basified with 1 M NaOH until the solution became pH 9–10.  The solution was 
extracted into DCM (4 × 50 mL) and dried over MgSO4.  The solvent was removed 
in vacuo to yield 121 (0.35 g, 58%) as a clear, colourless liquid.24 1H NMR (CDCl3): 
δ 2.74 (s, 3H), 2.60–2.54 (m, 1H), 1.20–1.18 (m, 2H), 0.88–0.83 (m, 2H).  13C NMR 
(CDCl3): δ 33.9, 32.2, 4.2 (2C). 
 
N
BocMe
NH
Me
  121   120 
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General Procedure A:  To a solution of 32 (1 equiv) in MeOH (10 mL) was added 
the primary or secondary amine (2 equiv) and the solution was allowed to stir 
overnight at 60–70 °C.  The mixture was allowed to cool and the MeOH was 
removed in vacuo.  The crude solid was purified by column chromatography (1:49 to 
1:19 MeOH−DCM) to yield the appropriate product. 
 
 
 
((1S,4R)-4-(2-Amino-6-(cyclobutylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 103:25 General Procedure A was followed to yield 103 (71 mg, 62%) as 
a cream coloured solid.  mp:  180–183 °C (for racemic lit.25 mp:  181–183 °C).  1H 
NMR (CDCl3): δ 7.46 (s, 1H), 6.08 (ddd, J = 5.2, 2.1, 2.0 Hz, 1H), 6.01 (br s, 1H), 
5.73 (ddd, J = 5.2, 2.0, 1.9 Hz, 1H), 5.41–5.37 (br m, 1H), 4.66 (br m, 1H), 3.85 (dd, 
J = 10.3, 4.0 Hz, 1H), 3.75 (dd, J = 10.8, 3.2 Hz, 1H), 3.48 (MeOH), 3.08–3.07 (m, 
1H), 2.75 (ddd, J = 14.5, 6.1, 6.0 Hz, 1H), 2.39–2.38 (m, 2H), 2.09 (ddd, J = 14.5, 
N
N
N
NH2N
Cl
OH
N
N
N
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N
N
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6.0, 5.6 Hz, 1H), 1.94–1.89 (m, 2H), 1.73–1.70 (m, 2H).  13C NMR (CDCl3): δ 
159.6, 154.7, 138.5, 137.1, 130.8, 115.4, 65.5, 61.8, 50.4 (MeOH), 48.2, 32.9, 32.1, 
15.4.  m/z (ES+) 301.1783 calculated for C15H21N6O:  [M+H]+ 301.1777.  IR (cm-1):  
3313 (N−H), 3213 (N−H), 2938 (C−H), 1589 (C=C aromatic), 1477 (CH2), 1392 
(CH3), 1257 (C−N), 1033 (C−O). 
 
 
 
((1S,4R)-4-(2-Amino-6-(cyclopentylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 104:25 General Procedure A was followed to yield 104 (0.10 g, 85%) as 
a pale brown solid.  mp:  142–145 °C (for racemic lit.25 mp:  143–146 °C).  1H NMR 
(CDCl3): δ 7.47 (s, 1H), 6.10 (ddd, J = 5.5, 2.1, 2.1 Hz, 1H), 6.02 (br s, 1H), 5.76 
(ddd, J = 5.4, 2.2, 2.1 Hz, 1H), 5.42–5.41 (br m, 1H), 4.86–4.84 (m, 1H), 4.48 (br s, 
1H), 3.86 (dd, J = 10.8, 4.1 Hz, 1H), 3.76 (dd, J = 10.8, 3.4 Hz, 1H), 3.48 (MeOH), 
3.11–3.09 (m, 1H), 2.77 (ddd, J = 14.5, 6.0, 5.9 Hz, 1H), 2.12–2.05 (m, 2H), 1.75–
1.72 (m, 1H), 1.65–1.62 (m, 4H), 1.54–1.49 (m, 2H).  13C NMR (CDCl3): δ 159.4, 
155.0, 138.2, 136.5, 130.5, 115.1, 65.2, 61.4, 50.4 (MeOH), 47.8, 33.4, 32.6, 23.8 
(2C).  m/z (ES+) [M+H]+ 315.1492 calculated for C16H23N6O found  [M+H]+ 
315.1933.  IR (cm-1):  3324 (N−H), 3205 (br, O−H), 2931 (C−H), 1581 (C=C 
aromatic), 1477 (CH2), 1392 (CH3), 1249 (C−O). 
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((1S,4R)-4-(2-Amino-6-(cyclohexylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 105:  General Procedure A was followed to yield 105 (87 mg, 71%) as 
a cream coloured solid.  mp:  191–194 °C.  1H NMR (CDCl3): δ 7.53 (s, 1H), 6.13 
(ddd, J = 5.5, 2.2, 2.1 Hz, 1H), 5.79 (ddd, J = 5.5, 2.2, 2.1 Hz, 1H), 5.44–5.43 (br m, 
1H), 4.03 (br s, 1H), 3.81 (dd, J = 10.8, 4.4 Hz, 1H), 3.71 (dd, J = 10.8, 3.9 Hz, 1H), 
3.48 (MeOH), 3.42–3.38 (m, 1H), 3.11–3.05 (m, 1H), 2.79 (ddd, J = 14.4, 6.2, 6.0 
Hz, 1H), 2.04–1.94 (m, 3H), 1.80–1.75 (m, 2H), 1.66–1.62 (m, 1H), 1.48–1.37 (m, 
2H), 1.33–1.18 (m, 3H).  13C NMR (CDCl3): δ 159.6, 154.1, 138.2, 135.8, 129.7, 
113.8, 64.7, 59.9, 50.4 (MeOH), 47.5, 33.8, 32.9, 29.5 (2C), 25.4 (2C), 24.6.  m/z 
(ES+) 329.2095 calculated for C17H25N6O:  [M+H]+ 329.2090.  IR (cm-1):  3317 
(N−H), 3209 (br, O−H), 1597 (C=C aromatic), 1481 (CH2). 
 
 
 
((1S,4R)-4-(2-Amino-6-(benzylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 106:26 General Procedure A was followed to yield 106 (90 mg, 81%) as 
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an orange solid.  mp:  174–176 °C (for racemic lit.26 mp:  174–176 °C).  1H NMR 
(MeOD): δ 7.74 (s, 1H), 7.47–7.30 (m, 5H), 6.24 (ddd, J = 5.3, 2.1, 2.0 Hz, 1H), 5.93 
(ddd, J = 5.3, 2.1, 2.1 Hz, 1H), 5.59–5.55 (br m, 1H), 4.80 (s, 2H), 3.73 (dd, J = 10.8, 
5.2 Hz, 1H), 3.66 (dd, J = 10.8, 5.2 Hz, 1H), 3.40–3.39 (m, 1H), 2.85 (ddd, J = 14.0, 
6.4, 6.2 Hz, 1H), 1.79 (ddd, J = 13.9, 6.3, 5.8 Hz, 1H).  13C NMR (MeOD): δ 159.9, 
154.6, 138.3, 137.9, 129.2, 128.2, 127.8, 127.8, 127.3, 127.2, 126.8, 126.5, 113.2, 
64.0, 59.0, 50.4 (MeOH), 44.2, 43.5, 33.8.  m/z (ES+) 337.1781 calculated for 
C18H21N6O:  [M+H]+ 337.1777.  IR (cm-1):  3298 (br, O−H), 3248 (=C−H), 2935 
(C−H), 1585 (C=C), 752 (C−H aromatic). 
 
 
 
((1S,4R)-4-(2-Amino-6-((cyclopropylmethyl)amino)-9H-purin-9-yl)cyclopent-2-
en-1-yl)methanol 107:26 General Procedure A was followed to yield 107 (57 mg, 
73%) as an off-white solid.  mp:  180–182 °C (for racemic lit.26 mp:  182–183 °C).  
1H NMR (CDCl3): δ 7.49 (s, 1H), 6.05 (ddd, J = 5.5, 2.1, 2.0 Hz, 1H), 5.72 (ddd, J = 
5.5, 2.1, 2.1 Hz, 1H), 5.45–5.32 (br m, 1H), 3.71 (dd, J = 10.8, 4.5 Hz, 1H), 3.61 (dd, 
J = 10.8, 4.1 Hz, 3H), 3.48 (MeOH), 3.37–3.19 (m, 2H), 3.00 (m, 1H), 2.71 (ddd, J = 
14.3, 6.3, 6.2 Hz, 1H), 1.85 (ddd, J = 14.3, 6.4, 5.7 Hz, 1H), 1.11–0.97 (m, 1H), 
0.53–0.44 (m, 2H), 0.26–0.17 (m, 2H).  13C NMR (CDCl3): δ 159.6, 155.0, 138.3, 
136.2, 130.1, 114.3, 64.9, 60.6, 50.4 (MeOH), 47.6, 33.2, 10.6, 3.3 (2C).  m/z (ES+) 
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301.1780 calculated for C15H21N6O:  [M+H]+ 301.1777.  IR (cm-1):  3340 (N−H), 
3.89 (N−H), 1593 (C=C aromatic), 1377 (CH2), 1261 (C−O). 
 
 
 
((1S,4R)-4-(2-Amino-6-(isopropylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 108:26 General Procedure A was followed to yield 108 (40 mg, 71%) as 
a colourless crystalline solid.  mp:  152–153 °C (for racemic lit.26 mp:  153–155 °C).  
1H NMR (CDCl3): δ 7.68 (s, 1H), 6.14–6.12 (m, 1H), 5.87–5.86 (m, 1H), 5.48–5.45 
(br m, 1H), 3.61 (dd, J = 10.9, 5.3 Hz, 1H), 3.55 (dd, J = 10.9, 5.2 Hz, 1H), 3.48 
(MeOH), 3.32–3.30 (m, 1H), 2.97–2.96 (m, 1H), 2.73 (ddd, J = 13.9, 6.4, 6.1 Hz, 
1H), 1.65 (ddd, J = 13.8, 6.5, 5.8 Hz, 1H), 1.23 (d, J = 6.5 Hz, 6H).  13C NMR 
(CDCl3): δ 161.8, 155.7, 151.3, 139.4, 136.8, 130.8, 114.5, 65.4, 60.5, 50.4 (MeOH), 
49.0, 47.2, 35.3, 22.9 (2C).  m/z (ES+) 289.1778 calculated for C14H21N6O:  [M+H]+ 
289.1777.  IR (cm-1):  3313 (N−H), 3012 (=C−H), 2927 (C−H), 1592 (C=C 
aromatic), 1481 (CH2), 1388 (CH3). 
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((1S,4R)-4-(2-Amino-6-(tert-butylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 109:  General Procedure A was followed using t-butylamine (10 equiv) 
to yield 109 (0.23 g, 57%) as a cream coloured solid.  mp:  159–161 °C (for racemic 
lit.26 mp:  161–163 °C).  1H NMR (CDCl3): δ 7.43 (s, 1H), 6.11–6.10 (m, 1H), 5.75–
5.73 (m, 1H), 5.65 (br s, 1H), 5.40–5.37 (br m, 1H), 4.72 (br s, 2H), 3.92 (dd, J = 
10.9, 3.5 Hz, 1H), 3.80 (dd, J = 10.8, 2.2 Hz, 1H), 3.48 (MeOH), 2.78 (ddd, J = 14.7, 
6.5, 6.3 Hz, 1H), 2.53–2.31 (m, 1H), 2.22 (ddd, J = 14.5, 6.3, 5.5 Hz, 1H), 1.64 (ddd, 
J = 14.4, 6.3, 6.2 Hz, 1H), 1.50 (s, 9H).  13C NMR (CDCl3): δ 159.0, 155.0, 154.9, 
149.0, 138.1, 135.7, 130.1, 115.0, 64.9, 60.7, 51.8, 50.4 (MeOH), 47.6, 35.0, 28.9 
(3C).  m/z (ES+) 303.1928 calculated for C15H22N6O:  [M+H]+ 303.1926.  IR (cm-1):  
3336 (N−H), 3313 (N−H), 2962 (C−H), 1593 (C=C), 1458 (CH2), 1203 (C−O). 
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((1S,4R)-4-(2-Amino-6-((2-morpholinoethyl)amino)-9H-purin-9-yl)cyclopent-2-
en-1-yl)methanol 110:  General Procedure A was followed to yield 110 (61 mg, 
70%) as a colourless crystalline solid.  mp:  148–151 °C.  1H NMR (CDCl3): δ 7.53 
(s, 1H), 6.45 (br s, 1H), 6.11 (ddd, J = 5.4, 2.1, 2.1 Hz, 1H), 5.77 (ddd, J = 5.4, 2.2, 
2.1 Hz, 1H), 5.45–5.41 (br m, 1H), 3.81 (dd, J = 10.8, 4.1 Hz, 1H), 3.77–3.72 (m, 
5H), 3.64 (br s, 1H), 3.48 (MeOH), 3.10–3.09 (m, 2H), 2.78 (ddd, J = 14.5, 6.2, 5.6 
Hz, 2H), 2.80–2.64 (m, 2H), 2.52–2.48 (m, 4H), 2.07 (ddd, J = 14.5, 6.3, 5.6 Hz, 
1H).  13C NMR (CDCl3): δ 159.4, 155.2, 138.1, 136.7, 130.3, 115.0, 66.8 (2C), 65.0, 
61.2, 57.4, 53.4 (2C), 50.4 (MeOH), 47.6, 36.8, 32.6.  m/z (ES+) 360.2150 calculated 
for C17H26N7O2:  [M+H]+ 360.2148.  IR (cm-1):  3340 (N−H), 3201 (br, O−H), 2947 
(C−H), 1643 (C=N), 1597 (C=C), 1462 (CH2), 1257 (C−N), 1107 (C−O). 
 
 
 
((1S,4R)-4-(2-Amino-6-(butylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 111:26 General Procedure A was followed to yield 111 (0.14 g, 81%) as 
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a cream coloured solid.  mp:  113–115 °C (for racemic lit.26 mp:  116–118 °C).  1H 
NMR (CDCl3): δ 7.66 (s, 1H), 6.12 (ddd, J = 5.0, 2.0, 2.0 Hz, 1H), 5.84 (ddd, J = 
5.1, 2.1, 2.0 Hz, 1H), 5.47–5.43 (br m, 1H), 3.59 (dd, J = 12.0, 4.0 Hz, 1H), 3.53 (dd, 
J = 12.0, 4.0 Hz, 1H), 3.48 (MeOH), 3.45 (br s, 1H), 3.27–3.25 (m, 1H), 2.97–2.92 
(m, 1H), 2.81–2.77 (m, 1H), 2.72 (ddd, J = 12.0, 6.4, 5.8 Hz, 1H), 1.66–1.54 (m, 
3H), 1.43–1.34 (m, 2H), 0.91 (t, J = 8.0 Hz, 3H).  13C NMR (CDCl3): δ 161.3, 156.1, 
150.7, 139.1, 136.5, 130.4, 114.2, 65.1, 60.2, 50.4 (MeOH), 40.7, 35.1, 20.6, 18.1, 
13.8.  m/z (ES+) 303.1930 calculated for C15H23N6O:  [M+H]+ 303.1933.  IR (cm-1):  
3329 (N−H), 3194 (br, O−H), 3163 (=C−H), 2927 (C−H), 1647 (C=C), 1503 (C=C 
aromatic), 1466 (CH2), 1385 (CH3), 1246 (C−N), 1199 (C−O). 
 
 
 
((1S,4R)-4-(2-Amino-6-(((1S,2S)-2-methylcyclopropyl)amino)-9H-purin-9-
yl)cyclopent-2-en-1-yl)methanol 112:  General Procedure A was followed to yield 
112 (0.14 g, 94%) as an off-white solid.  mp:  109–111 °C.  1H NMR (CDCl3): δ 
7.52 (s, 1H), 6.12 (ddd, J = 5.4, 2.1, 2.1 Hz, 1H), 5.79–5.77 (m, 1H), 5.46–5.41 (br 
m, 1H), 3.82 (dd, J = 10.8, 4.3 Hz, 1H), 3.72 (dd, J = 10.8, 3.7 Hz, 1H), 3.48 
(MeOH), 3.11–3.08 (br m, 2H), 2.79 (ddd, J = 14.4, 6.4, 6.3 Hz, 1H), 2.60 (br s, 1H), 
2.00 (ddd, J = 14.4, 6.3, 5.7 Hz, 1H), 1.15 (d, J = 6.1 Hz, 3H), 1.00–0.94 (m, 1H), 
0.76–0.72 (m, 1H), 0.66–0.61 (m, 1H).  13C NMR (CDCl3): δ 159.4, 155.9, 149.7, 
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138.2, 136.4, 130.2, 114.6, 64.9, 60.9, 50.4 (MeOH), 47.6, 32.9, 31.0, 17.2, 15.5, 
15.0.   m/z (ES+) 301.1776 calculated for C15H21N6O:  [M+H]+ 301.1777.  IR (cm-1):  
3316 (N−H), 3201 (br, O−H), 2950 (C−H), 1589 (C=C aromatic), 1465 (CH2), 1389 
(CH3), 1088 (C−O). 
 
 
 
((1S,4R)-4-(2-Amino-6-(isopropyl(methyl)amino)-9H-purin-9-yl)cyclopent-2-en-
1-yl)methanol 113:23 General Procedure A was followed to yield 113 (79 mg, 74%) 
as an off-white solid.23 mp:  135–139 °C.  1H NMR (CDCl3): δ 7.49 (s, 1H), 6.10 
(ddd, J = 5.5, 2.2, 2.0 Hz, 1H), 5.75 (ddd, J = 5.5, 2.2, 2.1 Hz, 1H), 5.43–5.40 (br m, 
1H), 3.91 (dd, J = 10.8, 3.8 Hz, 1H), 3.79 (dd, J = 10.8, 3.0 Hz, 1H), 3.48 (MeOH), 
3.24 (s, 3H), 3.13–3.11 (m, 2H), 2.77 (ddd, J = 14.6, 6.4, 6.3 Hz, 1H), 2.20 (ddd, J = 
14.6, 6.4, 5.6 Hz, 1H), 1.23 (d, J = 6.7 Hz, 6H).  13C NMR (CDCl3): δ 158.7, 155.3, 
151.8, 138.3, 135.9, 131.0, 116.3, 65.7, 62.1, 53.8, 50.4 (MeOH), 48.1, 32.3, 20.2.  
m/z (ES+) 303.1932 calculated for C15H23N6O:  [M+H]+ 303.1933.  IR (cm-1):  3320 
(N−H), 2966 (C−H), 1562 (C=C aromatic), 1454 (CH2). 
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((1S,4R)-4-(2-Amino-6-(cyclobutylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 114:23 General Procedure A was followed using N-
methylcyclopropanamine (20 equiv) to yield 114 (0.16 g, 77%) as a colourless 
crystalline solid.23 mp:  138–140 °C.  1H NMR (CDCl3): δ 7.69 (s, 1H), 6.13–6.12 
(m, 1H), 5.86–5.85 (m, 1H), 5.49–5.44 (br m, 1H), 3.60 (dd, J = 10.7, 5.2 Hz, 1H), 
3.53 (dd, J = 10.8, 5.1 Hz, 1H), 3.48 (MeOH), 3.27 (s, 3H), 3.11–3.07 (m, 1H), 2.96–
2.94 (m, 1H), 2.72 (ddd, J = 14.4, 6.8, 6.2 Hz, 1H), 1.67–1.60 (m, 1H), 0.89–0.85 
(m, 2H), 0.68–0.64 (m, 2H).  13C NMR (CDCl3): δ 158.3, 155.7, 150.7, 136.8, 134.2, 
128.3, 113.4, 62.9, 57.9, 50.4 (MeOH), 46.5, 34.5, 32.8, 31.4, 7.2, 7.1.  m/z (ES+) 
301.1779 calculated for C15H21N6O:  [M+H]+ 301.1777.  IR (cm-1):  3302 (N−H), 
3202 (N−H), 1679 (C=C), 1567 (N−H), 1205 (C−N), 1033 (O−H). 
 
 
 
((1S,4R)-4-(2-Amino-6-(propylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 115:27 General Procedure A was followed to yield 115 as a colourless 
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solid (70 mg, 68%).  mp:  140–141 °C (lit.27 mp:  144–146 °C).  1H NMR (CDCl3): δ 
7.46 (s, 1H), 6.12 (ddd, J = 5.5, 2.1, 2.1 Hz, 1H), 5.85 (ddd, J = 5.5, 2.1, 2.1 Hz, 1H), 
5.34–5.30 (br m, 1H), 4.06 (s, 2H), 3.60 (dd, J = 10.8, 4.7 Hz, 1H), 3.50 (dd, J = 
10.8, 3.9 Hz, 1H), 3.48 (MeOH), 2.93–2.89 (m, 1H), 2.65 (ddd, J = 14.2, 6.4, 6.0 Hz, 
1H), 1.69 (ddd, J = 14.2, 6.4, 5.7 Hz, 1H), 1.60–1.46 (m, 2H), 0.87 (t, J = 7.4 Hz, 
3H).  13C NMR (CDCl2): δ 159.8, 155.0, 149.5, 138.2, 135.5, 129.5, 113.6, 64.4, 
59.4, 50.4 (MeOH), 47.5, 41.9, 33.9, 22.4, 10.8.  m/z (ES+) 289.1777 calculated for 
C14H21N6O:  [M+H]+ 289.1773.  IR (cm-1): 3340 (N−H), 3259 (br, O−H), 2854 
(C−H), 1597 (C=N), 1470 (C=C), 1396 (C=C aromatic), 1389 (C−O), 1254 (C−N). 
 
 
 
((1S,4R)-4-(2-Amino-6-(ethylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 116:16 General Procedure A was followed to yield 116 (0.10 g, 65%) as 
an off-white solid.  mp:  161–163 °C (lit.16 mp:  162–164 °C).  1H NMR (MeOD): δ 
7.65 (s, 1H), 6.10 (ddd, J = 5.6, 2.1, 2.1 Hz, 1H), 5.85 (ddd J = 5.6, 2.2, 2.1 Hz, 1H), 
5.45–5.41 (br m, 1H), 3.59–3.47 (m, 4H), 3.26 (m, 1H), 2.96–2.91 (m, 1H), 2.70 
(ddd, J = 13.9, 6.5, 6.3 Hz, 1H), 1.60 (ddd, J = 13.9, 6.4, 5.9 Hz, 1H), 1.20 (t, J = 7.2 
Hz, 3H).  13C NMR (MeOD): δ 161.8, 156.3, 151.3, 139.3, 136.9, 130.8, 115.1, 65.5, 
60.5, 54.7, 36.2, 35.4, 15.01.  m/z (ES+) 275.1619 calculated for C13H19N6O:  
[M+H]+ 275.1620.  IR (cm-1):  3321 (N−H), 3197 (N−H), 3163 (br, O−H), 2927 
(C−H), 1689 (C=N), 1589 (C=C), 1466 (CH2), 1250 (C−N), 1120 (C−O).  
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((1S,4R)-4-(2-Amino-6-(phenylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 117:26 General Procedure A was followed to yield 117 (90 mg, 81%) as 
a brown solid.  mp:  173–176 °C (lit.26 mp:  177–179 °C).  1H NMR (CDCl3): δ 
7.80–6.83 (m, 5H), 6.07 (ddd, J = 5.4, 2.1, 2.0 Hz, 1H), 5.90–5.65 (m, 1H), 5.44–
5.39 (br m, 1H), 3.70 (dd, J = 10.8, 4.4 Hz, 1H) 3.60 (dd, J = 10.8, 4.0 Hz, 1H), 3.48 
(MeOH), 3.02–2.97 (m, 1H), 2.73 (ddd, J = 14.3, 6.5, 6.2 Hz, 1H), 1.83 (ddd, J = 
14.3, 6.4, 5.6 Hz, 1H).  13C NMR (CDCl3): δ 159.3, 152.8, 150.1, 139.0, 138.8, 
137.1, 130.0, 129.4, 129.0, 123.6, 120.7, 115.8, 114.8, 64.9, 60.8, 50.4 (MeOH), 
47.8, 33.6.  m/z (ES+) 323.1620 calculated for C17H19N6O:  [M+H]+ 323.1612.  IR 
(cm-1):  3329 (N−H), 3217 (br, O−H), 2945 (C−H), 1578 (C=N) 1454 (C=C), 1379 
(C=C aromatic), 1254 (C−O), 1032 (C−N). 
 
 
 
((1S,4R)-4-(6-(([1,1'-Biphenyl]-4-ylmethyl)amino)-2-amino-9H-purin-9-
yl)cyclopent-2-en-1-yl)methanol 118:  To a solution of 32 (90 mg, 0.4 mmol) in 
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MeOH (10 mL) was added 4-phenylbenzylamine (90 mg, 0.5 mmol) and the 
resulting solution was allowed to stir for 3 days at 80 °C.  The solvent was removed 
in vacuo and the crude product was purified by column chromatography (0.5:95.5 to 
7:93 MeOH−DCM) to yield the 118 as a yellow solid (40 mg, 31%).  mp:  198–200 
°C.  1H NMR (MeOD): δ 7.88–7.01 (m, 9H), 6.02–5.90 (m, 2H), 5.45–5.32 (br m, 
1H), 4.50 (s, 2H), 3.59 (dd, J = 10.8, 4.2 Hz, 1H), 3.53 (dd, J = 10.8, 3.9 Hz, 1H), 
3.01–2.88 (m, 1H), 2.70 (ddd, J = 14.0, 6.5, 6.2 Hz, 1H), 1.65 (ddd, J = 14.0, 6.3, 5.8 
Hz, 1H).  13C NMR (MeOD): δ 161.3, 154.9, 140.5, 140.0, 138.4, 137.0, 135.7, 
129.2, 128.0 (2C), 127.8 (2C), 126.6 (2C), 126.1 (2C), 114.3, 64.4, 59.5, 49.0, 43.5, 
34.0. m/z (ES+) 413.2090 calculated for C24H25N6O:  [M+H]+ 413.2091.   IR (cm-1):  
3483 (N−H), 3267 (N−H), 3147 (br, O−H), 3066 (C−H), 1639 (C=N) 1593 (C=C), 
1485 (C=C aromatic), 1261 (C−O), 1230 (C−N). 
 
 
 
((1S,4R)-4-(2,6-Diamino-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol 119:28 To a 
solution of 32 (0.10 g, 0.4 mmol) in MeOH (3 mL) in a sealed tube was added NH3 
solution (1 mL, 7 N in MeOH) and the resulting solution was allowed to stir for 24 h 
at 90 °C.  The solvent was removed in vacuo and the crude product was purified by 
column chromatography (3:97 to 7:93 MeOH−DCM) to yield 119 (89 mg, 96%) as a 
pale orange solid.  mp:  176–179 °C (lit.28 mp:  178–180 °C).  1H NMR (CDCl3): δ 
7.73 (s, 1H), 6.12 (ddd, J = 5.5, 2.2, 2.1 Hz, 1H), 5.86 (ddd, J = 5.5, 2.1, 2.1 Hz, 1H), 
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5.49–5.45 (br m, 1H), 3.57 (ddd, J = 24.4, 10.9, 5.3 Hz, 2H), 3.48 (MeOH), 2.98–
2.92 (m, 1H), 2.72 (ddd, J = 13.9, 6.6, 6.4 Hz, 1H), 1.65 (ddd, J = 13.9, 6.4, 5.8 Hz, 
1H).  13C NMR (CDCl3): δ 161.7, 157.6, 152.4, 139.6, 137.8, 130.9, 114.4, 65.6, 
60.7, 50.4 (MeOH), 35.5.  m/z (ES+) 247.1308 calculated for C11H15N6O:  [M+H]+ 
247.1307.   IR (cm-1):  3425 (N−H), 3313 (N−H), 2873 (C−H), 1631 (C=N), 1581 
(C=C), 1049 (C−O). 
 
 
 
tert-Butyl-3-((2-amino-9-((1R,4S)-4-(hydroxymethyl)cyclopent-2-en-1-yl)-9H-
purin-6-yl)amino)azetidine-1-carboxylate 123:  To a solution of 32 (0.15 g, 0.6 
mmol) in MeOH (5 mL) in a sealed tube, was added 1-Boc-3-(amino)azetidine (0.1 
mL, 0.6 mmol) and the solution was allowed to stir at 90 °C for 48 h.  The solvent 
was removed in vacuo and the crude mixture was purified by column 
chromatography (1:49 to 1:19 MeOH−DCM) to yield 123 (0.13 g, 57%) as an off-
white solid.  1H NMR (CDCl3): δ 7.72 (s, 1H), 6.14 (ddd, J = 5.1, 2.2, 2.2 Hz, 1H), 
5.86 (ddd, J = 5.0, 2.2, 2.2 Hz, 1H), 5.50–5.46 (br m, 1H), 4.28–4.24 (m, 2H), 4.08–
4.04 (m, 1H), 3.87–3.84 (m, 2H), 3.61 (dd, J = 8.1, 4.0 Hz, 1H), 3.55 (dd, J = 12.0, 
8.0 Hz, 1H), 3.02–2.94 (m, 1H), 2.73 (ddd, J = 13.9, 6.6, 6.3 Hz, 1H), 1.66 (ddd, J = 
13.8, 6.4, 5.8 Hz, 1H), 1.42 (s, 9H).  13C NMR (CDCl3): δ 161.7, 158.2, 155.7, 139.5, 
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137.6, 130.9, 114.8, 81.1, 80.9, 65.6, 60.7, 43.0, 41.8, 35.5, 30.7, 28.6 (3C).  m/z 
(ES+) 402.2258 calculated for C19H28N7O3:  [M+H]+ 402.2254. 
 
 
 
((1S,4R)-4-(2-Amino-6-(azetidin-3-ylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 124:  TFA (0.2 mL, 2.0 mmol) was added to a solution of 123 (0.13 g, 
0.3 mmol) in DCM (10 mL) at 0 °C and the solution was allowed to stir under 
nitrogen for 12 h after which time, the solvents were removed in vacuo and the crude 
product was purified by column chromatography (3:7 MeOH−DCM) to yield 124 (52 
mg, 53%, as TFA salt) as a yellow solid.  mp:  >250 °C.  1H NMR (MeOD): δ 7.97 
(s, 1H), 6.18–6.16 (m, 1H), 5.84–5.83 (m, 1H), 5.55–5.52 (br m, 1H), 4.36–4.31 (m, 
3H), 3.66 (dd, J = 10.5, 4.1 Hz, 1H), 3.54 (dd, J = 10.8, 4.5 Hz, 1H), 2.97–2.94 (m, 
2H), 2.79–2.73 (m, 1H), 1.71–1.67 (m, 1H), 1.37–1.21 (m, 1H).  13C NMR (MeOD): 
δ 163.4 (TFA), 155.5, 151.8, 143.0, 140.3, 130.1, 116.7 (TFA), 113.8, 110.8, 65.2, 
61.3, 55.6, 50.8 (2C), 43.3, 35.3.  m/z (ES+) 302.1729 calculated for C14H20N7O:  
[M+H]+ 302.1729.  IR (cm-1):  3340 (N−H), 2978 (C−H), 1666 (C=C), 1404 (C=C 
aromatic), 1184 (C−O). 
 
N
N
N
NH2N
OH
N
N
N
NH2N
OH
HN HN
NBoc NH
124 123 
Chapter 5 – Using Structure–Activity Relationships to Investigate Abacavir Toxicity 
331 
 
 
((1S,4R)-4-(2-Amino-6-(oxetan-3-ylamino)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 125:  To a solution of 32 (0.11 g, 0.4 mmol) was added 3-amino 
oxetane (0.2 mL, 2.0 mmol) in EtOH (3 mL) and the resulting mixture was allowed 
to stir in a sealed tube at 85 °C for 48 h.  The mixture was allowed to cool and the 
solvent removed in vacuo.  The crude product was purified by column 
chromatography (1:19 to 1:4 MeOH−DCM) to yield 125 (90 mg, 80%) as an orange 
solid.  mp:  Decomposed at 215 °C.  1H NMR (MeOD): δ 7.97 (s, 1H), 6.18–6.16 (m, 
1H), 5.88–5.86 (m, 1H), 5.55–5.50 (br m, 1H), 4.57–4.51 (m, 2H), 4.26–4.20 (m, 
1H), 3.78 (dd, J = 11.9, 3.2 Hz, 1H), 3.70 (dd, J = 11.8, 3.8 Hz, 1H), 3.64–3.60 (m, 
1H), 3.57–3.53 (m, 1H), 3.02–2.99 (m, 1H), 2.70 (ddd, J = 14.0, 6.4, 6.3 Hz, 1H), 
1.71–1.64 (m, 1H), 1.36–1.24 (m, 1H).  13C NMR (MeOD): δ 154.9, 152.3, 142.2, 
140.3, 130.3, 110.4, 78.2 (2C), 65.2, 63.6, 59.7, 48.6, 35.3.  m/z (ES+) 303.1573 
calculated for C14H19N6O2:  [M+H]+ 303.1569.  IR (cm-1):  3317 (N−H), 3155 
(=C−H), 1689 (C=C), 1295 (C−N), 1092 (C−O). 
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((1S,4R)-4-(2-Amino-6-((2,2-dimethylcyclopropyl)amino)-9H-purin-9-
yl)cyclopent-2-en-1-yl)methanol 126:  To a solution of 32 (0.11 g, 0.4 mmol) in t-
BuOH (3 mL) in a sealed tube was added 2,2-dimethylcyclopropylamine 
hydrochloride (0.05 g, 0.4 mmol) and K2CO3 (0.10 g, 0.7 mmol) and the pale yellow 
mixture was allowed to stir for 72 h at 90 °C.  The solvent was removed in vacuo and 
the crude mixture was purified by column chromatography (5:95 MeOH−DCM) to 
yield 126 (70 mg, 54%) as an off-white solid.  mp:  176–180 °C.  1H NMR (CDCl3): 
δ 7.70 (s, 1H), 6.14 (ddd, J = 5.5, 2.1, 2.0 Hz, 1H), 5.87 (ddd, J = 5.5, 2.1, 2.0 Hz, 
1H), 5.50–5.46 (br m, 1H), 3.61 (dd, J = 10.9, 5.4 Hz, 1H), 3.55 (dd, J = 10.8, 5.2 
Hz, 1H), 3.48 (MeOH), 3.10–3.06 (m, 1H), 2.98–2.96 (m, 1H), 2.74 (ddd, J = 14.0, 
6.5, 6.3 Hz, 1H), 2.70 (br s, 1H), 1.66 (ddd, J = 13.8, 6.3, 5.8 Hz, 1H), 1.14 (s, 3H), 
1.03 (s, 3H), 0.76 (dd, J = 7.6, 5.4 Hz, 1H), 0.41 (t, J = 4.7 Hz, 1H).  13C NMR 
(CDCl3): δ 161.8, 157.6, 139.3, 137.1, 130.8, 114.6, 65.5, 60.5, 50.4 (MeOH), 36.2, 
35.4, 25.1, 20.9, 19.5, 19.0.  m/z (ES+) 315.1931 calculated for C16H23N6O:  [M+H]+ 
315.1933.  IR (cm-1):  3325 (N−H), 3205 (br, O−H), 2939 (C−H), 1585 (C=C 
aromatic), 1469 (CH2), 1392 (CH3). 
 
N
N
N
NH2N
OH
HN
N
N
N
NH2N
Cl
OH
Me
Me
   32         126 
Chapter 5 – Using Structure–Activity Relationships to Investigate Abacavir Toxicity 
333 
  
 
General Procedure B:  To a solution of 32 (1 equiv) in the appropriate alcohol 
reagent (1 mL) was added NaH (60% dispersed in mineral oil, 3 equiv) and the 
solution was heated to 80 °C and allowed to stir for 4 h.  The mixture was allowed to 
cool, diluted with 1:99 MeOH−DCM and purified by column chromatography (3:97 
to 6:94 MeOH−DCM) to yield the appropriate product. 
 
 
 
((1S,4R)-4-(2-Amino-6-cyclobutoxy-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol 
132:  General Procedure B was followed to yield 132 (80 mg, 70%) as an off-white 
solid.  mp:  150–152 °C.  1H NMR (CDCl3): δ 7.65 (s, 1H), 6.12 (ddd, J = 5.5, 2.1, 
2.0 Hz, 1H), 5.77 (ddd, J = 5.5, 2.2, 2.0 Hz, 1H), 5.49–5.44 (br m, 1H), 5.42–5.34 
(m, 1H), 3.90 (dd, J = 10.8, 3.9 Hz, 1H), 3.80 (dd, J = 10.8, 3.2 Hz, 1H), 3.48 
(MeOH), 2.98–2.94 (m, 1H), 2.79 (ddd, J = 14.6, 9.6, 6.4 Hz, 1H), 2.50–2.42 (m, 
2H), 2.33–2.23 (m, 2H), 2.13 (ddd, J = 14.6, 6.3, 5.8 Hz, 1H), 1.89–1.81 (m, 1H), 
1.72–1.60 (m, 1H).  13C NMR (CDCl3): δ 161.1, 159.1, 153.2, 139.2, 138.7, 130.7, 
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116.7, 77.6, 71.4, 65.5, 61.9, 50.4 (MeOH), 48.1, 32.8, 31.0, 13.9.  m/z (ES+) 
316.1775 calculated for C16H22N5O2:  [M+H]+ 316.1774.  IR (cm-1):  3303 (N−H), 
3184 (=C−H), 2942 (C−H), 1627 (C=N), 1581 (C=C aromatic), 1461 (CH2), 1250 
(C−N), 1076 (C−O). 
 
 
 
((1S,4R)-4-(2-Amino-6-(cyclopentyloxy)-9H-purin-9-yl)cyclopent-2-en-1-
yl)methanol 133:26 General Procedure B was followed to yield 133 (43 mg, 73%) as 
an off-white solid.  mp:  187–189 °C (for racemic lit.26 mp:  188–190 °C).  1H NMR 
(CDCl3): δ 7.63 (s, 1H), 6.12 (ddd, J = 5.5, 2.1, 2.1 Hz, 1H), 5.77 (ddd, J = 5.5, 2.1, 
2.1 Hz, 1H), 5.66–5.62 (m, 1H), 5.49–5.44 (br m, 1H), 3.90 (dd, J = 10.8, 3.9 Hz, 
1H), 3.80 (dd, J = 10.8, 3.2 Hz, 1H), 3.48 (MeOH), 3.15–3.10 (m, 1H), 2.79 (ddd, J 
= 14.6, 6.3, 6.0 Hz, 1H), 2.14 (ddd, J = 14.6, 6.4, 5.6 Hz, 1H), 2.01–1.81 (m, 5H), 
1.63–1.60 (m, 2H), 1.35–1.28 (m, 1H).  13C NMR (CDCl3): δ 161.7, 159.1, 153.2, 
139.1, 138.6, 130.7, 117.0, 79.8, 77.6, 65.5, 61.9, 50.4 (MeOH), 48.1, 33.3, 32.7, 
30.1, 24.3.  m/z (ES+) 302.1614 calculated for C15H20N5O2:  [M+H]+ 302.1617.  IR 
(cm-1):  3325 (N−H), 3197 (=C−H), 2954 (C−H), 1581 (C=C aromatic), 1446 (CH2), 
1246 (C−O). 
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((1S,4R)-4-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol 
134:  General Procedure B was followed to yield 134 (36 mg, 57%) as a colourless 
crystalline solid.  mp:  171–175 °C.  1H NMR (MeOD): δ 7.81 (s, 1H), 7.47 (d, J = 
7.1 Hz, 2H), 7.39–7.22 (m, 3H), 6.15 (ddd, J = 5.5, 2.2, 2.0 Hz, 1H), 5.91–5.82 (m, 
1H), 5.58–5.53 (br m, 1H), 5.52 (s, 2H), 3.70 (dd, J = 10.8, 3.8 Hz, 1H), 3.65 (dd, J 
= 10.8, 3.7 Hz, 1H), 2.98 (m, 1H), 2.75 (ddd, J = 13.9, 6.4, 6.3 Hz, 1H), 1.69 (ddd, J 
= 13.9, 6.3, 5.8 Hz, 1H). 13C NMR (MeOD): δ 161.9, 161.4, 154.6, 139.6, 139.2, 
137.8, 130.7, 129.4, 129.3, 129.2, 129.0, 115.4, 68.9, 65.4, 60.8, 35.3.  m/z (ES+) 
360.1440 calculated for C18H19N5O2:  [M+H]+ 360.1436.  IR (cm-1):  3302 (N−H), 
3301 (N−H), 1601, 1574 & 1523 (C=C aromatic), 1234 (C−O). 
 
 
 
((1S,4R)-4-(2-Amino-6-methoxy-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol 
135:16 General Procedure B was followed to yield 135 as a colourless solid (0.66 g, 
75%).  mp:  134–136 °C (lit.16 mp:  135–137 °C).  1H NMR (CDCl3): δ 7.61 (s, 1H), 
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6.17–5.59 (m, 2H), 5.42–5.38 (br m, 1H), 3.96 (s, 3H), 3.75 (dd, J = 10.8, 3.2 Hz, 
1H), 3.69 (dd, J = 10.8, 3.7 Hz, 1H), 3.48 (MeOH), 3.01–2.99 (m, 1H), 2.80–1.84 
(m, 2H).  13C NMR (CDCl3): δ 161.9, 159.3, 153.2, 139.1, 138.9, 130.4, 116.3, 65.2, 
61.2, 54.2, 50.4 (MeOH), 48.16, 33.3.  m/z (ES+) 262.1304 calculated for 
C12H15N5O2:  [M+H]+ 262.1303.  IR (cm-1):  3321 (N−H), 3201 (br, O−H), 2935 
(C−H), 1581 (C=N), 1477 (C=C), 1392 (C=C aromatic), 1246 (C−O), 1038 (C−N). 
 
 
 
((1S,4R)-4-(2-Amino-6-propoxy-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol 
136:  General Procedure B was followed to yield 136 as a yellow solid (40 mg, 
85%).  mp: 128–130 ºC.  1H NMR (CDCl3): δ 7.60 (s, 1H), 6.21–5.55 (m, 2H), 5.40 
(ddd, J = 9.4, 5.2, 1.9 Hz, 1H), 4.34 (t, J = 6.8 Hz, 2H), 3.79 (dd, J = 10.8, 3.7 Hz, 
1H), 3.69 (dd, J = 10.8, 3.1 Hz, 1H), 3.48 (MeOH), 3.15–2.94 (m, 1H), 2.82–1.90 
(m, 2H), 1.84–1.62 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H).  13C NMR (CDCl3): δ 162.0, 
159.2, 153.2, 139.2, 138.8, 130.6, 116.6, 68.8, 65.3, 61.6, 50.4 (MeOH), 48.2, 33.0, 
22.6, 10.8. m/z (ES+) 312.1436 calculated for C14H20N5O2:  [M+H]+ 312.1436.  IR 
(cm-1):  3321 (N−H), 3201 (br, O−H), 2967 (C−H), 1578 (C=N), 1450 (C=C), 1404 
(C=C aromatic), 1238 (C−O), 1061 (C−N). 
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((1S,4R)-4-(2-Amino-6-butoxy-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol 
137:26 General Procedure B was followed to yield 137 as a pale yellow solid (50 mg, 
63%). mp:  121–122 ºC (for racemic lit.26 mp:  122–123 °C).  1H NMR (CDCl3): δ 
7.61 (s, 1H), 6.12 (ddd, J = 5.5, 2.1, 2.1 Hz, 1H), 5.70 (ddd, J = 5.5, 2.1, 2.0 Hz, 1H), 
5.42–5.39 (br m, 1H), 4.37 (t, J = 6.6 Hz, 1H), 3.84 (dd, J = 10.8, 3.8 Hz, 1H), 3.68 
(dd, J = 10.8, 3.1 Hz, 1H), 3.48 (MeOH), 3.02–2.98 (m, 1H), 2.70 (ddd, J = 14.3, 
6.4, 6.1 Hz, 1H), 2.07–1.81 (m, 1H), 1.80–1.54 (m, 2H), 1.52–1.47 (m, 2H), 0.88 (t, 
J = 7.4 Hz, 3H).  13C NMR (CDCl3): δ 161.9, 159.2, 153.2, 139.0, 138.8, 130.5, 
116.4, 67.0, 65.2, 61.4, 50.4 (MeOH), 48.1, 33.2, 31.3, 19.5, 14.2.  m/z (ES+) 
304.1774 calculated for C15H22N5O2:  [M+H]+ 304.1778.  IR (cm-1):  3313 (N−H), 
3201 (br, O−H), 2951 (C−H), 1581 (C=N), 1508 (C=C), 1462 (C=C aromatic), 1400 
(C−O), 1245 (C−N). 
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((1S,4R)-4-(2-Amino-6-isopropoxy-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol 
139:26 General Procedure B was followed to yield 139 as a colourless solid (70 mg, 
80%).  mp:  180–182 °C (lit.26 mp:  188–191 °C).  1H NMR (CDCl3): δ 7.71 (s, 1H), 
6.14–6.11 (m, 1H), 5.79–5.74 (m, 1H), 5.49–5.38 (m, 2H), 3.78 (dd, J = 10.8, 3.6 
Hz, 1H), 3.68 (dd, J = 10.8, 3.4 Hz, 1H), 3.48 (MeOH), 3.16–2.98 (m, 1H), 2.76 
(ddd, J = 14.3, 6.4, 6.3 Hz, 1H), 2.09–1.89 (m, 1H), 1.40 (d, J = 6.2 Hz, 1H).  13C 
NMR (CDCl3): δ 161.3, 159.4, 153.4, 138.9, 130.4, 116.4, 70.0, 65.1, 61.0, 50.4 
(MeOH), 48.2, 33.5, 22.4. m/z (ES+) 290.1617 calculated for C14H20N5O2:  [M+H]+ 
290.1616.  IR (cm-1):  3325 (N−H), 3192 (br, O−H), 2980 (C−H), 1579 (C=N) 1454 
(C=C), 1404 (C=C aromatic), 1246 (C−O), 1059 (C−N). 
 
5.5.2 Docking study protocols. 
5.5.2.1 Ligand preparation. 
Ligands prepared for docking in Spartan ‘08 (Wavefunction INC., Irvine 1991–
2009).  Native SMA ligand exported from PDB, 3UPR2 crystal structure and opened 
in Spartan.  For each required analogue the cyclopropyl ring was replaced.  
Molecular mechanics, MMFF energy minimisation calculation performed with all 
atoms frozen except the newly added substitution.  Structures were saved using SD 
file format ready for docking. 
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5.5.2.2 Docking study. 
GOLD 5.1 (CCDC Software Limited, Cambridge, UK) was used to find potential 
binding poses of ABC 7 and 6-position amine and oxy analogues in the F-pocket of 
HLA-B*57:01 (PDB code 3UPR).2 Hydrogen molecules were added to the protein 
and the native ligand ABC was removed and used to define the binding site as 6 Å 
around the ligand.  Rigid docking was performed such that the option to ‘Fix Ligand 
Rotatable Bonds’ was checked.  Ligands were loaded and docked using the rescore 
option and the GOLDScore fitness function, with the ‘Perform Local Optimisation’ 
option unchecked.  All other settings were left at default. 
 
5.5.3 Immunological studies. 
5.5.3.1 T-cell culture and cloning. 
Cells from three HLA-B*57:01 positive individuals were selected from our cell bank 
containing peripheral blood mononuclear cells (70–150 × 106; stored in vials of 10 × 
106 cells) from 1000 HLA-typed donors.  The demographics of the first 400 study 
subjects and HLA allele frequencies have been reported previously.29 Ethical 
approval for the study was obtained from the local research ethics committee and all 
volunteers were consented prior to blood donation.  Confidentiality was maintained 
throughout the study. 
 
5.5.3.2 Drug-specific T-cell responses. 
ABC-specific proliferative responses were assessed by culturing T-cell clones (5 × 
104/well; 200 µL) with autologous irradiated EBV-transformed B-cells (used as 
antigen presenting cells; 1 × 104/well) and ABC (50 µM).  IFN-γ secretion after 
abacavir stimulation was measured using ELISpot in accordance with the 
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manufacturer’s instructions (Mabtech AB, Sweden).  The effect of chemical 
modification of the 6-amino cyclopropyl group of ABC on the T-cell response was 
measured by incubating clones and irradiated EBV-transformed B-cells with the 
compounds (10, 25, 50, 100 and 250 µM) and measuring IFN-γ secretion.  Cytokine 
secretion was selected as a T-cell readout as it provided the greatest discrimination 
between ABC-treated and control cells.  HLA-B*57:01-restricted T-cell activity of 
the ABC analogues was tested using 6 clones selected from all 3 donors.  ABC was 
used as a positive control.  
 
5.5.4 Pharmacological studies. 
For the determination of compounds 103–108, 110, 113, 115, 132 and 133, 
cytotoxicity and inhibition of HIVIIIB replication in MT4 cells, the procedure in 
Chapter 3, Section 3.5.3 was followed. 
 
5.5.5 PK profiling. 
PK experiments were carried out by Shanghai ChemPartner Co. Ltd., China.  Brief 
experimental conditions and parameters can be found overleaf. 
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Test system 6 male SD rats (210–240 g) (for each compound) were purchased 
from SLAC Laboratory Animal Co. Ltd. 
 
Food status 
 
Fasted overnight, free access to water and fed 4 h post dose 
 
Administration 
 
IV:  1 mg/kg via foot dorsal vein injection (n = 3 per compound) 
PO:  10 mg/kg via oral gavage (n = 3 per compound) 
 
Blood 
collection 
 
The animal was restrained manually at the required time points 
and approximately 150 µL of blood sample was collected via the 
tail vein or via pre-cannulated jugular vein into EDTA-2K tubes.  
The blood samples were kept on ice then centrifuged (2000 × g, 4 
°C, 10 min) to obtain plasma within 20 min post sampling 
 
Sampling 
intervals 
 
0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 h 
 
IV and PO solutions were prepared in 10% DMSO, 10% solutol HS15 and 80% 
saline to achieve the correct concentration.  The bioavailability was determined 
using:   
 
 
 
 
 
 
5.5.5.1 LC-MS/MS sample preparation and conditions for PK profiling. 
Plasma samples were prepared for LC-MS/MS analysis as follows:  To an aliquot of 
plasma sample (30 µL) was added ACN (150 µL) containing the IS (diclofenac, 80 
ng for ABC 7 and dexanethasone, 40 ng for compound 108).  The mixture was 
vortexed for 2 min and centrifuged (6000 rpm, 10 min).  The supernatant (1 µL) was 
injected into the LC-MS/MS for analysis.  All samples were analysed on an LC-
! 
AUClast
AUCinf
> 80%
F = (AUCinf"ex *DoseIV )(AUCinf"IV *Doseex )
*100
When: 
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MS/MS API 5500 triple quadrupole system.  An Acquity UPLC BEH C18 column 
(2.1 × 50 mm, 1.7 µm) was used for chromatographic separation at 60 °C. The 
mobile phases were as follows:  Mobile phase A – NH4OAc (1 mM) in H2O, 0.1% 
formic acid (FA); mobile phase B – NH4OAc (1 mM) in MeOH, 0.1% FA.  The 
compounds, including all metabolites, were eluted from the chromatographic column 
using a linear gradient as depicted below, using a flow rate of 0.6 mL/min. The mass 
spectrometer was operated in positive ion ESI mode and analyses were performed in 
MRM scanning mode.  
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6.1 Final Conclusions & Future Work 
 
ADRs remain a major issue within health care and imperatively, the mechanisms of 
these ADRs must be resolved.  Type A and type B reactions are the most common 
ADRs but in particular, type B are most frequently researched due to their 
idiosyncratic and unpredictable nature.  Drug-induced HSRs fall within the type B 
category and the fundamental mechanisms surrounding DHS toxicity is largely 
influenced by genetic variability.1 ABC-HSR, as with many drug-induced HSRs, is 
genetically influenced, with only those patients bearing the HLA-B*57:01 allele 
susceptible to this toxicity.2,3 The principal mechanism of ABC toxicity is largely 
unknown although hypotheses have been proposed.  Two major mechanisms of 
immune-mediated toxicity are the hapten mechanism and the p-i concept, and in 
particular, the hapten mechanism has been implemented in explaining ABC-HSR.4 
During the latter stages of this research, an alternative mechanism was proposed:  
The ‘altered repertoire’ mechanism.1,5-7 The main aim of this thesis was to establish 
the major route of ABC toxicity. 
 
In 2002, Walsh and co-workers proposed the first mechanism of ABC-HSR:  
Metabolism of ABC 7 by ADH to a highly reactive aldehyde species.4 Such species 
have been known to cause toxicity in vivo.8 The short-lived aldehyde metabolite 
proved difficult to isolate, as shown by Charneira et al.9 and in this thesis (Chapter 
2).  With no specific evidence of this species, it was difficult for Walsh et al. to 
prove their theory, although the isolation of haptenated proteins resulting from 
reactions with an aldehyde intermediate was discovered.  Charneira et al.,9,10 Grilo et 
al.,11 and Meng et al.12 have further researched this:  Protein adducts, both in vitro 
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and in vivo, have been isolated.  More importantly, these adducts were formed from 
one aldehyde metabolite, ABC-CHO 16c (Figure 6.1).10 The formation of this 
aldehyde further adds to the complicated nature of ABC metabolism and the specific 
ADH and/or ALDH isozymes involved in this process.   
 
Walsh et al.4 were first to uncover the ADH isozymes involved in the metabolic 
process, but the involvement of ALDH was not suggested.  It has been shown in this 
work that there is some contribution of ALDH to ABC metabolism (Chapter 3), 
although ADH is itself capable of metabolising ABC-16 to ABC-17 (Figure 6.1).4 It 
has been shown, through methoxylamine trapping experiments, that aldehyde 
formation does occur, although the half-life of the aldehyde has not been determined, 
due to its highly reactive nature.  The aldehyde would react with proteins 
spontaneously; the effects of which would be seen close to the site of metabolism.  
The location of this would be predicted to be in the liver, although these metabolites 
are able to travel in the circulatory system.  However, certain classes of ADH and 
ALDH enzymes are also found within the skin.13 Grilo et al.11 have experienced 
difficulty in obtaining haptenated adducts from patients in vivo and as such would 
show that although adduct formation is occurring the contribution to ABC toxicity 
could be relatively small. 
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Figure 6.1:  Biochemical oxidation of ABC 7 to its stereo-equivalent aldehyde intermediate 16a by 
ADH and further metabolism of 16a to the major carboxylic acid isomer 17a in vitro by ADH1A 
(αα)/ALDH.  At the beginning of this work, the involvement of ALDH in this oxidation pathway was 
unknown and ADH1A was shown to oxidise ABC to 17a.4 Aldehyde 16a can undergo epimerisation 
to 16b, which in turn is oxidised by ADH1A to carboxylic acid 17b or reduced to an isomer of ABC, 
7b.  Alternatively, 16a can undergo isomerisation to aldehyde 16c, which has shown to undergo in 
vitro and in vivo protein adduct formation.  Isomer 16c can also undergo further oxidation to 
carboxylic acid 17c or reduction to an isomeric parent compound 7c.  Adapted from Walsh et al.4 and 
Charneira et al.9  
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The use of deuterium in drug therapy and to research drug mechanisms is widely 
recognised14-16 and this idea was adopted in this work (Chapters 2 and 3).  The 8-step 
total synthesis of D2-ABC 42 (Figure 6.2) was successfully completed (Chapter 2) 
and this was further used in in vitro experiments with crude liver cytosol, where the 
metabolism of D2-ABC mimicked that of ABC (Figure 6.2) (Chapter 3).  The rate of 
metabolism of the deuterated form was retarded and a primary KDIE of 1.88 was 
calculated between ABC and D2-ABC.  Interestingly, as shown by Stringer et al.,17 
metabolic switching can occur, in which an alternative metabolic pathway becomes 
more dominant over the usually preferred pathway.  This may occur if the normal 
dominant pathway is slowed.  In the case of D2-ABC, this may result in the 
glucuronidation pathway becoming more preferable, resulting in a pharmacologically 
inactive metabolite.  However, the in vitro antiviral results for D2-ABC shows that it 
has comparable efficacy to ABC, at least in MT4 cells, but this would need to be 
confirmed in vivo.  The in vitro T-cell assays showed that D2-ABC stimulated ABC-
specific T-cell clones to the same extent as ABC.  It can be concluded from this, that 
although we have shown that the oxidative metabolism can be slowed, the toxicity is 
likely to be maintained.  Metabolism of D-ABC aldehyde 58 to ABC-COOH 17 
(Figure 6.2) by ADH/ALDH would be slowed and this may result in higher 
accumulations of 58, allowing for adduct formation.  Alternatively, the oxidative 
metabolism at 5'-C may not contribute to ABC-HSR, thus another part of the 
molecule must be involved (Chapter 5).  It would be interesting to perform the T-cell 
assays over a shorter time period (the assays are normally conducted over 48 h).  
This would show at which time point and/or concentration, is the stimulation of T-
cells by D2-ABC to that of ABC should there be any variation at all.  
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Figure 6.2:  D2-ABC 42 has been shown to mimic the oxidative metabolism exhibited by ABC:  D2-
ABC is metabolised by ADH to an aldehyde intermediate 58a.  This intermediate can be further 
oxidised by ADH/ALDH to ABC-17a.  Alternatively, 58a can undergo epimerisation or isomerisation 
to form aldehydes 58b and 58c respectively, which in turn can be oxidised to their carboxylic acid 
equivalents, 17b and 17c respectively. 
 
There is much further work required in this metabolism area:  The calculation of the 
relative rate constants k is much needed in order to fully define any KDIE.  Due to 
the two-step metabolism of ABC/D2-ABC, 1st step being oxidation to their aldehyde 
equivalents (compounds 16 and 58) and the 2nd step, further oxidation to ABC-17, it 
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is difficult to define the RDS of this oxidative metabolism.  Therefore the KDIE 
calculated is an overall value and this must be calculated for the individual steps.  
Although widely researched, oxidation of alcohols to carboxylic acids by ADH is a 
complex process, with a number of transition states and hydrogen tunnelling.18 There 
is comparatively less literature for the oxidation and direct involvement of ALDH 
and together with the complex metabolism by ADH it further shows how intricate 
this metabolic process is.  The further in silico, chemical and mathematical research 
required for this work is far beyond the scope of this thesis.  Further chemical 
research would involve the synthesis of 4'-C and 5'-C methylated analogues (see 
Chapter 2, Section 2.4, Figure 2.11).  Methylation of molecules has been shown to 
increase the biological and pharmacological properties of a drug.19 The 4'-C methyl 
analogue would allow for oxidative metabolism to occur to a carboxylic acid, as with 
ABC, but double bond migration to ABC-16c, would not be allowed to occur.  This 
would prevent a 1,4-Michael addition mechanism from occurring; a mechanism 
known to contribute significantly in vitro and in vivo to ABC-HSR.  A 1,2-Schiff 
mechanism however may still be possible.  Although, using the 4'-C methyl 
compound, the contribution of other ABC-aldehyde isomers, 16a and 16b may 
become predominant perhaps resulting in similar haptenated adducts.  The 5'-C 
methyl analogue would prevent oxidative metabolism completely, and running this 
analogue in the relevant T-cell assays, could show greatly reduced stimulation of T-
cells.  Although metabolic switching (as previously discussed) is highly likely to 
occur with this analogue, potentially making this analogue antivirally inactive.  
Along with these two analogues, the synthesis of D-ABC (deuteration of 4'-C) would 
allow investigational work of a possible secondary KDIE.  Further metabolism 
experiments should be designed to measure substrate disappearance, rather than 
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product formation.  The method utilised within this work was adapted from Patenella 
et al.,20 it assumes that the substrates (ABC/D2-ABC) are fully converted to their 
respective products.  However, the metabolism experiments can be monitored more 
accurately by measuring substrate disappearance; this will provide more precise 
results as it allows the concentration of substrate used to be determined without 
assuming that it is fully converted to its product, which may not be the case. 
 
Although many total syntheses of ABC have been published, there is little available 
literature for the direct chemical reactivity of ABC.  The lack of solubility of ABC in 
a wide range of commonly used solvents for reactions was a major issue for the 
direct modification of ABC, particularly when trying to modify N2 (Chapter 4).  
Although, reactions conducted in polar solvents e.g. MeOH and DMF, yielded 
desired products, such as DH-ABC 20 (Figure 6.3 B).  Previous work published by 
Walsh et al. showed that DH-ABC reduced the number of non-extractable residues, 
implying less protein adduct formation compared to ABC.4 This was further 
supported in this work, in which DH-ABC greatly reduced IFN-γ release in ABC-
specific T-cell clones and reduced proliferation (LTT test) of T-cell clones (Chapter 
4).  There are two possible explanations of this:  i.) DH-ABC, in its parent form, has 
an altered conformation to ABC; ii.) It has a saturated cyclic ‘sugar’ moiety.  The 
saturation of the cyclopentane ring will remove the C=C restrictions experienced by 
ABC and will therefore alter its conformation, not only within the cyclopentane ring, 
but also the nucleoside base.  This may affect the binding within HLA-B*57:01 and 
as seen with the in silico binding of 6-position analogues, any slight alterations at the 
nucleoside base will affect its binding within the protein.  Further in silico analysis 
will assist in explaining this further.  Conversely, the absence of the alkene will 
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prevent covalent adduction in a 1,4-Michael addition manner, although a 1,2-Schiff 
base mechanism may still occur.  This is therefore interesting, such that protein 
adduct formation is still able to occur, but is restricted to a particular mechanism.  
This may explain the reduction, but not elimination, in T-cell stimulation.  DH-ABC 
could undergo a similar set of metabolism experiments, as applied to D2-ABC, to 
monitor the oxidative metabolism pathway, and this may highlight any formation of 
haptenated products. 
 
Although the total syntheses for ABC were challenging (Chapter 4), a synthesis was 
developed and this can be further adapted during the synthesis of a wider range of 
ABC analogues, particularly those containing ‘sugar’ moiety modifications.  The 
synthesis of the ABC enantiomer (ent-ABC) (Figure 6.3 C) was successful and the 
further immunological experiments of this compound were of interest (Chapter 4).  
The lack of a T-cell response, measured through the LTT test and ELISpot assay, 
from ent-ABC showed that ABC-HSR is stereospecific.  It is known that a wide 
range of biological systems and processes e.g. enzymes, are highly stereoselective 
and therefore it is difficult to determine at this stage which biological process is 
responsible:  ADH/ALDH (enzymatic) or HLA-B*57:01.  It may be that ent-ABC is 
unable to be metabolised by the stereospecific ADH/ALDH enzymes with no 
aldehyde formation and subsequently no immune-mediated response.  Conversely, 
ent-ABC may not bind in the same manner as ABC within the HLA-B*57:01 protein 
and therefore the intermolecular forces, as experienced with ABC, would not occur, 
failing to initiate an immune response via either the p-i concept or the altered 
repertoire mechanism.  In silico and additional immunological experiments are 
required to explain this finding further. 
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Figure 6.3:  ABC 7 (A), DH-ABC 20 (B), ent-ABC (C) and compound 108 (D). 
 
A wide range of 6-position analogues were synthesised and these analogues were 
used to probe the altered repertoire mechanism (Chapter 5).  The analogues, 
consisting of 1° and 2° amine and oxy analogues, were subjected to further 
experimental studies.  In silico studies allowed us to model these analogues within 
the HLA-B*57:01 protein to determine the interactions with specific amino acids.  In 
particular those within the F-pocket; these intermolecular forces have been suggested 
to assist with ABC’s binding within the protein.  The acquired GOLDScore values 
were used in a complimentary manner to explain the results obtained from the 
ELISpot assay, in which the majority of analogues did not stimulate ABC-specific T-
cell clones.  However, not all these analogues retained efficacy with comparison to 
ABC.  It was found that the i-Pr analogue 108 (Figure 6.3 D) had the most significant 
results, with negative stimulation of in vitro T-cell clones and efficacy maintained.  
In initial PK testing, positive results were obtained, as compound 108’s PK 
parameters were almost comparable to ABC’s.  Those analogues, which failed to 
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stimulate T-cell clones and sustained similar efficacy values to ABC, must be 
subjected to similar PK testing, as with compound 108.  Further to this, there are 
several analogues in which T-cell and antiviral experiments have not been 
completed.  Once these results are obtained, all collated results will assist in directing 
future 6-position analogue synthesis.    
 
It would be interesting to subject these analogues to the metabolism experiments (as 
shown with D2-ABC, Chapter 3) to monitor the oxidative metabolism, compared to 
ABC.  These analogues, should they be substrates for ADH/ALDH, form their 
respective aldehyde intermediates.  It is interesting that most of these analogues did 
not stimulate an immune response in vitro, even though the aldehyde metabolites are 
theoretically formed.  The metabolism experiments would confirm presence of these 
metabolites and would therefore help to determine the mechanism of ABC-HSR:  
The presence of aldehyde metabolites would suggest that the altered repertoire 
mechanism is the prevailing pathway to explaining ABC-HSR.  However, it could 
also be possible that an alternative metabolism of these analogues exists, although, 
the same pathway as ABC would be expected.  The metabolism of alcohols to 
aldehydes could also occur via an alternative enzymatic pathway.8 
 
Although several mechanisms of ABC toxicity have been proposed, a definite 
mechanism has yet to be determined.  Our findings have confirmed the oxidative 
pathway of ABC metabolism and the involvement of ALDH in this metabolism has 
also been determined (Chapter 3).  The altered repertoire mechanism appears to be 
the most plausible explanation for ABC-HSR, and our initial experiments have 
supported this (Chapter 5).  It was stated by Illing et al.,5 that the 6-position 
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cyclopropyl amino moiety of ABC assists with its binding within the HLA complex. 
In silico studies have allowed us to model our rationally designed analogues and data 
supports the altered repertoire hypothesis since compounds with larger or more bulky 
6-position substituents exhibited higher GOLDScore values with positive in vitro T-
cell responses.  The p-i mechanism has been discarded, as it was shown by 
McCluskey et al.,21 that ABC must undergo intracellular processing.  However, this 
should be confirmed with the synthesised 6-position analogues.  The application of 
the hapten mechanism with the 6-position analogues is still under investigation.  
With respect to the hapten mechanism not all of these analogues are likely to be 
substrates of ADH/ALDH, so aldehyde formation may not be possible for all 
compounds, limiting the T-cell response to certain analogues.  Alternatively, the 
hapten mechanism may not be applicable at all if we can show that the entire set of 
analogues are substrates for ADH/ALDH enzymes but the relative aldehyde 
intermediates formed do not stimulate ABC-like toxicity.  It has been shown in vitro 
that in ABC-specific T-cell clones, stimulation of T-cells can be eliminated with 
antiviral activity maintained, solely through subtle modification at the 6-position.  It 
would be beneficial to analyse the repertoire of peptides that are displayed by HLA-
B*57:01, using experimental techniques as applied by Illing et al.5 and Ostrov et al.,6 
in the presence of all synthesised analogues, regardless of whether an immune 
response is stimulated or not.  These results would assist in confirming or rejecting 
the altered repertoire hypothesis.  Furthermore, in vivo experiments are required for 
all synthesised analogues:  Detection should be directed to haptenated products or 
parent/metabolite compounds.  Haptenated products would assist with further 
developing the hapten theory, as suggested by Walsh et al.,4 Charneira et al.,9,10 
Grilo et al.11,22 and Meng et al.12 
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In initial studies, Illing et al.5 have demonstrated that CBZ-induced HSR can also be 
explained by the altered repertoire mechanism; the genetic association with this drug 
is HLA-B*15:02.  Although these studies are extremely preliminary, this 
demonstrates that this mechanism is not limited to ABC, nor to HLA-B*57:01.  It is 
unclear as to what the relationship is between these immune-stimulating molecules 
and their associated HLA alleles.  The strong association of these drugs with HLA 
molecules, e.g. ABC (HLA-B*57:01),2,3 CBZ (HLA-B*15:02)23,24 and allopurinol 
(HLA-B*58:01),25,26 are open to questions:  Is there a key link between the structures 
of these drugs that are associated with this form of toxicity?  Alternatively, is there a 
link with these HLA molecules, in which they share a common structural component, 
which is strongly associated with immune-related ADRs?  It would be beneficial to 
discover whether there is a unified link so to apply predictive measures in future drug 
design efforts. 
 
There are many drugs that require genetic screening pre-prescription or before 
market release, and in particular, all prospective ABC patients must undertake 
genetic screening for the HLA-B*57:01 allele before administration of therapy.  This 
leads to the question, would it be beneficial to conduct HLA screening for all pre-
released drugs?  If so, the genetic variations of HLA molecules may prove a 
hindrance for its application.  There are over 8500 alleles for HLA class I molecules 
alone,27 and with such genetic variation, which are usually ethnicity linked, would it 
make genetic screening of every drug unaffordable?  Screening of patients’ HLA 
alleles before commencing drug therapy may certainly benefit the patient and reduce 
HLA-associated ADRs, but it should also be noted that other external factors, such as 
chemical toxins, might induce these adverse reactions, and these issues should be 
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considered.  Evidently, it would be paramount to firstly identify the HLA 
association, should it occur, with future drugs.  The cost-to-benefit ratio, along with 
potentially denying a patient a breakthrough drug treatment where ADRs may 
outweigh the benefits, should be carefully calculated and considered. 
 
What is still undetermined, is the reason why only 50% of patients bearing the HLA-
B*57:01 allele experience ABC-HSR.28 Other genetic or environmental factors must 
contribute to ABC’s toxicity.  Additionally, the mechanism of cardiac toxicity 
resulting from ABC administration has been less widely studied and it is unknown 
whether either any of the proposed mechanisms for ABC-HSR also contribute to this 
alternative toxicity.   
 
The research discussed in this thesis shows that the mechanisms underlying ABC-
HSR is complex and one defining mechanism to explain this toxicity is still under 
investigation.  The new hypothesis, the altered repertoire mechanism, is in its infancy 
and there is clearly much further research that should be conducted, to fully define 
whether this mechanism could be applied to ABC toxicity.  In particular, future 
research should be applied further afield with the use of other drugs that induce 
HSRs, to explaining their HLA-associated toxicity.  This additional research will 
lead to safe drug design and ultimately, this specific toxicity could be prevented in 
future drugs. 
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